0000950170-24-09090510-Q Arcturus Therapeutics Holdings Inc. 20240805202408051650111650111650111650111650111 0 0000950170-24-090905 10-Q 57 20240630 20240805 20240805 Arcturus Therapeutics Holdings Inc. 0001768224 2834 000000000 DE 1231 10-Q 34 001-38942 241175638 10628 SCIENCE CENTER DRIVE SUITE 250 SAN DIEGO CA 92121 8589002660 10628 SCIENCE CENTER DRIVE SUITE 250 SAN DIEGO CA 92121 10-Q 1 arct-20240630.htm 10-Q 10-Q 0001768224falseQ2--12-31http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent0001768224arct:JanssenMemberarct:CollaborationRevenueMember2023-04-012023-06-300001768224arct:CollaborationRevenueMember2023-01-012023-06-300001768224arct:ManufacturingAndSupplyOfArct154DrugProductMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2024-06-300001768224us-gaap:GrantMember2024-01-012024-06-300001768224us-gaap:RetainedEarningsMember2022-12-310001768224022-12-310001768224us-gaap:EquipmentMember2024-06-300001768224arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember2024-01-012024-06-300001768224us-gaap:GrantMember2023-04-012023-06-300001768224us-gaap:AdditionalPaidInCapitalMember2024-06-300001768224arct:CslCollaborationAgreementMember2024-01-012024-06-300001768224arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2022-08-012022-08-310001768224arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember2024-01-012024-06-300001768224us-gaap:GrantMemberarct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2024-01-012024-06-300001768224us-gaap:CommonStockMember2022-12-310001768224us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001768224us-gaap:GrantMemberarct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2023-04-012023-06-300001768224us-gaap:CommonStockMember2024-03-310001768224arct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMembersrt:MaximumMember2022-11-010001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMemberarct:LUNARCFMember2019-07-312019-08-010001768224us-gaap:RetainedEarningsMember2023-04-012023-06-300001768224arct:WellsFargoCreditAgreementMember2024-06-262024-06-260001768224srt:MaximumMemberarct:CslCollaborationAgreementMemberarct:PhaseIClinicalStudyMember2023-01-012023-12-310001768224arct:CslSeqirusMemberarct:CollaborationRevenueMember2024-04-012024-06-300001768224arct:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001768224arct:ManufacturingAndSupplyOfArct154DrugProductMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2024-04-012024-06-300001768224arct:OctoberTwoThousandAndSeventeenLeaseAmendmentMember2017-10-310001768224202312-310001768224us-gaap:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2024-04-012024-06-300001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2024-01-012024-06-300001768224arct:OctoberTwoThousandAndSeventeenLeaseAmendmentMember2017-10-012017-10-310001768224arct:WellsFargoCreditAgreementMember2024-01-012024-06-300001768224arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2024-04-012024-06-300001768224us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001768224us-gaap:AdditionalPaidInCapitalMember2023-12-310001768224arct:CollaborationRevenueMember2024-01-012024-06-300001768224us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-300001768224arct:TwentyTwentyOneInducementEquityIncentivePlanMember2022-04-300001768224us-gaap:CommonStockMember2023-04-012023-06-300001768224us-gaap:RetainedEarningsMember2024-04-012024-06-300001768224arct:CslSeqirusMemberarct:CollaborationRevenueMember2024-01-012024-06-300001768224arct:LanceKuratаMember2024-04-012024-06-300001768224us-gaap:RetainedEarningsMember2023-01-012023-03-310001768224arct:WellsFargoCreditAgreementMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2024-06-260001768224arct:CslCollaborationAgreementMember2024-06-300001768224us-gaap:ConstructionInProgressMember2023-12-310001768224us-gaap:CommonStockMember2024-04-012024-06-300001768224us-gaap:LeaseholdImprovementsMember2024-06-300001768224arct:OtherMemberarct:CollaborationRevenueMember2024-01-012024-06-300001768224arct:WellsFargoCreditAgreementMember2024-06-260001768224us-gaap:RetainedEarningsMember2024-01-012024-03-310001768224arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember2020-02-290001768224202401-012024-06-300001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2023-01-012023-12-310001768224arct:Covid19VaccineMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2022-11-012022-11-010001768224us-gaap:GrantMember2024-04-012024-06-300001768224202401-012024-03-310001768224arct:TwoThousandNineteenOmnibusIncentivePlanMember2024-06-300001768224arct:JanssenMemberarct:CollaborationRevenueMember2023-01-012023-06-300001768224arct:DirectorsOrOfficersMember2024-04-012024-06-300001768224arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMembersrt:MaximumMember2021-09-012021-09-300001768224arct:CollaborationRevenueMember2024-04-012024-06-300001768224arct:OtherMemberarct:CollaborationRevenueMember2023-04-012023-06-300001768224us-gaap:FurnitureAndFixturesMember2023-12-310001768224us-gaap:AdditionalPaidInCapitalMember2023-03-310001768224arct:TwoThousandNineteenOmnibusIncentivePlanMembersrt:MaximumMember2024-06-300001768224us-gaap:FurnitureAndFixturesMember2024-06-300001768224us-gaap:GrantMember2023-01-012023-06-300001768224us-gaap:CommonStockMember2024-01-012024-03-310001768224arct:CslCollaborationAgreementMemberarct:PhaseIClinicalStudyMember2024-06-300001768224us-gaap:RetainedEarningsMember2023-03-310001768224arct:ManufacturingAndSupplyOfArct154DrugProductMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2023-12-310001768224us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001768224arct:OtherMemberarct:CollaborationRevenueMember2024-04-012024-06-300001768224us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2023-04-012023-06-300001768224us-gaap:EmployeeStockOptionMemberarct:TwentyTwentyOneInducementEquityIncentivePlanMember2024-06-300001768224srt:MinimumMemberarct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember2021-09-012021-09-300001768224us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001768224arct:Covid19VaccineMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2023-12-310001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2023-01-012023-06-300001768224202306-300001768224arct:CslSeqirusMemberarct:CollaborationRevenueMember2023-01-012023-06-300001768224us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001768224us-gaap:GrantMemberarct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2023-01-012023-06-300001768224arct:CslSeqirusMemberarct:CollaborationRevenueMember2023-04-012023-06-300001768224us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001768224arct:WellsFargoCreditAgreementMembersrt:MaximumMember2022-12-232022-12-230001768224arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember2024-01-012024-03-310001768224arct:CslCollaborationAgreementMemberarct:PhaseIClinicalStudyMember2023-01-012023-12-310001768224arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember2021-09-300001768224arct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2022-11-012022-11-010001768224us-gaap:CommonStockMember2023-03-310001768224srt:MaximumMemberarct:TwentyTwentyOneInducementEquityIncentivePlanMember2021-10-150001768224arct:OtherMemberarct:CollaborationRevenueMember2023-01-012023-06-300001768224arct:CslCollaborationAgreementMember2023-12-310001768224us-gaap:RetainedEarningsMember2024-03-310001768224us-gaap:RetainedEarningsMember2024-04-012024-06-300001768224202408-020001768224us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001768224arct:CollaborationRevenueMember2023-04-012023-06-300001768224us-gaap:RetainedEarningsMember2023-06-300001768224us-gaap:LeaseholdImprovementsMember2023-12-310001768224us-gaap:CommonStockMember2023-12-310001768224202303-012023-06-300001768224us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001768224us-gaap:AdditionalPaidInCapitalMember2023-06-300001768224arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2024-01-012024-06-300001768224arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2023-04-012023-06-300001768224arct:TwoThousandNineteenOmnibusIncentivePlanMemberus-gaap:EmployeeStockOptionMember2024-06-300001768224us-gaap:CommonStockMember2024-06-300001768224202303-310001768224us-gaap:CommonStockMember2023-06-300001768224202404-012024-06-300001768224us-gaap:AdditionalPaidInCapitalMember2022-12-310001768224us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001768224us-gaap:EquipmentMember2023-12-310001768224arct:LanceKuratаMember2024-06-300001768224us-gaap:AdditionalPaidInCapitalMember2024-03-310001768224arct:Covid19VaccineMemberarct:ResearchCollaborationAndLicenseAgreementMemberarct:SeqirusIncMember2024-03-310001768224us-gaap:ComputerEquipmentMember2023-12-310001768224us-gaap:ComputerEquipmentMember2024-06-300001768224us-gaap:RetainedEarningsMember2023-12-310001768224arct:WellsFargoCreditAgreementMember2024-06-300001768224us-gaap:GrantMemberarct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2024-04-012024-06-300001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMemberarct:LUNARCFMember2019-08-022023-09-250001768224arct:UnderlyingAgreementMemberarct:CysticFibrosisFoundationTherapeuticsIncMember2019-08-022023-09-250001768224arct:WellsFargoCreditAgreementMember2024-06-012024-06-30xbrli:purexbrli:sharesarct:Segmentiso4217:USDiso4217:USDxbrli:shares Â cs UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Â FORM 10-Q Â (Mark One) Â â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the quarterly period ended June 30, 2024 OR Â â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Â For the transition period from to Â Commission File Number: 001-38942 Â Â ARCTURUS THERAPEUTICS HOLDINGS INC. (Exact Name of Registrant as Specified in its Charter) Â Â Delaware Â 32-0595345 (State or other jurisdiction ofincorporation or organization) Â (I.R.S. EmployerIdentification No.) Â 10628 Science Center Drive, Suite 250San Diego, California Â 92121 (Address of principal executive offices) Â (Zip Code) Â (858) 900-2660 (Registrantâ€™s telephone number, including area code) Â Securities registered pursuant to Section 12(b) of the Act: Â Title of each class Â TradingSymbol(s) Â Name of each exchange on which registered Common Stock, par value $0.001 per share Â ARCT Â The NASDAQ Stock Market LLC Â Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated filer â˜ Accelerated filer â˜’ Â Â Â Â Non-accelerated filer â˜ Smaller reporting company â˜’ Â Â Â Â Â Â Â Emerging growth company Â â˜ Â Â Â Â Â If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ Â As of August 2, 2024, the registrant had 27,042,246 shares of voting common stock outstanding. Â Â Â Â ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES Â TABLE OF CONTENTS Â Â Page PART I. FINANCIAL INFORMATION 1 Item 1. Financial Statements (unaudited) 1 Condensed Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 2 Â Condensed Consolidated Statements of Changes in Stockholdersâ€™ Equity for the three and six months ended June 30, 2024 and 2023 3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 4 Notes to Condensed Consolidated Financial Statements 5 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3. Quantitative and Qualitative Disclosures About Market Risk 26 Item 4. Controls and Procedures 26 PART II. OTHER INFORMATION 28 Item 1. Legal Proceedings 28 Item 1A. Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 3. Defaults Upon Senior Securities 28 Item 4. Mine Safety Disclosures 28 Item 5. Other Information 28 Item 6. Exhibits 29 Signatures 32 Â i Â Special Note Regarding Forward-Looking Statements Â This Quarterly Report on Form 10-Q (this â€œQuarterly Reportâ€), including the section entitled â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operations,â€ and the documents incorporated by reference herein may contain express or implied â€œforward-looking statementsâ€ within the meaning of the federal securities laws, Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended (the â€œExchange Actâ€), and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth below under Part II, Item 1A, â€œRisk Factorsâ€ in this Quarterly Report. Except as required by law, we assume no obligation to update these forward-looking statements, whether as a result of new information, future events or otherwise. These statements, which represent our current expectations or beliefs concerning various future events, may contain words such as â€œmay,â€ â€œwill,â€ â€œexpect,â€ â€œanticipate,â€ â€œintend,â€ â€œplan,â€ â€œbelieve,â€ â€œestimateâ€ or other words indicating future results, though not all forward-looking statements necessarily contain these identifying words. Such statements may include, but are not limited to, statements concerning the following: Â â€¢our compliance, and ability to remain in compliance, with the requirements of our collaboration agreements, including our collaboration with Seqirus Inc. (â€œCSL Seqirusâ€); â€¢the anticipated benefits and success of our collaboration agreement with CSL Seqirus related to the licensure of our STARRÃ® mRNA technology and LUNARÃ® lipid-mediated delivery, including our timely receipt of upfront and potential royalty and other payments thereunder; â€¢the continued development activities of the LUNAR-COV19 and LUNAR-FLU programs under our collaboration with CSL Seqirus; â€¢the status, success and benefits of our arrangements with private and governmental entities, some of which are subject to termination for convenience by our counterparties; â€¢our compliance, and ability to remain in compliance, with the stringent requirements of our current and potential government contracts, including our arrangements with the Biomedical Advanced Research and Development Authority, a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services and the Department of Defense; â€¢our plans to conduct and advance any of our research programs; â€¢the initiation, design, cost, timing, progress, enrollment and results of, and our expected ability to undertake certain activities and accomplish certain goals with respect to, our research and development activities, preclinical studies and clinical trials, including those related to our therapeutics pipeline candidates ARCT-810 and ARCT-032; â€¢the potential safety, immunogenicity, efficacy or regulatory approval of any of our product candidates; â€¢the potential safety, immunogenicity, efficacy or regulatory approval of any of our COVID-19 vaccine candidates as a booster or primary vaccination series; â€¢the potential effects and benefits of our technologies and product candidates on their own and in comparison to technologies, drugs or courses of treatment currently available or that may be developed by competitors; â€¢the likelihood that preclinical or clinical data will be predictive of future clinical results or efficacy or safety of a product candidate; â€¢the anticipated timing of enrollment, duration, milestones and announcements of results of clinical trials, and the submission of applications to conduct clinical trials; â€¢the likelihood that clinical data will be sufficient for regulatory approval or completed in time to submit an application for regulatory approval within a particular timeframe; â€¢the likelihood or timing of any regulatory approval, and the likelihood that the marketing approval of ARCT-154 in Japan will be predictive of any future marketing approvals in other countries or for other versions of our LUNAR-COV19 or other product candidates or of any commercial sales; â€¢the potential administration regimen or dosage, or ability to administer multiple doses of, any of our

product candidates; â€¢our ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations, and/or warnings in the label of an approved product candidate; â€¢our plans to develop and commercialize our product candidates; â€¢our ability to successfully commercialize, and our expectations regarding future therapeutic and commercial potential with respect to, our product candidates; â€¢the rate and degree of market acceptance of our product candidates; ii Â â€¢the success of competing therapies that are or may become available; â€¢the size and growth potential of the markets for our product candidates, and our ability to serve those markets and address unmet medical needs; â€¢our ability to obtain and maintain intellectual property protection for our product candidates; â€¢interactions with regulatory authorities in the United States and foreign countries; â€¢our ability to attract and retain experienced and seasoned scientific and management professionals; â€¢the performance of our third-party suppliers and manufacturers, including our ability to scale-up manufacturing levels as necessary; â€¢our strategic alliance partnersâ€™ election to pursue development and commercialization of any programs or product candidates that are subject to our collaboration and license agreements with such partners; â€¢our ability to attract collaborators with relevant development, regulatory and commercialization expertise; â€¢future activities to be undertaken by our strategic alliance partners, collaborators and other third parties; â€¢our ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; â€¢our ability to avoid, settle or be victorious at costly litigation with shareholders, former executives or others, should these situations arise; â€¢our ability to obtain and deploy funding for our operations and to efficiently use our financial and other resources; â€¢our ability to continue as a going concern; and â€¢the accuracy of our estimates regarding future expenses, future revenues, cash flows, capital requirements need for additional financing, and possible sources of revenue. Â These and other forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industryâ€™s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. In addition, historic results of scientific research, preclinical and clinical trials do not guarantee that future research or trials will suggest the same conclusions, nor that historic results referred to herein will be interpreted in the same manner due to additional research, preclinical and clinical trial results or otherwise. The forward-looking statements contained in this Quarterly Report are subject to risks and uncertainties, including those discussed in our other filings with the United States Securities and Exchange Commission (the â€œCommissionâ€). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof unless specifically stated otherwise. Although we currently believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. iii Â PART Iâ€”FINANCIAL INFORMATION Item 1. Financial Statements. ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS Â Â Â June 30,2024 Â Â December 31,2023 Â (in thousands, except par value information) Â (unaudited) Â Â Â Â Assets Â Â Â Â Â Â Â Current assets: Â Â Â Â Â Â Â Cash and cash equivalents Â $ 260,329 Â Â $ 292,005 Â Restricted cash Â Â 55,000 Â Â Â 55,000 Â Accounts receivable Â Â 24,085 Â Â Â 32,064 Â Prepaid expenses and other current assets Â Â 7,594 Â Â Â 7,521 Â Total current assets Â Â 347,008 Â Â Â 386,590 Â Property and equipment, net Â Â 11,182 Â Â Â 12,427 Â Operating lease right-of-use assets, net Â Â 28,533 Â Â Â 28,500 Â Non-current restricted cash Â Â 1,885 Â Â Â 1,885 Â Total assets Â $ 388,608 Â Â $ 429,402 Â Liabilities and stockholdersâ€™ equity Â Â Â Â Â Â Â Current liabilities: Â Â Â Â Â Â Â Accounts payable Â $ 13,905 Â Â $ 5,279 Â Accrued liabilities Â Â 35,450 Â Â Â 31,881 Â Deferred revenue Â Â 42,362 Â Â Â 44,829 Â Total current liabilities Â Â 91,717 Â Â Â 81,989 Â Deferred revenue, net of current portion Â Â 11,344 Â Â Â 42,496 Â Operating lease liability, net of current portion Â Â 26,964 Â Â Â 25,907 Â Other non-current liabilities Â Â â€” Â Â Â 497 Â Total liabilities Â Â 130,025 Â Â Â 150,889 Â Stockholdersâ€™ equity Â Â Â Â Â Â Common stock, $0.001Â par value; 60,000Â shares authorized; issued andoutstanding shares were 27,042Â at June 30, 2024 and 26,828Â at December 31, 2023 Â Â 27 Â Â Â 27 Â Additional paid-in capital Â Â 670,455 Â Â Â 646,352 Â Accumulated deficit Â Â (411,899) Â Â (367,866) Total stockholdersâ€™ equity Â Â 258,583 Â Â Â 278,513 Â Total liabilities and stockholdersâ€™ equity Â $ 388,608 Â Â $ 429,402 Â The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Â ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) Â Â Â Three Months Ended Â Â Six Months Ended Â Â Â June 30, Â Â June 30, Â (in thousands, except per share data) Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Revenue: Â Â Â Â Â Â Â Â Â Â Â Collaboration revenue Â $ 45,976 Â Â $ 9,565 Â Â $ 78,574 Â Â $ 89,294 Â Grant revenue Â Â 3,883 Â Â Â 954 Â Â Â 9,297 Â Â Â 1,510 Â Total revenue Â Â 49,859 Â Â Â 10,519 Â Â Â 87,871 Â Â Â 90,804 Â Operating expenses: Â Â Â Â Â Â Â Â Â Â Â Research and development, net Â Â 58,669 Â Â Â 52,668 Â Â Â 112,242 Â Â Â 104,436 Â General and administrative Â Â 12,316 Â Â Â 13,225 Â Â Â 27,167 Â Â Â 26,987 Â Total operating expenses Â Â 70,985 Â Â Â 65,893 Â Â Â 139,409 Â Â Â 131,423 Â Loss from operations Â Â (21,126) Â Â (55,374) Â Â (51,538) Â Â (40,619) (Loss) gain from foreign currency Â Â (388) Â Â 149 Â Â Â (441) Â Â (179) Gain on debt extinguishment Â Â â€” Â Â Â â€” Â Â Â 33,953 Â Finance income, net Â Â 4,148 Â Â Â 3,252 Â Â Â 8,164 Â Â Â 5,729 Â Net loss before income taxes Â Â (17,366) Â Â (51,973) Â Â (43,815) Â Â (1,116) Provision for income taxes Â Â (150) Â Â 577 Â Â Â 218 Â Â Â 680 Â Net loss Â $ (17,216) Â $ (52,550) Â $ (44,033) Â $ (1,796) Net loss per share, basic and diluted Â $ (0.64) Â $ (1.98) Â $ (1.64) Â $ (0.07) Weighted-average shares outstanding, basic and diluted Â Â 26,967 Â Â Â 26,563 Â Â Â 26,923 Â Â Â 26,557 Â Comprehensive loss: Â Â Â Â Â Â Â Â Â Â Â Net loss Â $ (17,216) Â $ (52,550) Â $ (44,033) Â $ (1,796) Comprehensive loss Â $ (17,216) Â $ (52,550) Â $ (44,033) Â $ (1,796) The accompanying notes are an integral part of these condensed consolidated financial statements. 2 Â ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERSâ€™ EQUITY (unaudited) Â Â Â Â Â Â Â Â Â Â Additional Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-In Â Â Accumulated Â Â Stockholdersâ€™ Â (in thousands) Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balance at December 31, 2023 Â Â 26,828 Â Â $ 27 Â Â $ 646,352 Â Â $ (367,866) Â $ 278,513 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (26,817) Â Â (26,817) Share-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 10,088 Â Â Â â€” Â Â Â 10,088 Â Issuance of common stock upon exercise of stock options Â Â 89 Â Â Â â€” Â Â Â 2,188 Â Â Â â€” Â Â Â 2,188 Â Balance at March 31, 2024 Â Â 26,917 Â Â $ 27 Â Â $ 658,628 Â Â $ (394,683) Â $ 263,972 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (17,216) Â Â (17,216) Share-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 9,424 Â Â Â â€” Â Â Â 9,424 Â Issuance of common stock upon exercise of stock options Â Â 125 Â Â Â â€” Â Â Â 2,403 Â Â Â â€” Â Â Â 2,403 Â Balance at June 30, 2024 Â Â 27,042 Â Â $ 27 Â Â $ 670,455 Â Â $ (411,899) Â $ 258,583 Â Â Â Â Â Â Â Â Â Â Additional Â Â Â Â Â Total Â Â Â Common Stock Â Â Paid-In Â Â Accumulated Â Â Stockholdersâ€™ Â (in thousands) Â Shares Â Â Amount Â Â Capital Â Â Deficit Â Â Equity Â Balance at December 31, 2022 Â Â 26,555 Â Â $ 27 Â Â $ 608,426 Â Â $ (338,141) Â $ 270,312 Â Net income Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 50,754 Â Â Â 50,754 Â Share-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 8,182 Â Â Â â€” Â Â Â 8,182 Â Balance at March 31, 2023 Â Â 26,555 Â Â $ 27 Â Â $ 616,608 Â Â $ (287,387) Â $ 329,248 Â Net loss Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (52,550) Â Â (52,550) Share-based compensation expense Â Â â€” Â Â Â â€” Â Â Â 8,383 Â Â Â â€” Â Â Â 8,383 Â Issuance of common stock upon exercise of stock options Â Â 19 Â Â Â â€” Â Â Â 94 Â Â Â â€” Â Â Â 94 Â Balance at June 30, 2023 Â Â 26,574 Â Â $ 27 Â Â $ 625,085 Â Â $ (339,937) Â $ 285,175 Â The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Â ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Â Â Â Six Months Ended June 30, Â (in thousands) Â 2024 Â Â 2023 Â Operating activities Â Â Â Â Â Â Net loss Â $ (44,033) Â $ (1,796) Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Â Â Â Â Â Â Depreciation and amortization Â Â 1,813 Â Â Â 1,315 Â Share-based compensation expense Â Â 19,512 Â Â Â 16,565 Â Foreign currency transaction loss Â Â 441 Â Â Â 160 Â Gain on debt extinguishment Â Â â€” Â Â Â (33,953) Other non-cash expenses Â Â â€” Â Â Â 502 Â Changes in assets and liabilities: Â Â Â Â Â Â Accounts receivable Â Â 7,979 Â Â Â (35) Prepaid expense and other assets Â Â (73) Â Â 4,712 Â Right-of-use assets Â Â 2,703 Â Â Â 1,992 Â Accounts payable Â Â 8,626 Â Â Â 5,593 Â Accrued liabilities Â Â 2,631 Â Â Â (2,983) Deferred revenue Â Â (33,619) Â Â 24,969 Â Lease liabilities Â Â (1,679) Â Â (2,105) Net cash (used in) provided by operating activities Â Â (35,699) Â Â 14,936 Â Investing activities Â Â Â Â Â Â Â Acquisition of property and equipment Â Â (568) Â Â (1,045) Net cash used in investing activities Â Â (568) Â Â (1,045) Financing activities Â Â Â Â Â Â Â Proceeds from exercise of stock options Â Â 4,591 Â Â Â 94 Â Payments on debt obligations Â Â â€” Â Â Â (27,364) Net cash provided by (used in) financing activities Â Â 4,591 Â Â Â (27,270) Net decrease in cash, cash equivalents and restricted cash Â Â (31,676) Â Â (13,379) Cash, cash equivalents and restricted cash at beginning of the period Â Â 348,890 Â Â Â 393,977 Â Cash, cash equivalents and restricted cash at end of the period Â $ 317,214 Â Â $ 380,598 Â Â Â Six Months Ended June 30, Â Â 2024 Â Â 2023 Â Supplemental disclosure of cash flow information Â Â Â Â Â Â Cash paid for interest Â $ â€” Â Â $ 2,102 Â Non-cash investing activities Â Â Â Â Â Â Non-cash asset disposal Â $ 473 Â Â $ â€” Â Right-of-use assets acquired through operating leases Â $ 2,736 Â Â $ â€” Â Purchase of property and equipment in accounts payable Â $ â€” Â Â $ 577 Â Â Â Â Â Â Â Â Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Â ARCTURUS THERAPEUTICS HOLDINGS INC. AND ITS SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited) Note 1. Description of Business, Basis of Presentation and Summary of Significant Accounting PoliciesDescription of BusinessArcturus Therapeutics Holdings Inc. (the â€œCompanyâ€ or "Arcturus") is a global messenger RNA medicines company focused on the development of infectious disease vaccines and significant addressing unmet medical needs within liver and respiratory rare diseases. The Company became a clinical stage company during 2020 when it announced that its Investigational New Drug (â€œINDâ€) application for ornithine transcarbamylase (â€œOTCâ€) deficiency and its Clinical Trial Application (â€œCTAâ€) for candidate LUNAR-COV19 were approved by applicable health authorities.Basis of PresentationThe accompanying condensed consolidated financial statements include the accounts of Arcturus and its subsidiaries and are unaudited. All intercompany accounts and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (â€œGAAPâ€) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In managementâ€™s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023. These condensed consolidated financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on managementâ€™s knowledge of current events and actions the Company may undertake in the future, actual results may ultimately differ from these estimates and assumptions.Joint Ventures, Equity Method Investments and Variable Interest EntitiesInvestments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. (â€œAxceleadâ€). The Companyâ€™s share of the investee's results is presented as either income or loss from equity-method investment in the accompanying condensed consolidated statements of operations and comprehensive loss. LiquidityThe Company has incurred significant operating losses since its inception. As of June 30, 2024 and December 31, 2023, the Company had an accumulated deficit of $411.9 million and $367.9 million, respectively.The Companyâ€™s activities since inception have consisted principally of research and development activities, general and administrative activities, and raising capital. The Companyâ€™s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Companyâ€™s inception through June 30, 2024, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements, the sale of capital stock, expense reimbursements from government contracts and proceeds from long-term debt. At June 30, 2024, the Companyâ€™s balance of cash and cash equivalents, including restricted cash, was $317.2 million.Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these condensed consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in securing additional funding, that the Companyâ€™s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.5 Â Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Companyâ€™s operations and manage its business in one operating segment, which is the research and development of medical applications for the Companyâ€™s nucleic acid-focused technology.Revenue RecognitionAt contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of Accounting Standards Codification (â€œASCâ€) Topic 808, Collaborative Arrangements (â€œASC 808â€). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606.The Company determines revenue recognition for arrangements within the scope of ASC 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation. The terms of the Companyâ€™s revenue agreements include license fees, upfront payments, development or regulatory milestone payments, profit-sharing arrangements, reimbursement for research and development activities, option exercise fees, drug substance and drug product supply fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur.A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in ASC 606. A contractâ€™s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified. See â€œNote 2, Revenueâ€ for specific details surrounding the Companyâ€™s arrangements. LeasesThe Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has

elected the practical expedient to not separate lease and non-lease components.See â€œNote 9, Commitments and Contingenciesâ€ for specific details surrounding the Companyâ€™s leases.6 Â Research and Development Costs, Net All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), in-process research and development expenses, pre-launch inventory and license agreement expenses. Research and development expenses are presented net of any grants. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed.The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations ("CROs") and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.Pre-Launch InventoryPrior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its condensed consolidated statements of operations and comprehensive loss, in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory.Restricted Cash Restricted cash includes collateral pledged and held at the Companyâ€™s securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association (â€œWells Fargoâ€) (Note 5). At June 30, 2024, such collateral amounted to $55.0 million. Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Companyâ€™s offices. At June 30, 2024 and 2023, the Company had restricted cash of $1.9 million and $2.1 million, respectively, in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term.The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statement of cash flows as of June 30, 2024 and 2023:Â (in thousands) Â June 30, 2024 Â Â June 30, 2023 Â Cash and cash equivalents Â $ 260,329 Â Â $ 323,471 Â Restricted cash Â Â 55,000 Â Â Â 55,000 Â Non-current restricted cash Â Â 1,885 Â Â Â 2,127 Â Total cash, cash equivalents and restrictedÂ Â Â cash shown in the statement of cash flows Â $ 317,214 Â Â $ 380,598 Â Â Net Loss per ShareBasic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the three and six months ended June 30, 2024 were comprised of stock options and restricted stock units. Dilutive shares of common stock for the three and six months ended June 30, 2023 were comprised of stock options. No dividends were declared or paid during the reported periods.Recently Issued Accounting Standards Not Yet Adopted7 Â From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the condensed consolidated financial statements and disclosures. 8 Â Note 2. RevenueThe Company has entered into license agreements and collaborative research and development arrangements with pharmaceutical and biotechnology companies, as well as consulting, related technology transfer, product revenue and government grant agreements. Under these arrangements, the Company is entitled to receive license fees, consulting fees, product fees, technological transfer fees, upfront payments, milestone payments if and when certain research and development milestones, technology transfer milestones or success-based milestones are achieved, royalties on approved product sales and reimbursement for research and development activities. The Companyâ€™s costs of performing these services are included within research and development expenses. The Companyâ€™s milestone payments are typically defined by achievement of certain preclinical, clinical, and commercial success criteria. Preclinical milestones may include in vivo proof of concept in disease animal models, lead candidate identification, and completion of IND-enabling toxicology studies. Clinical milestones may, for example, include successful enrollment of the first patient in or completion of Phase 1, 2 and 3 clinical trials, and commercial milestones are often tiered based on net or aggregate sale amounts. The Company cannot guarantee the achievement of these milestones due to risks associated with preclinical and clinical activities required for development of nucleic acid medicine-based therapeutics and vaccines.The following table presents changes during the six months ended June 30, 2024 in the balances of contract assets and liabilities as compared to what was disclosed in the Companyâ€™s Annual Report.Â (in thousands) Â December 31, 2023 Â Â Additions Â Â Deductions Â Â June 30, 2024 Â Contract Assets: Â Â Â Â Â Â Â Â Â Â Â Â Accounts receivable Â $ 32,064 Â Â $ 55,132 Â Â $ (63,111) Â $ 24,085 Â Contract Liabilities: Â Â Â Â Â Â Â Â Â Â Â Â Deferred revenue Â $ 87,325 Â Â $ 54,252 Â Â $ (87,871) Â $ 53,706 Â The following table summarizes the Companyâ€™s revenues for the periods indicated.Â For the Three MonthsEnded June 30, Â Â For the Six MonthsEnded June 30, Â (in thousands) 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Collaboration Revenue: Â Â Â Â Â Â Â Â Â Â Â Â CSL Seqirus Â $ 45,911 Â Â $ 7,607 Â Â $ 78,292 Â Â $ 85,824 Â Janssen Â â€” Â Â Â 170 Â Â Â â€” Â Â Â 660 Â Other collaboration revenue Â Â 65 Â Â Â 1,788 Â Â Â 282 Â Â Â 2,810 Â Total collaboration revenue Â $ 45,976 Â Â $ 9,565 Â Â $ 78,574 Â Â $ 89,294 Â Grant revenue: Â Â Â Â Â Â Â Â Â Â Â Â BARDA Â $ 3,883 Â Â $ 954 Â Â $ 9,297 Â Â $ 1,510 Â Total grant revenue $ 3,883 Â Â $ 954 Â Â $ 9,297 Â Â $ 1,510 Â The following paragraphs provide information regarding the nature and purpose of the Companyâ€™s most significant collaboration and grant arrangements.9 Â CSL SeqirusOn November 1, 2022, the Company entered into a Collaboration and License Agreement (as amended, the â€œCSL Collaboration Agreementâ€) with Seqirus, Inc., a part of CSL Limited (â€œCSL Seqirusâ€), for the global exclusive rights to research, develop, manufacture, and commercialize vaccines. Under the terms of the CSL Collaboration Agreement, the Company provides CSL Seqirus with an exclusive global license to its mRNA technology (including STARRÂ®) and LUNARÂ® lipid-mediated delivery, along with mRNA drug substance and drug product manufacturing process. CSL Seqirus will lead development and commercialization of vaccines under the collaboration. The collaboration plans to advance vaccines against SARS-CoV-2 (COVID-19), influenza, pandemic preparedness as well as three other respiratory infectious diseases.The Company received a $200.0 million upfront payment and is eligible to receive over $1.3 billion in development milestones if all products are registered in the licensed fields and entitled to potentially receive up to $3.0 billion in commercial milestones based on â€œnet saleâ€ of vaccines in the various fields. In addition, the Company is eligible to receive a 40% net profit share for COVID-19 vaccine products and up to low double-digit royalties for vaccines against flu, pandemic preparedness and three other respiratory pathogens. During the second quarter of 2024, the Company achieved a $17.0 million development milestone related to the CSL Collaboration Agreement which was included in accounts receivable as of June 30, 2024.In evaluating the CSL Collaboration Agreement in accordance with ASC 606, the Company concluded that CSL Seqirus is a customer. The Company identified all promised goods/services within the CSL Collaboration Agreement, and when combining certain promised goods/services, the Company concluded that there are five distinct performance obligations. The nature of the performance obligations consists of delivery of the vaccine license, research and development services for COVID and non-COVID vaccines and regulatory activities for COVID vaccines. For each performance obligation, the Company estimated the standalone selling price based on 1) in the case of the license, the fair value using costs to recreate plus margin method and 2) in the case of research and development services and regulatory activities, cost plus margin for estimated full-time equivalent (â€œFTEâ€) costs, direct costs including laboratory supplies, contractors, and other out-of-pocket expenses for research and development services and regulatory activities. As of June 30, 2024, the transaction price consisted of upfront consideration received and milestones achieved. Additional variable consideration was not included in the transaction price at June 30, 2024 because the Company could not conclude that it is probable that including the variable consideration will not result in a significant revenue reversal.The Company allocated the transaction price to the performance obligations in proportion to their standalone selling price. The vaccine license was recognized at the point in time it was transferred in 2022. The research and development and regulatory activities performance obligations are recognized over a period of time based on the percentage of services rendered using the input method, meaning actual costs incurred divided by total costs budgeted to satisfy the performance obligation. Any consideration related to sales-based royalties will be recognized when the amounts are probable of non-reversal, provided that the reported sales are reliably measurable and the Company has no remaining promised goods/services, as they are constrained and therefore have also been excluded from the transaction price. The revenue recognized in the second quarter of 2024 relates to the license delivered, milestones achieved and services performed through June 30, 2024. Total deferred revenue as of June 30, 2024 and December 31, 2023 for the CSL Collaboration Agreement was $53.7 million and $87.1 million, respectively. During 2023, the Company also received an advance payment of $23.6 million for the manufacturing and supply of ARCT-154 drug product. The advance payment was for specified manufacturing runs of ARCT-154 which include the drug substance utilized, as well as the reservation fees and related manufacturing requirements. The Company concluded that the promise to manufacture and supply ARCT-154 drug product is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The Company recognized $18.0 million in revenue related to this customer option during the second quarter of 2024. No amount related to this customer option remained in deferred revenue as of June 30, 2024.During 2023, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the Company agreed to sponsor and conduct a Phase 1 clinical study in the influenza field. As part of the amendment, the Company received $17.5 million from CSL Seqirus. The amendment also provides for up to $1.5 million in additional payments which are achievable upon meeting certain clinical milestones relating to the Phase 1 clinical study in the influenza field. The Company previously concluded that the expansion of research and development support services under the CSL Collaboration Agreement represented an option that was not a material right. Therefore the Company concluded the promise to sponsor and conduct the Phase 1 clinical study is a separate contract and the sole performance obligation under the new arrangement. During the quarter ended June 30, 2024, the Company recognized $3.0 million related to the performance obligation and the remaining amount of $9.8 million is included in deferred revenue.During the fourth quarter of 2023, the Company received an advance payment of $5.3 million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. During the first quarter of 2024, the Company received an additional advance payment of $5.1 million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. The Company 10 Â concluded that the promise to perform manufacturing activities is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The advance payments are included in deferred revenue as of June 30, 2024 and will be recognized as revenue when the vaccine product is transferred to CSL Seqirus. In March 2024, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the parties agreed to, among other things, adjust (i) the development plans for certain product candidates, (ii) various development milestones related to such product candidates, (iii) provisions of the CSL Collaboration Agreement related to specific royalty payments, (iii) provisions of the CSL Collaboration Agreement related to distributors, and (iv) proprietary payment calculations related to the foregoing. BARDA GrantIn August 2022, the Company entered into a cost reimbursement contract (the â€œBARDA Contractâ€) with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) for an award of up to $63.2 million for the development of a pandemic influenza vaccine using the Company's STARRÂ® self-amplifying mRNA vaccine platform technology. The Company earns grant revenue for performing tasks under the agreement. The Company determined that the BARDA Contract is not in the scope of ASC 808 or ASC 606. Applying International Accounting Standards No. 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, the Company recognizes grant revenue from the reimbursement of direct out-of-pocket expenses, overhead allocations and fringe benefits for research costs associated with the grant. The costs associated with these reimbursements are reflected as a component of research and development expense in the Companyâ€™s condensed consolidated statements of operations and comprehensive income (loss).The Company recognized $3.9 million and $1.0 million of revenue during the three months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, the remaining available funding net of revenue earned was $44.5 million. Note 3. Fair Value MeasurementsThe Company establishes the fair value of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure fair value.The three levels of the fair value hierarchy are as follows:Level 1: Quoted prices in active markets for identical assets or liabilities.Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.Level 3: Unobservable inputs in which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect those that a market participant would use.The carrying value of cash, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values due to their relative short maturities.As of June 30, 2024 and December 31, 2023, all assets measured at fair value on a recurring basis consisted of cash equivalents and money market funds, which were classified within Level 1 of the fair value hierarchy. The fair value of these financial instruments was measured based on quoted prices. Note 4. Balance Sheet DetailsProperty and equipment, net balances consisted of the following:Â (in thousands) Â June 30, 2024 Â Â December 31, 2023 Â Research equipment Â $ 16,784 Â Â $ 16,046 Â Computers and software Â Â 1,131 Â Â Â 1,275 Â Office equipment and furniture Â Â 703 Â Â Â 958 Â Leasehold improvements Â Â 2,644 Â Â Â 2,655 Â Construction in progress Â Â â€” Â Â Â 233 Â Total Â Â 21,262 Â Â Â 21,167 Â Less accumulated depreciation and amortization Â Â (10,080) Â Â (8,740) Property and equipment, net Â $ 11,182 Â Â $ 12,427 Â Â 11 Â Â Depreciation and amortization expense was $0.9 million and $1.8 million for the three and six months ended June 30, 2024, respectively, and $0.7 million and $1.3 million for the three and six months ended June 30, 2023, respectively. Construction in progress is primarily comprised of research equipment not yet placed in service.Accrued liabilities consisted of the following:Â (in thousands) Â June 30, 2024 Â Â December 31, 2023 Â Accrued compensation Â $ 9,206 Â Â $ 5,918 Â Cystic Fibrosis Foundation liability Â Â 6,870 Â Â Â 7,633 Â Income tax payable Â Â â€” Â Â Â 641 Â Current portion of operating lease liability Â Â 3,917 Â Â Â 4,309 Â Clinical trial accruals Â Â 968 Â Â Â 2,333 Â Vinbiocare contractual liabilities Â Â 2,514 Â Â Â 2,514 Â Other accrued research and development expenses Â Â 11,975 Â Â Â 8,533 Â Total Â $ 35,450 Â Â $ 31,881 Â Â Note 5. DebtWells Fargo Credit AgreementThe Companyâ€™s wholly-owned subsidiary, Arcturus Therapeutics, Inc. (â€œArcturus Therapeuticsâ€) entered into a credit agreement with Wells Fargo Bank on April 21, 2023, and amended on June 26, 2024, whereby Wells Fargo will make a $50.0 million revolving credit line available to the Company (the â€œLoanâ€) and each draw on the Loan evidenced by a revolving line of credit note (the â€œNoteâ€). Borrowings under the agreement will bear interest at a rate of 1.00% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Note), with â€œSOFRâ€ being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If an Event of Default (as defined in the agreement) occurs, then all Loans shall bear interest at a rate equal to 2.00% above the interest rate applicable immediately prior to the occurrence of the Event of Default. The term of the agreement was originally two years, with an option for one-year renewals subject to Wells Fargo approval and Arcturus Therapeutics furnishing to Wells Fargo a non-refundable commitment fee equal to 0.25% of the Loan amount for each such renewal. There is no penalty for terminating the facility prior to the maturity date of the Note. As collateral, the Company has agreed to pledge $55.0 million in cash to be held at the Companyâ€™s securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement. In June 2024, Arcturus Therapeutics and Wells Fargo entered into an amendment to the Note, whereby the term of the Note was extended by one year to April 2026. No borrowings were outstanding as of June 30, 2024. Note 6. Stockholdersâ€™ EquityNet Loss per Share Potentially dilutive securities that were not included in the calculation of diluted net loss per share for the three and six months ended June 30, 2024 as they were anti-dilutive totaled 1.1 million and 1.3 million, respectively, and 1.0 million and 0.8 million for the three and six months ended June 30, 2023, respectively. 12 Â Sales AgreementOn December 23, 2022, the Company entered into a Controlled Equity Offeringâ„¢ Sales Agreement, which was amended on August 7, 2023 (as amended, the â€œSales Agreementâ€) with Cantor Fitzgerald & Co. (â€œCantorâ€),Wells Fargo Securities, LLC (â€œWells Fargo Securitiesâ€), and William Blair & Company, L.L.C. (â€œWilliam Blairâ€) relating to shares of the Company's common stock. In accordance with the terms of the Sales Agreement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $200,000,000 from time to time through Cantor, Wells Fargo Securities, or William Blair, each acting as the Company's sales agent. During the period ended June 30, 2024 the Company did not offer or sell any shares of common stock pursuant to the Sales Agreement. Note 7. Share-Based Compensation ExpenseIn June 2024 at the Companyâ€™s 2024 Annual Meeting of

Stockholders (the "2024 Annual Meeting"), the stockholders of the Company approved an amendment to the Companyâ€™s 2019 Omnibus Equity Incentive Plan (as amended, the â€œ2019 Planâ€) which, among other things, increased the aggregate number of shares authorized for use in making awards to eligible persons under the 2019 Plan by 2,000,000 shares, for a total of up to 10,750,000 shares available for issuance. As of June 30, 2024, following the 2024 Annual Meeting, a total of 2,236,360 shares remain available for future issuance under the 2019 Plan, subject to the terms of the 2019 Plan. In October 2021, the Company adopted the 2021 Inducement Equity Incentive Plan which covers the award of up to 1,000,000 shares of common stock (the â€œ2021 Planâ€) effective as of October 15, 2021. Approval of the Companyâ€™s stockholders is not required as a condition to the effectiveness of the 2021 Plan for so long as the plan is in compliance with applicable Nasdaq inducement plan rules. In April 2022, the compensation committee of the Companyâ€™s board of directors approved a proposal to reduce the total number of shares available for future issuance under the 2021 Plan to 130,000. As of June 30, 2024, a total of 124,697 shares remain available for future issuance under the 2021 Plan, subject to the terms of the 2021 Plan.Â Stock OptionsShare-based compensation expense included in the Companyâ€™s condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023 was as follows: Â Â Â For the Three MonthsEnded June 30, Â Â Â For the Six MonthsEnded June 30, Â (in thousands) Â 2024 Â Â Â 2023 Â Â Â 2024 Â Â Â 2023 Â Â Research and development Â $ 4,378 Â Â Â $ 3,741 Â Â Â $ 9,180 Â Â Â $ 7,249 Â Â General and administrative Â Â 5,046 Â Â Â Â 4,642 Â Â Â Â 10,332 Â Â Â Â 9,316 Â Â Total Â $ 9,424 Â Â Â $ 8,383 Â Â Â $ 19,512 Â Â Â $ 16,565 Â Â Note 8. Income TaxesThe Company is subject to taxation in the United States and various states. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate is due to federal and state income tax expense offset by valuation allowance on the Company's deferred tax assets. For the three and six months ended June 30, 2024, the Company recorded $(0.2) million and $0.2 million of income tax expense, respectively. For the three and six months ended June 30, 2023, the Company recorded $0.6 million and $0.7 million of income tax expense, respectively. No tax benefit was provided for losses incurred in United States because those losses are offset by a full valuation allowance. Note 9. Commitments and Contingencies Cystic Fibrosis Foundation AgreementOn September 25, 2023, the Company amended its Development Program Letter Agreement, dated May 16, 2017 and as amended July 13, 2018 and August 1, 2019, with the Cystic Fibrosis Foundation (â€œCFFâ€). Pursuant to the amendment, CFF increased the amount it will award to advance LUNAR-CF to $24.6 million from approximately $15.6 million and the Company agreed to incur at least $15.0 million toward activities under the research plan. Total contra expense of $0.8 million was recognized during the three and six months ended June 30, 2024. For the three and six months ended June 30, 2023, the Company recognized no contra expense 13 Â related to the agreement. As of June 30, 2024 and December 31, 2023, $6.9 million and $7.6 million, respectively, remained in accrued liabilities.LeasesIn October 2017, the Company entered into a non-cancellable operating lease agreement for office space adjacent to its previously occupied headquarters. The commencement of the lease began in March 2018 and the lease extends for approximately 84 months from the commencement date with a remaining lease term through March 2025. Monthly rental payments are due under the lease and there are escalating rent payments during the term of the lease. The Company is also responsible for its proportional share of operating expenses of the building and common areas. In conjunction with the new lease, the Company received free rent for four months and received a tenant improvement allowance of $0.1 million. In March 2024, the Company negotiated with the lessor to extend the lease through March 2027.The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $0.1 million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.In February 2020, the Company entered into a second non-cancellable operating lease agreement for office space near its current headquarters. The lease extended for 13 months from the commencement date and included a right to extend the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Companyâ€™s headquarters. In January 2024, the Company vacated this office space with no intention of operating out of the location in the future. Because Arcturus was still engaged in the lease for the property and obligated to make the remaining lease payment through March 31, 2025, the Company recorded an impairment loss in the amount of $1.3 million during the three months ended March 31, 2024, as it would not receive any future economic benefit from the lease. In July 2024, the Company terminated the existing lease agreement, in accordance with its terms, thereby ending their contractual obligation to pay for premise. In September 2021, the Company entered into a third non-cancellable lease agreement for office, research and development, engineering and laboratory space near its current headquarters, and such lease term commenced during the second quarter of 2022. The initial term of this lease extends ten years and eight months from the date of possession, and the Company has the right to extend the term of the lease for an additional five-year period. When the lease term was determined for the operating lease right-of-use assets and lease liabilities, the extension option for the lease was not included. The lease has a monthly base rent ranging from $0.3 million to $0.4 million which escalates over the lease term. The Company received a free rent period of four months and also pays for various operating costs, including utilities and real property taxes. The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $2.0 million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.Operating lease right-of-use asset and liability on the condensed consolidated balance sheets represent the present value of remaining lease payments over the remaining lease terms. The Company does not allocate lease payments to non-lease components; therefore, payments for common-area-maintenance and administrative services are not included in the operating lease right-of-use asset and liability. The Company uses its incremental borrowing rate to calculate the present value of the lease payments, as the implicit rate in the lease is not readily determinable.As of June 30, 2024, the remaining payments of the operating lease liability were as follows:Â (in thousands) Â Remaining Lease Payments Â 2024 Â $ 2,838 Â 2025 Â Â 5,019 Â 2026 Â Â 5,274 Â Thereafter Â Â 23,703 Â Total remaining lease payments Â Â 36,834 Â Less: imputed interest Â Â (5,953) Total operating lease liabilities Â $ 30,881 Â Weighted-average remaining lease term Â Â 7.5 Â Weighted-average discount rate Â Â 4.8 % Â Operating lease costs consist of the fixed lease payments included in operating lease liability and are recorded on a straight-line basis over the lease terms. Operating lease costs were $1.5 million and $2.9 million for the three and six months ended June 30, 2024, respectively, and $1.4 million and $2.8 million for the three and six months ended June 30, 2023, respectively. 14 Â Note 10. Related Party Transactions See â€œNote 1, Joint Ventures, Equity Method Investments and Variable Interest Entitiesâ€ for specific details surrounding the Companyâ€™s agreement with Axcelead to form the joint venture entity, ARCALIS, Inc. Â 15 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations. The following is a discussion of the financial condition and results of operations of Arcturus Therapeutics Holdings Inc. for the three and six month periods ended June 30, 2024. Unless otherwise specified herein, references to the â€œCompany,â€ â€œArcturus,â€ â€œewe,â€ â€œourâ€ and â€œusâ€ mean Arcturus Therapeutics Holdings Inc. and its consolidated subsidiaries. You should read the following discussion and analysis together with the interim condensed consolidated financial statements and related notes included elsewhere herein. For additional information relating to our managementâ€™s discussion and analysis of financial conditions and results of operations, please see our Annual Report on Form 10-K for the year ended December 31, 2023 (the â€œ2023 Annual Reportâ€), which was filed with the U.S. Securities and Exchange Commission (the â€œCommissionâ€) on March 14, 2024. Unless otherwise defined herein, capitalized words and expressions used herein shall have the same meanings ascribed to them in the 2023 Annual Report. This report includes forward-looking statements which, although based on assumptions that we consider reasonable, are subject to risks and uncertainties which could cause actual events or conditions to differ materially from those currently anticipated and expressed or implied by such forward-looking statements. You should read this report and the documents that we reference in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect. You should also review the factors and risks we describe in the reports we will file or submit from time to time with the Commission after the date of this report. Overview We are a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. In addition to our messenger RNA (â€œmRNAâ€) platform, our proprietary lipid nanoparticle (â€œLNPâ€) delivery system, LUNARÂ®, may enable multiple nucleic acid medicines. Our proprietary self-amplifying mRNA technology (STARRÂ® technology) provides a longer-lasting and broader response at lower dose levels than conventional mRNA. In 2023, our COVID-19 vaccine, ARCT-154 (also referred to as KostaiveÂ®), received marketing authorization approval in Japan and became the worldâ€™s first approved self-amplifying RNA (sa-mRNA) vaccine. We are leveraging our proprietary LUNAR platform and our nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. We continue to expand this platform by adding new innovative delivery solutions that allow us to expand our discovery efforts. Our proprietary LUNAR technology is intended to address the major hurdles in RNA drug development, namely the effective and safe delivery of RNA therapeutics to disease-relevant target tissues. We believe the versatility of our platform to target multiple tissues, its compatibility with various nucleic acid therapeutics, and our expertise in developing scalable manufacturing processes can allow us to deliver on the next generation of nucleic acid medicines. Â 16 Â Business Updates Vaccine Collaboration with CSL Seqirus In November 2022, we entered into a Collaboration and License Agreement (as amended, the â€œCSL Collaboration Agreementâ€) with Seqirus, Inc. (â€œCSL Seqirusâ€), a part of CSL Limited, and one of the worldâ€™s leading influenza vaccine providers, for global exclusive rights to research, develop, manufacture and commercialize self-amplifying mRNA vaccines against COVID-19, influenza and three other respiratory infectious diseases and global non-exclusive rights to pandemic pathogens. The CSL Collaboration Agreement became effective on December 8, 2022. The collaboration combines CSL Seqirusâ€™ established global vaccine commercial and manufacturing infrastructure with Arcturusâ€™ manufacturing expertise and innovative STARR self-amplifying mRNA vaccine and LUNAR delivery platform technologies. Under the framework of our collaboration with CSL Seqirus, we continue the development of the COVID-19 vaccine to establish a differentiated platform and address routine recommendations for periodic vaccine composition updates in a timely manner. In November 2023, ARCT-154, our self-amplifying RNA (sa-mRNA) vaccine, received marketing authorization approval from the Japanese Ministry of Health, Labour and Welfare for use as a primary immunization and booster in Japan. The approval was based on positive clinical data from several ARCT-154 studies, including the pivotal 19,000 subject efficacy, safety and immunogenicity study performed in Vietnam as well as the pivotal Phase 3 booster study in Japan. In May 2024, we announced that Nature Communications published results from the 19,000 subject study performed in Vietnam, with results demonstrating that two 5Âµg doses of ARCT-154 were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19. The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) is currently reviewing a partial change application to update our COVID-19 vaccine (KostaiveÂ®) with the JN.1 Variant of Concern. The European Medicines Agency (EMA) is currently reviewing a marketing authorization application for ARCT-154. The review procedure started on August 17, 2023. We continue to collect data from the various ongoing studies described below. Key Updates on Our COVID Collaboration Program Pivotal Phase 3 Non-Inferiority Study of ARCT-154 in Japan Meiji Holdings Co., Ltd. (â€œMeijiâ€) sponsored a randomized, multicenter, Phase 3, observer-blind, active-controlled comparative study to evaluate the safety and immunogenicity of a booster dose of ARCT-154 and to evaluate the non-inferiority of ARCT-154 over COMIRNATY (Monovalent, Original strain). The study targeted a total of 780 adult participants, with half in the ARCT-154 group and half in a comparator group, and completed enrollment with 828 participants in February 2023. As previously announced, the study met all primary and secondary immunogenicity endpoints, including a secondary pre-defined superiority assessment over COMIRNATY (Omicron BA.4/5 strain). Overall, the safety and immunogenicity results of the study support the favorable benefit/risk profile of the ARCT-154 vaccine when administered as a booster dose in adult individuals who previously received other mRNA COVID-19 vaccines. On February 1, 2024, the journal Lancet Infectious Diseases published the article â€¯Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT154) versus BNT162b2â€™ (https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00060-4/fulltext), with 6-month follow-up results from this study. These additional data demonstrate the extended persistence of neutralizing antibodies after ARCT-154 compared with conventional mRNA vaccine in the clinical setting, indicating longer-lasting immunity and implying a longer duration of protection by ARCT-154. Phase 3 Study of Bivalent Version of COVID-19 Vaccine Candidate in Japan On September 29, 2023, Meiji initiated an additional Phase 3 clinical study with a bivalent version of our COVID-19 vaccine candidate (ARCT-2301, which combines ancestral strain, ARCT-154 and Omicron BA.4/5) to further support immunogenicity and safety data for our self-amplifying mRNA platform, which may facilitate the timely release of future seasonal updates of our COVID-19 vaccine against evolving variants of concern. On March 19, 2024, Meiji announced that the bivalent vaccine met the primary endpoint (non-inferiority) in the study. The study enrolled 930 healthy adults and individuals with comorbidities, who previously received three to five doses of mRNA COVID-19 vaccines, including the last booster at least three months prior to recruitment. The study compares the investigational vaccine (ARCT-2301) and COMIRNATY (ancestral strain and BA.4/5), to evaluate safety and immunogenicity between observer-blind groups. Both the geometric mean titer (GMT) ratio and seroresponse rate (SRR) difference of neutralizing antibodies against SARS-CoV-2 (Omicron strain BA.4/5) met non-inferiority criteria. In addition, the superiority of 17 Â ARCT-2301 to COMIRNATY (BA.4/5) was confirmed for both SARS-CoV-2 (Omicron strain BA.4/5 and Wuhan strain). There were no causally-associated severe or serious adverse events with ARCT-2301. The results of this study of the bivalent version of our COVID-19 vaccine candidate were not required for approval of ARCT-154 in Japan but will facilitate the timely release of future seasonal updates of the COVID-19 vaccine. Â Figure: Geometric mean titers (GMT) of surrogate neutralizing antibodies at Days 1 (baseline) and 29, and geometric mean-fold rises (GMFR) in titers from Day 1 to Day 29; B) GMT Ratio; C) seroresponse rates (SRR) at Day 29; D) SRR Difference â€“ Study ARCT-2301-J01. Note: GMT â€“ Geometric Mean Titer; SRR â€“ seroresponse rate. All values are from the Per Protocol Subset 1 (PPS-1) and are shown with 95% confidence intervals in parentheses. Solid circles (â—) represent the Wuhan variant, open circles (â—‹) represent the Omicron BA.4/5 variant, and open squares (â˜) represent the Omicron XBB.1.5 variant. Vertical lines represent the threshold for achieving the non-inferiority and superiority comparisons of ARCT-154 to Comirnaty. Bivalent ARCT-2301, when administered intramuscularly as a booster dose in subjects who had received three to five doses of authorized mRNA COVID-19 vaccines at least three months before the recruitment, demonstrated immunological superiority over the comparator vaccine (COMIRNATYÂ® bivalent: Wuhan strain/Omicron strain BA.4/5), as measured by GMT ratios and seroresponse rates differences for both vaccine strains (prototype Wuhan strain and Omicron BA.4/65 variant). In addition, ARCT-2301 induced a higher immune response against the epidemiologically dominant Omicron XBB.1.5 variant. Phase 3 Study in Southern Hemisphere of Monovalent XBB1.5 COVID-19 Vaccine Candidate In March 2024, Arcturus and CSL Seqirus initiated a Phase 3 pivotal study with the ARCT-2303 candidate vaccine containing the XBB1.5 Omicron variant. The purpose of this study is to generate additional immunogenicity and safety data in multiple ethnicities to support regulatory filings globally. In addition, the study will assess the co-administration of the ARCT-2303 vaccine 18 Â with the age-appropriate seasonal influenza vaccines. Overall, 1,499 young and older adults were recruited in the study in Australia, Costa Rica, Honduras and the Philippines. The results of this study are expected in the fourth quarter of 2024. Flu Collaboration Program Updates LUNAR-qsFLU (Quadrivalent Seasonal Influenza) Our LUNAR-qsFLU (qs; quadrivalent seasonal) program, now exclusively licensed to CSL Seqirus, has the objective of producing a safe and effective seasonal influenza vaccine candidate with significant advantages over the traditional egg-based inactivated quadrivalent vaccine. Inaccurate predictions of circulating influenza strains as well as mutations due to adaptation in egg-grown vaccines can substantially reduce efficacy on a year-to-year basis. We believe the ability of mRNA platforms to nimbly adapt to new viral strains should help improve efficacy. In addition, we do not expect mRNA vaccines to face the challenge from mutations common to egg-grown vaccines. LUNAR-qsFLU has been designed to take advantage of our expertise in both LUNAR lipid delivery systems and our STARR self-amplifying mRNA technology. This platform has been shown to deliver effective protection against COVID-19 and has been optimized to elicit robust immunogenicity with acceptable reactogenicity at a lower dose than conventional mRNA vaccines with the objective of creating a highly effective influenza vaccine for use in general and high-risk populations. Working with CSL Seqirus, we generated a comprehensive non-clinical data package to support the initiation of the Phase 1 clinical trial with a novel influenza mRNA vaccine candidate. A Phase 1 dose-finding safety and immunogenicity study was initiated in January 2024 in Australia. As of August 1, 2024, 100 healthy young adults and 35 older adults were recruited in the study and received one of four dose levels of the study vaccine or a licensed influenza vaccine. Pandemic Influenza Program Our LUNAR-pandFLU program continues to progress under the award from the Biomedical Advanced Research and Development Authority (â€œBARDAâ€) that we obtained in 2022. The program includes all non-clinical, manufacturing, and regulatory support to advance a vaccine to protect against disease caused by H5N1 highly-pathogenic avian influenza. A pre-IND meeting was granted and Written Response Only (â€œWROâ€) was received for integration into future development plans. Nonclinical safety studies have been completed that will enable the Phase 1 clinical trial. Enrollment for a Phase 1 clinical trial designed to evaluate the safety and immunogenicity of ARCT-2304 (LUNAR-pandFLU candidate vaccine) is expected to begin before the end of 2024. Key Updates on Arcturus-Owned mRNA Therapeutic Development Candidates The following chart represents our current pipeline of Arcturus-owned mRNA therapeutic candidates: Â Â â€¢LUNAR-OTC/ARCT-810 oA Phase 1b study in stable OTC-deficient adults completed dosing in the United States in August 2023. The

trial was designed to assess safety, tolerability and pharmacokinetics of a single dose of ARCT-810, as well as exploratory biomarkers of drug activity. The Phase 1b study was a single ascending dose, placebo-controlled study that enrolled 16 adults with mild OTCD. ARCT-810 was generally safe and well tolerated at doses ranging from 0.1-0.5mg/kg and no severe adverse events were observed. Sporadic infusion-related reactions (IRRs) could be managed with symptomatic treatment and appear to be less frequent with slower infusion rates. In plasma, ARCT-810 mRNA could be detected up to 4 weeks, while ionizable lipid was no longer measurable after 48 hours, indicating rapid degradation of the lipid nanoparticle that was utilized to deliver ARCT-810 mRNA. oA Phase 2 double-blind multiple-dose study of ARCT-810 in OTC-deficient adolescents and adults in the European Union and United Kingdom initiated dosing in December 2022. In July 2024, the Phase 2 study completed enrollment of eight subjects, including adolescents and adults, at the 0.3 mg/kg dose level. The participants in this 19 Â group are randomized 3:1 to receive 6 doses of ARCT-810 or placebo administered every 14 days. Treatment and follow-up are ongoing. oWe are expanding the Phase 2 clinical program of ARCT-810 by enrolling patients in the U.S. with more serious disease. Patient screening has been initiated in the study. â€¢LUNAR-CF/ARCT-032 â€“ Our program for cystic fibrosis is being supported in part by the Cystic Fibrosis Foundation (â€œCFFâ€). In 2023 we initiated and successfully achieved the recruitment target in a Phase 1 single ascending dose study of ARCT-032 (LUNAR-CF), our mRNA therapeutic candidate for cystic fibrosis (CF), in 32 healthy participants (eight subjects in each of four dose cohorts). In August 2023 we received regulatory approval of a protocol amendment to transition to a Phase 1b clinical study of ARCT-032 in up to eight adults with CF, with each participant receiving two administrations of ARCT-032. oOn June 7, 2024, we presented Phase 1 interim data of ARCT-032 at the 47th Annual European Cystic Fibrosis Conference. ARCT-032 was generally safe and well tolerated with no serious or severe adverse events in healthy volunteers and in the first four dosed participants with CF in Phase 1b, of which one had 2 Class I mutations and the other three had F508del mutations and were being treated with TrikaftaÂ®. oWe submitted an IND application at the end of July 2024 for an ARCT-032 Phase 2 multiple ascending dose study designed to identify a safe and effective dose in Class I (null) and other CF participants who do not benefit from CFTR modulators. This study is supported by safety and tolerability data collected in healthy volunteers (N = 32) and the ongoing two-administration Phase 1b study. No serious adverse events (SAEs) have been observed in any clinical trial participants to date. No febrile reactions have been observed within the target dose range of the planned Phase 2 study. The Phase 1b study has completed dosing and follow-up visits. Of the seven total CF participants in Phase 1b, six are receiving CFTR modulator treatment while one subject has Class I mutations and therefore does not benefit from modulator therapy. The Class I CF subject had low lung function at baseline (ppFEV1 below 50%) and showed an improvement of 4% in ppFEV1 on Day 8, after receiving two well-tolerated administrations, with no febrile reactions.. oIn February 2024, the European Commission (EC), based on a positive opinion issued by the European Medicines Agency (EMA), granted Orphan Medicinal Product Designation for ARCT-032 to treat CF. ARCT-032 was granted Rare Pediatric Disease Designation in October 2023, and Orphan Drug Designation in November 2023 by the FDA. Â Updates on Collaboration Agreements CSL Collaboration Agreement. In March 2024, we entered into Amendment Number Two to Collaboration and License Agreement between CSL and the Company to reflect updates to the development program and other adjustments consistent with our prior disclosures regarding the Collaboration and License Agreement (â€œAmendment Number Twoâ€). Amendment Number Two, among other things, adjusts (i) the development plans for certain product candidates, (ii) various development milestones related to such product candidates, (iii) provisions of the CSL Collaboration Agreement related to specific royalty payments, (iii) provisions of the CSL Collaboration Agreement related to distributors, and (iv) proprietary payment calculations related to the foregoing. Â Updates on Research and Platform Activities We continue to conduct exploratory platform development activities, including the evaluation of genome editing, and new targeting approaches, where our LUNARÂ® and STARRÂ® platforms could potentially be useful for identification and development of additional products for our portfolio. Discovery Programs â€“ Vaccine Programs (Lyme Disease and Gonorrhea) Based on the clinical and regulatory validation of LUNAR and STARR technologies provided by the approval of ARCT-154, our next-generation vaccine for COVID-19, we have initiated new vaccine discovery programs for Lyme disease and gonorrhea. The new discovery programs rely on the evidence of superior immunogenicity, durability, and breadth of immune response compared to conventional mRNA vaccines, as observed in the COVID-19 program. Lyme disease is a bacterial infection and is the most common vector-borne disease in the United States. Infection can spread to joints, the heart and the nervous system. Gonorrhea is a sexually transmitted disease (STD) that can infect the mucous membranes of the reproductive tract. It is the second most commonly reported bacterial sexually transmitted infection in the United States. We selected these diseases based on high unmet medical needs, good understanding of the path forward in vaccine target selection, and demonstration of proof of concept, as well as platform advantages that may be translated in a favorable vaccine product. Updates on Supply and Manufacturing 20 Â We have built a global manufacturing footprint with our partners, including Aldevron, Catalent, Recipharm, Polymun and ARCALIS. With such collaborations we have established an Integrated Global Supply Chain Network with our primary and secondary sourcing contract development & manufacturing organizations (CDMOs) based in the United States, EU and Asia for producing critical raw materials, drug substance, and packaged finished product. As the market for COVID vaccines shifts from multi-dose vial formats to lower and single-dose vial formats, we continue, with our collaborator CSL Seqirus, to evaluate and advance manufacturing process and capabilities and technology transfers, and prepare for stockpiling and commercialization of COVID vaccines. Results of Operations The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and related notes appearing elsewhere in this Report and our audited financial statements and related notes for the year ended December 31, 2023. Our historical results of operations and the year-to-year comparisons of our results of operations that follow are not necessarily indicative of future results. Revenue We enter into arrangements with pharmaceutical and biotechnology partners and government agencies that may contain upfront payments, license fees for research and development arrangements, research and development funding, milestone payments, option exercise and exclusivity fees, royalties on future sales, consulting fees and payments for technology transfers. The following table summarizes our total revenues for the periods indicated: Â Â Â Three Months Ended June 30, Â Â 2023 to 2024 (in thousands) Â 2024 Â Â 2023 Â Â $ change Â Â % change Revenue Â $ 49,859 Â Â $ 10,519 Â Â $ 39,340 Â Â * * Greater than 100% Revenue increased by $39.3 million during the three months ended June 30, 2024 as compared to the three months ended June 30, 2023. The increase was primarily attributable to the receipt of a milestone payment from CSL pursuant to the CSL agreement as $45.9 million total revenue was recognized during the second quarter of 2024, compared to $7.6 million total revenue related to CSL during the second quarter of 2023, resulting in an increase of $38.3 million primarily due to the timing and value of milestone achievements and the recognition of revenue from a supply agreement during the current quarter. Additionally, there was an increase in revenue of $2.9 million related to the BARDA Contract during the second quarter of 2024 as compared to the second quarter of 2023. The total increase in revenue was offset by a $1.9 million decrease in revenue recognized from other agreements during the second quarter of 2024 as compared to the second quarter of 2023 due to lower activity or completion of collaboration agreements. Â Â Â Six Months Ended June 30, Â Â 2023 to 2024 Â (in thousands) Â 2024 Â Â 2023 Â Â $ change Â Â % change Â Revenue Â $ 87,871 Â Â $ 90,804 Â Â $ (2,933) Â Â -3.2 % Â Revenue decreased by $2.9 million during the six months ended June 30, 2024 as compared to the six months ended June 30, 2023. We received revenue under the CSL agreement of $78.3 million during the six months ended June 30, 2024, compared to $85.8 million total revenue related to CSL during the six months ended June 30, 2023, resulting in a decrease of $7.5 million primarily due to the timing and value of milestone achievements and the achievement of a conditional payment during the first half of 2023, offset by the recognition of revenue from a supply agreement during the current year. Additionally, there was a decrease of $3.2 million in revenue recognized under other agreements during the six months ended June 30, 2024 as compared to the six months ended June 30, 2023 due to lower activity or completion of collaboration agreements. The total decrease in revenue was offset by a $7.8 million increase in revenue recognized from the BARDA Contract during the six months ended June 30, 2024 as compared to the six months ended June 30, 2023. Â Our operating expenses consist of research and development and general and administrative expenses. Â Â Â Three Months Ended June 30, Â Â 2023 to 2024 Â Â Six Months Ended June 30, Â Â 2023 to 2024 Â (in thousands) Â 2024 Â Â 2023 Â Â $ change Â Â % change Â Â 2024 Â Â 2023 Â Â $ change Â Â % change Â Operating expenses: Â Â Â

(as defined in the credit agreement) occurs, then all Wells Fargo Loans shall bear interest at a rate equal to 2.00% above the interest rate applicable immediately prior to the occurrence of the Event of Default. As of June 30, 2024, no borrowings were made against the Wells Fargo Note. The term of the agreement was originally two years, with an option for one-year renewals subject to Wells Fargo approval and the Company furnishing to Wells Fargo a non-refundable commitment fee equal to 0.25% of the Wells Fargo Loan amount for each such renewal. In June 2024, Arcturus Therapeutics and Wells Fargo entered into an amendment to the Note, whereby the term of the Note was extended by one year to April 2026. There is no penalty for terminating the agreement. There is no penalty for terminating the facility prior to the maturity date of the Wells Fargo Note. As collateral, the Company has agreed to pledge $55.0 million in cash to be held at the Companyâ€™s securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement. Grant from the Biomedical Advanced Research and Development Authority On August 31, 2022, we entered into a cost reimbursement contract (the â€œBARDA Contractâ€) with the Biomedical Advanced Research and Development Authority (â€œBARDAâ€), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to support the development of a low-dose pandemic influenza candidate based on our proprietary self-amplifying messenger RNA-based vaccine platform. The BARDA Contract is to support our non-clinical and pre-clinical development, early-stage clinical development through Phase 1, and associated drug product manufacturing, regulatory and quality-assurance activities over a period of three years. It provides for reimbursement by BARDA of our permitted costs up to $63.2 million. Vinbiocare Agreement During 2021, we entered into a technology license and technical support agreement and the framework drug substance supply agreement with Vinbiocare, a member of Vingroup Joint Stock Company (collectively, the â€œVinbiocare License & Supply Agreementsâ€), whereby we would provide technical expertise and support services to Vinbiocare to assist in the build out of an mRNA drug product manufacturing facility in Vietnam. We received an upfront payment in aggregate of $40.0 million as part of the Vinbiocare License and Supply Agreements. In October 2022, in association with the termination of the Vinbiocare License and Supply Agreements, we signed the Vinbiocare Support Agreement with Vinbiocare which continues Vinbiocareâ€™s clinical obligations and reserved a portion of the original $40.0 million upfront payment received from the License and Supply Agreements to be paid over the future periods. The Vinbiocare Support Agreement requires us to pay to Vinbiocare certain limited payments, including upon the occurrence of specified events through the first quarter of 2025. Vinbiocare is also eligible to receive a single digit percentage of amounts received by Arcturus on net sales, if any, of ARCT-154 (or next-generation COVID vaccine) up to a capped amount. General Financial Resources A portion of our current cash balance is expected to be utilized during fiscal year 2024 to fund (i) advances to our LUNAR-CF program in clinical trials, (ii) the continued Phase 2 trial of ARCT-810, our LUNAR-OTC candidate, (iii) expenses incurred prior to customer payments under the CSL Collaboration Agreement and BARDA Contract and (iv) continued exploratory activities related to our platform and other general administrative activities. Our future capital requirements are difficult to forecast and will depend on many factors that are out of our control. If we are unable to maintain sufficient financial resources, our business, financial condition and results of operations will be materially and adversely affected. There can be no assurance that we will be able to obtain additional needed financing on acceptable terms or at all. Additionally, equity or debt financings may have a dilutive effect on the holdings of our existing shareholders. We expect to continue to incur additional losses in the long term, and we will need to execute on milestones within the CSL Collaboration Agreement, raise additional debt or equity financing or enter into additional partnerships to fund development. Our ability to transition to profitability is dependent on executing on milestones within the CSL Collaboration Agreement, successful 24 Â clinical trials for OTC and CF and identifying and developing successful mRNA drug and vaccine candidates. If we are not able to achieve planned milestones or incur costs in excess of our forecasts, we will need to reduce discretionary spending, discontinue the development of some or all of our programs, which will delay part of our development programs, all of which will have a material adverse effect on our ability to achieve our intended business objectives. Funding Requirements We anticipate that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin commercialization of our products. As a result, we will require additional capital to fund our operations in order to support our long-term plans. We believe that our current cash position will be sufficient to meet our anticipated cash requirements through at least the next twelve months, assuming, among other things, no significant unforeseen expenses and continued funding from partners at anticipated levels. We intend to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements with partners or through other sources of financing. Should we seek additional financing from outside sources, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to scale back or discontinue the advancement of product candidates, reduce headcount, liquidate our assets, file for bankruptcy, reorganize, merge with another entity, or cease operations. Our future funding requirements are difficult to forecast and will depend on many factors, including the following: â€¢the development of our LUNAR-COV19 and LUNAR-FLU vaccine candidates; â€¢the achievement of milestones under our strategic alliance agreements; â€¢maintaining and/or expanding our manufacturing network and capabilities; â€¢the terms and timing of any other strategic alliance, licensing and other arrangements that we may establish, including those with CSL Seqirus and CSL Seqirusâ€™ arrangement with Meiji, and any related payments thereunder; â€¢the initiation, progress, timing and successful completion of preclinical studies and clinical trials for our product candidates, including OTC and CF; â€¢the number and characteristics of product candidates that we pursue; â€¢the outcome, timing and cost of regulatory approvals; â€¢delays that may be caused by changing regulatory requirements; â€¢the cost and timing of hiring new employees to support our continued growth; â€¢the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims; â€¢the costs and timing of procuring clinical and commercial supplies of our product candidates; â€¢the costs and timing of establishing sales, marketing and distribution capabilities; â€¢the costs associated with legal proceedings; â€¢the costs associated with potential litigation related to collaboration agreements; and â€¢the extent to which we acquire or invest in businesses, products or technologies. Critical Accounting Policies and Estimates We prepare our condensed consolidated financial statements in conformity with GAAP. As such, we make certain estimates, judgments and assumptions that we believe are reasonable, based upon information available to us. These judgments involve making estimates about the effect of matters that are inherently uncertain and may significantly impact our reported results of operations and financial condition. We describe our significant accounting policies more fully in Note 2 to our consolidated financial statements for the year ended December 31, 2023. There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations, included in the 2023 Annual Report. 25 Â Item 3. Quantitative and Qualitative Disclosures About Market Risk. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of interest rates in the United States. Due to the nature of our cash and cash equivalents, we believe that we are not subject to any material market risk exposure. We do not have any foreign currency or other derivative financial instruments. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures As required by Rule 13a-15(b) and Rule 15d-15(b) of the Exchange Act, our management, including our principal executive officer, our principal financial officer and our principal accounting officer, conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, management has concluded that as of June 30, 2024, our disclosure controls and procedures were not effective due to the material weaknesses in internal control over financial reporting described below. The Companyâ€™s disclosure controls and procedures have been designed to ensure that: (i) information required to be disclosed by us in reports that we file or submit to the SEC under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in applicable rules and forms and (ii) material information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including the CEO and the CFO, as appropriate, to allow for accurate and timely decisions regarding required disclosure. Management does not expect that our disclosure controls and procedures will prevent all error and all fraud. The effectiveness of our or any system of disclosure controls and procedures, however well designed and operated, can provide only reasonable assurance that the objectives of the system will be met and is subject to certain limitations, including the exercise of judgment in designing, implementing, and evaluating controls and procedures and the assumptions used in identifying the likelihood of future events. Material Weaknesses in Internal Control over Financing Reporting Existing as of June 30, 2024 A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. Management concluded that the material weaknesses disclosed in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 continued to exist as of June 30, 2024. Specifically, management concluded that the following material weaknesses exist as of June 30, 2024: â€¢A material weakness related to information technology general controls (â€œITGCsâ€) that support our financial reporting processes; Management determined that we did not maintain effective controls over (i) user access to ensure appropriate segregation of duties and adequately restrict user and privileged access to financial applications, programs and data to the appropriate personnel; (ii) program change management for financial applications to ensure that information technology (â€œITâ€) program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately; and (iii) IT operations controls to ensure that critical interface jobs are monitored. As a result, our related IT dependent manual and application controls that rely upon the affected ITGCs, or information coming from IT systems with affected ITGCs, were also deemed ineffective. â€¢A material weakness related to revenue recognition. Management determined that certain control activities within the area of revenue did not operate effectively, specifically controls over the review of costs incurred in satisfaction of our performance obligations under collaboration arrangements. Notwithstanding the identified material weaknesses, management does not believe that the deficiencies had an adverse effect on our reported operating results or financial condition, and management has determined that the financial statements and other information included in this report and other periodic filings present fairly in all material respects our financial condition and results of operations at and for the periods presented. Plan for Remediation of Material Weaknesses Our remediation efforts are ongoing, and we will continue our initiatives to implement measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated, such that these controls are designed, implemented, and operating effectively. We are committed to making the necessary changes and improvements to our system of controls to address the material weaknesses in internal control over financial reporting described above. Our renewed emphasis of designing and implementing improved processes and controls involves but is not limited to the following: 26 Â â€¢Expand available resources with experience designing and implementing control activities, including ITGCs and automated controls, both by hiring internally and the use of third-party consultations and specialists. â€¢Adjust access profiles in IT systems and relevant software, and adjust access review controls accordingly. â€¢Refine the control to identify access profiles in IT systems and software that result in risks of segregation of duties. â€¢Perform ongoing training with control performers to improve documentation that supports effective control activities, including evidence over the completeness and accuracy of information produced by the Company. â€¢Add additional technical accounting resource to review our revenue accounting along with financial disclosures for collaboration arrangements on a quarterly basis. We are in the process of implementing the remediation activities as of the date of this report and believe that upon completion, we will have strengthened our ITGCs, and controls related to accounting for collaboration arrangements to address and successfully remediate the identified material weaknesses. However, control weaknesses are not considered remediated until new internal controls have been operational for a period of time, are tested, and management concludes that these controls are operating effectively. We expect to complete the remediation activities in the fiscal year 2024. We will continue to monitor the effectiveness of these remediation measures, and we will make any changes to the design of this plan and take such other actions that we deem appropriate given the circumstances. Changes in Internal Control over Financial Reporting As required by Rule 13a-15(d) and Rule 15d-15(d) of the Exchange Act, our management, including our principal executive officer and our principal financial and accounting officer, conducted an evaluation of the internal control over financial reporting to determine whether any other changes occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, our principal executive officer and our principal financial and accounting officer concluded that there were no changes in our internal controls over financial reporting during the periods covered by this Quarterly Report on Form 10-Q that materially affected, or were reasonably likely to materially affect, our internal control over financial reporting. 27 Â PART IIâ€”OTHER INFORMATION Item 1. Legal Proceedings. From time to time, we may be involved in various legal proceedings and subject to claims that arise in the ordinary course of business, including those related to governmental inquiries, intellectual property and commercial relationships. The subject matter of any such legal proceedings or claims are or will be highly complex and subject to substantial uncertainties. The outcome of any such proceedings or claims, regardless of the merits, are and will be inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment. Item 1A. Risk Factors. Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, which we strongly encourage you to review. There have been no material changes from the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Commission on March 14, 2024. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None. Item 3. Defaults Upon Senior Securities. None. Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. Rule 10b5-1 Trading ArrangementsDuring the three months ended June 30, 2024, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, other than as follows:â€¢Lance Kurata, our Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement as of June 12, 2024. Mr. Kurata's trading arrangement provides for the exercise of up to an aggregate of 35,000 options to purchase shares of common stock and subsequent sale of such underlying shares of common stock, until June 12, 2025. Â 28 Â Item 6. Exhibits. Â Exhibit Index Â Exhibit Number Â Description Â Â 1.1 Â Controlled Equity Offeringâ„¢ Sales Agreement, dated as of December 23, 2022 by and between Cantor Fitzgerald & Co, Wells Fargo Securities, LLC and Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 1.2 to Registration Statement on Form S-3 filed on December 23, 2022 (File No. 333269003). Â Â Â 1.2 Â Amendment No. 1 to Controlled Equity Offeringâ„¢ Sales Agreement by and between Cantor Fitzgerald & Co, Wells Fargo Securities, LLC, William Blair & Company, L.L.C., and Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 1.1 to Form 8-K filed on August 7, 2023. Â Â Â 3.1 Â Certificate of Incorporation. Incorporated by reference to Annex B to the proxy statement/prospectus which forms part of the Registration Statement on Form S-4 filed on March 18, 2019 (File No. 333-230353). Â Â Â 3.2 Â Certificate of Amendment, dated November 25, 2020. Incorporated by reference to Exhibit 3.1 to Form 8-K filed on November 25, 2020 (File No. 001-38942). Â Â Â 3.3 Â Bylaws of Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 3.2 to the Companyâ€™s Registration Statement on Form S-3, filed with the SEC on May 8, 2020 (File No. 333-238139). Â Â Â 4.1 Â Description of Registrantâ€™s Securities. Incorporated by reference to Exhibit 4.1 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2021 filed on February 28, 2022 (File No. 001-38942). Â Â Â 10.1â€ Â Form of Indemnification Agreement. Incorporated by reference to Exhibit 10.1 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942). Â Â Â 10.2â€ Â Amended and Restated 2019 Omnibus Equity Incentive Plan. Incorporated by reference Exhibit 4.3 to the Registration Statement on Form S-8 filed on August 5, 2020 (File No. 333-240397). Â Â Â 10.3** Â Amended and Restated Amendment to Development and Option Agreement, dated as of September 28, 2018, by and between CureVac AG and Arcturus Therapeutics Inc. Incorporated by reference to Exhibit 99.2 to the Companyâ€™s Report of Foreign Private Issuer on Form 6-K filed on October 1, 2018 (File No. 001-35932). Â Â Â 10.4** Â Research and Exclusive License Agreement, by and between Arcturus Therapeutics, Inc. and Synthetic Genomics, Inc., effective October 24, 2017. Incorporated by reference to Exhibit 4.8 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.5** Â Research Collaboration and License Agreement, by and between Arcturus Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc., entered into as of October 26, 2015, as amended October 17, 2017 and April 20, 2018. Incorporated by reference to Exhibit 4.10 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.6** Â Third Amendment to Research Collaboration and License Agreement, by and between Arcturus Therapeutics, Inc. and Ultragenyx Pharmaceutical Inc., effective June 18, 2019. Incorporated by reference to Exhibit 10.2 to Form 8-K filed on June 20, 2019 (File No. 001- 38942). Â Â Â 10.7** Â Letter Agreement, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation, dated May 16, 2017. Incorporated by reference to Exhibit 4.11 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.8** Â Amendment No. 2 to Letter Agreement, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation, dated August 1, 2019. Incorporated by reference to Exhibit 10.16 to Form 10-Q filed on August 14, 2019. Â Â Â 10.9** Â Development and Option Agreement, by and between Arcturus Therapeutics, Inc. and CureVac AG, dated January 1, 2018, as amended May 3, 2018. Incorporated by reference to Exhibit 4.12 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.10** Â Third Amendment to Development and Option Agreement, by and between Arcturus Therapeutics, Inc. and CureVac AG, dated July 26, 2019. Incorporated by

reference to Exhibit 10.20 to Form 10-Q filed on August 14, 2019 (File No. 001-38942). Â Â Â 10.11** Â License Agreement, by and between Arcturus Therapeutics, Inc., as successor-in-interest to Marina Biotech, Inc., and Protiva Biotherapeutics Inc., dated as of November 28, 2012. Incorporated by reference to Exhibit 4.14 to Form 20-F/A filed on July 10, 2018 (File No. 001-35932). 29 Â Â Â Â 10.12** Â Patent Assignment and License Agreement, by and between Arcturus Therapeutics, Inc. and Marina Biotech, Inc., dated as of August 9, 2013. Incorporated by reference to Exhibit 4.15 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.13 Â Share Exchange Agreement, dated as of February 11, 2019, by and between Arcturus Therapeutics Ltd. and Arcturus Therapeutics Holdings Inc. Incorporated by reference to Exhibit 10.13 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2018 filed on March 18, 2019 (File No. 001-35932). Â Â Â 10.14 Â Lease Agreement, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated October 4, 2017. Incorporated by reference to Exhibit 4.6 to Form 20-F filed on May 14, 2018 (File No. 001-35932). Â Â Â 10.15 Â First Amendment to Lease Agreement, by and between Arcturus Therapeutics Holdings Inc. and ARE-SD Region No. 44, LLC dated February 1, 2020. Incorporated by reference to Exhibit 10.23 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942). Â Â Â 10.16** Â Acceptance Letter, dated March 4, 2020, by and between Arcturus Therapeutics Holdings Inc. and the Economic Development Board of Singapore. Incorporated by reference to Exhibit 10.24 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 16, 2020 (File No. 001-38942). Â Â Â 10.17â€ Â 2020 Employee Stock Purchase Plan. Incorporated by reference to Exhibit 4.3 to Form S-8 filed on August 5, 2020 (File No. 333-240392). Â Â Â 10.18 Â Second Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated November 13, 2020. Incorporated by reference to Exhibit 10.29 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 1, 2020 (File No. 001-38942). Â Â Â 10.19 Â Third Amendment to Lease, by and between Arcturus Therapeutics, Inc. and ARE-SD Region No. 44, LLC, dated February 25, 2021. Incorporated by reference to Exhibit 10.30 to the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2020 filed on March 1, 2020 (File No. 001-38942). Â Â Â 10.20 Â Arcturus Therapeutics Holdings Inc. Severance Policy for Executives. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on April 26, 2021 (File No. 001-38942). Â Â Â 10.21 Â Lease, by and between Arcturus Therapeutics, Inc. and TPSC IX, LLC, dated September 29, 2021. Incorporated by reference to Exhibit 10.35 to Form 10-Q filed on November 9, 2021 (File No. 001-38942). Â Â Â 10.22â€ Â Arcturus Therapeutics Holdings Inc. 2021 Inducement Equity Incentive Plan. Incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 filed on October 20, 2021 (File No. 333-260391). Â Â Â 10.23â€ Â Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-8 filed on June 30, 2022. Â Â Â 10.24** Â Cost Reimbursement Contract dated August 31, 2022, by and between Arcturus Therapeutics Holdings Inc. and Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Incorporated by reference to Exhibit 10.36 to Quarterly Report on Form 10-Q filed on November 9, 2022 (File No. 001-38942). Â Â Â 10.25** Â Study Support Agreement, dated October 31, 2022, by and between Arcturus Therapeutics, Inc. and Vinbiocare Research and Manufacture Joint Stock Company. Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on November 4, 2022 (File No. 001-38942). Â Â Â 10.26** Â Collaboration and License Agreement, dated November 1, 2022, by and between Arcturus Therapeutics Holdings Inc. and CSL Limited. Incorporated by reference to Exhibit 10.38 to Quarterly Report on Form 10-Q filed on November 9, 2022 (File No. 001-38942). Â Â Â 10.27** Â Manufacturing Support Agreement Termination Letter, dated March 23, 2023, by and between Arcturus Therapeutics, Inc. and the Economic Development of Singapore. Incorporated by reference to Exhibit 10.41 to Annual Report on Form 10-K filed on March 29, 2023 (File No. 001-38942). Â Â Â 10.28** Â Credit Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.28 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). Â Â Â 30 Â 10.29** Â Security Agreement dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.29 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). Â Â Â 10.30** Â Revolving Line of Credit Note dated April 21, 2023, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Incorporated by reference to Exhibit 10.30 to Quarterly Report on Form 10-Q filed on May 9, 2023 (File No. 001-38942). Â Â Â 10.31** Â Amendment Number One to Collaboration and License Agreement, dated August 3, 2023, by and between Arcturus Therapeutics, Inc. and Seqirus Inc. Incorporated by reference to Exhibit 10.31 to Quarterly Report on Form 10-Q filed on November 14, 2023 (File No. 001-38942). Â Â Â 10.32** Â Amendment No. 4 to Letter Agreement, dated September 25, 2023, by and between Arcturus Therapeutics, Inc. and the Cystic Fibrosis Foundation. Incorporated by reference to Exhibit 10.32 to Quarterly Report on Form 10-Q filed on November 14, 2023 (File No. 001-38942). Â Â Â 10.33** Â Amendment Number Two to Collaboration and License Agreement, dated March 29, 2024, by and between Arcturus Therapeutics, Inc. and Seqirus Inc. Incorporated by reference to Exhibit 10.33 to Quarterly Report on Form 10-Q filed on May 8, 2024 (File No. 001-38942). Â Â Â 10.34â€ Â Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on June 14, 2024 (File No. 001-38942). Â Â Â 10.35* Â First Amendment to Credit Agreement and First Amendment to Revolving Line of Credit, dated June 26, 2024, by and between Arcturus Therapeutics, Inc. and Wells Fargo Bank, National Association. Â Â Â 31.1* Â Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended. Â Â Â 31.2* Â Certification by Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended. Â Â Â 32.1* Â Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â 32.2* Â Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â Â 101* Â The following financial statements and footnotes from the Registrantâ€™s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 formatted in Inline Extensible Business Reporting Language (Inline XBRL): Â Â 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document Â Â 101.SCH Inline XBRL Taxonomy Extension Schema Â Â 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Â Â 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Â Â 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Â Â 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase 104 Â Cover Page Interactive Data File (embedded within the Inline XBRL document) Â Â Â Â * Filed herewith. ** Certain confidential portions of this exhibit have been redacted from the publicly filed document because such portions are (i) not material and (ii) would be competitively harmful if publicly disclosed. â€ Management compensatory plan, contract or arrangement. Â 31 Â SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Â ARCTURUS THERAPEUTICS HOLDINGS INC. Date: August 5, 2024 By: /s/ Andy Sassine Andy Sassine Â Chief Financial Officer Principal Financial and Accounting Officer Â 32 EX-10.35 2 arct-ex10_35.htm EX-10.35 EX-10.35 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Exhibit 10.35 First Amendment to Credit Agreementand First Amendment to Revolving Line of Credit Note This First Amendment to Credit Agreement and First Amendment to Revolving Line of Credit Note (the â€œAmendmentâ€) is entered into as of June 26, 2024 (the â€œAmendment Effective Dateâ€), by and among ARCTURUS THERAPEUTICS, INC., a Delaware corporation (â€œBorrowerâ€) and WELLS FARGO BANK, NATIONAL ASSOCIATION (the â€œBankâ€). Recitals: A. The Borrower and the Bank are party to that certain Credit Agreement dated as of April 21, 2023 (as amended, modified, restated, or supplemented from time to time prior to the date hereof, the â€œExisting Credit Agreementâ€ and the Existing Credit Agreement as amended hereby, the â€œCredit Agreementâ€). B. Pursuant to the terms of the Existing Credit Agreement, the Borrower delivered to Bank that certain Revolving Line of Credit Note dated as of April 21, 2023 (as amended, modified, restated, or supplemented from time to time prior to the date hereof, the â€œExisting Noteâ€ and the Existing Note as amended hereby, the â€œNoteâ€). C. The Borrower has requested that the Bank amend the Existing Credit Agreement and the Existing Note, in each case, to extend the Maturity Date, and the Bank is willing to do so under the terms and conditions set forth herein. Now, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: Section 1.Incorporation of Recitals; Defined Terms. The Borrower acknowledges that the Recitals set forth above are true and correct. This Amendment shall constitute a Loan Document, and the Recitals shall be construed as part of this Amendment. Each capitalized term used but not otherwise defined herein, including capitalized terms used in the introductory paragraph hereof and the Recitals, has the meaning assigned to it in the Existing Credit Agreement. Section 2.Amendments to Existing Credit Agreement. Subject to the satisfaction of the conditions precedent set forth in Section 4 below, the defined term â€œMaturity Dateâ€ set forth in Section 1.1 of the Existing Credit Agreement is hereby amended and restated in its entirety as follows: â€œMaturity Dateâ€ means April 21, 2026; provided, however, that if such date is not a Business Day, the Maturity Date shall be the immediately preceding Business Day. Section 3.Amendments to Existing Note. Subject to the satisfaction of the conditions precedent set forth in Section 4 below, the last sentence of clause (a) of the section titled â€œBORROWING AND REPAYMENTâ€ of the Existing Note is hereby amended and restated in its entirety as follows: Â Â The outstanding principal balance of this Note shall be due and payable in full on April 21, 2026. Section 4.Conditions Precedent. The effectiveness of this Amendment is subject to the satisfaction of the following conditions precedent: 4.1.The Borrower and the Bank shall have executed and delivered this Amendment. 4.2.The Bank shall have received, a certificate from the Secretary of Borrower certifying that (a) the resolutions, organizational documents and incumbency previously provided to the Bank pursuant to Section 4.1(a)(ii) of the Existing Credit Agreement remain in full force and effect and have not been amended or otherwise modified from such delivered documents, and (b) the Borrower is in good standing, as certified as of a recent date by the Secretary of State of Delaware. 4.3.The Bank shall have received payment in full of the extension commitment fee of $[***], which shall be due and payable to the Bank on the date hereof, and counsel to the Bank shall have received all reasonable and documented fees and out-of-pocket expenses to the extent accrued and unpaid prior to the Amendment Effective Date. Section 5.Acknowledgement of Liens. The Borrower hereby acknowledges, confirms, and agrees that the Bank has a valid, enforceable (except as enforceability may be limited by applicable bankruptcy, insolvency, or similar laws affecting the enforcement of creditorsâ€™ rights generally or by equitable principles relating to enforceability) and perfected first-priority lien upon and security interest in the Collateral granted to the Bank pursuant to the Loan Documents, and nothing herein contained shall in any manner affect or impair the priority of the Liens created and provided for thereby as to the Obligations which would be secured thereby prior to giving effect to this Amendment. Section 6.Representations and Warranties of Borrower. To induce the Bank to enter into this Amendment, the Borrower hereby represents and warrants to the Bank that, as of the date hereof: (a) after giving effect to this Amendment, each representation and warranty of the Borrower in each Loan Document, including those in Article III of the Existing Credit Agreement, is true and correct (or, in the case of any representation or warranty not qualified as to materiality, true and correct in all material respects) as of the date hereof, except to the extent that such representation or warranty expressly relates to an earlier date, in which case it is true and correct (or, in the case of any representation or warranty not qualified as to materiality, true and correct in all material respects) as of such earlier date, (b) after giving effect to this Amendment, no Event of Default, and no condition, event or act which with the giving of notice or the passage of time or both would constitute such an Event of Default, has occurred and is continuing or exists, or would result herefrom, and (c) the Borrower has the power and authority to execute, deliver, and perform - 2 - Â this Amendment and has taken all necessary action to authorize their execution, delivery, and performance of this Amendment. Section 7.Miscellaneous. 7.1.Successors and Assigns. This Amendment shall be binding on and shall inure to the benefit of the Borrower and the Bank and their respective successors and assigns. The terms and provisions of this Amendment are for the purpose of defining the relative rights and obligations of the Borrower and the Bank with respect to the transactions contemplated hereby, and there shall be no third-party beneficiaries of any of the terms and provisions of this Amendment. 7.2.Entire Agreement. This Amendment constitutes the entire agreement of the parties with respect to the subject matter hereof and supersedes all other understandings, oral or written, with respect to the subject matter hereof. Except as specifically amended hereby, all of the terms and conditions set forth in the Existing Credit Agreement and the Existing Note shall stand and remain unchanged and in full force and effect. On and after the date hereof, each reference in the Existing Credit Agreement to â€œthis Agreementâ€, â€œhereunderâ€, â€œhereofâ€, â€œhereinâ€ or words of like import referring to the Existing Credit Agreement, and each reference in the other Loan Documents to the â€œCredit Agreementâ€, â€œthereunderâ€, â€œthereofâ€ or words of like import referring to the Existing Credit Agreement shall mean and be a reference to the Existing Credit Agreement as amended hereby. On and after the date hereof, each reference in the Existing Note to â€œthis Noteâ€, â€œhereunderâ€, â€œhereofâ€™, â€œhereinâ€ or words of like import referring to the Existing Note, and each reference in the other Loan Documents to the â€œNoteâ€, â€œthereunderâ€, â€œthereofâ€ or words of like import referring to the Existing Note shall mean and be a reference to the Existing Note as amended hereby. 7.3.Headings. Section and sub-section headings in this Amendment are included herein for convenience of reference only and shall not constitute a part of this Amendment for any other purpose. 7.4.Severability. Wherever possible, each provision of this Amendment shall be interpreted in such a manner as to be effective and valid under applicable law, but if any provision of this Amendment shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provision or the remaining provisions of this Amendment. 7.5.Conflict of Terms. Except as otherwise provided in this Amendment, if any provision contained in this Amendment conflicts with, or is inconsistent with, any provision in any of the Loan Documents, the provision contained in this Amendment shall govern and control. 7.6.Counterparts. This Amendment may be executed in any number of separate counterparts, each of which shall collectively and separately constitute one agreement. Delivery of an executed signature page to this Amendment by facsimile transmission or by - 3 - Â e-mail transmission of an Adobe portable document format file (also known as a â€œPDFâ€ file) shall be effective as delivery of a manually executed counterpart hereof. 7.7.Incorporation of Credit Agreement. The provisions contained in Sections 8.10 (Governing Law), 8.13 (Arbitration) and 8.15 (Acknowledgement Regarding Any Supported QFCs) of the Credit Agreement are incorporated herein by reference to the same extent as if reproduced herein in their entirety, except with reference to this Amendment rather than the Credit Agreement. [Signature Pages to Follow] - 4 - Â IN WITNESS WHEREOF, the parties hereto have caused their duly authorized officers to execute and deliver this Amendment as of the date first set forth above. â€œBorrowerâ€ Arcturus Therapeutics, Inc. By Lance Kurata Name Lance Kurata Title Chief Legal Officer Â [Signature Page to First Amendment to Credit Agreement and First Amendment to Revolving Line of Credit Note] Â â€œBankâ€ Wells Fargo Bank, National Association By Derek Jensen Name Derek Jensen Title Vice President [Signature Page to First Amendment to Credit Agreement and First Amendment to Revolving Line of Credit Note] EX-31.1 3 arct-ex31_1.htm EX-31.1 EX-31.1 Â Exhibit 31.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER I, Joseph E. Payne, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Arcturus Therapeutics Holdings Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Date: August 5,

2024 By: /s/ Joseph E. Payne Joseph E. Payne President and Chief Executive Officer Â Â EX-31.2 4 arct-ex31_2.htm EX-31.2 EX-31.2 Â Exhibit 31.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER I, Andy Sassine, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Arcturus Therapeutics Holdings Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): (a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and (b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Â Date: August 5, 2024 By: /s/ Andy Sassine Andy Sassine Chief Financial Officer Â Â EX-32.1 5 arct-ex32_1.htm EX-32.1 EX-32.1 Â Exhibit 32.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, the President and Chief Executive Officer of Arcturus Therapeutics Holdings Inc. (the "Company"), hereby certifies on the date hereof, pursuant to 18 U.S.C. 1350(a), as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Form 10-Q"), filed concurrently herewith by the Company, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: August 5, 2024 By: /s/ Joseph E. Payne Joseph E. Payne President and Chief Executive Officer Â Â EX-32.2 6 arct-ex32_2.htm EX-32.2 EX-32.2 Â Exhibit 32.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, the Chief Financial Officer of Arcturus Therapeutics Holdings Inc. (the "Company"), hereby certifies on the date hereof, pursuant to 18 U.S.C. 1350(a), as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q for the period ended June 30, 2024 (the "Form 10-Q"), filed concurrently herewith by the Company, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company. Â Date: August 5, 2024 By: /s/ Andy Sassine Andy Sassine Chief Financial Officer Â Â GRAPHIC 7 img267163886_0.jpg GRAPHIC begin 644 img267163886_0.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBJJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76UJC9VN'BX^3EYN? HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+ _\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D- $149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@#)\27OV'0[AP_ MVAHUM.3E]NU_]X<'_'\:YCQS>[[]WLE/$:^8WU/3]!^M2^!;WFYL6/I*@_0_ MTIVT%?4[.BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH *0D*"2< @__M3%2Z)>_V?K%M<$X0/M?_ '3P:SZ*L@]EHK-T"]^WZ);3$Y<+L?ZCC_Z_XUI5 M!8444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5POCB]\R^@ MLU/$2[V_WC]8?K72:C=M?ZC/=-_RTP[#\L4T)E:BB MBK(.P\#7NV6YLF/# 2H/<<'^GY5VM>4:/>_V?JUM#^AKU>H9:" MBBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#%\57OV/0I@#A MYOW2_CU_3->:5U/C>]\W48K13\L"9;_>;_ZV/SKEJM$,****8@KU'P[>_;#M MMI"[+BXLF/#KYB#W'!_3'Y5+*1V]%%%24%%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11 M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !37=8XV=SA5!)/H*=6'XLO?LFA2 MH#AYSY0^AZ_IG\Z //KZZ:^OI[E^LKEL>@["]%%69A1113 *N:3>?V?JMM< MYPJ.-W^Z>#^-A4Z*0SV4$$ @Y!Z&BLCPU>_;=*MV)R\8\IOJ.GZ8K7J"PHHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X#QM>^=JD=JI^6!.?]YN?Y8KO M)9%AB>5SA$4LQ] *\DO+E[R\FN7^]*Y8^\>U-"8EK;2WERE0 NZ1\'T&:AK MK/]EYEW/>L.(EV+]3U_3^=8NOV7V#6[F(#"%MZ?0__ %OPJKZDV,VBBBF(M**** .L\#WOEW<]DQ^61=Z_4=?T_E7Z'2-P6^G0_IFO600P! M!R#R"*AEH6BBBD,**** "BBB@ HHHH **** "BBB@ HI&8*I+$ #J35"?7-+ MML^;?0Y'4*VX_D* -"BN=F\:.5%GR_/F_P!Q,?SQ5=?%\]R<66CSS9[Y)_D# M3L*YU5%=N?;-(9+111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !

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Ÿ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Ÿ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Ū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ŸT/XIW6D#6=4U"T;1EN0FH7)FVR&8K MD<#' JN7S%<] HHHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 49%%G_P#/[K/_(-[G_XNC_A"]/\ ^?W6?_!O< \ Q= 'Ō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Ŷ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Ÿ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Ÿ<:Y*IG@$DCGL,U>%K^TU#1E>QN;NX6 M*1X9#>_ZY)%.&5^!@@T ;-%% !1110!E>*+&?4_">JV%H T]S:211@G +,I M YK2B&V% W!"@&N1URXU>T^)'AU4U0KIMZ\T3621 [8BVYF.23D<8P![U9^ M(&IWFD^$)KNPF:)UEB#^61YKQEPÞ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~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Ÿ"3D#UX[5>?P_:71N1 MJH_M2&:<31P7L:2) =H&$!' ZGG)Ÿ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

MED@CMI3&C,+=2ZG'_)('!.<]Q7J&E_\@BS_P"N"?\ H(H M4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %% M8&K: _=Q:[!HFAV<-U?O ;F5KB4QQ01;MH)(!))/ '8UC:EX^O\ 1IM&@U/0 MS!+>Z@]G<'KZ4 =Q17%Z_X^?1MG:5)?M, M9=NZ1<'RL8]"#GMD<4DWB_5['PK?:Y=VNDS16UG]H6&TO7=RQP0K908')YH M[6BN6LO$NJ1>)-/TG7+*SC.I6\DUM)9W#28,84L&#*N.&&",\U=\7:]/X=T> M*ZM+:.YFFNX;5$ED**#(X0$D G SGI0!M/&CLI=58J[AN8)R\3(A D!+*I4KD'T(-6(O&V@S(7%XT8#QH1-!)$?WAV MH<,H.TG@-T]Z -^BJD&J6ESJ5S802A[FT"&= #\FX97)Z9('2LG1_%8U?Q7J MNCIIJQ;II\4;B>==GGEF<$]IYVC9U/7Z7%)()(XHU MFD\M"SN%RS8. ,YZ=JG\/ZG-JNEBZFEL)MSD*^GSF6,@>Y Y]J --45<[0!D MY.!UIU?V?;S33;$>8*6D+''RH@!R>22",5J^&-;GUW2 M3=7$$$965HU>VG$T4P'1T;K@^A ((- &U17)WOB+7;/Q?IVCC3]/G2^D=LQW M+^9#;I]Z5@4QW48SR376 T %%9OB'6%T#P[>ZJT$ER+6(OY4?5O\!ZGL,FL[MPSXEN-9OM0L+VWMTN+$1,TMG,9H9!(N0 Q ^88Y&/0]Z .CHKEM;\5:AHVI MRZ7&=.^T16RNUQB>X:0@9BC .X*2,Y(/!P.*U--UK[7K6HZ5@>'[K5;J-I$MH]YCC/+GH%'U) M H TF4,"&&0>"".M &!@=*Y_1?$%],B@#7HKG?"'BM?%MO MJ-Q%:/:Q6MZUM%YA^:5 JD28[[L@>F*HW'C24^-Y] M&TN/[.8E8WEV4EE9 MP6(1 IS@8ZD9)H ["BBJ] _>1Z?IUQ>3?ZNWB:5OHHR?Y4 6**Y?P9XIN/$]G M]JE.EA&B1_*LKMII(F89VN"H /T[U#XA\9OI7BBWT2V;3(I)+;SVDU"[,(Y? M:]J IR3@G* .NI H4D@ 9.3@=:R8=&:::&&. M.2=@TKHH!D(& 2>YQQ4U% &;+X=T:?4&OIM*LI+ML;IWMU+G&,?-C/&!^56/ M[-LLW/\ HL/^E_\ 'Q^['[[C'S?WN..:M44 9J>'M'CTM]-CTNS6QEVFI2:A:Z=:
MPWDN?,N(X%5WSURP&35JYMH+RWDM[N))H9%VO'(H96'H0>M2T4 4+30]+L+. M2TL=.M;>VESYD,4"JCY&.0!@\46NA:79010V>G6L$4,GFQI% JA'QC< !P<' M&:OT4 4QI-@%0"RMP$9W4>4ORL^=Q'N]6Z* */1[% M(6*EHUMD"G:1B.[ACGC#!@DB!AD'(.#W!&:;>Z?::E:/:ZA;0W5N_WH MID#JW.1D'BK%%
&='H&DPVC6L6F6B6[.KF)8%"EEQM)&,9&!@^U27&C:;=:A M#?7-A;2WU6<ACC@5=BQ(H" MJOH .,4U;"T6Q^Q+;0K:;/+\@(-FS&-NWICVJQ10!4BTJPM[66V@L[>.";/F M1)$ KY&#D=#P,57NO#>BWL$$-YI-E<16R[8(Y;=66(>B@C@<5IT4 02V-M/' MDUOZL0LKQJR A&7H0.Q';G7-K!>VTEO=PQSP2*5DBD4,K@]B#U%2T4 9=IX M8T.P$HLM'L;
<3)YO]TX'(]JDCT#28=,?38M-M$L9,[[98%$;9ZY7& M#6A10!4BTJP@T[^SX;."SVE/LZQ@1[3U&WI@U:551 J *]C ' %+10 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 ?9?8KNSEF\K>@8LK*^#@C+ @]0?:N7@^'.I2 MSVSW2V\%L]Y@YKU&B>@8 _ NOW.C7'VR2UDU M*YKU&B@*W\TN[@N9!(=K32E0G./MA4
S6]K'@Z.7X=W^CZ/8V5M>W=B(&:..8U=@!]X@ M=.M=A10!Q6G^#6\/>+K34]"MX?LEQ;?9K^*25BT1'*R1$YQDY#+QG@]JT?'. MD7^LZ%;Q:5'"+<6] ;W0CDD\L.(Y Q&[!P<"NDHH X+6/#OB'Q+=7&HS1VVE M7$&G36EA$)O/ >2%29'.W &% P>I-8P\(26:Z[?^(XX].L;S2UMFDDOGNYO M.$A8.SL.>2NT#TZ5ZM10!S'@'3[ZU\-)>:V,:MJ3?:KSC&&(5?P4*,?6K5I MI-
S#XZU+5WV?9KFRMX(P&^;!MQS MWYKDVL?$&E>--,MVKLZ*/+Y? &LVEG M8VL1CU*#[-.+]);MK5#<22F0NVT9>/+$;"1T]ZJ_\(M MN11$E3;1D.#GW92HSU#FO6]*
,3Q6FN/H#0^%A$MY(ZH7>0(8X\ ,5R"-V.F M1C-<,E=-X>\/20?;[O5 M8T2>^U#[QHY;:&VM,-D MJB[F?(QQEC^@]SJ/AZ'4KLW$E_]<#%0NRID(DX_V5(&:UJ* .?\1>'[G4/! M<^CZ9>2I,54))
<3,QD"L&*N_WL, 5)ZX-9V@>&9UU'4;K4--M=+LKJ**-=,M M9=R;D))E)4* 3D#@=%YKL:* .+\5:)K6O/+8"UL?(:6-[34@Y6:Q *EL#&2W MRG!! Y -6]*MWO?B%JFKJ"+:WM(J.1BN/-
<.7<^X&X#ZYKJ:* "BBB@ HHHH M **** "@]*** .5\2Z=K% \.;[.QL:">VU*T^S&X=MDMN2&!9N#O7YL@#&.' MUJ36/"$>H>#[C28I<74EG';BYDR=QCP5++#ZCGZUTU% '+:)I>JS>*)]?URVM M[.;[$EE%!#-YO 8NSEL#J2,#VK-703,B_1MDL(7;G20AOM6EO8I#I[6'V:WEWK,&8$MP!M4;< =1DU)KVFZK*+BTTS3]/G MM+RR^R>:(VR2#@C+$@[U ((7@Y!]:ZJB@#BK+2G_
,$RT6WC=Y8O#NF-#-<. MO^MDD5%"Y^B%C]17:T44 %%% !1110 4444 %%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%% !1110 4444 %%% M% !1110 4444 %%% !1110 4444 %%% !1110 4444 M %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%% !1110 4444 %%% M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !2 M.ZQHSN0JJ,DGL*6B@"I :MC_
,.1\9PK9JQ M1BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH ***\DU.[\7>/\ XA:YH7ASQ&WAO3/#_EQRS0PAY;B9UW=SPH% 'K=%>4>(
M+WQSX2^%"ZQKVIP2ZIHUZDLLEK]V\MMX4K(".I4YX]][#QEK6IVGPXU'6/"T M)N;X6?GVJ:=QY .=O? ,<>U '3T5X3\,?$NMZAXHTW[A0+;O);741.I:=>H
M+>XM6VY'E*1EL'KCL*X[_A.-2FCURYO?BO>Z5J-K>7"6ND_9#+Y@5CL&0,<] M* /J>BOG?O;XU\0,? XUSQ7<^#5U+2GGOYXX-P$H/RY0UW3Y=?F\4:+:)$]K]\ML8BTC?>C&>N/Z>] 'KM%%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M&@
HKPC3+#QWXSUGO==:3X]O-,&E:I+:VUF85>,A0&4$]ASCH:O0_$;69_!/ M@[O?^'I7&?#SQ!K$]]]2OCOXU\6Z5_9\DQDE AN[6+#C]V>= MOOTS0!{517R:8^/|;_X1*+5H/BI>W'B$"*: UD9/,;?@(6
P.[GP7:-H\%P5C@,J^>WWDP.1WY]] /H.BO,_@KXAUG7M'U==5U&36 M+.SO3%8:K+ 8C=OXR3@^A[^]9_CG_A)=;^.NG^&="\57F@6\FDO=.UN@<,RO MCH<=CZ]|
/7**^?]6\8^+ #GA3QGX=U36WN=6T%K66UU6)0DDD,K@88=,]OQ MJ#QCXKO4^*6IZ;]7Q)NO"=C!:6TENJ0&5969,MP.GK^- '7/17S]XY\0ZCH] MUX,T]OB1=Z?[]YITLT^MK!N^T'(*,4'/(.*C\2>
(M1TCX8Z/>Z9\2KS4+>_U ML12ZV+?888=N&79U(4@F@#Z%HKPOPWK3MHWB6\TKXJ77BF:STJ618&M3%Y#8 M^60$]P1C\:XK3O'NN0Z3I.I:3\3;S7->FDA\SPU\UD6#%B Z%L8X]: /JFBOG
MCQCXLO5^*^NZ;]?Q)NO"-G;10-;PI;F979DRP&.F# .I?&/BSQ+X>*^";GP MIXGNO$CW5S/*]SY6PW\:?,4*GG 8>M 'T%17C:?$V2?QO>:O9WDL^A1^$_[M42S#:Y@8Y_X%QM-1Z'I7Q4UO1I-\7VGC"W^TWO2?^QI8 MJL+'[NX)DE9V34I(O+,@W$8V^V,4 =1110 4444 %%% !1110 4444 % M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M 44 %%%
!1110 4444 %%% !1110 5Y?K_@[QEHGC74/GPWNM-8ZPB"^L= M2#!/,48$BD=\=]J0HH \>\:6/B'2_@9=Z/XGU;^V->UJY2UB,: *'ED&(U&, MD UWVJ^'K^Y\!?V)HVJRZ7?1VL<,%
[$>8V0#!^AQ@^QKH)((IBAEB1S&VY" MR@[3ZCT-/H \9TSX>>.-9\:;)]GC,Z!:Q:+/]H%SID1%Q>,!@!VP.#U/U-/L M_@U+<^]9T[4TM+?6I=4GO\ 3;^ Y>%BVZ/+X!]B/>O8Z* /+8O!/B+7/%OA
M/6?&%MIMQ_9NGSVVHIO\Q97;A752N#GJ?0U\>!/^LZ>"$FKZ=:/#+X2N'^T MV$9D/F6DA^]&%Q]SKWI5Z'@>E% !1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444
%%% !1110 4444 %%% M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %!HNH \5@\)?%3 M0-9\2+X7_L!+#6K^2Y$UU([2QAAC(
&.!SCGFF>*?!J;%\//"'P^M)S=7E]K M$3RRXQOVL99I,=@*]MIC01/,DKQ(TB9V.5!*YZX/:@#GO'&BZWK7AWR?"VL- MI.IPRK-#+SLDQUC<=U-)/%B:%\]K8SVT,&CQE?M#2*5W2- MZ#->QT4
>+P _![4;?X6Z+!8_8[#QEHLIGMXV$X5FWD['<#+*5/<5NP^ +S6O MB:!UP>M>ET8H X;X:>&]?\ !]I?:%]T M\5WI-M,3I,XE+2C*?^6;@CMV.:Q_& ACQPWQ-LO%7@=-)D:#3VLW749x ^9L MG
4?3O7J-% 'BU[*O%&K>#_ !1#K/3$ET[44O!;W*A(6"@\ M%0.53MBNEQB2-V ^8'U(]:]AHO0!XKK/@GO\GQ"U M?O!H.E>&:N+5(H
T>JDRF)D3!V\>N>>_%:Z^#_%NJWW@F^URVT>UGT6^GENX M;!BL0B9<+L4CD^HKU.B@#QOP_P#!;31OB'XDG9XV\-;M82VT,0D/F0^8, M^(_ WCF/XEZKX@\-:?X=U&VO[>&' B<
NP*#DA0."37HO@F#7K;PU'#X]M=., MM;Y9&Q%I:D0]F>,]^N:Z&B@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BLOQ'XBT[PKH4^KZS*T=I!C<40LQ M)(
Y)R;RM5^(F@Z1X=TO6IGN9[35F5;06MNTKR%EW ;5YS@&@#J:*Y32/B M3X'49/M$]@=.C$MW']%N]N\49Z.5< X..M,T3XG>'->U3^SK1[R&Z:)IH M([JSDA-P@Y+1[@-P^E '745PEE\7?#^H;T-
*M[+7/M>Y%>-M*F7RPQPK/Q\] MGU/%;?BCQKH_A!+;^UGG:6Z+""WM8&FEDVC+$*H)P!U- '045Q>N_%GPEIMG MI]U+?3307\'VF.2WMWD$<6>G>8^!\B@\9-6-3^)GAC2-
>@TB\O7\^81DR1PL\ M4/F?ZOS' PN[MGK0!UE%8LOB[1HO%UOX9-XKZM<1/,+=!N**O4L1]WVSUK:H M **** "BBB@ HHHH **** "BBL[7=?TWPUI,FI:S]@RET^+S[']4+=[=XH_[Y5P/E]ZKZ/\
%3PQK>JV MUA;37<+WA(LY;JSDABNC_P!,W8 -^% '945QEM\5O"MWHFN:K%=S"VT*7RKW M="0R-G' [Y/ Q4?_MSPI_9+90$1'<)B2 K#JO3O0!UE%<_/XWT2W\:0>$Y;EAJT\G)'L.W&"<%N@))
MQ65KGQ5T'P]KO]D:A:.P;IG*1B'399%F(&2$8##X'I0!VM%<9'5O##^&[S6 MGFNH8;*Y6TF@FMF2<2MC:GEGYLG/XUV$,HFA20*R;U#;7&&&>O'8T /HHHH M **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HJO+?V\.H6]E(^)[ME7:)"8W?^A"K% !1110 4444 %%% !1110 445GZOJBZ5':NT9D^T7<5 ML #C!D8+G\,T :-%%% !1110 4444 %%% !1110 4444 %%% !1110
444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !17G>N76L>*OB3/X4TW5[C1=,TVRCN[R>SP+B=Y"0B*Q!VJ I M)..>E<]IOQ"UWP]#]&C8;Q/

(4TC3YIY!&\ZLF]M[@8)3D$X^M 'LM%>2Z M5\8-5N[W2TU#P[!;6UWJ-S82SQWV\;H02SH-O*#;R3CVJIX5^)/B'5;1HO#> MAS:S?2(VIW,=[J 400R.1%'&=HR2HR%.
/6@#V6BO.-5^)>]6GB;5;"ST.)[M+1;*&\U.[GNMGV<,I=D ,Y@^O0 \GO4>C_%'4IM1M(_$>@1Z7:ZGI\VH:?[T MUYCF.-=Q$]X&TE<'C(H]+HKR_PA\4]9\0Z]H%E]?AR*PM]E6O@KXLU/7[OQ#;
MZUK4.K3*\%W&UO*)(X%E0DQ*1V0C'UH]8HKRGXL?$&\'T^*7P[X3N4BU0M"E MW=F0+]C65PJA<]9#G/L 2>U-\;ZWXANK+4X_"=Q>RG3(H]/B:U8![J\D*AFR M>#Y:<^FYCZ4
>L45PGPJOOMNCZBL]YK M/6K7B74=6O\ Q79^%]#O?[-.ELUY=WH0.Z1!MH5 >,D]^P%-*[[&BN&M)]9 M*>+]-TG4=7EUC3M7$B027*])H)D7?@E0 RE0>W!%=S0U804444AA1110 44 M44
>;_$ZU+5W)-Z)X>M8F1+EM0N9[V)VM5\H?(CE>Y8Y SVK@X?#7BN M44 >'^(HC\,K+PMHOA/7I=-EL/] N%B99A=]YVI<1_PH3\O+?*:H^(M!\2Z MYUW1I]%N[B\\2#2WBN[:'-O"T(7S=S#A-
I4X_2O?L48H \ZOO#HM/C9X=U'3 M]-*PM9W9O+N.'AI&"@%V]3CC->BT44 %%% !1110 4444 %%% !7#_ !/T MK4;VQT34=+M)+\Z-JL5]-9Q$;YHU!!"@]6&
<@>U=Q10!Y;X@NM1^)7A;Q+I> MD>&=0TP36*1#?:C$+=[F0-N\K8?FQCC/3FJ.IW^I>.;3PWH%CX6U72[BQOK: MYO+F]MO)BLUA(+!'Z.3C V]]]@Q01GK0!\U:9X\02W=O9MI=U%IVLZG=-J8
M>%EPDSRQ\='S@'OQBH5*Z^WA#48/[&U%)9/#=C JBV:=YBW:,R@8^\!SB MOINB@#Q8^&-7T3QT_P#:)(+C2)XI*U"8%S8RM&0\3A !EN,.1[5R=ES%
M\0Z%9^!VTW3KK^SM0N[2YU2T\IBUIZU]*X%% 'SWJ>@^-[MZ35/&]MIT"F+6TOK>TD@E^WM%"?*55'3;R%CC&<$UZ-XMMKO4?'G@"^M:.X> MWANIY9V$9Q"&@(&_^[R<<]Z[[%&*
/+]8\&P7?Q\TC5#83O9M9/&X7RV;YGW!.5'MMY^HK8H **** "BBB@ HHHH **** "N>\8?\ 'KI7_87L M_P#T:*Z&N>\8?\>NE?\ 87L__1HH Z&BBB@ HHHH **** "BBC- !11FB@ H MHHS0 4444
%%&:* "BC-% !1110 4444 %%% !1110 4444 %%% !1110 M4444 %%% !1110 4444 %%% !1110!RGB/X>Z7XCU=-5-YJ6EZBL/D/=:9 M=&!Y8LYV-P<*"?SJ&3QIOU:2PTK1=0U*2.TBNW:
M(Q1@))G:.2.IS\IXQ0!GK\)_#Z;?8V:2WPCL:6YMH3YPW?Z1GS')QRYR0#VI)OA)X=DN:26&74;1;>VAM9(K6[:)+]_+_5B4#[V/PJY#X^@U":OAT32[[4I+ MRS-ZHC:*/8@?80VlQ\P;C
S6UH&N6_B'25OK1)(QO>*2*4 /%(C%64XR,@@] M.* *-IX*TFU;7BTHW=OI,QANKB$Q84A0S$*7#-@,# MP*V1XBT>HH HV/@S3-.\0P:Q;^=]HM].7 M3849\I'"#G@8ZG R;I>)OA[8^*-
>LJ8GU75]/O;*%H89-/NA#M5CEOX2>?Z5 MTK:A9I#-*]U"([=BLSF08C(ZACV/(ZUFZWXDCTBYL[2"RNM1O;P.T-M:A=Q1 M "S$L0H R.IY) % &';?"GP_!]E\UZ\,-[]OF-W<>:;R2;M#S9'S;1T' %7
MI_&EMJU_J-A-=:7&Y(SZ57'Q&TZ:UBFT^SOKU?L MGVVX$2*#:Q:BI+AB,D%6&U6D5S;.)(9D62-QT92,_E0!R>M? M"OPAK^I07^I:-:R744PF>;RU+7!"[<2$CYAWP>X%37?PYT.
[\)6_A]OM,4%K M,+F&XAFV3OS!BWF!P/O9)[=ZZNB@#(\-^&=.*Z6;'2TDVO(TLLTTA>2:1CE MG=CU)JGXE\,3ZK?6FJZ/J!TW5[(,D4YC\Q)(VZQNO=<@'U%=`11=H#D]'\+:
MF=>BUSO7JL6HWMO&T=&%>5! &^\P4DDL<8R3TKK***:;8!1112 ***QM9\ M1)I5U':06<^H7LD3<VMR@81K0%LN0.1 SDGI0!LT5R-[\0K*UC$D&FZE=) M'9+??FEPA3:0MG!<.0=W#?
*,GY36]?ZS9:=X?EUFYEQ90P>>>T@!.4QG('O0! MH45R0\?VR1SQW.F7UO?Q>1LL7\LR3*8XC*D,5Y((Y(Q@YK3TOQ+:ZN;06:2L M;B-Y'! _<;6VD/SUW KQG.#VH VJ*IZKJ=OI&ESWUXQ6*%
MIK(3Q5+-K+#JN>BABPS@D9 H_Z;BL? M0=:GUJU6YETJZL(G17C-Q)$Q<.,]$9B#CUQ5?5_%L&F7L]M#8WFH-:(LEW]D M56-NK?=)4D%B0]*=]@GZ 4_=!7-IXT7]2362:-$=HOM:@"
(RK&)&3KN!"' M.2,=LYK;TZ\^WZ?%=B*2)9EW*DHPV.Q(]QS^- %FBL#6/%MEI']H[XYYAIMN M[@P@'!8X2/DCYVZ@>G7K3)_%366F),(+G5(M[>"QO);26X:U2_C56B\U\8?\>NE?]A>S_P#1HH
Z&BBB M@ HHHH *XWXHE+?P5<7[ZC]ED]I\T*Z9<^0\\C?*D9.#D%B*[*],KZ-8ZY:I M,:I;BXACF2=4+$8=&#*>#V(!H Y[2(-8T?PI::!+=;T755T#O-?7VF)5('0[M2,X-
>P:A8P:GI\]E>)YEO<1M%*FXKN4C!&1R.*P]$^`_(:\-V5Y:;)QM5F0^(P9<$8&6..IZ8H P_!WBV&]UMH=4U626[O$2*SA",(V1%/[S.-H:0 M][@'G:1\4WBO7+^&\UO[%-\[X+GUVJ./0Y-
=#'X2T6+5K4XK" M-+NTB6&!U8X10I4?+G&0I(!QD FG7?A^*[UB2ZEV26]U:&UN[>17]K:R6[1//-YCQB1"6RS') (SCD\\5C>%]5U"[MUC3=0U%KV%=5>X1 USYD5,Y?
<#CH2,V.M:/C"=!X7O+N=+V)[5L6ZPW30F9SA4YC;.TLPX/Y5H7 MOAK3-0OEN[JV+2[%#8D95D"_=#]" ^.VX'%7+[3K;4H%AO(A+&LBRA22!N4Y M4\>A H YFRBO?#-YX;LKG4+F^-U$]I>H9?
H1GI785EW&D&Z M\0VNHSRAH[.)O!%CI(_#.3_N\>YK4H **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** //O$>G/+X@OII#U(7+ M(@L-4T24I(X'\$OS
9#9^\"NT_6J4/A+Q-J.L7T^H:G>;9?RZ):P_;;-U$6:-X5U.]U33"+;4/#"6NA/9LUI(N(YQ-V)SO4_M?&>O>NM\ 6=SIOA5-/O]/:RNK6:1)FSE;IMQ)G!R<[\[N>021VKIL#TI>E ' MGME-
J>BWOBR%=!U&ZFU#4'FLWCC7RI T**"7)^49!SGI7+ZOX/UZQT5]&BLK MJX*:)%:02Z?%&?M$]J^Y))7YC4,00 !GUKVK HP* /+IM%N9/&5GHJH&L-6@ M@OM4CR"8WMP
0P_VSY8]IKI/&M[JZ&TL-'L[P170876H6D(EDMXQCY4&1AV M[']H,9ZXKIHK&T@NIKF"VACGGOYL](TF.FX]3CWJ? H \PU70/L\G#*X;TO7 M+);G2S8E(4CQ(N6VI*6),:
L6WCLQ[UW^@:'=.TYVWM;6L<)8'J54 G] M*T,"B@ HHHH **** "BBB@ HHHH *X7Q7H"3>-+76K_1Y=8L/L#VC6\2B0I(M7#*Q0D C&1G^$UW5&*
/+);77FTO3O#>O6.IS:=%9H=0N+*+S7O6R<0;]V55 M1@,>K=!WKK_$VEWUWX2U&+0RRW-Q:"*&VEV[%'=0I& 2N1SQTKI,"B@#S?1? M"R7FHWVS3M2TS2FMH-
IN7Q<_;8V)5XV)9@%&!R<9Z#KG.OO"VM626DFDP7T; MS1.8EMYR/LT_F*8S-@C

**6SD;F;CFO6,"EP/2@#D_B!'+_ ,([:704O#8Z MC;75TH[Q)("QQWQ[[*R/$FC?VA?:A_97AXQZO=R1/9ZW$0R@#;\Y?K'@ C: M.HQZUZ$Z*\91U#
(PP5(R"/2FQQ1PQ+'"BQQH JJHP% [4 &:&XLPDLEON4@_(V MR8.W'/6NLP*,4 Z;:\D1D.1N'W=W>(YKR%?
O0M:1('X]5&16U10!YMXG\+R/XFUR];2)M1?5+**+3YH M@&%I.BLNXY(V')4[QZ&MN#2=1G\:Z1-[:M-!I6EG;<'[LETY"N1[A5/_'U7 M78!ZBC%
'"^./#DVJZ;;/&L]\MOJ4-Y+:>9@O&O#(G3L%'WG% "6Z-';1I(VYU0!F2!R:DHHH **** &3KOMY%"AR4(VDX!XZ9[5YI#
MX>9Y(5TCPI_9EO!8SPZC8NXC2]9E 2,2#EQD'YST_&O3]3]* .(\.Z,YURZ MGTS3;CP_I,E@L#6P00LT^[/F*HR,A>-W?*RO$7A2;_A(->N?[*GU"XU6UA3
M3;N/#?9)T0KN;)'EG.UMX[#';%>FXHQ0!PVH>"OM%_:.OG//,AENY6D_<^8(MPI8)_?? !/\ =#>M/^'EEK-G'=_VLE[$ABA5DO)2Y:X /G.A)/R$[<8P.. * M[:
HQB@#SU+/,WC#3+_2UU66:_CO1:-)L-Q;LJ!2#WVE&&/5<=ZHMH-^FI+K M.E:3/:Z59ZA;W,.DB,1R86-TF=8\X!.\"?;7IAMX3<"$[S2[MVQL[?3)H-
1MM6DN9/M5P"DMJSNVP/G/(8#9C .37J0&.E&!0!EZGIVJ7)?#VHZO\/M3T9KXWE[<0,J3NJQ:CG('R\#IC-=/ M10!Y_I%C>65YJ.HZ'HUQIENNE>6+*1
K7%V"2' S@G&\]FZ M:SRP31Q(\[QMAFE)WOD\]6)S]:Z' HH \MN?"=W!JNJQVNFS'5+W5UO;+5U& M4MXBR%QNSE.%<%%1][/O73:*C7/Q'\07]N?\
1%M[>T9@>'F3>S?D'45UF *C MA@BMT*6\21*6+$(H))R30!)1110 4444 %%% !1110 4444 %%% !1103 M@9-
%4:G8G4&L!>6YO$4.UOYH\P*>AVYSBK0.:\J\47_ (<\8:Y;R-QV2L<(<P2_9FN(A@A M@S-R0< C))ZT :&H17+>,-&DB60VT<-R)BOW02(]N?
R./QK:K%U"2Z7QAHR1 M&06S0W)F"YVD@1[<_KC\:V] "BBB@ HHHH **** "BBLW7+N_L=,DN-*@MKB M:/!,5S/Y*E>_SX.#0] -*N>\8?
\>NE?]A>S_P#1HK.\/_$O2-F_VG;K"; MN[M0&W[28QL?;([5E_\@G_ $'==_\ !@U 'OYHS7/](@G_0=UW_P8-1_P MB"?]!W7?_!@U 'OYHS7/?\
(@G_0=UW_P8-1_PB"?]!W7?_!@U '0YKE?$>OZ MHNO6OA[PS';G4;B%KB:XNLF.VA!QN('+$G@#VJS_,(@G_0=UW_P8-61?^#M M5TK6H-?\+W\E[?
QQ&WGM]5N&=;B(G(4/C*$'D'D_X M1!/^@[KO_@P:M/2],&EP-$+N\NMS;M]W,96'L">U %ZBBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1AE2!P M?6EHH
\]O=2@L_%%]IVI>*;C26ABA99/+M_])RIRQS$>01C&>F.!7;:3+'-I M%M)#>F_1D!6Z(7,H_O?* /R KD?$*WI\37AU,:\=/^S)_9_]C&0 /SOW^7SN
MSMQN^7'XUT_AL:F/#5A_:V#]/DC[1C'WO?'&?7'&,-'M8G86\\ M-RTJ@<,5$>W\LFMJL>^OYH/%ND62;?)N8;EI,KSE!'C!I?>-;% !1110 444 M4 %%%%
!7$?$"66;[+;_^A-8PS1SW46JLW(RVW@*01D#\17;US7CEY(-$@NX M+Z*REM;R*9&E5V$A!QY>Q/F%]?OM7NJ[#47M4EMU4FW6VF@E
M7/1BLO)4]B.X-2^,/^/72O\ L+V?_HT4 =#1110 4444 %%%% !1110 8HHH MH **** "BN7\:^.],\%6MJUY'+<7%W,D4-O$#DY8*6)QA5&X7'J1TH
[6BN/^(7Q!MO .GV,\]J+N6] MN/(CC:Y2!1\]D8N_ Q^M4U^)]K%K2V&H636P%D+N683I((_W7FD#;]Y<<;P
M<%L"@#O**IZ9>2WVE6]Y=6[6L_VO#++:'Q5+HC07& MZ&S>[EN#&1& I7Y03]XX;/'2@#?HKF_#WBTZU<0PW5@UB]U:"^M09A)YL!(& MXX
VMRIV\]>O6F7OC#[+K,ENMB\EC;W45G5+)C:-F.1\R9.>-W0\T M=/16?I&JKJL$K&,PS6\SP3PELF-U]^X(((]B*T* "BBB@ HHHH **** "BBB M@ HHHH
**** "BBB@ HHHH **** .?N/&VAVC:ZMS=F+^P$5[\M&0(PR[EQ_M>R/2F6OCO0KVWT*:VN))!K^?L"B%MS@#)8C'R@#J37FNM^%=5\0_&K6-)ELY
MD\.W8MM0OKC80EP8H]J0@]#EL$CVKFM'T/Q+'*=6UFZTR[6]MK3^QM,M5A8 MRPV[2_OI@F,Y(;MV6@#Z*N[ZWL;*>[N952&"-

I9'_NJHR3^0J#1M8M-=T:UU M33G9K6[C$L1="C%3T)!Y%>&ZI::I>Z?XGN-*TG58(CI]EX=TN*>W8/L?!DD*
M]A@\GMSFJ^K>&M0\,3>*XO#&EZD-.2VL=*=T,SM)GF6X4 [G*C"X7L<4 ?0^ M]<9W#'KFE#!NAS7S9X?\,ZS?^'&\.M!J=K::MXF0-
BVEMQ!:PQAV<*2=FXX[MGD>M>G?"31)-+/BBX6VN;.RNM7<6=M<;\K&@"[QOY^8Y.>] 'HI('6L>V\6^ M'[S4SIUIK-E-> X\E)E+$^@]36-
\67U*/X6ZTVB[_M/D6VHZ?K\]G'%%]DFL)KHJ?E.\,5DY8'G._6NTT@1#2+86\=S'%L&U+LL M90/]K<2V?J:\WUK.O^*8M8T7()KUHC1,J?:UB-
NAB<,F'QP^]6R.>.>@KO\ MPQ97.F^%]/L[ZY6ZN(8%1Y58L&/L3R0.F?:@!M]?&'Q7I-F(HV%Q#<,9&7YD MV!. >V=W/T%:]9%]=1Q>+-
)MFMD>2:&X9)C]Z(+LR!]TM_,9)@3MVCHQ&#E?0UTU1I@3M4;_)1GG)/;- $'A2$SZU>:C?MJDVH/"D/G7MC] ME18@20B+T)R235WQA_QZZ5_V%[/_ -
&BJ'@W7)]4N2EWJ%WA55U+4;72=-N+^_F$-M;QF25S_ M J* ..\5>";Z2UM/^$0CTP-#-BXKC+/]IKPS<^(!8R6-U!:L^P73 M$''/4KZ?C7M$4TVOB/4?
MDT\A M,;>'3+"XFL[2339A?+L>(@@>8C[M6R" #MX!XYXKT"DXI#.:U'PL7\'#3+9+>ZNEA@C>2ZW 3^5C&67YE/!PPY4G M-.*>&I-
#TN^24B&XU"X>XD$,K2>42H4 . +$!0=QZG/%=)10!CZ?H4]C=K. M^N:I>!008;F2,H<^NU ?UIEYHUQ<>*[;4E:,01V$ULRL,DL[(0<="/E.:VZ* M
.&\+>!7T_47NM6M;- MF;)(8)9)4D4N&+8?_5KP,1KP.>:FO_"FHW&K7<,; M6W]E7^H0:A/(S-YL;1[,H%Q@[C&O.1C)X-=GFCK0!SWA6WD,VL:E(C1QZC?
- M)"C*5.Q56,,0>F[:3],5T-& ** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH ***#TH 3BCBO+=9MI([_6-7OX;G4[*.Z+1ZKI5]B?340?,GE$X
M^1E.<9)W'(-8^LWMBU]XQOKO3M1U (*VE]#,5CMM\";&)W@H-S!B0N!U- ' MM7!HX->-WTD=IKVL/XIT[4-=-CHUD\LUC(2L;
['WN!O7J1G(!X&:]*\&1WL7 M@O24U2Z2[NA:H9)T?>'R,@AOXN,<]Z -JEKR*TTVV/PY\0>(3)/%JUG=W\T- MZ+A]R-'*^P7TLK9]+O; M;?
Y*,B#S22/E!+AB=WW@1CTKU^!F>"-G&&9 2/0XI 24444 %%%% !1110 4 M444 %&<45Y=K'BR*]^*>AQ)JWV:TL[^6T-IN*FXD,39=A_=!PJ^IR?2@#U'-
M&:\NT;Q6FM_%ZVF35<6LUC9A=JY$>2PR<]?3- '9YI 0:\EO)+O4=/L-8TNTGMK*T MA,.7ES_)9317&)6.2"X95*KPQ/3 S71^%/$[3ZY-97MG/'-
>7$P%PT@*F6(+ MOC"]5"J0,]R#0!W&11FN4O[E]1^(4>E-.T%O8:>;TE&P6D=BBL?90&//&2*Y
M+4[+4M%U6\TOPY)=12WVCRFSE^U&5K^9&4M*2>$D"L<8Z[NV!0!ZQD9Q17G/ MA*_^R>+-2L])L-233%TV&Y6VN582&;>RMM$A!!(SG
)&11XML;N+7=1\1W] MK:WVEZ=91-]G>[D22,+N=RJK\H8Y'WNN!0!Z-G-%9EUK=M8:?;W4L5T\4X!0 M6]K),PR,\A 2/QI=-
UJWU9)6MH[N(18W?:;22#KZ;U&?PH TLT5Y/9^+#K7Q M12XM]658I--NXK.P9RH4HRXD<=F;!//11]:T_!UO)X7U*RTO5+*&34KRP>9;
MNUN9)C,8]N\-OP,DL"".* /1EZAJ^M6U]EM9K&TT]Y'LKN[>)P[M,"3MCR,A5P"3CDT^PUI&\1>&;[3A)'8>(;%E:WD8G84C#HV,]<94XZ\4 =S1 M110
4444 &<4F15'6;2._P!+FM)KJ6TCF 1I89!&P!/0-VST]>>*\[BBMX3X MATK6;^?0M-L;FWNI+1)VD4VQ4C:LF=W[QU.5'.1@9S0!ZGG-)D"N0\$17]AH
MDS3V=W':W=^[V-K*^^2UMVQMW[FR!D%MN20& [5',FH0_%ZT\[4Y9+:?2[EH MK3:%CA*O$,\?>8Y/)[<"@#L\BESFO'D?
5_#EM=0:E#=@3PQB\7SPS7GG-* MAW'8)"\:#.._'RUZ3H6MKJNC2W1MFMI+:22":!G#&-XR0RAAU''6@#8R#1FO
M,HC::CX(T_Q#XEU.X2VO)VN[BS@9LW;-E88% .?EP/E'4CGO5;4=&G@^'&GV MVKVS'6[RX^Q6"S7#,]JLTA*AF!^8QQ\YYY6@#U;-&:Y?6))?"?
@.\@TF.XE 'HU&:Q+OQ58V5Y);2VVIN\9P3%IL\BGZ,J$'*?K-E;ZWI4,4\L MT<4C+((5D,)GP,B)CU /<<'CZT ;&:.UXS:76J7VJ6?A580X6]O1/8W-RXB@
M"*C11^8/F= KY&,#-0:;PK;06\5V[1RX3VS232B41/&[+@N<%ER,*< M$X S0!U>12YKR30&O+37_#ME=VNII?WPN8-=>Y+A)V"%@5).&Y&5*= <<9Q7
M;>!K^>ZTB[L[N1II-+OIK$3,M%(V=IV\'M0!YK>:3I,_C75M.LM.\,::;>.&5WOM/65 M[@N#\P&]0 ,8[Y.:[[1X%M='MH4-JRI& #:1>7$?]UYDAN##-NQY8
3<,=\Y'Y5L5CWS68\6:0LZ2&[,-Q]G9 M3\H7";_^.X_&MB@ HHHH **** "BBB@
KGO&9MVT:*WN+7[3+W.:Z&L#QAI=KJ^A_9;Z>R@B\U'WWT>^/(.1QO7G/3F@#&\ M$:?!H6LW>C369CU&*VBD\\7;W*F#)"H&<
K@AOEQWSS6OXP_X1=*_P"PO9_^ MC17*>MTN+QU>0;=,OI+>VAN8[RPC="K;F&USYK D8R!Z9KJ_&'_'KI7_87 ML \ T:* .AHHHH **** "BBB@
K.U71QJGEYO[^T\O/_ !YW!BW9]<=:T:* M.>_X1%?^@[KO_@P;_"C_ (1%?^@[KO\ X,&_PKH:* .>_P"$17_H.Z[_ .#! MO*/^$17_H.Z[_X,&_PKH:* .>_X1%?
^@[KO_@P;_"L;Q=\/'UOPGJ.G6NM: MK)//"1&MS>LT;,.0&'ID5W5&*:=G<#XAT_X*^.)_$::_X1%?^@[KO_@P;_"C_A$5_P"@ M[KO_(,&_P
*Z&B@#GO^$17_*#NN_\ @P;__H_X1%?^@[KO_@P;_"NAHH MK6%G]@M$MQ/<7 7/[RXDWN?J>]6;** "BBB@ HHHH **** "BBB@ HHHH ** M**
"BBB@ HHHH **** "BBB@# N_!.AWM[<7,UO*OVI@US#'<2)#<$=Y(PP5 MCCKD!YVN'M'O)6@:0MN),1;:?FYQC&:?J7@30-5N[BXO;65 MS!7144
<]8^'&C\8WOB*_\ L[74D M()0C M;"&+?,3U8DC... 5+]7A+3-4U8:G.;R*\$/D"6VO)83LSG;\C#OS6Y10!AS^ M#]
(N;R.YN4N)601AD>ZD*2[/N%TW;7(]6!K.O!(YJW10!4DTNTEU:'4GBS=P1- M#')N/",02,=.JC\J@U70+#63"UXLJRP$F*>"9HI(\\, ZD$]QGFM*B@"@FB
M:?'I]O8QVRK:VSJ\<2Y"@J<@GUYYY[\U#;>&M*L]WMBMW-N+'S&*@MC< MP7.T$X&2!DXYK5HH Q=0T'[5X@M-5@9%DCB>VN4=E;]%
&;I&@6&B"4V2RM),09)IY MGFD? P 7MJB@ HHHH **** M*VHZ=:ZK8RV>H0K-;RC#HW?G(/L0<$'L:Q9? >A3VODS1W3M]H2Y,[7DIF:1 M!A"9-
VX[1T&<"NCHH IZ;ID.E6[0P2W4JLVXM' M4WBS=P0O#')N/",06&.G51^56Z* ,Z]T'3M0BO([RV$HO55)LL<[$ MW$[%_P!D8' K6HH
3%4]4TBSUBT%O?QEU5Q(C(Y1XW'1E8$%2/45=HH PCX- MT;[!':K!*ACE:=;A+AQ.)&X9_-!WY(X)SR.*U+'3K73;&.SLHA%!&,*HY]R2 M>Y)Y)/6K-%
&'9^%=/TB>2ZTN)_M6QDA-S/)*L(8Y(0,3L4G&0N.E6/#VC+H M6DI:!_-E+-+/,1@RRN=SMCW)_+%:E% !1110 4444 %%%% !1110 4444 %% M%%
!1102 ,DX% 'G6OZG!<>-[RPUW6KC2[6Q2WGL5AMU8,Y#%G+-&WS \ #& M!SWKN=(DCFT>VD@O)+Z-D!6YD W2CU. !^@KSOQ!XDTI_$]ZVI:O<7-
A]G0: M>-(U$*(WY\S>$<'=G&"V1C\:[CPE->7'A'39=3N(KJ[>!3+-$ZNKGUW+P?_)]OEQ^-;%8]]#;/XLTB66XV7,<-P(M8=O^L!";CGMC _.MB@ HHHH
**** "BBB@ K@O&NN26NI:A%.(6M--TDWR6\ M*NMU,S%$!W=E(' P:?I>GFR69X;%9H',_7SV)#*#P MJ]>AR30!
[%D4F17!>/M9D/A&_P!2TO6]2T9M*G:)Q!:KNNI.%6-?-4@@LPPR MUERS^.O#$>F7^LW_ -OL[:R3[8?W:-^?.P8&/:!N+EVB52O& V: /4LYHR*Y[
MP=JT>I:*J/JL6IWUO\MZ\>,)(>2HP!P.@/<"N?U#7M>F^'DNOZ7=0PM<7/F@ MRIDPV_F;0J#NQ &2>F3[4 >@Y%&:X#Q%K6J0:AK-
Y:7TL$6AM:JEJJJ4N/,P M7WY&3PV!@C&*V/&FI:K;>"]4O-!9+:YM4<^9J,Z:7J5G>/&,LMO.LA4>I /% %_M(HS7!6+:Z^OW6G6?B!
[Z1;:3[;6L8'.0I;*DG&%)ZUH>$]4NC) MJ5I>S7EU]FO%BA^U1 7"HR@[I H "D[L-CI0!UN0**X>%M7;Q@VG0Z]/>N\< MS7PCB18;%6'[D)QD2=."3D9)
XKH?"^JR:QX=MKJX $XW138& 71BK'\2N?Q MH UZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ IKG"G-.H/- 'D][K.G M>+KZ:VU*"ZT?0(I"C0+ILRW&H8/.XJGR1'T!W-WP.*],TG[%_9%L-*B6&S$8
M$,:Q&,*HZ#:0"/IBK>*6@#'OK6.7Q9I%RUS&DD$-PJ0G[TFX)DCZ8&?J*V*Q M[ZR:;Q9I%X)(U6WAN%*,WS-N"<@=\;>?J*V* "BBB@ HHHH ****
"BBB@ K MGO&'_'KI7_87L_\ T:*Z&N>\8?\ 'KI7_87L_P#T:* .AHHHH **** "BBB@ M HHHH **** "BBC(/>@
HHS1F@#/U[1+/Q'H=SI.IJ[6MTNV0(VTD9!X/;I6 M-JOP\/ZSKUOJU];S-<0K&K(D[+'.(SF/S$!P^T\C-=3FC- &9KF@67B"S@M
MM2$C1P7,5TH1]N7C;\5G%G.)XTW84N 0"1WQG(]^:O M9HS0!B>'?">E^&/M7]E)*OVEE+^9(7VJN=J+GHHR<#WJ*T\,1CP_=:%?$/8- M,Q@$9*LL9?
>%/T.1QVQ3?&/B.[\.V-B^FV,=]=7U]'9Q123>4NYP<$M@XZ>E M8.L^+_&VA:+=:IJ'A33A;6L9DE*;J6;:/0>7S5*+8KG2:AX3TW4M4%]<>>&8
MQF:))2L=P8SE-Z_Q;3TK1U+3H-5TNYL+P,8+J)HI K8.UA@X/:I[>7SK:*4C M;O0-CTR,U)FI&1^1&;=860/&%"[6&00*:EI!%N\F%(BPP3&H4_I4V:,T
XGN"#+<7,F M^23 PH)] .E:>;,T @:;2NB M.';6"MO,2DN_]R2S-^))-:-% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444
';W2=AO;>_D7$:O]QPX.TJ?4'K5#Q9I.OV7Q TSQ;X?TN/6E@L9+ M&>R,ZPR*&8,'1FX[8(KE]4^'GB/Q&T]_KEG MSK^I6@O[6*8,EG80L).-[M$]<>M
'I<7C;PO.8A#XATR0S3_9XPMTAWR_W!SR?:JB^/-(ADU-]6NK/3;.Q MN_LBW4]Y%MFD !88!RI&<8/->;M\,M5EO/M/]A6\#WGB7[=/Y9C4PVD
_:JZ;\/O%>C7&F:M<>'+37KF>VNOM5C /$]C+H$$^@6MBWAN2XNI-1CN$>35)F#!0,Z#H7:Z8?(A/5@,]N.* MZ_XBZ;XC\3VAK@[SP5XMC^$-CX-
/AY;Q++5@LPM[F.'[99HQ!7EOA+X?:OIOB?0+ZQ\)S:#'I$3FZDN-5%T;S,> B)DA"6YSQBNW M\=Z=KOBSX8R65II'V;4]1\N&:!YD8VT3./,^?H?
E':@#I=%U]=6\)VFNRV[V M<5Q:BZ,4K LB$;N2..G-8O@CQU>>-$^U+X=N-/TYXO,ANY;J*02<\#8I+*2. M>0*FUJVU>?
0=4\/Z/I42Q)IHBM;FXF'E3,5VF+:I# 8_BXZ\5SOPO\%W^@ZU MJ.JSZ);^&[6YM8;:/2K><2@NGWIF(XR**1H=1=V'F2*@('EC
M/+>M6O'IO+77_"NJVNEWVI16%Y,\\=E%YCJ&A90<9',?$-_XH\/C2K'P MCXBAFEN[9_,N+(*BA)D8DD,>P-:16VA+9ZC1116904444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
%%%% & M-?V$_B[2+V,+Y-M#,/\ MCUTK_L+V?_HT4 =#1110 4444 %%%% !1110 4444 %9&H>'8=1NS<27^IP$ MJ!LMKZ2)./\ 94XS6O10!SW_
AUM_T%M<_\&LW_ ,51_P (=;?]!;7/_!K- M_P#%5T-% '/?\(=;?]!;7/\ P:S?_%4?\(=;?]!;7/\ P:S?_%5T-% '/?\ M"'6W_06US_P:S?\ Q5'_ AUM_T%M<_\&LW_
,570T4 >>^+_"5Y;QZ1?:&- M5UB>QU2&Y>UGU%F#(N[./,;;GIS5?Q7J7BOQ'X1U+1X? U[ ]I_8EE>^@(4G
MN<-7I5)BJ4MA6.;MO!L"VL0DU36U8(H91JDV <=/O5)_PAUM_P!!;7/_:S M?_%5T-%2,Y[_(0ZV_Z"VN?^#6;_
.*H_P"$.MO^@MKG_@UF_P#BJZ&B@#GO M^$.MO^@MKG_@UF_^*H_X0ZV_Z"VN?^#6;_XJNAHH Q+3PO!9W<=PNI:O*8SD M)-J,KH?JI.#6W110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%%!H M1G5/OL%SZG%(TB)]]U7ZG%<'XGTM]4$8.]O;;;KYMK "31[Z4QM%N8XEC)4K
ME@"D)Q]TA)I0P894@CU%>(;? +G_A#B^F1ZU;W#ZC-%IN]"+=#@K$?,.,Q M]".QR!7=?"_#Z#]Q$@M+:?49FAT]/-@!A3$PZ!MP+$#@;N*
.T:5%.&=0?0 MFG9%>?VFA:5K?Q,\6C6+"WO5CAL@AGC#>6#&^<$]/PK TKQ5K8\-Z?9:==W$ MTZPW,L;1P++(*3M'$[O(0BIM'+$[CB@#U_(]:0L
,D@#U)KS*/QIJRZ7!/. ML)N-:TF"XTI%3C[2Q"/'_M %U;Z9KHO%UMI_]A6#^*+B6>&WF1I+6%,_VA+M MPL?EC[V6Y"]..>!0!U9=0H)8
'H30>&=0LH=*_M[2);_ $O;=O\ V3"X ME%BTCAH@02 P5.*[+X<7-Y=_#W2)M39FN6A(8L^XD!B <]^ .>] ' M3T444 %%%% "8HQ2T4 %%%% !2%U#
%@">@SUI:\AU\W-UJ_BS5-1M[:XM]# MNX?+W%A3=]H9B)2,X0@$XP3D#@T =OO7 .X8/0YZTN1G&>:\8_L6^NM&O(%BC9 M=*N[V.2 S!8=.>15:.6-
C]Y8QDCHPW' '2NCT#Q1<1>)6BO[LUY<16DERTN M'CN MAZ2O$%V'?8%MV/85P_AQ[J.U\/Z_J26BWFJ-=>#[+_ (1/4M.TB2STN[NKS3GF2^T^(H\G
ME[YSWQD57TO6CJDKQ_P!FZA9[!G==P>6&]@I-&1G&>:YCQ!ID&O6\'VRRMY=22*1K;3;ZY_=,> 78+G=@8P0#C=VS7,Z
M/J#V^B^"-6@FFEGFG_LJZ,YRTRG>#GDYVNF0V: M(*-[NTK$[P0W#<8P.* /5 ZM]U@<>AH+*I 9@">F3UKS_P &;T MU[;1'M(X+2WSL:_="29\-]W(.
QY;J>U9'C>VGUC7]>-K D[Z=I,;N;F3:;! MCN?S(,=7PO.2HRH^;M0!ZON7=C(SZ9I00>AKRB2VU.VUJ'7:,%FOCYMO?.P\ MR:%K< 1,G4!"#
(>W']Z:ZCP%KXU+3Q9?8!9B&U@N8<3>;YD4P)5F.!AS@EASR M>IH Z[F>;Y;P3H;>%O"EC:Q6@>YNG\^],6$5))/F8@(!]E;Q(\]H[O]+
<$F+R"G3RMW'7. #M'6@#V*@G'6LK4]<.F7"Q? MV7J-YN7=OM+?S%'L3D5Y1((W-UP.^: -OS M8R"?,7 Z_,.*7=G;)#/?.)+ETX\
MU@,!B.F<<9J[10!AW_@S0=3U"6^O; 27,ZJDLBRNGF!> &"D X![T^^\(Z#J M(MA>:9"XM8_*A"@H%CX^3"XRO_^4\5LT4 @4G '/?
@5HZQX>TO7Q;_VM:B?[,YDA.]E,;$8)!4@I#BM.B@#!F\% M:!<6D%M/8>9' 6,>Z9RR[OO#=NR0>XSBMN&&.WA2*!%CC10J(HP% Z "GT4 M%%%%
!1110 4444 %%%% !67>>&])U#4H[^\LHY;F/&')(S@Y&X#AL=LYQ6I M10!DQ>%]&@UE]5BL(UO68N9D6.L6?V74[=;B'<& ; M(*L.C
CD$>HYJ[10!G6WA_2[/2_[.MK...T+;VB&2&;.[))Y)SSD]:#H&EMK M:ZNUG&;]5VB?G..8Z=,X.,]<<5HT4 96KZ*NHW5A>12^1=V$WF12[=V5(PZ$
M>C#]0#VI+?PSH]OJ$E]#81)<2[MQY(^;[V%Z#/? Y[UK44 9FE^'=*T66233 M+-('D&"02V!_=&2=H]A@5:O].M=3MOL]_"L\.]7V-TW*0RG\" :LT4
HHHH M K1:=:07]Q>PP*ES=!!-*.KA6248,59<]<,I!&>XSS59O#MQ_:NFS+MCM-,C(M; M1(P%1R-N_P#!<@#W)K:HH **** "BBB@!"
RD,,@C!!K#7P5X>6WN[<:9%Y- MY&8YHR6*E#U4#/RCV7 K=HH R]*\-Z7HDCOID#Q%U"G=,[C Z##$XIFJ>%=% MUJZ2YU33X[B95V;B2-
RYSM;!^89'(K7HH KM8VSW$@'8#@5HT4 9-MHHLO$-YJ5M*52^1/M$& MWAI%&!(#V.W@^N!Z5++X?TN:SO+66RC:"^E,US&1Q*YQR?\ OD?E6C10
@&* MR%*:&FL?VHNG1\WF3S!G Y*:)>:J-2N=.BDNPRN7.<,R_=9ESAB.Q()&!4FE: M.+"]U"]FE,]W?2AY)"NW:BC"(!Z ?F23WK4HH **** "BBB@
HHHH *S]4T. MPUE$348GD6,DJ%E>/!_X"1FM"B@#GO\ A!/#W_/I-_X&3?\ Q='_ @GA_\ MY])O_R;_P"+KH:* .%\7^$=&T[P=JEW903Q7$-
LSQR+>394XZ_?K8'@3P_C M_CTF_P# R;_XNKGBC3IM7\+:CI]H5$US T:;S@9/K6J/NB@#G_\ A!/#_P#S MZ3?^!DW_ ,71_P ()X?_ .?2;_P,F_\
BZZ&B@#GO^$$\/\ _/I-_P"!DW_Q M='_""'>'_ /GTF_\ R;_ .+KH:* .%O_ GH\/B[1[*."807,-RTJ?:YOF*> M7M_C[;C6S_P@GA__)])O_R;_XNK%_97$WB[1[R-
,V]M#'_ /GTF_\ R;_ .+H_P"$$\/_ //I-_X&3?\ Q=++10!SW_"" M>'_^?2;_ ,#)O_BZ/^$$\/?\^DW_ (&3?_%UT-!XH X7PQX0T:^TF:6Z@GD= M;Z[C!-Y-
PJ3NJCI_ & _"MG_A!/#_\ SZ3?^!DW_P 75SP[I\VF:;+!_X03P__P ^DW_@9-_\76+X3\(:-?\ MAR*XO()Y96FG4NUY-DA9G4?Q]@
/PKN\UD^&M/FTG0H[.Z*&199G.PY&'E=Q M^C"@"I_P@GA__GTF_P# R;_XNC_A!/#_/SZ3?\ @9-_\770T4 <]_P@GA__M])O_R;_XNC_A!/#__ #Z3?
^!DW_Q==#10!P?BWP;HEIX>,MO;3(_VJU7/ MVN;HUQ&"/O\ H36W_P ()X?_ .?2;_P,F_\ BZOZ]IK:OI)M(Y%C;SX9=Q&> M$E5\?

CMQ6EF@#GO^$$\/_P#/I-_X&3?_ !=' ""'>'_\ GTF_\#)O_BZZ&B@# MGO\ A!/#_P#SZ3?^!DW_ ,71_P ()X?_ .?2;_P,F_\ BZZ&B@#A7\):,/'$ M-@+>;
[,VG23%/MRN#XW@OPG^_MC+ITD)?(^^9$8#'T!K9H Y[_ (03P_\ \^DW_@9-_P#%T?\ ""'>'_P#GTF_\ M#)O_ (NNAHH Y[_A!/#_ /SZ3?\ @9-
_\71_P@GA[_GTF_\ R;_ .+KH:": M ,#P-+)-X'TMYI'E?R<%W8L3AB!DGKP*WZR?"VFSZ1X8LK"[*&:!"K[#D9R3 M_6M:@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "J&IZU8:,D;ZGGI5*XFFT;Q9?W_B5-96
MPDU",6=W%>G[+$C*BJKQJ_0R9SE2.>:Z+4O",6IZ_:ZM)JNI0S698P1PR($C MW !L H3R!SD_E2W?A&UU"^\V_OK^YMO/6X%A),#!O4Y'&,X!&=N<9[4
;PZ4 MM%% $5S7EW;VTH*RK:,J^:I_A)('TQ0!BZ@TVL M>,-/T.6\NK:T&F->R&UF:)Y7W! -ZD' R3@'DD9JYX!U*[U'PN/M\S7$UK=7 M%H9V^]*
(Y616/N0!GWJ6Y\'V]REDYU+48[VR1HX[^.55F*-U1CMVD<#MV%:N ME:5::+ID-AI\?EV\(PH)R22IC2C=*M_*A M:.'!R>#SG&.U:5,>,2(R,2
PP<'!_.@#@O!<\NEWEAIWB6/68-;NH'P][>F> M"X93E]@#LJD#!Y ..G>O0*PM/\)VUEJD.H7-]?:ERA_(#?>V@ 1@\GF@"3P9JEQK?
M@K2=2O,?:+JU224@8!8CDX]^M;=0VEI!8V<-I:1K%!"@CCC48"J!@ 5-0 44 M44 %>>QS3:-XJN;KQ.FLI!<:ILLKM;TFT5'"B-&C5^ 6R.5QDBO0JP)O"-
K= M:BEQ?7U_=P1W N8[*:8-"D@Y!QC)P>0"2 >W H WZ*** "BBB@#BI3J-K\7K M".35;F:S0*X<67"Q1[&C .!U;YCR?7M6%+J6H?\(R?
&"ZC>+=C5_)^R^7]W[O.[&<]Z[*Z\(Q77B>'76U74DN8%9(HTD01JC;2RXV9P=H[Y] MZC7P-I:ZC]H$EU]F^U?;?L!E'V<3]=^W&=1
MMOC!;PS:K<3V=UIL]JV9 6*+:\8& .K?,?F/KVJCI\TVC>)G?Q1'K,9N]4EC
MLKHWI:T*N3Y2&-7XR.!E<9KHI_",4_BF+7FU74EN85*)&LB>6L;$%DQLS@E1 MWS[TI\(VLNI0W5[?7][';SFX@M;B8-%%)SA@,9.,G&2<4 ;XZ4444 %
(PR.N M/>EI&&Y2,X]Q0!P#2SZ1XUGBTC4;^_ALM-GGU2.ZN&EC60X:$#/"N<-\JX^7 MMTJMIMU?V/\ PANK-J=Y>4-':!N MNP8STX&2<#@4
=&.E%% !7/>,8K)-%EO]3U*^L;>UC9O!#N&B+,>%^[RQSP M%Z$GH:Z&L/Q!X6MO$5Q8S7%Y>6SV.AEA^S2*%WXP&*LI!([<<4 5I"J["V'3)X;(!ZUV?
AS4;+5/#UG=Z7)+):O'A& MG+&08."&+<[@00<]Q5>X\-O<6\$8UW5HI(59&FBG4/*#_>^7&1V(-7]*TJT MT73(-/TZ+RK:!=J+G/N22>I)))/=?
$CXS:%\.6^R74%S>ZFZ;H[:-"JX[$N1C'TR:]%K,USP[I' MB73WL=>T^"^MV_@F0"N#U!]Q0!F6?C_ $2XL8)Y)+I'EC5V46%P0I(SC.SF MIO\
A.=!_P">]W_X+[C_ .(K]W_X+[C_XBN@HH Y__A.=!_Y[W?\ X+[C_P"(H_X3 MG0?^>]W_ ."^X_\B*Z"B@#G_P#A.=!_Y[W?_@ON/_B*/^$YT'_GO=_^"^X_
M^(KH** .?_X3G0?^>]W_ ."^X_\B*/^$YT'_GO=_P#@ON/_ (BN@HH Q+3Q M=I%]>1VUM+:Z#*2#BM#R/^ 5 MOT4 <_\ \)SH/_/>[_\ !?[_ /!?[_ /!?
K:59ZYI5QINIPB>TN4V31$D!U].* M .8^'_Q/T/XC6+S:,MQ%/" 9X)XB#&3_ +0^4_@:[.JFFZ78Z18QV>EVD-I; M1C"10H%4?@*MT %%%% !1110 4444
%%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110
4444 %>>R>+KZ?QKJ^D'7M,TM;.XBAMX9[0 MR23;XU;.=X[MCI7H58>CZ%)IFO:[?O.LBZI<1S(@7!C"Q*F">_WH0-- M"JQ$L
"%VE>H;+=V+"748KY;F>!I+A$1T;R%8G"I\O M!O_"M29M:D74MIN9XYM-!CR++;+YQ7'<&3D^V!VH W(?&^GO*EO,"2-I
2A."1M(!Y!/2FW'CO3H;E+:&TOKJXDO9;*.&"(%GDC77\,LL6HW5](L<14'SHPNP9/\ #CJ>M &OH_BRVUJ^,%I8WPA#21B[:(>2
MSQG#+D,2"#D?,!G!QFD\4Z]<:3_9UEIT<;ZA]MU]EMS+GRX_E+,[8Y("J>.Y MP*R[/P;=1>-4UII+"V6.25W:QB>*2[## 689VG'!SC)
('3FMCQ)H+ZS#:36E MP+;_T^X%S:3,FY0X!4]P[J02#WYH I_VMJ?AZ&]N/%,MM<6$*HT%W:Q.CR.Q MV^5Y66YR1@@\Y[8IDOQ T^#;%/8ZA'?-
<)UCFN+QN;K1H-.!$9&UHT M=2_7H=W3VH MVWC[3+B*1WM;^#;:)>1++!\UQ$YVJR!22,'.*34_ 5W?6:10:FL#QZ/%I
MP8(PW.DBODX(.QMNT@VBB*8='3=OWC/ 7:<_AZUOUP_AG06_ MX3O6-;,=Q#8%R+."XB,965P//D4'G#%%P>_-=Q0!RWQ%U>\T/P@][IUP]O-]
MIMXC+'$)&57E56VJ0*?#3Q0!BZ)\2]/U>[$#P>2O[]7N$F66$/$]N5#CKE&W ^QIEO\ M2En;!]131;H:?:^7]MG:10;?>
1A>K85E8XZ9[U'<_"Z&_T>]L[[5[B2:\OU MO6N(XUC,9V"-HU X"% 5QV!J]]/@*.]GOHH=2EMM,U)XWO;)(P?,*!1\K]4! M"*".>G&*
+"^-8'5"+.3#ZP=*'S#[PS_P!..G6LM?B2[:9:WS:*8(;ZY:VM M'N;Q(U=E+ EF(P@^0XSUR*M_\(&1JJ31ZM*EE'JG]J):"%?];CD%^I7G.,<> MM6$\
(26OA>VT>QU(*L$CLS7%JDR3!F9MK(?0MQ@CI0!NZ;>/?Z;!=2V[6SRH M&:%G5RA]-RD@_45P5UXYN8OB&$%_;+H<-ZFDR6Y*^8UPZ;O,S][
8JF.G)KL M?#V@1>&_#L&DV!V&!6.OPWT?_(0^319$22>5'+:B M85\\RLQ;S=V/O:CG\,4 -F]B MQ)'#9_*NGM[[6?$VOZK9VNHR:-
#I0BA80Q1R/+,\8W4*1WTAM5D M2X=!@2A"1M?'N1TXXH R?$C^)=-L=&FD\026]U=WUO9W,=I!$8<.2&9-Z%@3 MUY)
KI9+B6RTV6QL]1AO]82%O)6[E1&D?!*[@@&!TZ#I523P7:G1-+TV.[N MFG7D=YYLAWO,ZL6.XG^\2>GX5HZEHD%[#:IQ>*M6>:3 M1X-
0D:676(K"&\N;=4N8XS$9'=H]H7/RL%)4 CG!QST&D^#KW2]";28M:$4 M4>4]I:B&19 P8NS;CO)(^;/7)ILG@3[3)-?W>IN^LR3PSQWJ0A5B:($(!'D@
MC#,""=QY'% &-J'B;Q'9>%O%45A);WFHZ',Z+>70"CRO*$@L:;]?]]"C[1#_P]4_[Z%1_8+3_GUA_[]BC[M!:?\^L/_ '[% $GVB'_GJG_?0H^T0_\ /5/^^A4?V"T_Y]8?^_8H^P6G_/K# M_P!^Q0!)]HA_YZI_WT*/M$/_ #U3_OH5']@M/^?6'_OV*/L%I_SZP_\ ?L4 M2?:(?^>J?]]"C[1#_P]4_[Z%1_8+3_GUA_[]BC[!:?
\^L/_ '[% $GVB'_G MJG_?0H^T0_\ /5/^^A4?V"T_Y]8?^_8H^P6G_/K#_P!^Q0!)]HA_YZI_WT*/ MM$/_ #U3_OH5']@M/^?6'_OV*/L%I_SZP_\ ?L4 2?:(?
^>J?]]"C[1#_P] M4_[Z%1_8+3_GUA_[]BC[!:?\^L/_ '[% $GVB'_GJG_?0H^T0_\ /5/^^A4? MV"T_Y]8?^_8H^P6G_/K#_P!^Q0!)]HA_YZI_WT*/M$/_
#U3_OH5']@M/^?6 M'_OV*/L%I_SZP_\ ?L4 2?:(?^>J?]]"C[1#_P]4_[Z%1_8+3_GUA_[]BC[M!:?\^L/_ '[% $GVB'_GJG_?0H^T0_\ /5/^^A4?V"T_Y]8?
^_8H^P6G_/K# M_P!^Q0!)]HA_YZI_WT*/M$/_ #U3_OH5']@M/^?6'_OV*/L%I_SZP_\ ?L4 M2?:(?^>J?]]"C[1#_P]4_[Z%1_8+3_GUA_[]BC[!:?\^L/_ '[%
$

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}/++K(0,N/G('3%2P:UXCO_%EQ+ \L<=KK/V-X9+J%+?]."%(,9_>% MR#N!{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end GRAPHIC 9 img267163886_2.jpg GRAPHIC begin 644 img267163886_2.jpg M_]C_X 02D9)1@ ! 0$ D "0 #_X0+T17AI9@ 34T *@ @ ! $[(M . !2H=I 0 ! !6)R= $ < "T.H< < $, /@ M &UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT6QE(%-C=7)L;V-K/"]R M9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC&UP;65T83X-"B @(" @(" @(" @(" @ M(" @(" @(" @(" @

L M[N"[6:,H6VN T;%&.00>I'M7:ZJZ-\5M9L4D2*\U3PO]DM"S;=\[1IM7/J0I M KFK?2-1T7X&^(H-6A>TFDO;:5;2;Y947=MWM&>5#%2
2!G:>U3[1R2Z;#Y$ MK_,YO7/#]U=>(-)TW2/#3Z=>)-4UFSC:XMS:?8;J&Z66,;I624!HV*$\ $')&1TR,]LUQ&GCO3K0W"6 MUUJ/@Q+.RE<[0+AT.SD]"
<8'N0.]GYARJ[^9RMMX'\0WEOYMO8J[& W MOM$0N#&.=X M@+>801R/EY&",Y%:NC^!$U7X<7NOK1W210))?P11;#PV_>1M;/0$C(P0 M"#7=>!?!-
MH'CW0I[:SU+4$-M]H;6EG2.R)D1AL5=A+?>"X\P$G)QBN3\,6T M^K?!SQ%IFEP2WE\+^WF^S0(7D*=-P4L:M;?: M+2WB6
RB%)KBYB@260Y^1&D90YXZ+G"J*S[^PN]+OYK+4;>2VN8&V212#!4 MUZ3*IUCX;^&!H7AFW\1?84F@NH0)WEM9&83%"FY].MWEPUNF?
WI0OGG@[LCC&,"GZOI%YXL\!^#&T5!-#9P3V]Y<% ML1V:!@Q,S=$7;\V3VKGC)],6^O\ D;2BFVET.43P-XCE\07NB1:8\FI6$/G7 M%M'(C,J?+R,'#??
7@9/-5=5\,ZKHUC;WM[!$;2Y9DBN;>YCN(V8=5WQLP!]B M<]?2O5=7;_BZOQ)*G_F7)N1_US@KC[1XX_@@DDZ>9$GBE&=/[P^S'(_'%$:D
MG9^GX@X)7^9-X(^'&H7OB[2HO$&F*UA.OG36S72+-Y)! M'+W4M4U--*@06UC*WFRS3I%%"I?:H:21@H)/ !.37K5OH^HW?[0UOXCMXRVC
M7#+/#]J.X"&1&AV!5;H6)^78.?;'-<[IKB_\ VO:7I^EV^M:C!KINY-.D,V] MX2NP.BQ.K/M;J.0 P?$#PW8^)M,L]#6TM)X+*,,X: RJP7S!([.]DX ;!PP/0B]
MGAKP[J_A_P"'_CE-:M)+!I+2-$AG^5I-C\LJ]U&X#=T.>"><.525K>GYA&"_ M/\CC/!&A6WB7QKINCWSRQV]U(5=H2 X
4G@D$=O2MC_A%M$U;1/$5QHHO[*Z MT$AV%YK6&I M6-A.M>N^#)+#5?!NE^)]3(EN/!8G62-@,S)MWVX_!N!I@UX[T\-V<_PRO|
*Q$\DXN[;4([5$##RRK+DDC&<_C7,5WVG?\D$UC_L,P_^@"HF MVDK=T7%7N93_ W\5QSK!)IBI/(A>*%KJ$23@)O)C3?F3_N@^G7BLG1_#^I
MZ[IH.F6ZO':IYD\TLJ11Q+G +.Y"C/:)YY[*]5UAV_X:*\/?,>(I4#GH/+Z?
MJ:RC#)K'A'QGHFC(TVJ)KANVM(5W230!RORJ.6"M@G'3CUK%5965_(MTUWTS2Q9I932&:&2Z3R[)0Y 1IG(4X^Z"3SBN^NK*YTV'X565_(K7,&HRI*J
MR;_*/VF(^63V9<[2.Q!':H[VWDUG1O'NC:.&FU;^WVNGM(ES)<0+(P^4#EMK M'.!T_&E&HU_7F-P7]>AP#>$=;74#9M:*&6%9S,;B/[.(F'ROY^[R]IZ
[L$_M+UX]W:>"M3C\2:3INK11V\6HLC1SB[A\N6(D9*2[BC"0 DYQP3K+)"OGQN=[*JX.#G&T$9P>0:MU'?E3_*L2H*UV8_@I=&^*B:-_M!ID?
B"U:>5(+'^U(DEF"H3^\9#F,CK\P7.,>M2VF="$F7R6.4;HPY M'3UKEK*TFU_X-QZ9H$#W=_9ZLUS=V<"[IF1HPJRA!\S*,A<@<9].:F-1Z>B_M4IP7YG-?
\(AKA\06NB"QS?WB+);()4*3HR[@Z29V,I /(..",M/Q_!NNZ9I] MQ>WMDJ16I07*K<1O);E_N^9&K%X_P"T!7I7AXM8^*OAQH5](#JFGBY>ZBW;
MF@67+1QMZ,%'W>V:P_"C,]O\1]Y+;K"9CDYR?,/-/VLOZ];"Y%_7H>:4445T M&(4444 %%%% !1110 5U^K:#H?A)8+'Q$M_?ZR\:S7%O97,
<$=H&&5C9V1R[MXP3@ #._3UKDXI##,DBX)1@PS[5Z9XNM-5UOQ=+XN\&62ZW9ZG$A(2RCO3;. M$4-
%)&RML8;002!P>#UK,:LTNA<5HS%\&:/X>U_XE:=I\<%W-IEQ#(TMO=N MZNL#MMWQD;@<&4$-A<]QZ_I?AK5=8LYKRRMT%I
P62YN)XX(E8]%WR,J[N1Q MG->]V-O9VGQX\.P6D%G;S)I1%[%:1HBI>)/A#H]GX M=BDO9],O9S?V5O&7ES(08Y-HY*XRN??VK)5'?[OU+Y%;
[_T*O@[P:Q^*.G>'M_%FG.(YED9X3(0)%\IV5E=#R,J.5.#BL._|"&N:9ITM]>602& HMP%GC>2V
M+CY1+&K%H\XQ\X'/"7BO4M!E6W^(O@'1;B1'U/2["XCO65E;R6.010REV&Q6.&&W.#^(KL/ WA&STO7_ GJ5O::GJ!N
MHX[J74XITBL[9V)7RC\C:F!^4KO4DX ',*HW0 ^'?Q & -=CP/^VIH=1MV7 ME^8*"2OZ_D*?%/IG:F]PEN+:68FW=5<9YJWS.=EY$J
MRC=^8:MX,UW0K+[5]JI%:1,JL@DNHMTH.WE$W;G^\,[0<=\8-.G\$Z ;VL\T MMD@:V@%Q/;BYB-Q#&<'>\(;S% # DE1@')P*['XB7L5I\5?#US?
LQM;6UL7D MR"VV,'

HPB>U975_-0G&?E)P?8|^U7IO M!6O6U]=6EY:0VLEHRI,]S=PQ1[*&">8SA"Q4YV@YQGC@UW'@.&U\2^%=,_M M%E5?"&H-><3-
R,6;*TI'OF2/'L#^>/I^BQ^,K+7/%5Y;:EJU\^H8_LO2W42H' M^;S&)5SL'*C"=1Z='[1W:?3^D+D16\(>#6'Q2L/#OBW3F59!(98&D(#@1.RD
M.AY&0#D'"%<[I?AS4]7M)KNSAC6U@8+)V"8=C1F/08T*/,LK*1!,,%U #$8QN /6N9TH_VK\(;&ST?0[?7KJPU"5[RR M;SC*N\#9*$AD5F&/ER<_H:E5'OZ?
J5R+;U_0XZ+P7XAF\12:%'IDAU.-&D-N M64$J!G*DG##'0@G/:-,U+PCK6D:VJ?9DF\B22&XBF\J3&=CA&)1O9L&O
M1_"%_JMU\4K./6=/M],GL="> VBM;=FS%$L;% X9V96 ;HQ!'&17*>&B3\)/' M)R!)IY]#YKU7M)7^[\2>2/Y_@8]MX*UZ[L8+J&R3;/ES78>/\
M0=2\3:Q8ZQX>MGO=&ETR'RKB, 0VRQIAT=S\L>TAB=Q&,U:OU?6O ?A:?OO# M%OXBBL[1K:XC47#RVLP8EMR0R+@-U!(Y]>E+VCLG_2'R*
[/,+NTN+"\EM;V" M2WN(6*R12*593Z$&H:W/&>HZCJOC"_N];AMX+]G59X[9PT:LJA< AFY^7GD\ MYK#K>+;5V9/1E[3O^6GX?UJ[5+3O^6GX?
UJ[7CXG^*_ZZ'HT/X:"BBBNV@O=,U +Y\(E,;JRY*.CX(4@D'E2"!@BL2B@#?OO$D)\,_V M'HMB]C922B>X::X\Z6=QG&6"J H!'
7J,YKJO$^KZ78+X2_M/1OMTEOHMI/$ M\=QY1;[V4DRK;DRH(VD9;DYX\VHH ZB'QM//<:W_;MJ+ZVULAKF&.3RBC]< MHR-AMNWIR#D<'-
,TWQ39Z/>2KI^D,=.NK5K6\M;B[+O<*6SN+A5"L. "%X [MDDUS5% &]=^(K9?#KZ+H>GO96UQ*LMU)/<":6]:3^/=WQ
M&M_%7]FX\A57[+Y_WL1[/O[?QZ5Q]% &[IWB7[!HVO6'V3S/[86-?,\S'D[7 M+=,?-G..U:=KX]^S:
[X;M\KYLYQ@[NOM7HLKZM<)XPKQRB@"_KEK966O7UKI5S]KLH9V2"H/! MR.#]1P>HJA110 4444 >K?LY_P#(:\8?[MC_
"FKW6O"OV<_^0UXP_W;''^4U M>ZT >#?M,?\ 'QX2_P!^[_|08Z\2KVW]IC_(^/"7^_=_|H,=>)5ZN#_A_M,X,1\84445V',%%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%%
!1110!NVOB3['X'OO#IO:!9+^[CFN+O?R\ M:#Y8MN.S?-G/MBL*BBDDEL-ML****8@HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH O:=_RT_#^M7:I:=_
MRT_#^M7:\;$_Q7_70]*A_#04445SFP5ZS-X?TO5/A786UKI]O'K']G-J$4\4 M($DWEOAU+ 9;*MP/4>U>35WZ^,[/3O\ A";BQN#))I43QWL81AA68;EY !RI
M/3- %[X5:'IQV:CK=C#>#4+L6%G%! $NGFX_TJ^U",:WCV-\Z!LDYQ@<>N* -GQEH4WB#QIIMK M'-
';Q1Z)#/<7$OW88D4EG(')P.WK^=06DRQ7<5S;K! M)%O^XX =PRD@CJ"".F.1ULOC?28O&UO=P7.251]GB:XD7:#DLPEV#(XP!G)[C&2 -U_PSI_
MAV^FTZ]U>8ZC:^5Y\2V?[L[@I81OORO ;/S@.#STS]^/.@WWB7O!X.TS2T#W,AO64-G&%2, MGH#7 ?\ "E?&' /M#_WTW_Q-'>CA:D(0M)G'7A*4KI'G]%>@?|*5\8?|^T/_?3?_$T? M|*5|8?|/M#_-|-
_P#$T>WI?S![*?8_HKT#_A2OC#_GVA_P"^ MF_|B:/^%*^,/^?:'_OIO_B:/;TOY@]E/L>?T5Z!_P *5\8?|^T/_?3?_$T? M|*5|8?|/M#_-|-_P#$T>WI?S![*?8_HKT#_A2OC#_)]H?^^F_P#B:/\ MA2OC#_GVA_[Z;_XFCV]+^8/93['G]%>@?|*5|8?|^T/_'TW_P 31_PI7QA_MS[0_]]-
_|31[>E_'LI]CS^BO0/^%*^,/^?:'_OIO_B:/^%*^,/^?:'_+Z; M_P")H]O2_F#V4^QY_17H'_"E?&'_#[0_P#?3?|Q-'_I7QA_S[0_]]-_|M31[>E_'LI]CS^BO0/\
A2OC#_GVA_[Z;_XFC_A2OC#_)]H?^^F_P#B:/;T MOY@]E/L>?T5Z!_PI7QA_S[0_]]-_\31_PI7QA_S[0_|?3?_!-'MZ7\P>RG MV//Z*]_X4KXP_Y]H?|OIO_
(FC_A2OC#_GVA_[Z;_XFCV]+^8/93['G]%> M@?|"E?&'_/M#_WTW_Q-'_"E?&'_#[0_P#?3?|Q-'MZ7\P>RGV//Z*]_X M4KXP_P"?:'_OIO\ XFC_
(4KXP_Y]H?^^F_^)H]O2_F#V4^QY_17H'_"E?&' M_/M#_P!]-_|$T?|*5|8?|^T/_?3?_$T>WI?S![*?8_HKT#_A2OC#_GVA_[MZ;_XFC_A2OC#_GVA_P"^F_|
B:/;TOY@]E/L>?T5Z!_PI7QA_P^T/\ WTW_M,_31_P *5|8?|^T/_?3?_$T>WI?S![*?8_HKT#_(4KXP_Y]H?^^F_^)H_X M4KXP_P"?:'_OIO\
XFCV]+^8/93['G]%>@?|*5|8?|^T/_?3?_$T?|*5|8?|M^T/_'TW_P 31[>E_'LI]CS^BO0/^%*^,/^?:'_+Z;_P")H_X4KXP_Y]H?
M^^F_^)H]O2_F#V4^QY_17H'_I7QA_S[0_]]-_\31_PI7QA_P^T/\ WTW_M,_31[>E_'LI]CS^BO0/^%*^,/\ GVA_[Z;_.)H_P"%*^,/^?:'_OIO_B:/
M;TOY@]E/L>?T5Z!_PI7QA_S[0_|?3?_!-'_"E?&'_/M#_WTW_Q-'MZ7\P> MRGV//Z*]_X4KXP_Y]H?^^F_^)H_X4KXP_Y]H?\ OIO_(FCV]+^8/93['G]
M%>@?|*5|8?|/M#_-|-_P#$T?|"E?&'_/M#_WTW_Q-'MZ7\P>RGV//Z*] M_P"%*^,/^?:'_OIO_B:/^%*^,/\ GVA_[Z;_.)H]O2_F#V4^QY_17H'_"E?
M&'_/M#_WTW_Q-'_"E?&'_/M#_P!]-_|$T>WI?S![*?8_HKT#_A2OC#_GVA_M_P"^F_|B:/^%*^,/^?:'_OIO_B:/;TOY@]E/L>?T5Z!_P *5|8?|^T/_?3? M_$T?
|*5|8?|/M#_-|-_P#$T>WI?S![*?8_HKT#_A2OC#_)]H?^^F_P#B M:/\ A2OC#_GVA_[Z;_XFCV]+^8/93['G]%>@?|*5|8?|^T/_'TW_P 31_PI M7QA_S[0_]]-
_|31[>E_'LI]CS^BO0/^%*^,/^?:'_OIO_B:/^%*^,/^?:'_M +Z;_P")H]O2_F#V4^QY_17H'_"E?&'_#[0_P#?3?|Q-'_I7QA_S[0_]M]-_|31[>E_'LI]CS^BO0/\
A2OC#_GVA_[Z;_XFC_A2OC#_)]H?^^F_P#B M:/;TOY@]E/L>?T5Z!_PI7QA_S[0_]]-_\31_PI7QA_S[0_|?3?_!-'MZ7\ MP>RGV//Z*]_X4KXP_Y]H?\ OIO_
(FC_A2OC#_GVA_[Z;_XFCV]+^8/93[' MG]%>@?|"E?&'_/M#_WTW_Q-'_"E?&'_#[0_P#?3?|Q-'MZ7\P>RGV//Z* M]_X4KXP_P"?:'_OIO\ XFC_
(4KXP_Y]H?^^F_^)H]O2_F#V4^QY_17H'_" ME?&'_/M#_P!]-_|$T?|*5|8?|^T/_?3?_$T>WI?S![*?8_HKT#_A2OC#_G MVA_[Z;_XFC_A2OC#_GVA_P"^F_|
B:/;TOY@]E/L>?T5Z!_PI7QA_P^T/\ MWTW_,31_P *5|8?|^T/_?3?_$T>WI?S![*?8_HKT#_(4KXP_Y]H?^^F_^ M)H_X4KXP_P"?:'_OIO\
XFCV]+^8/93['G]%>@?|*5|8?|^T/_?3?_$T?|*5 M|8?|^T/_'TW_P 31[>E_'LI]CS^BO0/^%*^,/^?:'_+Z;_P")H_X4KXP_MY]H?
^^F_^)H]O2_F#V4^QY_17H'_I7QA_S[0_]]-_\31_PI7QA_P^T/\ MWTW_,31[>E_'LI]CS^BO0/^%*^,/\ GVA_[Z;_.)H_P"%*^,/^?:'_OIO
M_B:/;TOY@]E/L>?T5Z!_PI7QA_S[0_|?3?_!-'_"E?&'_/M#_WTW_Q-'MZ M7\P>RGV//Z*]_X4KXP_Y]H?^^F_^)H_X4KXP_Y]H?\ OIO_(FCV]+^8/93
M['G]%>@?|*5|8?|/M#_-|-_P#$T?|"E?&'_/M#_WTW_Q-'MZ7\P>RGV// MZ*]_P"%*^,/^?:'_OIO_B:/^%*^,/\ GVA_[Z;_.)H]O2_F#V4^QY_17H'_M_"E?
&'_/M#_WTW_Q-'_"E?&'_/M#_P!]-_|$T>WI?S![*?8_HKT#_A2OC#_M_GVA_P"^F_|B:/^%*^,/^?:'_OIO_B:/;TOY@]E/L>?T5Z!_P *5|8?|^T/_M_?3?_$T?
|*5|8?|\ /M#_-|-_P#$T>WI?S![*?8_HKT#_A2OC#_)]H?^^F M_P#B:/\ A2OC#_GVA_[Z;_XFCV]+^8/93['G]%>@?|*5|8?|^T/_'TW_P 3 M1_PI7QA_S[0_]]-
_|31[>E_'LI]CS^BO0/^%*^,/^?:'_OIO_B:/^%*^,/^ M?:'_+Z;_P")H]O2_F#V4^QONG?|M/P_K5VNLM_A#XJM-WG6|(W8Q|S=O^_U M-_PJWQ)_SQB_[Z;_
.)KR\1)2]-H[],6H),XVBNR_P"%6^)/^>,7_?3?_$T? M|*M|2?|\/&+_+Z;_P")K U.-HKLO^%6^)/^>,7_'TW_P 31_PJWQ)_SQB_ M[Z;_.)H
XVBNR_X5;XD_P">,7_?3?|Q-'_JWQ)_SQB_[Z;_XF@#C:*[+ M_A5OB3_GC%_WTW_Q-'_"K?$G_/&+_OIO_B:_.-HKLO|A5OB3_GC%_WTW_Q-_M'_"K?$G_
#QB_P"^F_|B:_.-HKLO^%6^)/^>,7_'TW_P 31_PJWQ)_SQB_M[Z;_.)H XVBNR_X5;XD_P">,7_?3?|Q-'_JWQ)_SQB_[Z;_XF@#C:*[+
M_A5OB3_GC%_WTW_Q-'_"K?$G_/&+_OIO_B:_.-HKLO|A5OB3_GC%_WTW_Q-_M'_"K?$G_ #QB_P"^F_|B:_.D_9S_P"0UXP_W;'^4U>ZUXS\#=&N]!\6>,K'
M4%59ECL&(4G&"LV.M>S4 <1XH_Y*YX$_W-1_]$I7;UQ'BC_DKG@3_SM(C+-(W|*CV[GL!W-_%VBN B|>
M>++NQ75;+X>7DFE,OF)YFH1I>/'UW"WQUQ_"7!/I76>'?$.G>*=_MM8T:8RV MERN5+#:RD'#*PL_"""/:@#3HHJMJ4]U:;5=SZ?:?;KN*%W@M?-$?
GN%)5-YX M7)P,G@9S0!9HKG9_%9L]>|-:+?:?)#?:Y#-*R"566V,4:LZEA]XY< $<'D^Q M?X3\4?|"41:N_V/[+_9NK7.FX\W?YGDMMW]!C/ISCU- &_16?
=WFHPZWI]M M;Z7]HL;A93=WOVA4^RE0"@V'E]Y)''3'6M"@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HH MHH HZE_RR_'^E4:O:E_RR_'^E4:!A1110 4444 %%>N2Z@V@>!HK MRULKZ:R,SZTD1=HVP3M,>1V-
3Q_%%&T=YYM&FMM1MM6@TN]T^:=0T#RL '#J M"&7!R.F<'IUH [^BBB@ HHHH ***R_$>O6GACP[>:S] D:WM$W,L:Y9R2 J@ M>I)
_&@#4HKB8O'.K66]:;!XJ\+OH]KJDXMK:Y2^2XVS-]Q)% &PMT&"PSQ7 M;4 %%%% !1110!S?@S_DK'C?_KWTW_T":OO*\|!G_)6/&_ _7OIO_H$U>@4
M".(\4?|)7/ G^YJ/_HE*[>N(\4?|E<|"?[FH_|HE*[>@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **Y+XJ_\DC\4?]@N?_T
MUN>'O^19TO\ Z]XO_0!0!HT5YQ\/_P#DJWQ_'P"OVS_]$58D_P"3D+?_+%. M7_TKCH[^BO /@QK%
[X/BTR'5YS)H/BJZN192M]VTO4GD3RCZ"14!''T#QU- M>@>!76/QJ\1'=@JKJ$DG_II6U\4[?PY=?%[P5%XS-BNDFTOO--_*L<6[:FW)8@= M<8H
]AHKPO5;7P5I_BSPM_PJ":R.NR:I$+B/1;GS8VL^?.\|*Q7:!CKSZ5[I M0 45Y-X1T"P^*B7_(]\8K)]=K+?30::ITLC"WM8(W*_^6" SL026.>V.5*F
MDV_A'XB6O@M7EG|*^+-/ND33KB9G%O+&H,BQL3N"-&Q^7/!Y&* /5**\0U?X M2^!K?XO>&])A\/0)8W=A>2SPB23#LACVG.[/&X_G6[XETRWTK4O"?
PU\)F71 M-,U66XN+Q[25ED6")=[1JY.1O9L$@Y SZT >I45YWJ?PHL=,C@U#XQ])D'Z-_[+56T)OJ=U14-S>6]H%-S,D>[A03RQ]
M.I_"HTNY)L&"TEVGH\N$'Y'YOTJ2BU14,EU#!Y:W4T4+R<*K2 ;C[9QFB>[M MK7:;I]N(H=WW?,<+G\J)!*9%-%.F^'1)%Z;D8$?
I42:A9RW1MH[N!YUZQ+(" MP_#K0!8HJHVJZ>K%6O[4,#@@S+Q^M2I>6TDHBCN(FD9=P0."2.N<>E $U%5Q M?V9A>47VHM?M)N81!_SU\P;?3KTH
GH]&.]M9KE3 @@$<@]#0 4444 %%%% !1110 4444 %>=_')&/PPED92UI#?6DMXH&

*B5%=6L%]9S6EY"D]O.ACEBD7VD-IM4!X6RJG(.5)Z|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

*JM0:?)/(MMY>RWLAG8$AY#E@, <<<=_>I/$'AZT\265O:WTDT:6]W%=]86)>-@R@Y!XR M.: .(N/#NF^#_BKX0'AR%[)=4%Y!?*LSL+D)!O4ON)RP89W=?6N;U>PT3Q!8 MZYJ6D^%=4\0GS+AO[?O[Y($A929; MC1VF:!48!&,D9C;<",G@\8(Y]:YY?A7HZK=N[;[4 <9<6VI>)?#W@J[NK.+Q6BZ.)KO1);\0RS,0@^T[2<28Z<]V]3 M4.H:]#IWPWO=+\)Q:UIUS)K4%E=:;>3!)K%9LI['"(P'RDM@;BU3P?#W0D\/ZCI-XEQJ*:H MXDO;F\F+S3N,;6+\8*X&,8 QQ0!PEAI5[X>\7^`Y]"\(3>%XYKL6]IY^L6[I M>Q,ISE/-)>13\]P(|;@]:]@GGAM;>2XN94AAB4O)([!510,DDGH*Y22OA]8Z=MK=MJM[JFK:ST<(Y (.,D$8..>,E ')6TMS\3?$6G:E%"]OX3TBY%U:R2 K)J5PF0CA M>HB4Y()ZG]/1JXO3?AR=+N[26+QEXIEBM71EM9;V,Q.JD$(RB,?*<8(&.*[2 M@ HHHH ****.;\&?!E8\;_]> ^F_^@35Z!7G_@S_)*QXW_Z]|-_] FKT"@1 MQ'BC_DKG@3_*/^2N>!/]S4?_ $2E=O0 4444 %-M;\2_%/Q%MI33^-8M-T5_L]M;^#X-SB09!DG;()!(.!WZ<8R0#Z0HKYXU7Q?XW/[,VJ7GB M'^U]&UVQOHK>.[DCDLYYHC)&0_8]&*G'7'U]+QA/XL^&GA+PKXY'C75M6GNI M8(KZPNI@UM(KQ%\(O0<(1N.6).[(- 'T939)$AB:25U2-%+,[' 4#J2>PKQ/MXG:W=:A\24\,Z3KWBF>>&T#MHWAA%MWC8X/F2W+,< @K\NW !7D$\\KH6IZ[MXQ^ 7CBU\2:SJGFZ'-(8W^T@RNJQG,,KX_>)GKZ^N,4 >|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|0-#U1M8\/^+?#MI]NU#09I?,L@P5KJWE7:(JD\;Q@%0>.OMX]Q10!YU]OC7Q'XAM8],\$>'-:TW4KB1%DU#6-/\B"R3<"[']?Q(< @*NP R33ZY+XAWXB MT*#2UF6*35KA;8NQQLB^]*Y/8!%;)]Z+6@1)=>%;B]U/$:ZIYEQ,6.W9&XX MY[ )BO(M(UY].\01>3?+ /,\IKA1N4*3M+8/48YK2N_$MW\3_%T7A?PR[6N@ MVO\ K94R-|:X&\^W0*OJ03[8/Q:T2'PCXBM11\?E65U;*8QZ.GH<_=)/JU M42SWI3](MM.RZ!IKAO\ 67,QW2/]3_0<5>KF?AYX@7Q+X$TZ^+]YEC\F?+9. M]/E)/N7?$'4&N?$-W!!G.EV*RMC^%FD3)_)A4WC?6+:YMO"=[M=,!;7?[R7T"GRRW3ZFN1CM_$7BS7/&6HZ&;;.V)>&478;=+&,[1'A3SB,>G: MLY-8EU'P_P"!H989"UMJ4UM(&0\C?"PS[8<#|*HDZ^PU9+2X\27WAUIET>*T M*QR,&P')4#!/.02Q&><5N>&O"MMJOAK2-2BGDMKO>9GF3DN-QP/;H.?KZURV MC6MU!=^,_A\%8,Z/<:?N(PQ&"JY)67R_I@U!X8^(>KII>B>%-"TR:^V8+EH[MQ;F [%CW$\\@C ;))QC;[T =)X@TS3H?B7I>GK!B&]7S)DWM\[%GR%U5&*&!K-X)^+ MUIXBU*UN)=+FM2GF0)G#;2NWD@9SM/7H: (K34-WP_\ $DF?N7<0_P#'Q4ND M7EE<^)_#J^&#(TXBC.H% VT'WYS[:LXXZ5SJG!?0_!'O!J5S;2Q"]O(GA5E M(+0%^8#TR3S[5IZ-=2>$O&WA6I*.MAX@TFVBE.WA9#&B_A\P0D_[1H V]/O M.S>/N?\ 4B:\/FDJE=2W#?#/0M12-I[.WN)3F>5(KI8==U3X?\ PU\/?VCHDES9 MS%_[2W+EK=`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|%>'Z7X,TB^\)^.?MR3W* M:'27MMI22W#D6*QQB1?+&>"&?KUP *]\!7T^I?#OP_>7DC2W$VGP-+(QR7;M8,L3ZD\T 8!\?>);WQ%K.F^'?!D>I1:3[M(/C@]RTQ@2P\+S/?W*'_4QF4,N?<89L<^N* /2*QAXBA/CAO#0@?SETX:M@TQ(V[3(8PH'7.03^77/'A_B:UM++X?OXD\-^%-6M9K817$'B?4K](]F0EUQ M(5#%GWYZ%0"&Z"NZ;P_HD7[0MS>S64"/%H*7YF(^[-Y[]9?KM 'T%']|%?/ MFO66FW7@6_U_0/"VL7,D<4EU#XIU* 6&-W;U)4$F@"Y1110!S?@S_DK'C?\ Z]|-_P#0)]] KS_P9_R5CQOO_M -:>^F_\ H$U>@4".(\4?\E<\"?[FH_\HE*[>N(\4?\ )7/ G^YJ/_HE*[>@ M HHHH *XK_A7?_%X_P#A//[4_P"7'[)]A^S^V-WF;OTV_C7:T4 <5XF^'?\ MPD7Q&\.>*O[4^S?V'N_T7[/O_)_O[AM_(UE:I\);N?QA?\ B3P:XLNO#-YJ MD?EZ@D=LMQ'.,8W ,1M;_:Y(.2,9->E44 >&?%/P7IO@'!F>]T/1][Q1W$$D MLTF-|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|0OZ5_P" 4?\ \30!QGP*\+#0OA[;ZEBZ=/-(065S<+$I9HRT8?'H<':,U9E\6I:>#;K M7KJT9?LLTL#P1OOR\<[0G!QR"RYSC..U;2:?91V:?YD)C!1]Q);(Z'))))G&!27EA:::C!Y.H6L%U$&W>7/&'7/K@]Z M ,KQ9XD_X1C2XKL6GVMI93$L?FB/D1N_WC[(1^-5_$?C&'0?#MG]T=I+=K>$M>5$N5./*>4DX!Q\D;>V<9(&2-74M#TS5[>WM]2LXKB"VD$L43KE P4J/EZ$8 M8C!XY^E3WEA9ZA;BWO[2"ZA#!A'-&'4$<@X/&10!F^)/$L7AS2X+V6!YDF.G! (M], "@"C?ZJUIXATG3U *WWG;B5R1L4-P<\?K4,7B)9QN^T^B+;@>1&'TS3*&+% M0V AY9<'[PS@\8[UKO#%)+'*|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|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

*(0<,W!R25.![QG!.>*ZN@#@6^$.C2:/+H|^K M:Y-I#(RPZ?)>CR;?.<%0%R=I.5#E@"!QQ7;V-]MCI]O:((R+;Q+$'DQN8*, MG SQV]>B@ HHHH YOP9 R5CQO_ -> ^F | H$U>@5Y_X,_Y*QXW_P"O?3?_M $":O0*!'$>*/^2N>!/]S4?_ $2E=O7$>*/^2N>!/]S4?_1*5V] !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F:[H-IX@LX(+Q MI8FMKF.ZMYX&"R0RHUEB262!I$*B6/&Y"1C<,@C(Z|@BI** *&AZ-9^'M#M-)TR,QVMI M&$C#'+'N6)[DDDD]R2:OT44 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !7G'A?_), |=?]>6G_ /H#5Z/7 M#ZQ|+K75?%E[XAM?$OB+1[R^CCCG73+N.)'$:X7@QD_KWH SO&)K[P=J%_K=]'-=)XFCUN" M'[.P9MK1AI08T3 &W ^Z'K'Q!\2O 5_P")]-L[G4[[1):B ^D1UD66>)8=KAD)4X).""1S5""XN'|%V MFBQW4MG:ZYX[N:&\FA|T&X^U3VMW?2:AYC2[989WD|S=&Z@ M%2K=/R.>:.:UKP/H7@Z#5IO#E]'I$5YH5[')HHDRMXRQY\Y59LAD!P2 #K747TR"]CMA/*0L89R[*'50/NY/+|C%>I6G MPSTV*2]GU'5=8UB\NK*2Q6[U&Y622WAD&&6.!0]D^NTDXYI]Y\-M(NM'T.SA MN]1LKG0;9+:QU*TG$=RD:H$(+;=K A1D%<>U 'F4UOJ>D^$/B-I3Z5)HNC?V M-Y]KI<^I0W+V#],|*>%?!_B+2?/CUW^T-.2XU M$SNTERLK*LB/DG*D'[O08 &!Q7>6WPRT:W\.:YI3W.H7,NO(R:AJ5S.'NI@5 MVCYBNT;0> %P/2M35_"-AK6A:?I5U+,;KQE$]_P#V=J1TVQM7E=5M(EC4[T (PSEB=W7CM4:V7_"(MZYX(UU-<_MZ+=)X=U#4@03*DC$P;R">4D4(23U//)KKM9^'5AJFMW.K6.K:Q MH=Y>(J7CZ5="(70484N&5AD#@,,''>N?|>Z%#:?#^W^'OACPY?SK?HL5K/#& M3;V3"0,999 M$:!C*V/[H4|_45T?B/P-I?B/4(-2>6|TW5K=/+AU+3IS#.J9R4)Y#+GG:P(I MF@^ M-T36&UB>[U#6-6,9B6_U2X|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|-W.B7]U=VMM< MJ1(]HX1R 0<9((P<<|=* ,2MJ:GXF^(M.U***%[?PGI%R+]UDD!634KA,A'"] M1$IR03U/Z6? A7NCL_%27#+YZ>);XRGIR64Y_$8/TJSIOPY.EW=I+%XR|4RQ6 MKHRVLM[&8G52"$91&/E.,$#'%3ZM\.]-U35+R^AU'5=,;4 %OHM/NO*CNP!C MYQ@\XXRN"1WH Y[X;Z]8^%_@C9ZKKERL-FLURT7&6<-<2;54=6P_=C4]@VJ M13ZJ1_%&GS0R0V#0Z;H\0W2Q09W_.!_RU=@N1_"./IK^(? AKI.OVFC6L=[J M.DV^B'-G'ILJ($. QW(V2 .#UY/K5O0/!TF@ZD;M_%'B#508RGD:C=I)&,D M?-@(.>/7N:/)'\1Z+;7GAC4;^ZNIM8N=;%_JTITVY4*?)=5C3=&"RH'"% 7) MX)QR:]]AE2>%)8R2DBAE)!'!&1P>16;K'AZTUN]TJZNI)D?2[O[7"(V #/M9 M<-D'(PQZ8K5H **** "BBB@#F_!G_)6/&_|U[Z;_P"@35Z!7G_@S_DK'C?_ M *]!-_|0)]J H$<1XH_Y*YX$_W-1_|1*5V]<'XPMH:KXK^!8[B.2(4U'*G M_KBE=;_8>F?|^F?|^F?|^F?|^F?|^F M?|^F?|/G'^5']AZ9_SYQ_E0!?HJA_8>F?|^F?|/G'^5 %^BJ']AZ9_SYQ_E1_8>F?|^F?|^F?|^F?|^F?|^F?|^F?|/G'^5 M5']AZ9_SYQ_E0!?HJA_8>F?|^F?|^F?|^F?|^F M?|^F?|/G'^5']AZ9_SYQ_E1_8>F?|^F?|^F?|^F?|/G'^5']AZ9_SYQ_E0!?HJA_8 M>F?|^F?|^F?|^F?|^F?|^F?|/G'^5 %^BJ']AZ9_ MSYQ_E1_8>F?|^F?|^F?|^F?|^F M?|^F?|/G'^5']AZ9_SYQ_E0!?HJA_8>F?|^F?|/G'^5 %^BJ']AZ9_SYQ_E1_8>F?|^F?|^F?|^F?|^F?|^!/]S4?_1*5V]<1 MXH_Y*YX$_P!S4?|T2E=O0 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 M444 %%%% !1110 4444 %%%% !116#]7C70-*F.5UJ*&4'!2(%R#[XZ5<*U+_)9?C_2]- PHHHH **** M .!B^*]O=7%Y'IOA+Q1]"6=S):R3VEE&\9=#A@#YG^AW.A)]<4=[C M^T(]-FMI(/+GMYW8*%=&(QC(SU]LUQ'P_P!:\5V%MXAAT#PE#]]K_;]XWVE] M52W(;?RNPH3QQSGO5?Q1X8UO3O"M]]FJS6UKK6O>(K&8);?O(]7:X2,98?,1 MU)Q@T >W45YTUI?>$OB5X8M+?7M5U"UUH745W#]-SYR[HXO,5T&,(YTT2ZBWAW*W!N"J[6;;AO+^\3M[]>,"FW7C1]+ M^&<|GAOQ)?:U-C+H0\;7UI=3_ &?4H]=LIVC5 M"#B97=<1D-C(& 0>@Q7]M[96FH6:VVHVT-U;/@O%/&'1L'(R#P<$ _A0!S-A M\1;"ZU6RL;_2=8T7RWDP6(X4 M$]2.U<;%|?| X92RK&GB=0S' +V5PH_$F/ _&@#T:BH;2[M[^SBN[*>.XMYD M#Q2Q,&5U(R"".HJ:@ HHHH ***Q+#QAH6I^*K_PW97WFZMIR"2ZM_)<>6IQ@ M[BNT_>'0GK0!MT444 %%,FFBMXS)/(D2 @%G8 DX']]SBGT %%%% !1110 M4444 %%%% !7(_%:]NM.^%'B&[T^YFM:F&S9HYH)"CHWOC+QY!>7EQ<16NK+';Q MRRLRPKY0.U03\HSS@5'I7QG^'TT-E9Q>);=KAUCB6/RLEC@ ?=]:QK7Q)W MPS^)'BQ?%WGZ?I^M7$-[8Z@T#0#(? +"NA90=K!AT/8_3(!N7>HWR_&S4+%;R MX%FGA-;A;<2MY:R_:9!O"YQNP ,]<"N7^!_C'6?L-AX>|9WDMW:5<4 =7|-]0N[V?QG]ONYKA;7Q-=0P^=*6$42QQ$(N3\JC)X")KC/"GBW66\ M?6/B74=0NI?#GB^]NK"QMI9#Y-KY6!:,JGA6D\N3IUW#ZU@:%XMOY_A#XQFA MMC9ZYXC\4RZ=;VI/S1SSQPJR^ORC>?PKI?$_PH\06_PW&GZ=XRO+Q=$A2YTZ MR.GVZ#S(!F,!U3?GC&: -/Q3:W.N_'33="DUH6+#3VT&2Y:+3M0EM@ MT@FVACL(SP<5#]MO<^!?B#X3M=$\2:QDJU>[:VO-+U*_:[S#L),R[\LFW R1 MP?SSAQ'0? BK\5O"U_JMA!?65[X5>X,$HRJ2B?:P^JMN6KZ:)IGP:^)EK?66G MVT/ACQ$PM'G\I2^FW)^Z/,(W")|="< @G@#D]DKRWPQ;ZC\5+2Y\2W_(@U M73M&FN98M*LM)NC:_N8W*>;(Z_,S,5)OG KHK3PYXSA\8-J-WX\^TZ,;B20: M1_8|*8C.=D?G [OER/FZG;SUKE/!'B/2_A5I$W@SQG*=)33KF9M/O)D8PWEO M)(TBLK@$;AN(*DYX[T :-['XM\.> _'5I]=_/=VECID\VC:PTP%TP|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|+ZQIE[X5UG5=8M)+E8M3L- M7OS./)/66-WY5EX.T'!]*Z/1/%NG:Y#JTD2S6IT>]EM+Q+H*I1HP"6X)^4@@ M@]Q7-W'Q1M=;U'3], ^'7EZ]=W%R@NYA$_P!GLX,_.[OP V.B]<]NF>8^(EK? MZ7XYO=(TE9%C^(-K%9-(@XAFC=4E<^F;9V/U3O0!UZ_%33)].TB>PT?6KZ[U M>V:\M].MK9&G6 -CS7RX15/&"6YR,_%8/Q!^);R?":\U;PM!]T%R+Q+.9A (MY;"031B1)0QRI*MM!7/+#D=1'\0K?P_I7B?18]2FU3PK|:::8;+Q'ITY1(\ M!]DD&TC;@!ANX/05@ZUJVN:U\!_%+ZI=3:O96FH6PL-4:S,$EY;)/"[2% .0 MOS?.!@A2>QH]$L/$5C<_$!C=-K>G7?_ CZWDMA>R(EK!%Y[C>R!CB;(()R M1M YJ"R^+FB7MQ9,=.UFVTS4)Q;V>KW-GY=K.[""@,6W_>A90#7*^(%3QKX M_P!?C\-W,=R-4\ M':2HWRR%KB50,^A/%7=,^(F@7'@[0O#\&D'5-=1;6UD\ M/S6[*]LZ%%=G#(0BQX+!B/X1@C.0 >L4444 %%%% !1110 4444 %%%% !11 M10 452UC5[+0-&NM5U6<6]G:1F6:0C.U1[#]?;O7-Z)]2M.U? 6;33+K2=9T: M?4(VDL6U2T$27849(0ACSMYVM@X]4 =C17#ZI\4+:P\2:AHMEX8]2:S-IK1I M]:SNK$SIO-M>($EC]F4$@'\: +=% M'[3 MP=:^)OM3SZ? >E%M!!SRWCG"QHG4N3D;>V#G@!TE%#BLD?%S0&N ZVF]'2#<_91K@M/] M!,F[9C?G.W=QOV|<]Z .ZHHK!\7>,M(\$Z.-1UR9E2258888\&29V.-J@D9] M3SP : -ZBLGQ+XFT[PII']H:L\FQI%ABBAC,DL\K'"QH@Y9CZ>Q/051|-^-K M'Q']-SIIL=1TG4[6-9I+#4H!%+Y;' D7!967(QD$X/!Q0!TE% <*/BYH#7 =; M35#I!N?LHUP6G^@F3=LQOSG:NXW[=N>]=U0 45Q&H_%?1-/O:Y!8ZM>6&FR^ M3?ZI:6GF6MJX^\&;.XI? XMJMCO6MXB\:Z9X=2P5H[K4KO4B?L5EIT8EFN !D MLHR!M ()8D 9ZT =#17.Z-XXT?6-%U#46:;3ETMF74(-0C\J6T*KN.\U+_)9?C_2]- PHHHH **** .>|'^%O^$4LM0M_MGVO M[;J,]]N\K9L\P@[.ISC'7C/I4OBOPY_PD^G6MK]J^R_9[Z"\W>7OW>4X;;C(MQG&,]O0T_P +>)K/Q;H2:MIL4\4#R21A;A0&RCE3P"1C(]:V: ,+5_#?]]^* M_#^M?:O* L5[A_)\O=YWFQ&/[V1MQG/0Y][Y]V^&FHV>FW>A6?BR>W\.W+RM M]CCLT\Y%D8LT8G))VDD_PYP>M=%)XPLK;1(M3U&SO[!);T620W5OLE:1I/+4 M[<_=)Y!STYK2@U/SM;NM.^Q7D?V:-)/M4D6()=V?E1|\L,+="%A:Q>-+0Z79L@-E%H4<0>,'E PD) M7(R-W)YSS7=T44 %%%% !1110!S?@S_DK'C?_KWTW_T":OO*_|_!G_)6/&_ M_7OIO_H$U>@4".(\4?\)7/ G^YJ/_HE*[>N(\4?\E<\"?[FH_|HE*[>@#R M|]HS_DB.J_|7:W_/1RUXG?>+[&?PG9^&&^#FGZ=JFJ626MEJ=RB0/,Y0*) MT9H4R22&SOQDC).:^BOBQX/O_'?P[O=TB:VANKB2)E>Z9E0!7#')52>@]*J M>*_AE!XO^$]IX7U%H5O[*SB6VNER5BG2,+D'&=IP0>,AZ9Q0!P^M>(M8^!WP M5|+:"9K<:U=2-"]W,K2Q6BES([8&2VP.]@#/0D XP6_#OXOWEY\3:/PM=>*K M?Q?8:C S1:BFF&QD@F56:84((PIYP>HY'(K9U#X5^*?$GPVT33?$&L6,/B: MP]H/)'(V@4>72_%7Q7J/B_6["\|<:?X-N[*[>*RTR_P!+ M!@G4'|RX8$IQWQSU%=A\6/&GC'PS\/_Q>:1?6,6LW]['!%-=TV[++!=ZQI^V]LT:C$?EIMW#LQYR M,\5QWQ@\(-X)^"_@SPY'J$ES):ZL ;HC'S,)&)49X +<#VH ZN]\5^,_'Q, M\,:=XNUNRUS3/$TQMQ';V2P?9)=R+A".64&1.6)R,\U:TSQQXAN/C%X]T.; M4-VG:1IIGLH/(C'E/L0YW;=S"2.:E7X;^+_$?Q"T37/B#K&DW5CX>)9+FQ-GKU@;:VC61_,1M MJ#+C;@#Y3T)H PO@WKGQ"\<:):^)-:|4P)IUK%?A1-X2UZYMWFN/M"O+9.S*%E!'!95.0#Z5P#?!/X@GX<3^!AK^@ M+HT/5?L N=3UZ>S0DX M!Y2'[H)QG'3Y@.,$U8\:?"_7_$7A'P9'IMYIT&M^&3"^V=I#;2LBH#\P7=C, M8[#@FI=?^'?BJ]\0:-XUT75-+L_%]G:_9KV-XY#970YX_O@?,?4].A&:*_A M?QMXFTOXA:MX"|97MOJEW!8&]L=4@MQ"9% SAXQ\H//;'Z>N16%)-8^)GQ(M\-OJUUXRCL+>VNI+8@:7"TEP=@. [=M"J%++C"G)W9KK/"OPWUJ'Q9JOC'QKJ M-G>Z_?6AM(8K%&6WM8\ 87=\QZ#D^_7-7?@YX%U/X=^!'T;6I[6>X-W)/NM' M9DVL% 'S*IS\I[4 !VKP'4-TCQ MO^U!%!X:U&'4=$F,&K:I]ED$D'FPAAC(R&R2!_VU:OIJ@ HHHH **** "BBN M/\7ZG[O)X'*O':P89E!'(+N43([%] .PHK@?BC>:A M>?V'X1T'4+C3M1UZ\(:ZM9"DD%M"/,E96'*GA5_X%CVI_@_Q-=Z_\()+R|=X MJ7L:6>SOOFP|=S""KXZD!O^!"@#NZ*\C^'_@X> (OAKH^M:MXM\6+=7=H)9 MI4UZ=5!YYP6P*JZ-\1-:T_X1ZG=BY76+^+79-%T2_N.8O@9 D4S$<,.6R1UV M?C0! [-17GES\.]2ZLO"B"7Q$D9D2:2['V:24#.TV^/+*$\8QD#O5C5/ M"5_XGT:UU?7-8U[0-5CT\+<66CZLT."R#*M0\5>)[R\FMQ-);W.K226[L01@QGJ_UKI? B=K]X?|&%M&F2#4K^ M[@T^UFX]* .OHKS.:VOOAYXR|-*GB+5=5T[7+EM/NX=5 MNO.(F*%HY8R1\G*D%1\O/ K,\:VU_H.F:KK?B7Q[>Z?K6'(ZT >OT5Q%WHWBGQ78^'1?ZG+H5H;(3:Q#I\QANGN2BXC M5P#M0$OG!!Z?6J'@]KR#QQX\'MK5_JVEV=K!(ES<3EKBSDE#;HO.^\3@!@2 MZ9]TK3:GH5|)IUS,WWIPF#'*?=D92??-=90 4444 M%%%% !114-Y+)!8SRP)YDL<;,B?WF R!1N#T*KZ!HTDC/)I-B[L2S,ULA)/< MGBF_\([HG_0'T_|\!4_PKSCP7HNDZ_I%IXEU[7+DZM)=DN_VSR]CAR%BQVR M,<#UXH\6:9]VE>,/[&T.^\FR|5MAPS$FW92#(4] 0?UQV%=WL??=/GU7Z;GG M>W7LU4Y-']^NWXZ'H_|PCNB?]?3_|P%3_]U:6%G8(RV-I!;*QRPAC" MGU.*\E\;Z$VDZK'-I3Z987 M,IEN;*WFD(P7DB5B? Q(J/^Q=*_Z!EG_X#K_A7G^HQR>'?B'8VFE--(EGH$[P MQR.7+L"Y&?4YJ#P3H.CZMI>F>)-6URZDU>;YW.YO=F9-QQ%C\!QW^E+V3C#F MYG;_(? S\A^UC*?)R*_7\/+S/1O[%TK_*!EG_X#K_A4L&FV-K)YEK9V\+XQ MNCB53CZ@5P7QB.QTS1(H%FD.NI(ABAD|MI<@_*&[9Z9K$U*SN-(\%Z6UI=2-972LM[%]'E?91U/[O/S\#M4GC'4$F\5K>20 MWNJ68T.&XS!<& KD@"4XS_>&1[^U-8'FLK[_/|_,EX_EN^79_Y^7ETN>WQ MP0P_ZJ)$_P!U0*DKQPB^OV\&^'?$>L2+87EH||TT4^/M#98HA?OA=H_'UQ5B M*VN-&\5ZWX9|*ZO(+*327GW33[ELIO\?_AX[]MP/:H6$459/SVTM>Q0]<;= M^73;?6]K[*K=%>(Z1Y&D:+XBTVXM:RTUM=&>5Y?MOGQ3KWD7'))![|>G=^A M6-[<^'_#NHW?F:CI4&BH\]E%?"&5&QS-@_>ZCL>E7]47-;F_JWK^I/UU\M^7 M7_@V[7_]KHK+\,W-I>>%].GT[SOLKVZ>5Y[%G Q_$>YK4KADK-H[XRYHIA1 M112*"BBB@ HHHH **** "BBB@ HKRKXFW-NWQ&\,Z=]_BR^\-Z5/97P.V0#U/6KWAK3O#5LNIW^B?$'6?$0M[.03Q?]) +T0J1G>%R0K_*= MI/O0!Z/7+P>$;N3QX?$>LZW)]$=]DB:78_9EB2R|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

M[/UW<_6O3/#=YG]D?9E\S9OW^3]HSGR\]MN['&ZNIF_ME? MB'91VL\@T(:;(;B#[,HC68.HC(E^\6*EOD' "Y/44 <5\+T-Q^SF[7\:&:XA MU)KI3R&#1? J#'%X!5H"3G#?:$7/7^X$_/\NMN_A=> ME-4TS2/%=SIOA[5II);O3EM4=U\PYE6*8G,:MD\;6QDXQ6KKG@)+I]&NO#6H MMH.HZ)";:SG2$31^05"F)XR1N7"KCD$$9!H \L^*TEU;WWQ2&GH LNC:89R# MC)|[:2>?^>9;\A]*[[XOIY'A+0S91KYMOKVGFV _A82@#'IPM_$%[+K-[XB&W4[QT$1D4)L145>$51TY)!YS5/3_AQ]OM(_X27Q5/K6G MZ)*L]A:-:)"?,48C>5P29"H/'"\|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|WS*&!/(]:W1\.)+72?#_ /9.MR6.LZ%:"TBU!;<.LT> &5XB M>5)&<;L@]ZDB^'DDNG^(7U?6I-0UG7K%[&2_:W")!$4956.('A06R1NY/>@# ME+JUUK0/ ?A[Q8?%&L7.IR26)N89KDM;RI*R*T?E]. WWOO'&2N(\4?\E<|"?[FH_P#HE*|>@ HHHH **** "J6IZ+I>MQ11:SIMG]$< M+B2-+N!90C_W@&!P>>M7:* "BBB@ HHHH **** "BBB@#.TGP]HN@K(-#TBP MTT2G,@L[9(=Y]H&:T:** "BBB@ HHHH *X'40;/]H/1;B?_ %5_H%U:0$_\ M]$FCD;'OMKOJQ?$GAU=? BL9(KDV=]IUVEW:7(3?L9>&4C(RK(64C(X;V% 'G MEKIN]^/?BQK^OZ/X@GT:WT(#1;2:"VBG\UA\|_$BD ABHR.>.O:J=A;7O@/Q MUXD\/:MJTT4 >%^$?@YX6\6 M_!'2)UTVWM=:N+)98]0"983 G!8'AESP5(P15L2WWCKX2-IEEIEO:>*O"&H0 MO-I,*B*,S0/D! , +(H8KQC/ Z9KVFB@#SV3XT^%O[):2V>[FU,]/>NGTV?5KGP1%/XCMX+75)+,O=00$E(W*D[1DGITZGGO6W10 M!Y[\-;6^O? @'H5MI&H_V9>R:IZ3K&C^.=&^SZQ" M9K:+2IK=IYKH?\LV@8+|V|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|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| M^!2?XT#-*BLW_A(M$_Z#&G_^!2?XT?\ "1:)_P!!C3__*3_&@#2JO?VOVW M3KFUW[//B:/=C.W<",X_&JO_D6B?\ 08T__P "D_QH_P"$BT3_*#&G_| M@4G^- $/A/0?^$7\):=HGVG[5]AA$7G>7LWX[[H>%=6T2T\ M1?9$U76IM3GD^Q[]R2-N\@C>,C.,MGG&,FVXVFQAT6.W#*%P%#*YV@<=!VQ M6GXRT"[\4>$[W1K'5&TJ2[41M+=+"%A:Q>-+0Z79L@-E%H4<0>,'E M PD)7(R-W)YSS4U]X$U%=5U.Y\->)9=&M]7?S+VW%HLV9- H4R1L2/+8@+>:S%TMPPQM+@LH.#N."""6Z<5L:)X?\36UX_| PDOBBWUN MQ:(H;3^R$@!;(P2P8Y P>,=ZU_\ A(M$_P"@QI__ (%)_C1_PD6B?]!C3_| MP*3_!H R=<\";:K%_HUQ%#:VJZ;>BZ>-;13YXV.NP],#YLYYZ=*Z=5"*%4! M5 P !P!6=_PD6B?]!C3_/P*3_&C_A(M$_Z#&G_^\22?XT :5%9Q_D6B?\ M08T__P "D_QH_P"$BT3_*#&G_| @4G^- &E16;_,)%HG_08T__,"D_P : M/^$BT3_H,:?_.!2?XT 9O@S_DK'C?\ Z]]-_P#0)]J KSKP'=V]|\4O&\MG M/% <1FWTT!XG#+]R;N*]%H$9NK^'-$\0>3_;VCZ?J?D;O*^VVJ3>7G&=NX'&< M#./05F_|*Y\$?]"=H'_@KA_^)HHH /\ A7/@C_H3M_|% EX-101.SCH 10 arct-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Grant Revenue link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Balance Sheet Details link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Share-Based Compensation Expense link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Balance Sheet Details (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Share-Based Compensation Expense (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Revenue - Summary of Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Revenue (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Revenue (Details Textual) [Default] link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Grant Revenue (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Balance Sheet Details (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Balance Sheet Details - Schedule of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Debt (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Debt - Summary of Final Payment Due at Repayment (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Share-Based Compensation Expense (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Share-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Income Taxes (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Related Party Transactions - Equity-Method Investment (Details Textual) link:presentationLink link:calculationLink link:definitionLink Statement [Line Items]Statement [Line Items]Increase (Decrease) in Accounts ReceivableAccounts receivablePlan Name [Domain]Plan NameEntity Address, Postal Zip CodeEntity Address, Postal Zip CodeRevenue, Remaining Performance Obligation, AmountRemaining performance obligationEntity Incorporation, State or Country CodeEntity Incorporation, State or Country CodeRevenue:Revenues [Abstract]Interest Paid, Excluding Capitalized Interest, Operating ActivitiesCash paid for interestContra expense included in research and development expense.Contra Expense Included In Research And Development ExpenseContra expense included in research and development expenseNumber of Operating SegmentsNumber of operating segment for research and developmentVinbiocare.Vinbiocare [Member]Vinbiocare [Member]September two thousand and twenty one lease agreement.September Two Thousand And Twenty One Lease Agreement [Member]September 2021 Lease Agreement [Member]COVID-19 vaccine development.C O V I D Nineteen Vaccine Development [Member]COVID-19 Vaccine DevelopmentShares, OutstandingBalance (in shares)Balance (in shares)Other Noncash Income (Expense)Other non-

cash expensesOther Noncash Income (Expense), TotalRight-of-use assetsIncrease Decrease Operating Lease, Right Of Use AssetIncrease decrease operating lease, right of use asset.Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]Share Based Compensation Arrangement By Share Based Payment Award [Line Items]Long-Term Debt, Type [Domain]Long-term Debt, TypeLong-Term Debt, Current MaturitiesCurrent portion of long-term debtLong-term Debt, Current Maturities, TotalLessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year2024Collaboration Partner Cure Vac entered into Co-Development Agreement.Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]Commitments and Contingencies Disclosure [Text Block]Commitments and ContingenciesStock, Class of Stock [Table]Schedule Of Stock By Class [Table]Product and Service [Axis]Product and ServiceInvestment, Name [Domain]Investment, NameCollaborative Arrangement and Arrangement Other than Collaborative [Domain]Collaborative Arrangement and Arrangement Other than CollaborativeRelated Party Transaction [Line Items]Related Party Transaction [Line Items]Janssen.Janssen [Member]Janssen [Member]Equity [Text Block]Stockholders' EquityCommitment and contingencies.Commitment And Contingencies [Line Items]Commitment And Contingencies [Line Items]Revenue from Contract with Customer [Text Block]RevenueSale of Stock [Domain]Sale of StockEntity Central Index KeyEntity Central Index KeyIncrease (Decrease) in Operating Capital [Abstract]Changes in assets and liabilities:Milestone payments.Milestone PaymentsMilestone paymentsInventory, Cash Flow Policy [Policy Text Block]Restricted CashProceeds from Issuance of DebtNet increase in indebtednessProceeds from debtPurchase of common stock, sharesCommon Stock, Shares, Issued, TotalIssuance of SharesCommon stock, shares issuedDirectors or Officers [Member]Directors or Officers [Member]Directors or Officers.Liquidity.Liquidity Policy Policy [Text Block]LiquidityIssuance of common stock under equity plansStock Issued During Period Value Under Equity PlanStock issued during period value under equity plan.Increase (Decrease) in Prepaid Expense and Other AssetsPrepaid expense and other assetsIncrease (Decrease) in Prepaid Expense and Other Assets, TotalEntity Address, State or ProvinceEntity Address, State or ProvincePotential Principal Repayments Of Debt Instrument.Potential Principal Repayments Of Debt InstrumentPotential principal repayment of loanNet loss before income taxesIncome (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestClinical trial accruals current.Clinical Trial Accruals CurrentClinical trial accrualsDeductionsContract with Customer, Liability, Revenue RecognizedDeductionsRevenue recognizedDebt Instrument, CollateralDebt instrument, collateralCystic Fibrosis Foundation Therapeutics, Inc.Cystic Fibrosis Foundation Therapeutics Inc [Member]Cystic Fibrosis Foundation [Member]CSL Collaboration Agreement [Member]CSL Collaboration Agreement [Member]CSL Collaboration Agreement.Equity Method Investment, Nonconsolidated Investee [Domain]Equity Method Investment, Nonconsolidated InvesteeCover [Abstract]BasicEarnings Per Share, BasicEarnings Per Share, Basic, TotalAccounts receivable, BalanceAccounts receivable, BalanceContract with Customer, Asset, after Allowance for Credit LossContract with Customer, Asset, after Allowance for Credit Loss, TotalLessee, Operating Lease, Option to ExtendLessee, operating leases, option to extendFinancial grants received from the Japanese governmentGrants Received From Japanese GovernmentGrants received from japanese government.Payments for matching funds for remaining budgeted costs.Payments For Matching Funds For Remaining Budgeted CostsPayments for matching funds for remaining budgeted costsOperating Expenses [Abstract]Operating expenses:Stock Issued During Period, Shares, AcquisitionsIssuance of common stock related to acquired in-process research and development (in shares)Schedule of Cash and Cash Equivalents [Table Text Block]Schedule of Cash and Cash Equivalents and Restricted CashShare-Based Payment Arrangement, ExpenseShare-based compensation expensesShare-based compensation expensesLong-Term DebtLong-term debtTotalFebruary two thousand and twenty lease agreement.February Two Thousand And Twenty Lease Agreement [Member]February 2020 Lease Agreement [Member]Revenue [Line Items]Revenue [Line Items]Revenue.Retained Earnings (Accumulated Deficit)Accumulated deficitAccumulated deficitRetained Earnings (Accumulated Deficit), TotalRetained Earnings (Accumulated Deficit), Beginning BalanceRetained Earnings (Accumulated Deficit), Ending BalancePlan Name [Axis]Plan NameAssets, Current [Abstract]Current assets:Common Stock, Capital Shares Reserved for Future IssuanceCommon stock reserved for future issuanceNet cash (used in) provided by operating activitiesNet Cash Provided by (Used in) Operating ActivitiesDisbursement period three.Disbursement Period Three [Member]Disbursement Due July 2020 [Member]Product and Service [Domain]Product and ServiceLessee, Operating Lease, Term of ContractLessee, operating lease, term of contractDebt Instrument [Line Items]Debt Instrument [Line Items]Term of agreementDebt Instrument, TermProperty, Plant and Equipment, NetProperty and equipment, netProperty and equipment, netProperty, Plant and Equipment, Net, Beginning BalanceProperty, Plant and Equipment, Net, Ending BalanceNet Cash Provided by (Used in) Operating Activities [Abstract]Operating activitiesResearch Collaboration and Exclusive License Agreement.Research Collaboration And Exclusive License Agreement [Member]Research Collaboration And Exclusive License Agreement [Member]Common Stock, Par or Stated Value Per ShareCommon stock, par valueEmployee Stock Option [Member]Deferred revenue, BalanceDeferred revenue, BalanceContract with Customer, LiabilityDeferred revenueContract with Customer, Liability, TotalBARDA [Member]Biomedical Advanced Research and Development Authority [Member]Biomedical Advanced Research and Development Authority.Income tax payableTaxes Payable, CurrentTaxes Payable, Current, TotalComprehensive loss:Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]Statement of Cash Flows [Abstract]Counterparty Name [Axis]Counterparty NameClass of Warrant or Right, Number of Securities Called by Warrants or RightsExercise of warrants for shares of common stockBalance Sheet Related Disclosures [Abstract]Equity Components [Axis]Common Stock [Member]Entity Address, Address Line OneEntity Address, Address Line OneEmployee-related Liabilities, CurrentAccrued compensationEmployee-related Liabilities, Current, TotalWells Fargo Credit Agreement [Member]Wells fargo credit agreement.Wells Fargo Credit Agreement [Member]Related Party Transaction [Table]Schedule Of Related Party Transactions By Related Party [Table]Computer Equipment [Member]Computer and software [Member]Property, Plant and Equipment [Line Items]Property Plant And Equipment [Line Items]Maximum sales required for loans forgivable .Maximum Sales Required For Loans ForgivableMaximum LUNAR-COVID 19 sales required for Loans forgivableLoan and security agreement.Loan And Security Agreement [Member]Loan and Security Agreement [Member]Subsequent Event Type [Axis]Amendment FlagAmendment FlagLease liabilitiesIncrease (Decrease) in Operating Lease LiabilityOperating Lease, Liability, NoncurrentOperating lease liability, net of current portionPrepayment fee percentage.Prepayment Fee PercentagePrepayment fee percentageOperating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]Operating Lease Liability Current Statement Of Financial Position [Extensible List]SOFR [Member]Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]Net lossNet lossNet income (loss)Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in PeriodIssuance of common stock upon exercise of stock options (in shares)Variable Rate [Domain]Research and Development Expense [Member]Research and Development [Member]Equity Component [Domain]Equity ComponentStatistical Measurement [Domain]Statistical MeasurementGeneral and Administrative ExpenseGeneral and administrativeGeneral and Administrative Expense, TotalUltragenyx.Ultragenyx [Member]Ultragenyx [Member]Supplemental Balance Sheet Disclosures [Text Block]Balance Sheet DetailsOther Nonoperating Income (Expense)Other Nonoperating Income (Expense), TotalFinance income, netDebt Instrument, Increase, Accrued InterestAccrued interest added to principal debt balanceFurniture and Fixtures [Member]Office equipment and furniture [Member]Disaggregation of Revenue [Table]Disaggregation Of Revenue [Table]Amount drawn from LoanProceeds from Lines of CreditProceeds from Lines of Credit, TotalAdditional payments upon meeting certain clinical milestonesAdditional Payments upon Meeting Certain Clinical MilestonesAdditional payments upon meeting certain clinical milestones.Deferred Revenue, CurrentDeferred revenueDeferred Revenue, Current, TotalProceeds from Stock Options ExercisedProceeds from exercise of stock optionsContra expense remaining amount included in accrued expenses.Contra Expense Remaining Amount Included In Accrued ExpensesContra expense remaining amount included in accrued expensesRestricted Cash, CurrentRestricted cashDeferred Revenue, NoncurrentDeferred revenue, net of current portionDeferred Revenue, Noncurrent, TotalRestricted Cash, NoncurrentNon-current restricted cashNon-current restricted cashCollaborative Arrangement and Arrangement Other than Collaborative [Axis]Collaborative Arrangement and Arrangement Other than CollaborativeComprehensive lossComprehensive Income (Loss), Net of Tax, Attributable to ParentCommon Stock, Shares, OutstandingCommon stock, shares outstandingCommon Stock, Shares, Outstanding, Beginning BalanceCommon Stock, Shares, Outstanding, Ending BalanceRevolving credit line availableLine of Credit Facility, Current Borrowing CapacityOctober 2017 lease amendment.October Two Thousand And Seventeen Lease Amendment [Member]October 2017 Lease Amendment [Member]Summary of significant accounting policy.Summary Of Significant Accounting Policy [Line Items]Summary Of Significant Accounting Policy [Line Items]Entity Interactive Data CurrentEntity Interactive Data CurrentWestern Alliance Bank.Western Alliance Bank [Member]Western Alliance Bank [Member]Disbursement period two.Disbursement Period Two [Member]Disbursement Due April 2020 [Member]Document Quarterly ReportDocument Quarterly ReportCash, Cash Equivalents, Restricted Cash, and Restricted Cash EquivalentsCash, cash equivalents and restricted cash at end of the periodCash, cash equivalents and restricted cash at beginning of the periodTotal cash, cash equivalents and restricted cash shown in the statement of cash flowsCash and cash equivalents, including restricted cash and non-current restricted cashCash and cash equivalents, including restricted cashRelated Party Transactions Disclosure [Text Block]Related Party TransactionsStatistical Measurement [Axis]Statistical MeasurementCOVID-19 vaccine.COVID-19 Vaccine [Member]COVID-19 Vaccine [Member]Other.Other [Member]Other Collaboration Revenue [Member]Operating Lease, CostOperating lease costsRelated and Nonrelated Parties [Domain]Related PartyDisaggregation of Revenue [Table Text Block]Schedule of RevenueLessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]Remaining Payments of Operating Lease LiabilityShare-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for GrantNumber of shares availableResearch and Development Costs, NetResearch and Development Expense, Policy [Policy Text Block]Statement of Income Location, Balance [Axis]Income Statement LocationMinimum incur amount under research planMinimum Incur Amount Agreed Under Research PlanMinimum yncur amount agreed under research plan.2021 Inducement equity incentive plan.Twenty Twenty One Inducement Equity Incentive Plan [Member]2021 Inducement Equity Incentive Plan [Member]Eligible to Receive Development Milestone PaymentEligible to Receive Development Milestone PaymentEligible to receive development milestone paymentInvestment Owned, Balance, SharesNumber of shares ownedAssetsTotal assetsGrant revenue.Grant revenueTotal grant revenueOrganization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]Description of Business, Basis of Presentation and Summary of Significant Accounting PoliciesSchedule of Long-Term Debt Instruments [Table]Debt Instrument [Table]Recently Issued Accounting Standards Not Yet AdoptedNew Accounting Pronouncements, Policy [Policy Text Block]Entity Address, City or TownEntity Address, City or TownLoss from equity-method investmentLoss from equity-method investmentIncome (Loss) from Equity Method InvestmentsIncome (Loss) from Equity Method Investments, TotalSchedule of Maturities of Long-Term Debt [Table Text Block]Schedule of Maturities of Long-term DebtDevelopment milestones received advance paymentDevelopment Milestones Received Advance

PaymentDevelopment milestones received advance payment.Share-Based Payment Arrangement, Cost by Plan [Table Text Block]Schedule of Share-based Compensation ExpensesDebt Instrument, Face AmountTerm loanLong-Term Debt [Member]Long-term Debt [Member]manufacturing and supply of ARCT-154 drug product.Manufacturing and Supply of ARCT-154 Drug Product [Member]Pre-launch inventory policy.Pre Launch Inventory Policy Policy [Text Block]Pre-Launch InventoryPrivate Placement [Member]Share-Based Payment Arrangement [Text Block]Share-Based Compensation ExpenseConstruction in Progress [Member]Construction in progress [Member]Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares AuthorizedShare-based compensation number of shares authorizedOperating Lease, Weighted Average Discount Rate, PercentWeighted-average discount rateGrant Revenue [Member]Grant [Member]Fair Value Disclosures [Abstract]Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or PremiumsLoan origination fee paidUnamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums, TotalStock Issued During Period, Value, New IssuesCommon stock issued, valueUpfront payment received.Upfront Payment ReceivedUpfront payment receivedStock Issued During Period, Value, Stock Options ExercisedIssuance of common stock upon exercise of stock optionsLiabilities, Current [Abstract]Current liabilities:Lease Contractual Term [Axis]Lease Contractual TermDocument TypeDocument TypeTitle of 12(b) SecurityTitle of 12(b) SecurityRevenue [Table]Revenue [Table]Revenue.Repayments of principal and interest on collateralized term loan.Repayments Of Principal And Interest On Collateralized Term LoanRepayment of principal and interest on collateralized term loanCash and Cash Equivalents, at Carrying ValueCash and cash equivalentsCash and Cash Equivalents, at Carrying Value, TotalCash and Cash Equivalents, at Carrying Value, Beginning BalanceCash and Cash Equivalents, at Carrying Value, Ending BalanceStatement of Stockholders' Equity [Abstract]ADAIR Technology.A D A I R Technology [Member]ADAIR Technology [Member]Document Fiscal Period FocusDocument Fiscal Period FocusResearch and Development ExpenseResearch and development, netResearch and Development Expense, TotalLong-term debtLong-Term Debt, Excluding Current MaturitiesLong-Term Debt, Excluding Current Maturities, TotalFebruary two thousand and twenty one lease agreement.February Two Thousand And Twenty One Lease Agreement [Member]February 2021 Lease Agreement [Member]Contra research and development expense.Contra Research And Development ExpenseContra research and development expense recognizedResearch Collaboration And License Agreement [Member]Research collaboration and license agreement.Research Collaboration And License Agreement [Member]Property, Plant and Equipment, GrossProperty and equipment, grossProperty, Plant and Equipment, Gross, TotalProperty, Plant and Equipment, Gross, Beginning BalanceProperty, Plant and Equipment, Gross, Ending BalanceSubsequent Event Type [Domain]AdditionsContract With Customer Liability AdditionsContract with customer liability additions.Lessee, Leases [Policy Text Block]LeasesPayments for (Proceeds from) Tenant AllowanceTenant improvement allowanceKeith C. Kummerfeld [Member]Keith C. Kummerfeld.Collateral amountDebt Instrument, Collateral AmountDebt instrument, collateral amountClass of Warrant or Right, Exercise Price of Warrants or RightsShare priceSale of Stock [Axis]Sale of StockNet Cash Provided by (Used in) Investing Activities [Abstract]Investing activitiesRevenue from Contract with Customer, Excluding Assessed TaxRevenueTotal revenueRevenue from Contract with Customer, Excluding Assessed Tax, TotalStatement of Comprehensive Income [Abstract]Income Tax Disclosure [Text Block]Income TaxesGrant one.Grant One [Member]Grant 1Vinbiocare contractual liabilities.Vinbiocare Contractual LiabilitiesVinbiocare contractual liabilitiesDepreciation, Depletion and Amortization, NonproductionDepreciation and amortizationDepreciation, Depletion and Amortization, Nonproduction, TotalIncrease (Decrease) in Accounts PayableAccounts payableIncrease (Decrease) in Accounts Payable, TotalEntity Address, Address Line TwoEntity Address, Address Line TwoLiabilities and Equity [Abstract]Liabilities and stockholders' equityCureVac AG.Cure Vac A G [Member]CureVac [Member]Document Period End DateDocument Period End DateNet Cash Provided by (Used in) Financing ActivitiesNet cash provided by (used in) financing activitiesAlexion Pharmaceuticals, Inc.Alexion Pharmaceuticals Inc [Member]Alexion [Member]Stockholders' Equity Note [Abstract]Antidilutive Securities Excluded from Computation of Earnings Per Share, AmountAntidilutive securities excluded from computation of earnings per shareGrant revenue outstandingGrant revenue outstanding.Grant Revenue OutstandingAPIC, Share-Based Payment Arrangement, Increase for Cost RecognitionShare-based compensation expenseAPIC, Share-based Payment Arrangement, Increase for Cost Recognition, TotalEquity Method Investment, Ownership PercentageEquity method ownership percentageAccrued Liabilities, CurrentAccrued liabilitiesTotalIncome tax expenseProvision for income taxesIncome Tax Expense (Benefit)Income Tax Expense (Benefit), TotalTrading SymbolTrading SymbolVallon Pharmaceuticals, Inc.Vallon Pharmaceuticals Inc [Member]Vallon Pharmaceuticals, Inc. [Member]Variable Rate [Axis]Equity, Attributable to ParentBalanceBalanceTotal stockholders' equityLong-Lived Tangible Asset [Axis]Long-Lived Tangible AssetOther Liabilities, NoncurrentOther non-current liabilitiesEquity method investment, sale of common stockSale of Stock, Number of Shares Issued in TransactionRelated Party Transactions [Abstract]Warrant fee payable.Warrant Fee PayableWarrant fee payableProperty, Plant and Equipment [Table]Schedule Of Property Plant And Equipment [Table]Minimum amount agreed to incur under research planMinimum Amount Agreed to Incur Under Research PlanMinimum amount agreed to incur under research plan.Monthly base rent.Monthly Base RentMonthly base rentInvestment Owned, Net Assets, PercentagePercentage of owned sharesSecurity DepositSecurity depositGeographical [Axis]GeographicalLeases [Abstract]Equipment [Member]Research equipment [Member]Other accrued research and development expenses.Other Accrued Research And Development ExpensesOther accrued research and development expensesGrant Revenue Abstract.Grant Revenue [Abstract]Proceeds from Issuance of Long-Term DebtProceeds from long-term debt agreementProceeds from Issuance of Long-term Debt, TotalClass of Stock [Line Items]Class Of Stock [Line Items]Percentage required to be maintained in consolidated unrestricted cash.Percentage Required To Be Maintained In Consolidated Unrestricted CashPercentage required to be maintain in consolidated, unrestricted cashScenario [Axis]ScenarioSummary of Changes in Balances of Receivables and Contract LiabilityContract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]Security Exchange NameSecurity Exchange NameLessee operating lease liability payments due after year three.Lessee Operating Lease Liability Payments Due After Year ThreeThereafterCounterparty Name [Domain]Counterparty NameOperating ExpensesTotal operating expensesLong-Lived Tangible Asset [Domain]Long-Lived Tangible AssetAccumulated Depreciation, Depletion and Amortization, Property, Plant, and EquipmentLess accumulated depreciation and amortizationAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, TotalAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning BalanceAccumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending BalanceFair Value Disclosures [Text Block]Fair Value MeasurementsInterest Expense, Long-Term DebtInterest expense related to long-term debtInterest Expense, Long-term Debt, TotalDisbursement period four.Disbursement Period Four [Member]Disbursement Due October 2020 [Member]Lessee, Operating Lease, Liability, to be Paid, Year Three2027Subsequent Event [Member]Subsequent EventMaximum [Member]Maximum [Member]Liabilities and EquityTotal liabilities and stockholders' equityGain on debt extinguishmentGain on debt extinguishmentGain (Loss) on Extinguishment of DebtGain (Loss) on Extinguishment of Debt, TotalOperating lease right-of-use assets, netOperating Lease, Right-of-Use AssetSupplemental Cash Flow Information [Abstract]Supplemental disclosure of cash flow informationDilutedEarnings Per Share, DilutedEarnings Per Share, Diluted, TotalThe BARDA Contract [Member]Biomedical Advanced Research And Development Authority Contract [Member]Biomedical advanced research and development authority contract member.Leasehold Improvements [Member]Leasehold improvements [Member]AdditionsContract With Customer Asset AdditionsContract with customer asset additions.DividendsDividends declared or paidDividends, TotalLiabilitiesTotal liabilitiesOption for renewal termDebt Instrument Option for Renewal TermDebt instrument option for renewal term.Borrowings under Guaranteed Investment AgreementsTerm loan draw downDevelopment milestones achieved.Development Milestones AchievedDevelopment milestones achievedAssets, CurrentTotal current assetsNet Cash Provided by (Used in) Investing ActivitiesNet cash used in investing activitiesStock Issued During Period, Shares, New IssuesIssuance of common stock, net of issuance costs (in shares)Issuance of common stockThe entire disclosure for grant revenue.Grant Revenue Disclosure [Text Block]Grant RevenueEntity Filer CategoryEntity Filer CategoryRemaining loan including accrued interest forgiveableRemaining Loan Including Accrued Interest ForgiveableRemaining loan including accrued interest forgiveable.Property, Plant and Equipment [Abstract]Current Fiscal Year End DateCurrent Fiscal Year End DatePayments for Advance to AffiliatePayments for advanceLessee, Operating Lease, Liability, Undiscounted Excess AmountLess: imputed interestShare-Based Payment Arrangement, Noncash ExpenseShare-based compensation expenseShare-based Payment Arrangement, Noncash Expense, TotalPercentage of net profits.Percentage Of Net ProfitsNet profits percentageVinbiocare agreement.Vinbiocare Agreement [Member]Vinbiocare Agreement [Member]Related and Nonrelated Parties [Axis]Related PartyLance Kurata [Member]Lance Kurata.Fee payableDebt Instrument, Fee AmountRevenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]SINGAPORESingapore Economic Development Board [Member]Entity Registrant NameEntity Registrant NameSchedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]Debt Instrument, Maturity DateLoan maturity dateEntity Emerging Growth CompanyEntity Emerging Growth CompanyBasicWeighted Average Number of Shares Outstanding, BasicWeighted Average Number of Shares Outstanding, Basic, TotalLUNAR-CF.L U N A R C F [Member]LUNAR-CF [Member]Common Stock, Shares AuthorizedCommon stock, shares authorizedReduction in number of common stock capital shares available for future issuance.Reduction in Number of Common Stock Capital Shares Available for Future IssuanceReduction in number of common stock shares available for future issuanceEquity Method Investment, Nonconsolidated Investee [Axis]Equity Method Investment, Nonconsolidated InvesteeDebt Disclosure [Abstract]Earnings Per Share, Policy [Policy Text Block]Net Loss per ShareGeneral and Administrative Expense [Member]General and Administrative [Member]Revenue [Policy Text Block]Revenue RecognitionPhase I Clinical Study [Member]Phase I clinical study.Share-Based Payment Arrangement [Abstract]Two thousand nineteen omnibus incentive plan.Two Thousand Nineteen Omnibus Incentive Plan [Member]2019 Omnibus Equity Incentive Plan [Member]Eligible to receive commercial milestone payment.Eligible to Receive Commercial Milestone PaymentEligible to receive commercial milestone paymentStock Issued During Period, Value, AcquisitionsIssuance of common stock related to acquired in-process research and developmentIsrael Ministry of Health [Member]Israel Ministry of Health [Member]Israel ministry of health.Accounting Policies [Abstract]Income Tax Disclosure [Abstract]Equity, Attributable to Parent [Abstract]Stockholders' equityCash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]Non-cash investing activitiesStatement [Table]Statement [Table]Segment Reporting, Policy [Policy Text Block]Segment InformationProperty, Plant and Equipment [Table Text Block]Summary of Components of Property and Equipment, NetStudy support agreement.Study Support Agreement [Member]Study Support AgreementSecurities Act File NumberEntity File NumberNet decrease in cash, cash equivalents and restricted cashCash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectRevenue from Contract with Customer [Abstract]Net loss per share:Earnings Per Share [Abstract]Long-Term Debt, Maturity, Remainder of Fiscal Year2022Lease Contractual

Term [Domain]Lease Contractual TermStatement of Financial Position [Abstract]Loss from operationsOperating Income (Loss)Long-Term Debt, Maturity, Year One2023Entity Shell CompanyEntity Shell CompanyBorrowings interest rate, percentageDebt Instrument, Interest Rate, Effective PercentageLoan accrued interest rate per annum, percentageEntity Tax Identification NumberEntity Tax Identification NumberAssets [Abstract]AssetsDeductionsContract With Customer Asset DeductionsContract with customer asset deductions.DeductionsEntity Current Reporting StatusEntity Current Reporting StatusLoans interest rate, percentageLine of Credit Facility, Interest Rate During PeriodLong-Term Debt, Type [Axis]Long-term Debt, TypeSubsequent Events [Abstract]Increase (Decrease) in Contract with Customer, LiabilityDeferred revenueGeographical [Domain]GeographicalDocument Fiscal Year FocusDocument Fiscal Year FocusPayment received first installment.Payment Received First InstallmentReceived first installmentRepayment of term loanRepayments of Long-Term DebtRepayments of Long-Term Debt, TotalPurchase of property and equipment in accounts payable and accrued expensesCapital Expenditures Incurred but Not yet PaidCity Area CodeCity Area CodeLiabilities, CurrentTotal current liabilitiesFinal payment of disbursement amount.Final Payment Of Disbursement AmountFinal payment of disbursement amountCSL Segirus [Member]CSL Segirus [Member]CSL segirus.Local Phone NumberLocal Phone NumberCommitment and contingencies.Commitment And Contingencies [Table]Commitment And Contingencies [Table]Operating Lease, Impairment LossImpairment lossAdditional Paid in CapitalAdditional paid-in capitalAdditional Paid in Capital, TotalAdditional Paid in Capital, Beginning BalanceAdditional Paid in Capital, Ending BalanceGrants ReceivableGrant awardedmRNA technology.M R N A Technology [Member]mRNA Technology [Member]Commitments and Contingencies Disclosure [Abstract]Operating Lease, Liability, CurrentCurrent portion of operating lease liabilityRetained Earnings [Member]Accumulated Deficit [Member]Payments to Acquire Property, Plant, and EquipmentAcquisition of property and equipmentPayments to Acquire Property, Plant, and Equipment, TotalAccrued Liabilities, Current [Abstract]Document Transition ReportDocument Transition ReportDebt Instrument, Date of First Required PaymentLoan first principal payment extended maturity dateLessee, Operating Lease, Liability, to be Paid, Year Two2026Schedule of summary of significant accounting policies.Schedule Of Summary Of Significant Accounting Policies [Table]Schedule Of Summary Of Significant Accounting Policies [Table]Arcalis, Inc.Arcalis, Inc [Member]Proceeds from Stock PlansProceeds from the issuance of common stock under equity plansThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer, as well as trade accounts receivable, notes and loans receivable.Prepaid Expenses And Other ReceivablesPrepaid expenses and other current assetsMinimum [Member]Minimum [Member]Common Stock [Member]Common Stock [Member]Restricted Cash, TotalRestricted CashRestricted cashInvestment, Name [Axis]Investment, NameAdditional Paid-in Capital [Member]Additional Paid-In Capital [Member]Business acquisition of holding shareBusiness Acquisition Of Holding ShareBusiness acquisition of holding share.Collaboration Revenue [Member]Collaboration Revenue [Member]Collaboration revenue.Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]Statement of Income Location, Balance [Domain]Income Statement LocationLessee, Operating Lease, Liability, to be Paid, Year OneLessee Operating Lease Liability Payments Due Next Twelve Months, Total2025Royalty payment percentage.Royalty Payment PercentageRoyalty payment percentage of proceeds from net salesDisbursed amount upon execution of amendment.Disbursed Amount Upon Execution Of AmendmentDisbursed amount upon execution of amendmentRealized Gain (Loss), Foreign Currency Transaction, before TaxForeign currency translation lossUnderlying agreement.Underlying Agreement [Member]Underlying Agreement [Member]Entity Common Stock, Shares OutstandingEntity Common Stock, Shares OutstandingDisaggregation of Revenue [Line Items]Disaggregation Of Revenue [Line Items]Debt instrument interest only payment extended maturity date.Debt Instrument Interest Only Payment Extended Maturity DateLoan interest-only payment extended maturity dateNon-Cash Asset DisposalNon - Cash Asset DisposalNon-cash asset disposalBasis of Accounting, Policy [Policy Text Block]Basis of PresentationJoint ventures, equity method investments and variable interest entities.Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block]Joint Ventures, Equity Method Investments and Variable Interest EntitiesScenario [Domain]ScenarioIssuance of common stock under equity plans (in shares)Stock Issued During Period Shares Under Equity PlanStock issued during period shares under equity plan.Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 27,042 at June 30, 2024 and 26,828 at December 31, 2023Common Stock, Value, IssuedCommon Stock, Value, Issued, TotalCommon Stock, Value, Issued, Beginning BalanceCommon Stock, Value, Issued, Ending BalanceExtended term periodDebt Instrument, Extended Term PeriodDebt instrument, extended term period.Operating Lease, LiabilityTotal operating lease liabilitiesOperating Lease, Liability, TotalSchedule of Accrued Liabilities [Table Text Block]Schedule of Accrued LiabilitiesDisbursement payment upon achievement of required manufacturing practices and IND application.Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D ApplicationDisbursement payment upon achievement of required manufacturing practices and IND applicationDilutedWeighted Average Number of Shares Outstanding, DilutedWeighted Average Number of Shares Outstanding, Diluted, TotalAccounts Receivable, after Allowance for Credit Loss, CurrentAccounts receivableAccounts Receivable, after Allowance for Credit Loss, Current, TotalLessee, Operating Lease, Renewal TermOperating lease extended additional termLessee, Operating Lease, Liability, to be PaidTotal remaining lease paymentsWeighted-average shares outstanding:Weighted Average Number of Shares Outstanding, Diluted [Abstract]Entity Small BusinessEntity Small BusinessDebt Instrument, Basis Spread on Variable RateInterest of the prime rate plusDebt Disclosure [Text Block]DebtSegirus, Inc.Segirus, Inc [Member]Segirus, Inc [Member]Segirus Inc [Member]Repayments of DebtPayments on debt obligations(Loss) gain from foreign currencyForeign currency transaction gain (loss)Gain (Loss), Foreign Currency Transaction, before TaxForeign Currency Transaction Gain (Loss), before Tax, TotalAcquisition of research and development in process through issuance of common stock.Acquisition Of Research And Development In Process Through Issuance Of Common StockAcquisition of in-process research and development through issuance of common stockGrant receivable number of installments.Grant Receivable Number Of InstallmentsGrant, number of installmentsDisbursement period one.Disbursement Period One [Member]Disbursement Due January 2020 [Member]Disbursement amount payable upon achievement of project goal.Disbursement Amount Payable Upon Achievement Of Project GoalDisbursement amount payable upon achievement of project goalNet Cash Provided by (Used in) Financing Activities [Abstract]Financing activitiesGrant two.Grant Two [Member]Grant 2Debt instrument interest only payment extended period.Debt Instrument Interest Only Payment Extended PeriodExtension to interest only periodRight-of-Use Asset Obtained in Exchange for Operating Lease LiabilityRight-of-use assets acquired through operating leasesNon-refundable commitment fee, percentageLine of Credit Facility, Commitment Fee PercentageCystic Fibrosis Foundation Liability (Note 9)Accrued Cystic Fibrosis Foundation LiabilityAccrued cystic fibrosis foundation liability.Cystic Fibrosis Foundation liabilityAxcelead, Inc.Axcelead Inc [Member]Axcelead, Inc [Member]Other collaboration agreements.Other Collaboration Agreements [Member]Other Collaboration Agreements [Member]Operating Lease, Weighted Average Remaining Lease TermWeighted-average remaining lease termSubsequent Events [Text Block]Subsequent EventsAccounts Payable, CurrentAccounts payableAccounts Payable, Current, TotalGRI Bio [Member]GRI Bio Inc MemberGRI Bio Inc.Increase (Decrease) in Accrued LiabilitiesAccrued liabilitiesIncrease (Decrease) in Accrued Liabilities, Total XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended Jun. 30, 2024	Aug. 02, 2024
Cover [Abstract]		
Document Type	10-Q	
Amendment Flag	false	
Document Period End Date	Jun. 30, 2024	
Document Fiscal Year Focus	2024	
Document Fiscal Period Focus	Q2	
Trading Symbol	ARCT	
Entity Registrant Name	ARCTURUS THERAPEUTICS HOLDINGS INC.	
Entity Central Index Key	0001768224	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Current Fiscal Year End Date	--12-31	
Entity Filer Category	Accelerated Filer	
Entity Small Business	false	
Entity Emerging Growth Company	false	
Entity Shell Company	false	
Title of 12(b) Security	Common Stock, par value $0.001 per share	
Security Exchange Name	NASDAQ	
Entity File Number	001-38942	
Entity Incorporation, State or Country Code	DE	
Entity Tax Identification Number	32-0595345	
Entity Address, Address Line One	10628 Science Center Drive	
Entity Address, Address Line Two	Suite 250	
Entity Address, City or Town	San Diego	
Entity Address, State or Province	CA	
Entity Address, Postal Zip Code	92121	
City Area Code	858	
Local Phone Number	900-2660	
Entity Common Stock, Shares Outstanding		27,042,246
Document Quarterly Report	true	

Document Transition Report	false

' XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:		
Cash and cash equivalents	$ 260,329	$ 292,005
Restricted cash	55,000	55,000
Accounts receivable	24,085	32,064
Prepaid expenses and other current assets	7,594	7,521
Total current assets	347,008	386,590
Property and equipment, net	11,182	12,427
Operating lease right-of-use assets, net	28,533	28,500
Non-current restricted cash	1,885	1,885
Total assets	388,608	429,402
Current liabilities:		
Accounts payable	13,905	5,279
Accrued liabilities	35,450	31,881
Deferred revenue	42,362	44,829
Total current liabilities	91,717	81,989
Deferred revenue, net of current portion	11,344	42,496
Operating lease liability, net of current portion	26,964	25,907
Other non-current liabilities		497
Total liabilities	130,025	150,889
Stockholders' equity		
Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 27,042 at June 30, 2024 and 26,828 at December 31, 2023	27	27
Additional paid-in capital	670,455	646,352
Accumulated deficit	(411,899)	(367,866)
Total stockholders' equity	258,583	278,513
Total liabilities and stockholders' equity	$ 388,608	$ 429,402

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]		
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	60,000,000	60,000,000
Common stock, shares issued	27,042,000	26,828,000
Common stock, shares outstanding	27,042,000	26,828,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenue:				
Total revenue	$ 49,859	$ 10,519	$ 87,871	$ 90,804
Operating expenses:				
Research and development, net	58,669	52,668	112,242	104,436
General and administrative	12,316	13,225	27,167	26,987
Total operating expenses	70,985	65,893	139,409	131,423
Loss from operations	(21,126)	(55,374)	(51,538)	(40,619)
(Loss) gain from foreign currency	(388)	149	(441)	(179)
Gain on debt extinguishment				33,953
Finance income, net	4,148	3,252	8,164	5,729
Net loss before income taxes	(17,366)	(51,973)	(43,815)	(1,116)
Provision for income taxes	(150)	577	218	680
Net loss	$ (17,216)	$ (52,550)	$ (44,033)	$ (1,796)
Net loss per share:				
Basic	$ (0.64)	$ (1.98)	$ (1.64)	$ (0.07)
Diluted	$ (0.64)	$ (1.98)	$ (1.64)	$ (0.07)
Weighted-average shares outstanding:				
Basic	26,967	26,563	26,923	26,557
Diluted	26,967	26,563	26,923	26,557
Comprehensive loss:				
Net loss	$ (17,216)	$ (52,550)	$ (44,033)	$ (1,796)
Comprehensive loss	(17,216)	(52,550)	(44,033)	(1,796)
Collaboration Revenue [Member]				
Revenue:				
Total revenue	45,976	9,565	78,574	89,294
Grant Revenue [Member]				
Revenue:				
Total revenue	$ 3,883	$ 954	$ 9,297	$ 1,510

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2022	$ 270,312	$ 27	$ 608,426	$ (338,141)
Balance (in shares) at Dec. 31, 2022		26,555		
Net Income (Loss)	50,754			50,754
Share-based compensation expense	8,182		8,182	
Balance at Mar. 31, 2023	329,248	$ 27	616,608	(287,387)
Balance (in shares) at Mar. 31, 2023		26,555		
Balance at Dec. 31, 2022	270,312	$ 27	608,426	(338,141)
Balance (in shares) at Dec. 31, 2022		26,555		
Net Income (Loss)	(1,796)			
Balance at Jun. 30, 2023	285,175	$ 27	625,085	(339,937)
Balance (in shares) at Jun. 30, 2023		26,574		

Balance at Mar. 31, 2023	329,248	$ 27	616,608	(287,387)
Balance (in shares) at Mar. 31, 2023		26,555		
Net Income (Loss)	(52,550)			(52,550)
Share-based compensation expense	8,383		8,383	
Issuance of common stock upon exercise of stock options	94		94	
Issuance of common stock upon exercise of stock options (in shares)		19		
Balance at Jun. 30, 2023	285,175	$ 27	625,085	(339,937)
Balance (in shares) at Jun. 30, 2023		26,574		
Balance at Dec. 31, 2023	278,513	$ 27	646,352	(367,866)
Balance (in shares) at Dec. 31, 2023		26,828		
Net Income (Loss)	(26,817)			(26,817)
Share-based compensation expense	10,088		10,088	
Issuance of common stock upon exercise of stock options	2,188		2,188	
Issuance of common stock upon exercise of stock options (in shares)		89		
Balance at Mar. 31, 2024	263,972	$ 27	658,628	(394,683)
Balance (in shares) at Mar. 31, 2024		26,917		
Balance at Dec. 31, 2023	278,513	$ 27	646,352	(367,866)
Balance (in shares) at Dec. 31, 2023		26,828		
Net Income (Loss)	(44,033)			
Balance at Jun. 30, 2024	258,583	$ 27	670,455	(411,899)
Balance (in shares) at Jun. 30, 2024		27,042		
Balance at Mar. 31, 2024	263,972	$ 27	658,628	(394,683)
Balance (in shares) at Mar. 31, 2024		26,917		
Net Income (Loss)	(17,216)			(17,216)
Share-based compensation expense	9,424		9,424	
Issuance of common stock upon exercise of stock options	2,403		2,403	
Issuance of common stock upon exercise of stock options (in shares)		125		
Balance at Jun. 30, 2024	$ 258,583	$ 27	$ 670,455	$ (411,899)
Balance (in shares) at Jun. 30, 2024		27,042		

XML 17 R6.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023
Operating activities		
Net loss	$ (44,033)	$ (1,796)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:		
Depreciation and amortization	1,813	1,315
Share-based compensation expense	19,512	16,565
Foreign currency translation loss	441	160
Gain on debt extinguishment		(33,953)
Other non-cash expenses		502
Changes in assets and liabilities:		
Accounts receivable	7,979	(35)
Prepaid expense and other assets	(73)	4,712
Right-of-use assets	2,703	1,992
Accounts payable	8,626	5,593
Accrued liabilities	2,631	(2,983)
Deferred revenue	(33,619)	24,969
Lease liabilities	(1,679)	(2,105)
Net cash (used in) provided by operating activities	(35,699)	14,936
Investing activities		
Acquisition of property and equipment	(568)	(1,045)
Net cash used in investing activities	(568)	(1,045)
Financing activities		
Proceeds from exercise of stock options	4,591	94
Payments on debt obligations		(27,364)
Net cash provided by (used in) financing activities	4,591	(27,270)
Net decrease in cash, cash equivalents and restricted cash	(31,676)	(13,379)
Cash, cash equivalents and restricted cash at beginning of the period	348,890	393,977
Cash, cash equivalents and restricted cash at end of the period	317,214	380,598
Supplemental disclosure of cash flow information		
Cash paid for interest		2,102
Non-cash investing activities		
Non-cash asset disposal	473	
Right-of-use assets acquired through operating leases	$ 2,736	
Purchase of property and equipment in accounts payable and accrued expenses		$ 577

XML 18 R7.htm IDEA: XBRL DOCUMENT

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended			6 Months Ended		
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure						
Net Income (Loss)	$ (17,216)	$ (26,817)	$ (52,550)	$ 50,754	$ (44,033)	$ (1,796)

XML 19 R8.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended Jun. 30, 2024 shares
Trading Arrangements, by Individual	
Material Terms of Trading Arrangement	***Rule 10b5-1 Trading Arrangements*** During the three months ended June 30, 2024, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, other than as follows: • Lance Kurata, our Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement as of June 12, 2024. Mr. Kurata's trading arrangement provides for the exercise of up to an aggregate of 35,000 options to purchase shares of common stock and subsequent sale of such underlying shares of common stock, until June 12, 2025.
Directors or Officers [Member]	
Trading Arrangements, by Individual	
Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Lance Kurata [Member]	
Trading Arrangements, by Individual	

Name	Lance Kurata
Title	Chief Legal Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 12, 2024
Expiration Date	June 12, 2025
Aggregate Available	35,000

XML 20 R9.htm IDEA: XBRL DOCUMENT

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]	
Description of Business, Basis of Presentation and Summary of Significant Accounting Policies	

Note 1. Description of Business, Basis of Presentation and Summary of Significant Accounting Policies

Description of Business

Arcturus Therapeutics Holdings Inc. (the “Company” or "Arcturus") is a global messenger RNA medicines company focused on the development of infectious disease vaccines and significant addressing unmet medical needs within liver and respiratory rare diseases. The Company became a clinical stage company during 2020 when it announced that its Investigational New Drug (“IND”) application for ornithine transcarbamylase (“OTC”) deficiency and its Clinical Trial Application (“CTA”) for candidate LUNAR-COV19 were approved by applicable health authorities.

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Arcturus and its subsidiaries and are unaudited. All intercompany accounts and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

Interim financial results are not necessarily indicative of results anticipated for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.

These condensed consolidated financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on management’s knowledge of current events and actions the Company may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

Joint Ventures, Equity Method Investments and Variable Interest Entities

Investments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. (“Axcelead”). The Company’s share of the investee's results is presented as either income or loss from equity-method investment in the accompanying condensed consolidated statements of operations and comprehensive loss.

Liquidity

The Company has incurred significant operating losses since its inception. As of June 30, 2024 and December 31, 2023, the Company had an accumulated deficit of $411.9 million and $367.9 million, respectively.

The Company’s activities since inception have consisted principally of research and development activities, general and administrative activities, and raising capital. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company’s inception through June 30, 2024, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements, the sale of capital stock, expense reimbursements from government contracts and proceeds from long-term debt. At June 30, 2024, the Company’s balance of cash and cash equivalents, including restricted cash, was $317.2 million.

Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these condensed consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in securing additional funding, that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.

Segment Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company’s operations and manage its business in one operating segment, which is the research and development of medical applications for the Company’s nucleic acid-focused technology.

Revenue Recognition

At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of Accounting Standards Codification (“ASC”) Topic 808, Collaborative Arrangements (“ASC 808”). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606.

The Company determines revenue recognition for arrangements within the scope of ASC 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation.

The terms of the Company’s revenue agreements include license fees, upfront payments, development or regulatory milestone payments, profit-sharing arrangements, reimbursement for research and development activities, option exercise fees, drug substance and drug product supply fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur.

A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in ASC 606. A contract’s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.

For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified.

See “Note 2, Revenue” for specific details surrounding the Company’s arrangements.

Leases

The Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components.

See *“Note 9, Commitments and Contingencies”* for specific details surrounding the Company’s leases.

Research and Development Costs, Net

All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), in-process research and development expenses, pre-launch inventory and license agreement expenses. Research and development expenses are presented net of any grants. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed.

The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered.

Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations ("CROs") and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.

Pre-Launch Inventory

Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its condensed consolidated statements of operations and comprehensive loss, in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory.

Restricted Cash

Restricted cash includes collateral pledged and held at the Company’s securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association (“Wells Fargo”) (Note 5). At June 30, 2024, such collateral amounted to $55.0 million.

Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Company’s offices. At June 30, 2024 and 2023, the Company had restricted cash of $1.9 million and $2.1 million, respectively, in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the

end of the lease term.

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statement of cash flows as of June 30, 2024 and 2023:

(in thousands)	June 30, 2024	June 30, 2023
Cash and cash equivalents	$ 260,329	$ 323,471
Restricted cash	55,000	55,000
Non-current restricted cash	1,885	2,127
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 317,214	$ 380,598

Net Loss per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the three and six months ended June 30, 2024 were comprised of stock options and restricted stock units. Dilutive shares of common stock for the three and six months ended June 30, 2023 were comprised of stock options.

No dividends were declared or paid during the reported periods.

Recently Issued Accounting Standards Not Yet Adopted

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the condensed consolidated financial statements and disclosures.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Revenue

6 Months Ended
Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Revenue

Note 2. Revenue

The Company has entered into license agreements and collaborative research and development arrangements with pharmaceutical and biotechnology companies, as well as consulting, related technology transfer, product revenue and government grant agreements. Under these arrangements, the Company is entitled to receive license fees, consulting fees, product fees, technological transfer fees, upfront payments, milestone payments if and when certain research and development milestones, technology transfer milestones or success-based milestones are achieved, royalties on approved product sales and reimbursement for research and development activities. The Company's costs of performing these services are included within research and development expenses. The Company's milestone payments are typically defined by achievement of certain preclinical, clinical, and commercial success criteria. Preclinical milestones may include in vivo proof of concept in disease animal models, lead candidate identification, and completion of IND-enabling toxicology studies. Clinical milestones may, for example, include successful enrollment of the first patient in or completion of Phase 1, 2 and 3 clinical trials, and commercial milestones are often tiered based on net or aggregate sale amounts. The Company cannot guarantee the achievement of these milestones due to risks associated with preclinical and clinical activities required for development of nucleic acid medicine-based therapeutics and vaccines.

The following table presents changes during the six months ended June 30, 2024 in the balances of contract assets and liabilities as compared to what was disclosed in the Company's Annual Report.

(in thousands)	December 31, 2023	Additions	Deductions	June 30, 2024
Contract Assets:				
Accounts receivable	$ 32,064	$ 55,132	$ (63,111)	$ 24,085
Contract Liabilities:				
Deferred revenue	$ 87,325	$ 54,252	$ (87,871)	$ 53,706

The following table summarizes the Company's revenues for the periods indicated.

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
(in thousands)	2024	2023	2024	2023
Collaboration Revenue:				
CSL Seqirus	$ 45,911	$ 7,607	$ 78,292	$ 85,824
Janssen	—	170	—	660
Other collaboration revenue	65	1,788	282	2,810
Total collaboration revenue	$ 45,976	$ 9,565	$ 78,574	$ 89,294
Grant revenue:				
BARDA	$ 3,883	$ 954	$ 9,297	$ 1,510
Total grant revenue	$ 3,883	$ 954	$ 9,297	$ 1,510

The following paragraphs provide information regarding the nature and purpose of the Company's most significant collaboration and grant arrangements.

CSL Seqirus

On November 1, 2022, the Company entered into a Collaboration and License Agreement (as amended, the "CSL Collaboration Agreement") with Seqirus, Inc., a part of CSL Limited ("CSL Seqirus"), for the global exclusive rights to research, develop, manufacture, and commercialize vaccines. Under the terms of the CSL Collaboration Agreement, the Company provides CSL Seqirus with an exclusive global license to its mRNA technology (including STARR®) and LUNAR® lipid-mediated delivery, along with mRNA drug substance and drug product manufacturing process. CSL Seqirus will lead development and commercialization of vaccines under the collaboration. The collaboration plans to advance vaccines against SARS-CoV-2 (COVID-19), influenza, pandemic preparedness as well as three other respiratory infectious diseases.

The Company received a $200.0 million upfront payment and is eligible to receive over $1.3 billion in development milestones if all products are registered in the licensed fields and entitled to potentially receive up to $3.0 billion in commercial milestones based on "net sale" of vaccines in the various fields. In addition, the Company is eligible to receive a 40% net profit share for COVID-19 vaccine products and up to low double-digit royalties for vaccines against flu, pandemic preparedness and three other respiratory pathogens. During the second quarter of 2024, the Company achieved a $17.0 million development milestone related to the CSL Collaboration Agreement which was included in accounts receivable as of June 30, 2024.

In evaluating the CSL Collaboration Agreement in accordance with ASC 606, the Company concluded that CSL Seqirus is a customer. The Company identified all promised goods/services within the CSL Collaboration Agreement, and when combining certain promised goods/services, the Company concluded that there are five distinct performance obligations. The nature of the performance obligations consists of delivery of the vaccine license, research and development services for COVID and non-COVID vaccines and regulatory activities for COVID vaccines. For each performance obligation, the Company estimated the standalone selling price based on 1) in the case of the license, the fair value using costs to recreate plus margin method and 2) in the case of research and development services and regulatory activities, cost plus margin for estimated full-time equivalent ("FTE") costs, direct costs including laboratory supplies, contractors, and other out-of-pocket expenses for research and development services and regulatory activities.

As of June 30, 2024, the transaction price consisted of upfront consideration received and milestones achieved. Additional variable consideration was not included in the transaction price at June 30, 2024 because the Company could not conclude that it is probable that including the variable consideration will not result in a significant revenue reversal.

The Company allocated the transaction price to the performance obligations in proportion to their standalone selling price. The vaccine license was recognized at the point in time it was transferred in 2022. The research and development and regulatory activities performance obligations are recognized over a period of time based on the percentage of services rendered using the input method, meaning actual costs incurred divided by total costs budgeted to satisfy the performance obligation. Any consideration related to sales-based royalties will be recognized when the amounts are probable of non-reversal, provided that the reported sales are reliably measurable and the Company has no remaining promised goods/services, as they are constrained and therefore have also been excluded from the transaction price. The revenue recognized in the second quarter of 2024 relates to the license delivered, milestones achieved and services performed through June 30, 2024.

Total deferred revenue as of June 30, 2024 and December 31, 2023 for the CSL Collaboration Agreement was $53.7 million and $87.1 million, respectively.

During 2023, the Company also received an advance payment of $23.6 million for the manufacturing and supply of ARCT-154 drug product. The advance payment was for specified manufacturing runs of ARCT-154 which include the drug substance utilized, as well as the reservation fees and related manufacturing requirements. The Company concluded that the promise to manufacture and supply ARCT-154 drug product is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The Company recognized $18.0 million in revenue related to this customer option during the second quarter of 2024. No amount related to this customer option remained in deferred revenue as of June 30, 2024.

During 2023, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the Company agreed to sponsor and conduct a Phase 1 clinical study in the influenza field. As part of the amendment, the Company received $17.5 million from CSL Seqirus. The amendment also provides for up to $1.5 million in additional payments which are achievable upon meeting certain clinical milestones relating to the Phase 1 clinical study in the influenza field. The Company previously concluded that the expansion of research and development support services under the CSL Collaboration Agreement represented an option that was not a material right. Therefore the Company concluded the promise to sponsor and conduct the Phase 1 clinical study is a separate contract and the sole performance obligation under the new arrangement. During the quarter ended June 30, 2024, the Company recognized $3.0 million related to the performance obligation and the remaining amount of $9.8 million is included in deferred revenue.

During the fourth quarter of 2023, the Company received an advance payment of $5.3 million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. During the first quarter of 2024, the Company received an additional advance payment of $5.1 million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. The Company concluded that the promise to perform manufacturing activities is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The advance payments are included in deferred revenue as of June 30, 2024 and will be recognized as revenue when the vaccine product is transferred to CSL Seqirus.

In March 2024, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the parties agreed to, among other things, adjust (i) the development plans for certain product candidates, (ii) various development milestones related to such product candidates, (iii) provisions of the CSL Collaboration Agreement related to specific royalty payments, (iii) provisions of the CSL Collaboration Agreement related to distributors, and (iv) proprietary payment calculations related to the foregoing.

BARDA Grant

In August 2022, the Company entered into a cost reimbursement contract (the "BARDA Contract") with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) for an award of up to $63.2 million for the development of a pandemic influenza vaccine using the Company's STARR® self-amplifying mRNA vaccine platform technology. The Company earns grant revenue for performing tasks under the agreement.

The Company determined that the BARDA Contract is not in the scope of ASC 808 or ASC 606. Applying International Accounting Standards No. 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, the Company recognizes grant revenue from the reimbursement of direct out-of-pocket expenses, overhead allocations and fringe benefits for research costs associated with the grant. The costs associated with these reimbursements are reflected as a component of research and development expense in the Company's condensed consolidated statements of operations and comprehensive income (loss).

The Company recognized $3.9 million and $1.0 million of revenue during the three months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, the remaining available funding net of revenue earned was $44.5 million.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Fair Value

6 Months Ended

Measurements	Jun. 30, 2024
Fair Value Disclosures [Abstract]	
Fair Value Measurements	

Note 3. Fair Value Measurements

The Company establishes the fair value of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure fair value.

The three levels of the fair value hierarchy are as follows:

Level 1: Quoted prices in active markets for identical assets or liabilities.

Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly.

Level 3: Unobservable inputs in which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect those that a market participant would use.

The carrying value of cash, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values due to their relative short maturities.

As of June 30, 2024 and December 31, 2023, all assets measured at fair value on a recurring basis consisted of cash equivalents and money market funds, which were classified within Level 1 of the fair value hierarchy. The fair value of these financial instruments was measured based on quoted prices.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Balance Sheet Details	6 Months Ended Jun. 30, 2024
Balance Sheet Related Disclosures [Abstract]	
Balance Sheet Details	

Note 4. Balance Sheet Details

Property and equipment, net balances consisted of the following:

(in thousands)	June 30, 2024	December 31, 2023
Research equipment	$ 16,784	$ 16,046
Computers and software	1,131	1,275
Office equipment and furniture	703	958
Leasehold improvements	2,644	2,655
Construction in progress	—	233
Total	21,262	21,167
Less accumulated depreciation and amortization	(10,080)	(8,740)
Property and equipment, net	$ 11,182	$ 12,427

Depreciation and amortization expense was $0.9 million and $1.8 million for the three and six months ended June 30, 2024, respectively, and $0.7 million and $1.3 million for the three and six months ended June 30, 2023, respectively. Construction in progress is primarily comprised of research equipment not yet placed in service.

Accrued liabilities consisted of the following:

(in thousands)	June 30, 2024	December 31, 2023
Accrued compensation	$ 9,206	$ 5,918
Cystic Fibrosis Foundation liability	6,870	7,633
Income tax payable	—	641
Current portion of operating lease liability	3,917	4,309
Clinical trial accruals	968	2,333
Vinbiocare contractual liabilities	2,514	2,514
Other accrued research and development expenses	11,975	8,533
Total	$ 35,450	$ 31,881

XML 24 R13.htm IDEA: XBRL DOCUMENT

Debt	6 Months Ended Jun. 30, 2024
Debt Disclosure [Abstract]	
Debt	

Note 5. Debt

Wells Fargo Credit Agreement

The Company's wholly-owned subsidiary, Arcturus Therapeutics, Inc. ("Arcturus Therapeutics") entered into a credit agreement with Wells Fargo Bank on April 21, 2023, and amended on June 26, 2024, whereby Wells Fargo will make a $50.0 million revolving credit line available to the Company (the "Loan") and each draw on the Loan evidenced by a revolving line of credit note (the "Note").

Borrowings under the agreement will bear interest at a rate of 1.00% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Note), with "SOFR" being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If an Event of Default (as defined in the agreement) occurs, then all Loans shall bear interest at a rate equal to 2.00% above the interest rate applicable immediately prior to the occurrence of the Event of Default.

The term of the agreement was originally two years, with an option for one-year renewals subject to Wells Fargo approval and Arcturus Therapeutics furnishing to Wells Fargo a non-refundable commitment fee equal to 0.25% of the Loan amount for each such renewal. There is no penalty for terminating the facility prior to the maturity date of the Note. As collateral, the Company has agreed to pledge $55.0 million in cash to be held at the Company's securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement. In June 2024, Arcturus Therapeutics and Wells Fargo entered into an amendment to the Note, whereby the term of the Note was extended by one year to April 2026. No borrowings were outstanding as of June 30, 2024.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Equity	6 Months Ended Jun. 30, 2024
Stockholders' Equity Note [Abstract]	
Stockholders' Equity	

Note 6. Stockholders' Equity

Net Loss per Share

Potentially dilutive securities that were not included in the calculation of diluted net loss per share for the three and six months ended June 30, 2024 as they were anti-dilutive totaled 1.1 million and 1.3 million, respectively, and 1.0 million and 0.8 million for the three and six months ended June 30, 2023, respectively.

Sales Agreement

On December 23, 2022, the Company entered into a Controlled Equity Offering℠ Sales Agreement, which was amended on August 7, 2023 (as amended, the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor"),Wells Fargo Securities, LLC ("Wells Fargo Securities"), and William Blair & Company, L.L.C. ("William Blair") relating to shares of the Company's common stock. In accordance with the terms of the Sales Agreement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $200,000,000 from time to time through Cantor, Wells Fargo Securities, or William Blair, each acting as the Company's sales agent. During the period ended June 30, 2024 the Company did not offer or sell any shares of common stock pursuant to the Sales Agreement.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Expense	6 Months Ended Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]	
Share-Based Compensation Expense	

Note 7. Share-Based Compensation Expense

In June 2024 at the Company's 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"), the stockholders of the Company approved an amendment to the Company's 2019 Omnibus Equity Incentive Plan (as amended, the "2019 Plan") which, among other things, increased the aggregate number of shares authorized for use in making awards to eligible persons under the 2019 Plan by 2,000,000 shares, for a total of up to 10,750,000 shares available for issuance. As of June 30, 2024, following the 2024 Annual Meeting, a total of 2,236,360 shares remain available for future issuance under the 2019 Plan, subject to the terms of the 2019 Plan.

In October 2021, the Company adopted the 2021 Inducement Equity Incentive Plan which covers the award of up to 1,000,000 shares of common stock (the "2021 Plan") effective as of October 15, 2021. Approval of the Company's stockholders is not required as a condition to the effectiveness of the 2021 Plan for so long as the plan is in compliance with applicable Nasdaq inducement plan rules. In April 2022, the compensation committee of the Company's board of directors approved a proposal to reduce the total number of shares available for future issuance under the 2021 Plan to 130,000. As of June 30, 2024, a total of 124,697 shares remain available for future issuance under the 2021 Plan, subject to the terms of the 2021 Plan.

Stock Options

Share-based compensation expense included in the Company's condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023 was as follows:

(in thousands)	For the Three Months Ended June 30, 2024	For the Three Months Ended June 30, 2023	For the Six Months Ended June 30, 2024	For the Six Months Ended June 30, 2023
Research and development	$ 4,378	$ 3,741	$ 9,180	$ 7,249

General and administrative	5,046	4,642	10,332	9,316
Total	$ 9,424	$ 8,383	$ 19,512	$ 16,565

XML 27 R16.htm IDEA: XBRL DOCUMENT

Income Taxes	6 Months Ended Jun. 30, 2024
Income Tax Disclosure [Abstract]	
Income Taxes	

Note 8. Income Taxes

The Company is subject to taxation in the United States and various states. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate is due to federal and state income tax expense offset by valuation allowance on the Company's deferred tax assets.

For the three and six months ended June 30, 2024, the Company recorded $(0.2) million and $0.2 million of income tax expense, respectively. For the three and six months ended June 30, 2023, the Company recorded $0.6 million and $0.7 million of income tax expense, respectively. No tax benefit was provided for losses incurred in United States because those losses are offset by a full valuation allowance.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	6 Months Ended Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]	
Commitments and Contingencies	

Note 9. Commitments and Contingencies

Cystic Fibrosis Foundation Agreement

On September 25, 2023, the Company amended its Development Program Letter Agreement, dated May 16, 2017 and as amended July 13, 2018 and August 1, 2019, with the Cystic Fibrosis Foundation ("CFF"). Pursuant to the amendment, CFF increased the amount it will award to advance LUNAR-CF to $24.6 million from approximately $15.6 million and the Company agreed to incur at least $15.0 million toward activities under the research plan. Total contra expense of $0.8 million was recognized during the three and six months ended June 30, 2024. For the three and six months ended June 30, 2023, the Company recognized no contra expense

related to the agreement. As of June 30, 2024 and December 31, 2023, $6.9 million and $7.6 million, respectively, remained in accrued liabilities.

Leases

In October 2017, the Company entered into a non-cancellable operating lease agreement for office space adjacent to its previously occupied headquarters. The commencement of the lease began in March 2018 and the lease extends for approximately 84 months from the commencement date with a remaining lease term through March 2025. Monthly rental payments are due under the lease and there are escalating rent payments during the term of the lease. The Company is also responsible for its proportional share of operating expenses of the building and common areas. In conjunction with the new lease, the Company received free rent for four months and received a tenant improvement allowance of $0.1 million. In March 2024, the Company negotiated with the lessor to extend the lease through March 2027.

The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $0.1 million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.

In February 2020, the Company entered into a second non-cancellable operating lease agreement for office space near its current headquarters. The lease extended for 13 months from the commencement date and included a right to extend the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Company's headquarters. In January 2024, the Company vacated this office space with no intention of operating out of the location in the future. Because Arcturus was still engaged in the lease for the property and obligated to make the remaining lease payment through March 31, 2025, the Company recorded an impairment loss in the amount of $1.3 million during the three months ended March 31, 2024, as it would not receive any future economic benefit from the lease. In July 2024, the Company terminated the existing lease agreement, in accordance with its terms, thereby ending their contractual obligation to pay for premise.

In September 2021, the Company entered into a third non-cancellable lease agreement for office, research and development, engineering and laboratory space near its current headquarters, and such lease term commenced during the second quarter of 2022. The initial term of this lease extends ten years and eight months from the date of possession, and the Company has the right to extend the term of the lease for an additional five-year period. When the lease term was determined for the operating lease right-of-use assets and lease liabilities, the extension option for the lease was not included. The lease has a monthly base rent ranging from $0.3 million to $0.4 million which escalates over the lease term. The Company received a free rent period of four months and also pays for various operating costs, including utilities and real property taxes. The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $2.0 million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.

Operating lease right-of-use asset and liability on the condensed consolidated balance sheets represent the present value of remaining lease payments over the remaining lease terms. The Company does not allocate lease payments to non-lease components; therefore, payments for common-area-maintenance and administrative services are not included in the operating lease right-of-use asset and liability. The Company uses its incremental borrowing rate to calculate the present value of the lease payments, as the implicit rate in the lease is not readily determinable.

As of June 30, 2024, the remaining payments of the operating lease liability were as follows:

(in thousands)	Remaining Lease Payments
2024	$ 2,838
2025	5,019
2026	5,274
Thereafter	23,703
Total remaining lease payments	36,834
Less: imputed interest	(5,953)
Total operating lease liabilities	$ 30,881
Weighted-average remaining lease term	7.5
Weighted-average discount rate	4.8%

Operating lease costs consist of the fixed lease payments included in operating lease liability and are recorded on a straight-line basis over the lease terms. Operating lease costs were $1.5 million and $2.9 million for the three and six months ended June 30, 2024, respectively, and $1.4 million and $2.8 million for the three and six months ended June 30, 2023, respectively.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Related Party Transactions	6 Months Ended Jun. 30, 2024
Related Party Transactions [Abstract]	
Related Party Transactions	

Note 10. Related Party Transactions

See "Note 1, Joint Ventures, Equity Method Investments and Variable Interest Entities" for specific details surrounding the Company's agreement with Axcelead to form the joint venture entity, ARCALIS, Inc.

XML 30 R19.htm IDEA: XBRL DOCUMENT

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	6 Months Ended Jun. 30, 2024
Accounting Policies [Abstract]	
Basis of Presentation	

Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Arcturus and its subsidiaries and are unaudited. All intercompany accounts and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management's opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented.

Interim financial results are not necessarily indicative of results anticipated for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023.

These condensed consolidated financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on management's knowledge of current events and actions the Company may undertake in the future, actual results may ultimately differ from these estimates and assumptions.

Joint Ventures, Equity Method Investments and Variable Interest Entities

Joint Ventures, Equity Method Investments and Variable Interest Entities

Investments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. ("Axcelead"). The Company's share of the investee's results is presented as either income or loss from equity-method investment in the accompanying condensed consolidated statements of operations and comprehensive loss.

Liquidity

Liquidity

The Company has incurred significant operating losses since its inception. As of June 30, 2024 and December 31, 2023, the Company had an accumulated deficit of $411.9 million and $367.9 million, respectively.

The Company's activities since inception have consisted principally of research and development activities, general and administrative activities, and raising capital. The Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company's inception

through June 30, 2024, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements, the sale of capital stock, expense reimbursements from government contracts and proceeds from long-term debt. At June 30, 2024, the Company's balance of cash and cash equivalents, including restricted cash, was $317.2 million.

Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these condensed consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in securing additional funding, that the Company's projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.

Segment Information

Segment Information

Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company's operations and manage its business in one operating segment, which is the research and development of medical applications for the Company's nucleic acid-focused technology.

Revenue Recognition

Revenue Recognition

At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of Accounting Standards Codification ("ASC") Topic 808, Collaborative Arrangements ("ASC 808"). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606.

The Company determines revenue recognition for arrangements within the scope of ASC 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation.

The terms of the Company's revenue agreements include license fees, upfront payments, development or regulatory milestone payments, profit-sharing arrangements, reimbursement for research and development activities, option exercise fees, drug substance and drug product supply fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur.

A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in ASC 606. A contract's transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied.

For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified.

See "Note 2, Revenue" for specific details surrounding the Company's arrangements.

Leases

Leases

The Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components.

See *"Note 9, Commitments and Contingencies"* for specific details surrounding the Company's leases.

Research and Development Costs, Net

Research and Development Costs, Net

All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), in-process research and development expenses, pre-launch inventory and license agreement expenses. Research and development expenses are presented net of any grants. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed.

The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered.

Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations ("CROs") and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services.

Pre-Launch Inventory

Pre-Launch Inventory

Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its condensed consolidated statements of operations and comprehensive loss, in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory.

Restricted Cash

Restricted Cash

Restricted cash includes collateral pledged and held at the Company's securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association ("Wells Fargo") (Note 5). At June 30, 2024, such collateral amounted to $55.0 million.

Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Company's offices. At June 30, 2024 and 2023, the Company had restricted cash of $1.9 million and $2.1 million, respectively, in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term.

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statement of cash flows as of June 30, 2024 and 2023:

(in thousands)	June 30, 2024	June 30, 2023
Cash and cash equivalents	$ 260,329	$ 323,471
Restricted cash	55,000	55,000
Non-current restricted cash	1,885	2,127
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 317,214	$ 380,598

Net Loss per Share

Net Loss per Share

Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the three and six months ended June 30, 2024 were comprised of stock options and restricted stock units. Dilutive shares of common stock for the three and six months ended June 30, 2023 were comprised of stock options.

No dividends were declared or paid during the reported periods.

Recently Issued Accounting Standards Not Yet Adopted

Recently Issued Accounting Standards Not Yet Adopted

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the condensed consolidated financial statements and disclosures.

XML 31 R20.htm IDEA: XBRL DOCUMENT

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract]

Schedule of Cash and Cash Equivalents and Restricted Cash

(in thousands)	June 30, 2024	June 30, 2023
Cash and cash equivalents	$ 260,329	$ 323,471
Restricted cash	55,000	55,000
Non-current restricted cash	1,885	2,127
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 317,214	$ 380,598

XML 32 R21.htm IDEA: XBRL DOCUMENT

Revenue (Tables)

6 Months Ended
Jun. 30, 2024

Revenue from Contract with Customer [Abstract]

Summary of Changes in Balances of Receivables and Contract Liability

The following table presents changes during the six months ended June 30, 2024 in the balances of contract assets and liabilities as compared to what was disclosed in the Company's Annual Report.

(in thousands)	December 31, 2023	Additions	Deductions	June 30, 2024
Contract Assets:				
Accounts receivable	$ 32,064	$ 55,132	$ (63,111)	$ 24,085
Contract Liabilities:				
Deferred revenue	$ 87,325	$ 54,252	$ (87,871)	$ 53,706

Schedule of Revenue

The following table summarizes the Company's revenues for the periods indicated.

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
(in thousands)	2024	2023	2024	2023
Collaboration Revenue:				
CSL Seqirus	$ 45,911	$ 7,607	$ 78,292	$ 85,824
Janssen	—	170	—	660
Other collaboration revenue	65	1,788	282	2,810
Total collaboration revenue	$ 45,976	$ 9,565	$ 78,574	$ 89,294
Grant revenue:				
BARDA	$ 3,883	$ 954	$ 9,297	$ 1,510
Total grant revenue	$ 3,883	$ 954	$ 9,297	$ 1,510

XML 33 R22.htm IDEA: XBRL DOCUMENT

Balance Sheet Details (Tables) — **6 Months Ended Jun. 30, 2024**

Balance Sheet Related Disclosures [Abstract]

Summary of Components of Property and Equipment, Net

Property and equipment, net balances consisted of the following:

(in thousands)	June 30, 2024	December 31, 2023
Research equipment	$ 16,784	$ 16,046
Computers and software	1,131	1,275
Office equipment and furniture	703	958
Leasehold improvements	2,644	2,655
Construction in progress	—	233
Total	21,262	21,167
Less accumulated depreciation and amortization	(10,080)	(8,740)
Property and equipment, net	$ 11,182	$ 12,427

Schedule of Accrued Liabilities

Accrued liabilities consisted of the following:

(in thousands)	June 30, 2024	December 31, 2023
Accrued compensation	$ 9,206	$ 5,918
Cystic Fibrosis Foundation liability	6,870	7,633
Income tax payable	—	641
Current portion of operating lease liability	3,917	4,309
Clinical trial accruals	968	2,333
Vinbiocare contractual liabilities	2,514	2,514
Other accrued research and development expenses	11,975	8,533
Total	$ 35,450	$ 31,881

XML 34 R23.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Expense (Tables) — **6 Months Ended Jun. 30, 2024**

Share-Based Payment Arrangement [Abstract]

Schedule of Share-based Compensation Expenses

Share-based compensation expense included in the Company's condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023 was as follows:

	For the Three Months Ended June 30,		For the Six Months Ended June 30,	
(in thousands)	2024	2023	2024	2023
Research and development	$ 4,378	$ 3,741	$ 9,180	$ 7,249
General and administrative	5,046	4,642	10,332	9,316
Total	$ 9,424	$ 8,383	$ 19,512	$ 16,565

XML 35 R24.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Tables) — **6 Months Ended Jun. 30, 2024**

Commitments and Contingencies Disclosure [Abstract]

Remaining Payments of Operating Lease Liability

As of June 30, 2024, the remaining payments of the operating lease liability were as follows:

(in thousands)	Remaining Lease Payments
2024	$ 2,838
2025	5,019
2026	5,274
Thereafter	23,703
Total remaining lease payments	36,834
Less: imputed interest	(5,953)
Total operating lease liabilities	$ 30,881
Weighted-average remaining lease term	7.5
Weighted-average discount rate	4.8%

XML 36 R25.htm IDEA: XBRL DOCUMENT

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) — **6 Months Ended**

	Jun. 30, 2024 USD ($) Segment	Jun. 30, 2023 USD ($)	Jun. 26, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Summary Of Significant Accounting Policy [Line Items]					
Accumulated deficit	$ 411,899,000			$ 367,866,000	
Cash and cash equivalents, including restricted cash	$ 317,214,000	$ 380,598,000		348,890,000	$ 393,977,000
Number of operating segment for research and development | Segment	1				
Non-current restricted cash	$ 1,885,000	2,127,000		$ 1,885,000	
Dividends declared or paid	0	$ 0			
Wells Fargo Credit Agreement [Member]					
Summary Of Significant Accounting Policy [Line Items]					
Debt instrument, collateral amount	$ 55,000,000		$ 55,000,000		

XML 37 R26.htm IDEA: XBRL DOCUMENT

Description of Business, Basis of Presentation and Summary of Significant Accounting Policies -

	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022

Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands				
Accounting Policies [Abstract]				
Cash and cash equivalents	$ 260,329	$ 292,005	$ 323,471	
Restricted cash	55,000		55,000	
Non-current restricted cash	1,885	1,885	2,127	
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 317,214	$ 348,890	$ 380,598	$ 393,977

XML 38 R27.htm IDEA: XBRL DOCUMENT

Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Revenue from Contract with Customer [Abstract]	
Accounts receivable, Balance	$ 32,064
Additions	55,132
Deductions	(63,111)
Accounts receivable, Balance	24,085
Deferred revenue, Balance	87,325
Additions	54,252
Deductions	(87,871)
Deferred revenue, Balance	$ 53,706

XML 39 R28.htm IDEA: XBRL DOCUMENT

Revenue - Summary of Revenues (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Disaggregation Of Revenue [Line Items]				
Total revenue	$ 49,859	$ 10,519	$ 87,871	$ 90,804
Collaboration Revenue [Member]				
Disaggregation Of Revenue [Line Items]				
Total revenue	45,976	9,565	78,574	89,294
Grant Revenue [Member]				
Disaggregation Of Revenue [Line Items]				
Total revenue	3,883	954	9,297	1,510
CSL Seqirus [Member] | Collaboration Revenue [Member]				
Disaggregation Of Revenue [Line Items]				
Total revenue	45,911	7,607	78,292	85,824
Janssen [Member] | Collaboration Revenue [Member]				
Disaggregation Of Revenue [Line Items]				
Total revenue		170		660
Other Collaboration Revenue [Member] | Collaboration Revenue [Member]				
Disaggregation Of Revenue [Line Items]				
Total revenue	65	1,788	282	2,810
BARDA [Member] | Grant Revenue [Member]				
Disaggregation Of Revenue [Line Items]				
Total revenue	$ 3,883	$ 954	$ 9,297	$ 1,510

XML 40 R29.htm IDEA: XBRL DOCUMENT

Revenue (Details Textual) - USD ($)		1 Months Ended	3 Months Ended		6 Months Ended	12 Months Ended	
	Nov. 01, 2022	Aug. 31, 2022	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Dec. 31, 2023	Mar. 31, 2024
Revenue [Line Items]							
Deferred revenue			$ 53,706,000		$ 53,706,000	$ 87,325,000	
Revenue recognized					(87,871,000)		
BARDA [Member]							
Revenue [Line Items]							
Revenue recognized			3,900,000	$ 1,000,000			
Total grant revenue		$ 63,200,000					
Grant revenue outstanding					44,500,000		
Research Collaboration And License Agreement [Member] | Seqirus Inc [Member]							
Revenue [Line Items]							
Upfront payment received	$ 200,000,000						
Research Collaboration And License Agreement [Member] | Seqirus Inc [Member] | COVID-19 Vaccine [Member]							
Revenue [Line Items]							
Net profits percentage	40.00%						
Development milestones received advance payment						5,300,000	$ 5,100,000
Research Collaboration And License Agreement [Member] | Seqirus Inc [Member] | Manufacturing and Supply of ARCT-154 Drug Product [Member]							
Revenue [Line Items]							
Deferred revenue			0		0		
Revenue recognized			18,000,000				
Development milestones received advance payment						23,600,000	
Research Collaboration And License Agreement [Member] | Maximum [Member] | Seqirus Inc [Member]							
Revenue [Line Items]							
Eligible to receive development milestone payment	$ 1,300,000,000						
Eligible to receive commercial milestone payment	$ 3,000,000,000						
CSL Collaboration Agreement [Member]							
Revenue [Line Items]							
Development milestones achieved					17,000,000		
Deferred revenue			53,700,000		53,700,000	87,100,000	
CSL Collaboration Agreement [Member] | Phase I Clinical Study [Member]							
Revenue [Line Items]							
Deferred revenue			9,800,000		9,800,000		
Milestone payments						17,500,000	
Remaining performance obligation			$ 3,000,000		$ 3,000,000		
CSL Collaboration Agreement [Member] | Maximum [Member] | Phase I Clinical Study [Member]							
Revenue [Line Items]							

Additional payments upon meeting certain clinical milestones	$ 1,500,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property Plant And Equipment [Line Items]		
Property and equipment, gross	$ 21,262	$ 21,167
Less accumulated depreciation and amortization	(10,080)	(8,740)
Property and equipment, net	11,182	12,427
Research equipment [Member]		
Property Plant And Equipment [Line Items]		
Property and equipment, gross	16,784	16,046
Computer and software [Member]		
Property Plant And Equipment [Line Items]		
Property and equipment, gross	1,131	1,275
Office equipment and furniture [Member]		
Property Plant And Equipment [Line Items]		
Property and equipment, gross	703	958
Leasehold improvements [Member]		
Property Plant And Equipment [Line Items]		
Property and equipment, gross	$ 2,644	2,655
Construction in progress [Member]		
Property Plant And Equipment [Line Items]		
Property and equipment, gross		$ 233

XML 42 R31.htm IDEA: XBRL DOCUMENT

Balance Sheet Details (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Balance Sheet Related Disclosures [Abstract]				
Depreciation and amortization	$ 900	$ 700	$ 1,813	$ 1,315

XML 43 R32.htm IDEA: XBRL DOCUMENT

Balance Sheet Details - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]		
Accrued compensation	$ 9,206	$ 5,918
Cystic Fibrosis Foundation liability	6,870	7,633
Income tax payable		641
Current portion of operating lease liability	$ 3,917	$ 4,309
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Total	Total
Clinical trial accruals	$ 968	$ 2,333
Vinbiocare contractual liabilities	2,514	2,514
Other accrued research and development expenses	11,975	8,533
Total	$ 35,450	$ 31,881

XML 44 R33.htm IDEA: XBRL DOCUMENT

Debt (Details Textual) - Wells Fargo Credit Agreement [Member] - USD ($)	Jun. 26, 2024	1 Months Ended Jun. 30, 2024
Debt Instrument [Line Items]		
Revolving credit line available	$ 50,000,000	
Loans interest rate, percentage	2.00%	
Term of agreement	2 years	
Extended term period		1 year
Option for renewal term	1 year	
Non-refundable commitment fee, percentage	0.25%	
Long-term debt		$ 0
Debt instrument, collateral amount	$ 55,000,000	$ 55,000,000
SOFR [Member]		
Debt Instrument [Line Items]		
Loan accrued interest rate per annum, percentage	1.00%	

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual) - USD ($)	Dec. 23, 2022	3 Months Ended Jun. 30, 2024	3 Months Ended Jun. 30, 2023	6 Months Ended Jun. 30, 2024	6 Months Ended Jun. 30, 2023
Class Of Stock [Line Items]					
Antidilutive securities excluded from computation of earnings per share		1,100,000	1,000,000	1,300,000	800,000
Wells Fargo Credit Agreement [Member]					
Class Of Stock [Line Items]					
Issuance of common stock				0	
Wells Fargo Credit Agreement [Member] | Maximum [Member]					
Class Of Stock [Line Items]					
Common stock issued, value	$ 200,000,000				

XML 46 R35.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Expense (Details Textual) - shares	Jun. 30, 2024	Apr. 30, 2022	Oct. 15, 2021
2019 Omnibus Equity Incentive Plan [Member]			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Share-based compensation number of shares authorized	2,000,000		
2019 Omnibus Equity Incentive Plan [Member] | Maximum [Member]			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Share-based compensation number of shares authorized	10,750,000		
2019 Omnibus Equity Incentive Plan [Member] | Employee Stock Option [Member]			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Common stock reserved for future issuance	2,236,360		
2021 Inducement Equity Incentive Plan [Member]			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Reduction in number of common stock shares available for future issuance		130,000	
2021 Inducement Equity Incentive Plan [Member] | Maximum [Member]			
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]			
Number of shares available			1,000,000

2021 Inducement Equity Incentive Plan [Member] | Employee Stock Option [Member]	
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	
Common stock reserved for future issuance	124,697

XML 47 R36.htm IDEA: XBRL DOCUMENT

Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Share-based compensation expenses	$ 9,424	$ 8,383	$ 19,512	$ 16,565
Research and Development [Member]				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Share-based compensation expenses	4,378	3,741	9,180	7,249
General and Administrative [Member]				
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]				
Share-based compensation expenses	$ 5,046	$ 4,642	$ 10,332	$ 9,316

XML 48 R37.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended	
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]				
Income tax expense	$ (150)	$ 577	$ 218	$ 680

XML 49 R38.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual) - USD ($)	1 Months Ended		3 Months Ended			6 Months Ended		12 Months Ended	50 Months Ended	
	Aug. 01, 2019	Sep. 30, 2021	Oct. 31, 2017	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023	Sep. 25, 2023	Feb. 29, 2020
Commitment And Contingencies [Line Items]											
Operating lease costs				$ 1,500,000		$ 1,400,000	$ 2,900,000	$ 2,800,000			
October 2017 Lease Amendment [Member]											
Commitment And Contingencies [Line Items]											
Operating lease extended additional term			84 months								
Lessee, operating lease, term of contract			4 months								
Tenant improvement allowance			$ 100,000								
Security deposit			$ 100,000								
February 2020 Lease Agreement [Member]											
Commitment And Contingencies [Line Items]											
Operating lease extended additional term											13 months
Lessee, operating leases, option to extend							the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Company's headquarters.				
Impairment loss					$ 1,300,000						
September 2021 Lease Agreement [Member]											
Commitment And Contingencies [Line Items]											
Operating lease extended additional term		10 years 8 months									
Lessee, operating leases, option to extend							the Company has the right to extend the term of the lease for an additional five-year period.				
Security deposit		$ 2,000,000									
Underlying Agreement [Member] | Cystic Fibrosis Foundation [Member]											
Commitment And Contingencies [Line Items]											
Contra expense remaining amount included in accrued expenses							$ 6,900,000		$ 7,600,000		
Minimum amount agreed to incur under research plan										$ 15,000,000	
Contra expense included in research and development expense				$ 800,000		$ 0	$ 800,000	$ 0			
Underlying Agreement [Member] | LUNAR-CF [Member] | Cystic Fibrosis Foundation [Member]											
Commitment And Contingencies [Line Items]											
Payments for advance	$ 15,600,000									$ 24,600,000	
Maximum [Member] | September 2021 Lease Agreement [Member]											
Commitment And Contingencies [Line Items]											
Monthly base rent		400,000									
Minimum [Member] | September 2021 Lease Agreement [Member]											
Commitment And Contingencies [Line Items]											
Monthly base rent		$ 300,000									

XML 50 R39.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Leases [Abstract]	
2024	$ 2,838
2025	5,019

2026	5,274
Thereafter	23,703
Total remaining lease payments	36,834
Less: imputed interest	(5,953)
Total operating lease liabilities	$ 30,881
Weighted-average remaining lease term	7 years 6 months
Weighted-average discount rate	4.80%

EXCEL_51 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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|!^IH/T^$2?:7 M;'?/MML-XJ6)ENAA)$0;S[SU[RBC@4V!4"F@OH_P1VU2\XN2"KN=:N9!G6 M'5-LT)=B2Z1^&MSTAZON,C70!+%NQJF2\&T .C6X$UX*K:((BWUR'ZM O9)1 MO.L>NIJ;)%DQR9-^2|&O:4W+RYUO=|ZTPKE+/HI8K1)P];G_5M^"4A9%I?NB MWE+4|+0+9Y(\ MP$WC1(5[5?&AJII\O8*O]TU\>7-6$N)NGZF)#]74Y+LN^*[1$LTD|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|-X.EF31[J@ZN?Z3NC9 MN/:2L(SFDO$<"+J\&EVCBQGVC4&)^(?1K=P; Q/* ^>_S.1KB.IJGQI'G\KIR.ZG<:P_WQB_?/9? ZF RO(OV%98.)Q(17/*F/-(&/Y[C]YJA*Q9X#<'@-<&>#7 M&CB5@5,&NF-6AC4GBDPG@F^!,&CMS0S*W)36.AJ6F\^X4$(_9=I.36??;^QG'UOD^[]^&>]_U5Y.? @:< 0^Q:S&?#YG,::W-4FCN'YF.= M>1T^KL/'I3^G+_Q"")HK0*2D2E[8XMDY<.T.S"]JD&L2TZN17D:2B@T=33]^ M0#Z\M$7W3LX.8G7J6)TA[],9D2N@OQJ(S8#^+MB&I#IXZU? WHL]#T+8HG<, M=<#.J]EY@^RNXY@7.FVZB\54Y_ AI3:&7N?=V(6AUV+813D8^JZ=H5\S] <9 MW@FZ)BP!]$EW>TEE^=6Y6E&A6\I^P=MX^QU&@1>Y+=HV$$9VUD'-.AAD?<|5 M25]!,.BFS T@#%L4+;#0]Z*>CQ_6),,CJ=4**M1SF5*SAM9:T]0IR*FR<0T[M)!!"(6Y1M:"PBB,[TZAF&@TR_:YY$L7R1Y!2K7- &$$[X\NS0D]VV>VE'75K M-_0V%EGQU"'7/?4$[VB9OMK MM3(_K,+0[Q2K!>?BR(6XAV"C;^AU I#J.>S- *'AA5.,Q2%+NJ]SV(EV14PQW.] MMLS98+JZ>_HQ:H0.#2O=G"ZI+I]$+|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|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|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|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|CIPV,X-=1*(P[&'6M ;8WA]\CAG3 M6X-G.77EG[@A=KTV)X/=V/&CL9D3:?H$8N\39MO-)F.Z.- ,):F,.RZWHBAH M!9%%!A[3O#QGZ/EB1([:0QS+V^&$-#T$L?<0TZ*>Z#T>< ;FBNG8&FD?=>]- MNLT%M+,]FRO2]!8$6^-

2026	5,274
Thereafter	23,703
Total remaining lease payments	36,834
Less: imputed interest	(5,953)
Total operating lease liabilities	$ 30,881
Weighted-average remaining lease term	7 years 6 months
Weighted-average discount rate	4.80%

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|G6FSX"]F%5OC+>H_JFM).[]%27B!I>*B!(GIW%N&)Z?AQ"A8B3\Y M;E5G#,:4E1#W9G*9S+W ,,(<8VT@&/UL| SSW" 1CY| [4*_=TRAVQWOTK]9X M,F;%%)Z)_ "^>Z&SN33U(,&5UKF_$]E?<&30V>+'(E?T/VT9V2,)QK;0H=LK$ MH.!E\|L>=H[H*$R#9Q2BG4)D>3<;69;G3+/%3(HM2"--;&9@3;7:1(Z7)BJW M6M)73GIZ<4G^35#"G60)+]>PE)*5:R2_:S7S->U@Y/QXAW;:H$7/H WA2I0Z M4W!1)I@\U?>)64LOVM,[C9R O]7E$0R# 41!- *5,8G* 3MLK1Y:V.$SL'W6 M#F#U")=EPC<\J5G>9WP#.NH'-?5SHBH6X]RC E$H-^@MWK|+)|$7!^512WGD M0E]<,8V2LQSN4!8*1-H7LC[23MA^TC=UCA &J_&GL# #4Z8(R:H$> F7&@L8!5.SW0VNZYS9VK_]],VL&+X7#W%FU&$9 MZX^DHAO.6H B694^6BE&S$S-TXEAX.D4OH@%)8>!L]O,/L0?X2Z-%7TWPT&`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|-) [7S7N/3P_R+K5=FS98URIO%L^/ M9J<_O'Q(ZWG|:];3G$>U7 MN2;P?]5-7'MRI*H^=&X='P8%:]O*O_ISE,/7(' 6'SACNN4@IO*5[O2+9][= M*$ ^KL1O]P:SRTR#.MJ24J\[C5XOGNA>O3*B\W;"W*I[,6A#!1+W6P@;YZ M[TTP;:=%B&VMKD1_]-N57:9V82O==FI65:YO.]LNU7O7V,J:\.Q!!Q+IH =5 M).>ED'-V@)S'ZF?7=]N@?FIK4X^??P#6,G]GB;^79W=N^+>^G:KSDXDZ.SE[M>,=^YUE>Y[S?^8']]G"I_GLV#YV'??W//H9EOX?[]R.? ^R%&=>6'VU(T/[: M'+WX\Y].'Y_|> >U#$.U#^_;:X1##<(M;1T1:-L%ARA05MM@$&+4M:YD!V(]%/S]NH9D O';MVO$;#X,)+3&U &QHUO9 M5C4(=)Z?Q>*-]:IS$)W7WJ03PI2DH"*+:FXJO39@J(+*>+_0(21G!NK>TY'P MH1-ULS*MLB"E;2'Z"FQU*]WA&Q+AM0F=7;+:L,D[!.57OE^J>U&D;]Z|BN*| MK_1F X6)AI%<(-^6J3<*OM2&2ONY7M\V)(T^"\?+O+CB+RD[K:Z94;I^(M$ M_ =O\=]9<4#;X>+#+.] AT*HM:TUS/+MK^]FE\|<7O_QV^KVZ.9 4Z//N&NS-M;Q.M\|:HE=%-MU*Z[U;.V\Z2*/>;+0D8>A01DO@JAZ#6DB'@KP!SI8-KM;"M M;BLK0N\,F46 451-7QNV%RU&SB=D(TY,AWX>;&VUM|% <2.M]_O:8O.IFC4- M-NN,3[K,N]%B%K7F!!G42E\;F +4:Q!+7,/4P9P&:K&,#2>8?XF986/$N T(MY&V)$%]CM6&[5:].KZ9J:5HX9].PG69#6^K!QSS]2*7, MK%T7E,#!.($S]3,^%9LUMQ.2+HS;J=9U6>(XG 1-@B\>9&DMG.NP%*=[\X_> M>C$.HD","1)N#&QIGQ"F\ XD[A9N19^)Y-,G/T*G&QBM:R=9TW_(7 !E",*

&"]')78:K*YZSQZ]N[8VQ%9K*H09"KC$F%8+;;W:E-8= M182O@'\"+Q.1B?0W^*]#1(K/D"6^V5%,>IA,EE203K50OVUK=EY8#H[**V$' M, 11#QRT8/I6Z/]'S'-L')] S42)SI9^T?$-6:2[9(5(^[T%1N.]20:%6_< M#0$W:W_6MCV>OS0;YSO*#P0UU>G)\=|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|NU#|R%P3V9^,INO9^":0QLT:M^Q$_;OQ512;EY M$SO(V89'C]K[S_|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|%Q7"87FEN0EJ[@ICC1J,J62$]=.O= M$IG;D%Y+;L/DA^X09YI'B$,W\3:\-5)HP&;77K.=O1^%=0B>?-_%P(K]?L-/ M4&D3BMHF%:HCP9PA^-QMH).4_+C$20+@D0OG/XW[WMW*^]JKMMM3]JZA2"11P@_V%G88R,\$1HSL*>* MAF/ Q5@XARX:]=Z-66)+4_73:'0J@PF6',H6:V]BR(KE;* Q@*G6-%$I\??4 :&K5NHFLGVDOG-A; M.J2DEE1&2W0>F5)LV'2-30';6H9YT'N+0"6'$,2E!37,@P2GXR| M%L'^RWF'#$WN_OX=HTB3K5)V2-_ ;T/P/*^P3T+\KD _#ZCM)<0.W>X\?_DU M$I3)+3<7.+O=UH9%.)9#-=SR9^ 7 <%0!.;>>Y>'Q.XZ6BJB*!? E%MT7BC!+>5:6IU8.1! M!B4D)J:!>GAQZ+6 3)U6W!:(@;WW=|/ J5YKOW3JI6X_ ^C@F0^\%WU' R 4 M5W:XIT-IND[MCM=MS0:)7-WN5-W9]'3_3-UD[VPXI39#F"0V-K#F"C[VRJE M0Z4 :UW0>RUZ$KV3>V]"2.S'BBME^:*FXY=.HMF9=JLO.%0]P[5KQU=&,1 MET!O&\GH0,3[8>5N6O6U9^4(FWE;0!:3\['N:+#L[GSQ|C0Y.3F)_WSS#I5E&I;>%O7I MY.G31^ILGHR>?3]4RX+W])0+4Q27?%X M+KV95'&]T:0?9& [7DGLW51PVG=.L-:PG%;;Y@3B4=,,OMR+A:Z UP@IMS].L M5!;2=OEZE:Y;:6A0N;[C>PQN"48_3BUNLBJ:G1I?S'\=R7/D#A'0R7L%!N1>2:C:]- ;H]EJW0_|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|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|>C$29S<__KA]F+XXIPPRS)K5/Z'!'0'1VJ#*HL2R14K M)[6=20U9U'#*0H^4VAL;DJ":DL>)S251V1:@,+U#BG\%P5D,.@/"#EDQ/A6 M$\|:HK| M"9A#]RRUY3MN>@JT:?C**-BST13T"W(>I(CXV(_' OQR(4HHC("7B| ^.N1U/ M#ZAYI$K+4A^1#Z/:XK];H.U1DQ23@? @;XSU(O]38<$W24R+PAO>;1OJ!Y%8R M)&J1F@94+U)0KZ,&B$CL.!;\YZ#OY.E!IP$"7IL5M-\7MQ$"4T!4]?@=T!.& M(O50!>[*[5LS]J;A=>1,>WVA;9[- "PO-<'',+/ !:0;B*FR&W.^ MZR$]V4#8:/+%E0%&N@Q!G&L=G\W9;1-N-@N =|C7-G][21\5@MQ!<5 NR6>1 M-J R9%/7\+)&#/JQ%3/BTHF# Z[$"B51Q+:] <\^K?LUWNU=W/<.M\Q!02%L M^)7DG@4\&##[" A3B@E8WU78H-5*"4RA.% M29;9<@,>VR0S//=)))$M5@K"]B2M=+V^QDFOK"+"*D_RFVIG)\4G. M\Y+VT6[MI IK"YY+23N(MY9TODO67(;2R ^!!#Q"]K4T[PZM7%;LAU80E8AJ M":>K+@U*<-3AQTEN/T.(U6X/O%");"JU%=M-EC)!'^4VR%$[-,/\!?- @GP73 M^%]WCS\"3$0/>F\RFRD[Z-YW'O2W1#WMIC]D.Y.$L-D5RA6'0PG$IC3]NVF) M?1E!=+B$&@]+|_#|\&#* M.223A3^!'892TG7.G"> (GY!'G'8@22U7'.K!STMJ9HA3FSWH39T73>TR!3H' M);DZ$"3FWM0%9,/RI9K0/H\2:]>[TN^+)ETI5Z.KL%PMGXZ8""YN*THG+$*1 MYY&L&PZUV(5]:M'1 MS+*@/%E.N:B$\ ^Y-D; MZ_?!0%E:A$L!^&.257/H"\KIL]2SWNGH3$S ;_ M<19E+9:F6:VW,90=,*3;@Z0]>(L)[T["?,- [%.?)BF=/_>N '8D83:OZ0_^(MT4&A^(0T>PHPE3;9 J2D^B@OAR;.-S7@''W/N'\5=O-,=KM'UA25*08L|[N; MSQ?#Z:33;UK+;6] \A!)8M=BOB[ALLFK#DD+='7(UF][SVU]39U^VNLV@#8I ME0]6H72.XY*1C;ZM7>U$U\U:.A/F'33H8X!*QH^Q"K9JX\N!!:FL-.8*@Q* MGG,%UW ZC._&SS2V@<_2L*I6 2_L-+4^:M"&S*(V1.=1:$6]![;99C1]KO7I MBX_&Y:=GB=F$8]/XSP30$9?NSKIR.\1B?3W?1?5H6%?&H* PO; (#.\BFT=..T*%,*36|9I&XA|$-ZV M5"Z^@K@T,/4%?:"R5'03VB$-6N3>7M>.I8?*%&VA,7FQ[= MJ];^((10GA2$^>ELRPXEF7=7VP[UD)V$L<^/CFEL;W2',EV9[!#RB&3.U6,\ M3.Y,.7P,[SM$VG'+-HF,HQRR-;0XP(YGN842+E5PQ7G1G[4>VAUI:*>'#OM+ MTY3U>BL3C0_$TZ%R-^V/#P89Q]%6Z8L/ H/HA^9577;Y1/7HR*C+;0C4 XP/ M_TK&_WP9==#8_O-__O? 1MZ6OK%L*?K#IVE+2+QF4XTFN!^9:VB-NX6R)%QZG[M0RY^XMRUZP%_14$C/?,AKR]H/0H_V.C.$VBPMB(0G_X;-A)G^MP"K2BGVK$] MJ3T:IK&DX?H"")QI+/5CX0/S[KC_:6B\M)|._"$QJ[@K_!,^$M.UX#)Q3=53 M='"G? Z1,X[]2+YIV(G.F'Y@>NA55RS+L!7FRA/I>WF4K25+!6*'#7O6%/Z;'0ZGN19Y0'LZB\SM+WI^!=X_LZ+5WVO M!>28N8V95-S% MA?4VLN*|0>= <:BCT[])0)GY[321^URKXH&123>/P;*6Q?<-$@^HNVI_)O[] M_;G-$(B>1UFZ&94%0U?C_FBGN=EZQ"';&4(6K/@(;| <)SC1_K[IG>)7*EA=T MT48OG^A5/IP+^0%^P+FR/0SL9EIH'O[2/;8F-N,+5I)NKK0%/MR8ZU)*%1UT M,LP.2;OK#I2E['3-PHG$%&PV&N[/!C.ZA>/F_ "OU-G0[A_($7/I'I.[F<$' MF3QV*M,*C4 ?'@PG^3"_QP?RDN@]DN;[]M8?N[[U@%M[U\2-SJ-WO \EJL=W MN[S%'< H.QHSP\7NN%"0W<[BMT_3NWQ[&E-AZ%N3&?G4SF-*R"'0E7(U9). M=SN#5SLGVKY7Q ?;Q)8_$SWP4K7%II_5+.D>M*T]DB_J()=:(9Z[2W?HW@[!*

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|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|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|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|*NY;:@<*&H)2&PO=V]R:W-H965T/-W+I,!MRZ MQ8E?.253WI29DV&_?WJ229UWKB[XV9V[NK!%,#I7=T[X(LND>WBMC-U<=@:= MZL%'O5@&>G!R=;&2"_5)A=]7=PYW) [645&=Z\/+UF-;S@G]H MM?&-:T&>S*S]2C>_I]>=/AFDC$H"29#XMU8WRA@2!#.^E3([M4K:V+RNI-^R M[_!E)KVZL>:+3L/RLC/MB%3-96'"1[OYNRK]F9"\Q!K/?\4FKIT,.R(I?+!9 MN1D69#J/_^5]&8?&AFG_D0W#W&OO"U8W-,AT0Y>'"%S%-Q8 .@\X7*$ZW\Q4F "EIXDI3B7D=QPT?$ MG8KW$++#TXI<|56E[_PE,J^T;5O:I'CXI\V1|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|IPQ'M -4#BQ:^Y^) $RJ4!+>]@HW*L0R"##S+CQ."C3%R9I"'E7*2 M"I+3W'\,H#/#[D&PIAT@+<_\"^'ENH,'+36MQ E4V28J6A98D&_JV0#CIA MWV?8D:#^4>Q1)@)%MD55,[60.?GVGL%25]EVA;H/R)IG4]HHGHZKM#+$PZXB MJNY8GK(,X]9%V$8[G"T6RUKW<-*+/<80$')"[$H^E+0%WDX+U4!X&;MH+-[2 M"N43:6(H2Q/*I+H9A!BC*E=@#FF\91A8#"B4((]1MNNK"-*@6E^21HA M:)N^$JB^$C\KM$GI!5E)L2'$$:OT""]]Q!%'B>8FL5R##MLU5Y=*" R1:B5 MBKZ147,+>BB30#KJ91)NYD1N.H/1ZY@0:3"G,5V5E3^H4,_VU&D8MW7G:F&# MYLJKS33*>RIT6^*CD9&]K)ZU]PN!H#/ <,VX4KP 5[,'B")6P7,! FGS+J5 M8BPP%JS'>!1>@2!U>,"TM@+KASW/1($LPDBL"Q4"HIV;I89]2#=(UA3$2]^E ML5@2(9M":4STO"#\,_6MT"ZR#VM5I:RVI2^HF#CW & (9;J[WPG'6 *O@=$+! M3*1? S:\;"KL@%\'W836I986*13U41N MS3]EE9:R:3(8G+WR.Q&!/6]E7IFS4QIKF<2.M-2^'6?6EU,'AYU4P)D7 >#]B=NS-&'(P? *E_@5)56.[91I3LB*>50 M$I0/.S-Z437-3'Y5Y7#09N.2)G=B6/;.R7Z'=ISAG,A%:L=;,5K[RIYR6.)2 M'/1&=2GNS1.MJ:"E%'&&MU3XMC $^%!QFR C8HP$58/-,/3-5*[F6%VCLR1V M2AY-D/N9(P#HO$P>H5W[0P74+?L^7.9JYK12^=!^WXVM9T9UFI:N:5>.+<@: MR*-.0!S7*-"<)[3M3)<&- L;J/:COE#]@YO:K_&:[VI'0)#NAW*NX0AS#7* M5>T)LBS :8'S/\$4W3C9%9#<**B*$UJC8\E9Y4Y"!?P<1JH!"-%93*,<44?M MN0-_Q0-,B0V.3^) [7,3T@^UH >B^GL>XW:%Z'3PQ]@_0TMY($+M+WNH"P-XQ M&5(SU9>ERG'LLX$YQ MSE8TWI;Q: (QAYVV[QC3%D.Z_$L%&8=Z<6GK=0&G'(7$M'$VTC9HGUP7=+]^@! M6GD,3SGTT*!8L5Z0]\K_SR>.8>-8]O\^<7SX+A@C%DL4HNGF9<<'3^=T(L:5 MMT:'XWNEEC]4D=7\782["36C>+V6IF#+'FD]#5 =.BKL)#2U*B*>)EKJP+O" M$#$*07P*5D)&Z/FKR-=()*BQ7DQYCI^L;L["=LF?2<#4'=(S3^A? A8R^3SM;@K)1_QT1[UUIV.ID<\Y4VZ_<$Y M79[B-1Z(U.(6U\] ZMXR6%IPB1+!25CG@. ML>>3D7A1BGG,*:*C9Q2:Z71P](4;E4J/)6"-6>WP ?BL-]E? F6J?]%5G>R7+C,AE"%Q6T9[K>Y7N^M8$Y^/I8)@[M1WNZ*]"/*.7?]N2+U#'^1^ MX?D M\6$^4VI"/]S03I"Z^(V^?EK_PG$=/^QOE\>? 1S#YHA?3X#/'UG[O;-*)I%'= M!+OBS_PS&X+-^)*&,>5H =[/K0W5#2FH?_>Y^@]02P,$% @ 0X8%64 & MIB:1 @]@4 !D !X;"]W;W)K&ULE53?;]HP M$'[?7W%*I3XA$@+]H0*1@'5:IW5"L'4/TQY,CG3:/-D"X+9<=!3E3=A*%-H*%>^LM2D%<6@VH:T, MBLR#RB*,H^@R+(5403+R:W.3C'1-A50X-V#KLA1F/\5"[\9!+WA96,A-3FXA M3$:5V. 2Z4/@ M.H ,UZ(N:*%WG_%0SX7C2W5A_1=V36Z?D]/:DBX/8%902M6,XOEP#T> Z^@- M0'P Q%YWQ\&NRLF0X^OU:W0WMX'5:YYL;6XD4QP$; MPZ+98I"X?I70V9>F,0W2GL M$,IA\IRRM44&I!U?Z3%_O-!M(Q30';OOP&0QFWR]6W984-I][47" (_^4:#:^ M2UA(60XU5FI7VT8T:?SW+[WI8O?";"3_3P6N&1IUKRX",$UG: +2E7?2C2A-[MVT]S+@.-2^#]M>9+/P3N@+8])W\!4$L#!!0 ($.&!5D2SDLI618 "]$ M 9 >&PO=V]R:W-H965T^]>O[1=6YM&OW?*=ZM5X39O M=&WO7IU,3N*##V:Q;.G!V>N7ZV*A;W3[R_]]PZ^SM$IE5KKQQC;*Z?FKDZO) M-V\FCVD"C_C5Z#N?_;WH*#-K/]&/=]6KDW.B2->Z;&F) O^[U=>ZKFDET/%[M6/0D[4D3\[_CZM_QX7&86>'UM:U_,U6[?'7R[$15>EYT=?O!WOU3AP-=TGJE MK3W_5]V%L>:UK]]J7SJS9@[9N7K3>0SP?J3>%-*

*YX>O3> M:;^;MA F-I6ZD0ND=S=FT9BY*8NF55=E:;NF-U*8WVZF'\Z]'+LQ;4 MTIYG9:#LC5 V/4#9$_6#;=:]E5]\VE:Z&\\|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|Y4_P=NG8GPTD95LF/).G)6S*]"F_G@3X0$RI=17T.=&) MBVO(. (7]2EO7Q97#*2@)^V1HR=^S8J:81Z3Y$7^^ |R5X!I M0GE_U>1%G"D9]V(80"%X"$V9/!U/HZ:,U0\]-)PA;N0[9AQE6F:Z[^:D>O2> M<,Q"/F N7G=@!XWR74D0@&(2LO6L M(1)G;>O(:&>-=$^ 3+XZV(Z("G<%8FKX*4=!C8L$KPW)K%MP(8XW$AQ]$!HEG1O M5T/O8MB370\.+Y@5R#F["IPC;$^AR%&D]33YF:='G<6-7K# O.L#['T>YP|O MHGY*;L7+6S%WB&IQKKD1QTW.TS;1L^)VR:4[F '(#K094$<0D]<@B<2*<+T; M!O9Y:@# H)<@0D"ZCWEF&[YB,G[SS.E5&G +[T\IE",(.03%5_B*/HJ"'MG,E MIR9LV:B.3#_*4OTA? UQ*5.\3Q2W8(>$!+SB+"1%B78P,UL[M<#[&D,:'1,%^KX'LUNO:E&&_&/]ND]1T9:U-"5$WU>G]O+ M96- KN]@<$\]G23R?'96L#R%_*!+"^=X2#R/+K(?T^]9F8QWM/6]2QLZ+[*] MWOR:\@ETET.GXV"1%L&:M38(!7BO&9W"BV'8X!&+1E0P=/]M64((8B3I+>@ M_Q0K D%B(B90^% 7I+SE)4#N.VAAL2DU@N@WP|UG+Z#H"- FU6M*6Q/_'V+9P+E_)[Q,VMVPBR^",,3D/B7*_)S5XL ^8I^ MM"#^4PJ\V0)EC:PF.6F'L%3E8B@IC1")16KEMPJ:1E=O "] @45!TTP7=P M/9LPF% C:1V1Q/8I9"22CY&[Y=24#A:(V4U1LSW"Y@3|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|R)X_VV"R1I;'Z=M#!F& ,Z1D\4GZK [.470KIV/&5;I1""XTGFIS3+=C"R:G#>X,<"\1M?A4L+[MF!:B$CVE6%D^8C$@9B](4MHB=%;*M<3<@ECG@2B%S"_37YWR?<]U;%]@H\T^ MN>.JMDPZZFFS+V,F1WWB>QCF[\4POXN&>:]K_>/+J/?1W-H9J2-=68R9LD(" M [Q::F6@"VQ"=UT(V(HZI?1+,(D[/[90:M11\962_)!^IC SL#WS.U]V623S M4IO]*WKY1ENIAAXQ_+8=IZ26FWT;? M+CM ."WSH>P;51(Z#MBDCY13;:1-79;'=A:)1O#!#G/4I[Z(Ş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|*. MZ6+_*?7D^$? 0'S2EXA%BO^/NZ?U=+|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|HI_1.W&F03Y9/VO " M;OA*23(.-[(3Y2"Z=^L)4C?/?,C@F&/T+(G>U&.%$CC8++LE+)$ M:VU- "82BL+4C1+&&VO+L!6Y$+F00NY$_G2PI9;P@^AC%Z4X9:F_HTCB5?9"-PGBX3GY2ME3 PXE0>T[RE*HQ >:QT-'X*-- M#ND2C:990IQ+1B:?0)2X<>+;1>#F>7"06]Z+^=.@6O=3UE:R$V881>/L,.@O MA_GU+#[\!7QF:LV%ID15I.J?9\0J-4S686-DVT^SE30T&_OEAGY&4%D!^EY) M:?8;:V#|O5G|E!+ P04 " !#A@59,[]YP0H# "5!@ &0 'AL+W=O M250"I%*U^Y% MJH1*MWV8]L$D!XG]V.QV@/[[G9V0,8FB?>'.SCW/W=GGA_%6R%=5 &BRJQA7 M$Z?0>CWR/)454%%U+=; \,IK&)MP'?2]BJ_Y^83A9"O)K%EWSB^*8@8)!IPT#1;. >&#-$ M6,;OEM/I4AK@H;]G? [2]8R\+JN!>L:]EKHN),W1(#DM:,_TLMI^A[:=O^#+! ME/TEVR8V3AR2U4J+]@5C!57)&TMWI3D< (;^.X"P!82V]B:1K?(CU30=2[$E MTD0CFW%LJQ:-Q97<7,I<2_Q:(DZG\X)*^##%OG)R+R]\:T7M<3WLC_D\H4N M&*BKL:$?AB?X(NZWB/+%_U'[S/ZA].FR9V4E*_^C_O%DI+G)M?QYION./CW.8M MC=2;9C!Q\+$HD!MPTHNS(/%O3U0>=Y7'I]C3.;[-O&9 Q)(T72S>O4%UK/B3 M],>+/\R3'>:!=E)*GK$:;QH=H@NPQ5#^=G$V# (/!K4(0S@%OX%P)5N94XT)I M-.:\E>D&U49:6D4H;Q))*(P(:(PH11'(:+TNI -DB5.U(UHP9FU @."G2# M8D/0B+%.[K/O-.9(V6[U+VY"H%3*IJX:4$G9> [QE/ MBT.G9/8C09#M)$[B .T-VXP]-$.W#"^Z7T"C@TSBZ,Y/O#2 MC)Q1*M)W_3A!>!*')/#=* H1&P5)[T5H1!BF&/.?DZ$;#2.TP8W;#T+C)&X_ MZ9-C@^8=2$4%(M;$2P66BQML*S$!IES+H%_F^ - 'X?2F$WBI,@NZ?*/T#4$L#!!0 ($.& M!5E1=,&'V0(%$& 9 >&PO=V]R:W-H965T:8F>V4]K_?V8&4 MJ92'O8 _[GX?A^!&;93^;3)$"X^YD&8<9-86PS TRPQS9EJJ0$DW*Z5S9FFK MUZ$I-++4)^4BC*.H%^:,RV R\F=S/1FIT@HN<:[!E'G.]-,,A=J,@W:P.[CA MZ\RZ@W R*M@:;]%^+^::=F&-DO(%*@L;5.)BVA[..B_NGZ_"62AC_"9LJMAL'L"R-5?DVF13D7%;?['%; MA[V$0?1*0KQ-B+WNBLBKO&26349:;4" [:$)S"V_59Y,X+MV/?<4I6M 293N%#21HX/2.+02:LU%HBW52Z=YX:CA9. M(&X.DH';=*;C-KG;MFC9=SO-.XR F []5O=E9$JO3972 K$@=%H#>'OH>81[;9ZC7OMA9L"G5AU?G];S?P:MA>,]WFTI"R%:5&K7XW %T-L&IC5>&'QD)9&D%^F=',1^T"Z'ZEE-UM M'$']+S+Y"U!+ P04 " !#A@597I;D!V,$ 8%0 &0 'AL+W=O)XDF'U:0$R/\,V3@L2R&XQU((YGV9X!QL0'L,UDV[F MC1*1!%).:(H8:&2&H_T0V(5 L>,O D=^]HR4*\^4? E$O[Z.982F+((90* @L M_QU@"7&LD*0=7RM0H]:I!,^?3^A!X:QTYAES6+XXG?F9X!HI@B_-8?*#' M=U Y-%)X(8UY\1<=]FV6@<*<"YI4PM*"A*3E? _Q2!>),8/":@%,).!<"CO.* MP* 2&%PK.*P$AM<*C"]!T:4";B7@%K$O@U5$VL<"SZ>.'A%3NR6:>BCH*J1E M@$FJ.FLCF/Q*D)R8^\!#1K*"9:I%BYS+#9S? H07FA*NE-0.,J4N>/_M3YAC(_)B71>P$)_[LK9THUPVXUJAL_\R',#,R ME;WL ,;\IQ]LU_JEBV"=8+Y.L)5.L$ 36(/X84W\L]]+AG.DSS& B+5]V5W MZ"JU10GB%B#J3#S,A[:M32:694W-PSEGO>INY4PGV*KMP\ =>Z[:\B'0I+9! MR*@F9-1+R!+S?=`-0_4 7W-RP+%L@++SDS2,\T@5HU0K& D5:6I;%V.CMK?V MV+&';<8Z=GK6:.*U=OJ!EM]*1PDV.E<[]#R549=T=!@X&4S&X_.=C5B[=:S= MWEC_GB?/P-1Y*2^$#!=]CI? G#9)W0Q5FP"PL^8C@(*][6?'QGYYC:>&V'+,O M(MYKU:TUHA-LI1,LT 36H'9<4SONIY:F/XXVXEY4KC DU*&_'VZGA[O?'VR8%D9W'IA; [VXZ03S=8*M=((%FL :1-O6]Q^(UO]S9Z_T:.)>*YJO M%6VE%2W0A=;D_VQ 8/>W7'@6\DXHS[9<5? <="FFL+O(.QP@G*@O_F8BK]6[TJHWT(56DF2>#7028+MB],9147'EI*->K<=[C\50ZV)] M83\LRR'==YAR9O@D>[=D% <6PE9#6_5@>DZPA|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|)S5G$+D3Z(W_>D?]LCZ3:<.)(PB81X2 MQI PCH3Y()BBN,%> <0,3O?H"+$6>BT75*C32TZG-2#A7;4@8W<)&#:QNI)ZF M0W=LC2S+NNH_'2H)F96=FI4?[S@9N\[P:$\FX\G8/A8*,]T/@BEB&NW%-#**Z69V M3V? DCUN1/(I<6[J,|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

CMGN>YL^^.\8:+9YD"*/*29X6< M6*E2Y+Z' G247.54X%2M;E@)H8HSRS/8<)[1SR@HK'INUF8C' MO%(9*V FB*SRG(KM-61\,[%<:[=PQU:IT@MV/" [I"NY!/98S@3.[14E8#H5D MO" "EA/KRAU=N\; G/C&8"/WQD2[,N?\64|^)1/+T8H@@X72$!0_:YA"EFDD MU/&S ;5:3FVX/]ZA?S#.HS-S*F'*LR>6J'1B119)8$FK3-WQS4=H' HTWH)G MTOR237/6L78 M5JA6<]J+1MEUK/]#3D_N_@3QD9G6X^]UF//X/I' M<(UB2;Y?S:42^"A^=$FK(?K=$#I31K*D"YA8F H2Q!JL^.T:-W3>GQ#HMP+] M4^BQ]K=+4VT5&BN=;.O8B_QH:*\[N/HM5_\UK]"+J[8*]K@"QQUV8-^-U?81? \3SJ)41G91Q"U*.",O+2D&"*8@A *FZZ*,#^LM@ M&!R)PK"E'_Y#%'A;'^HH9$U]P)K2I61X\+)])XK<;B6N\[NT.2>U/)F2#,DE M7:.<%1Q<#L8F[RQ.IW$'9 M42!*2'*ME*D_DO+M7A|W_$YLPN>!5H0A&$CI5 M-I7=V8N;TW/Z?Y<$>Z\[Z$[[A8H5*R3&8(EV3F^ 3T#4S:N>*%Z:AC'G"MN/ M&:;8\$'H [B_Y%SM)KH'M7\AXE]02P,$% @ 0X8%6=NGU?LI P 2A(M T !X;"]S='EL97,N>&UW5A=:]LP%/TK1EU'"Z-.XL6-UR2P!0J#:13: MA[T5)983@2QYLM(E^_73E1SGH[JEZ\6S"&U=(_.N4?2=64RK,U:L-L%8R9: ME4+6([(PIOH0Q_5LP4I:7ZB*28L42I? 4V*Z>QW6E&M'IX,(8N+I\|2?TL:D+_>EW?!3*^2)IQAM$*#9 M+%LF=!PY;C9E/"R4W,Y-0GS]M.210]4C,B$"C[5'%@%+;E8^W / C,EE(Z, M+0J;K@N1^I>'N[X']=+HE%PJ[7+[#/[OM!E^ &QZ8) +T1KL$1\8#RMJ#-/R MVG;<8!=\!$5-^VY=68=S3=?=7I]L">YFDTR5SIENTW3))C0>"E: 'IN_%GO:JV-FW#NR:;)O64-/T,KX# M^KMJ7GM7|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end XML 52 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)? w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent) {a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html1322031false370false5 falsefalseR1.htm100000 - Document - Document and Entity InformationSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETSSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSCONDENSED CONSOLIDATED BALANCE SHEETSStatements2 falsefalseR3.htm100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParentheticalCO CONSOLIDATED BALANCE SHEETS (Parenthetical)Statements3 falsefalseR4.htm100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSSSheethttp://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCONDE CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSSStatements4 falsefalseR5.htm100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITYStatements5 falsefalseR6.htm100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSCONDENSEI CONSOLIDATED STATEMENTS OF CASH FLOWSStatements6 falsefalseR7.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes7 falsefalseR8.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes8 falsefalseR9.htm995455 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting PoliciesSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAc of Business, Basis of Presentation and Summary of Significant Accounting PoliciesNotes9 falsefalseR10.htm995465 - Disclosure - RevenueSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueRevenueNotes10 falsefalseR11.htm995485 - Disclosure - Fair Value MeasurementsSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurementsFair Value MeasurementsNotes11 falsefalseR12.htm995495 - Disclosure - Balance Sheet DetailsSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsBalance Sheet DetailsNotes12 falsefalseR13.htm995505 - Disclosure - DebtSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDebtNotes13 falsefalseR14.htm995515 - Disclosure - Stockholders' EquitySheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityStockholders' EquityNotes14 falsefalseR15.htm995525 - Disclosure - Share-Based Compensation ExpenseSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseShare-Based Compensation ExpenseNotes15 falsefalseR16.htm995535 - Disclosure - Income TaxesSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesIncome TaxesNotes16 falsefalseR17.htm995545 - Disclosure - Commitments and ContingenciesSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes17 falsefalseR18.htm995555 - Disclosure - Related Party

TransactionsSheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsRelated Party TransactionsNotes18 falsefalseR19.htm995575 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificant of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)Policieshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignifica falsefalseR20.htm995585 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantA of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)Tableshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificant falsefalseR21.htm995595 - Disclosure - Revenue (Tables)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueTablesRevenue (Tables)Tableshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenue21 falsefalseR22.htm995605 - Disclosure - Balance Sheet Details (Tables)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsTablesBalance Sheet Details (Tables)Tableshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetails22 falsefalseR23.htm995625 - Disclosure - Share-Based Compensation Expense (Tables)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseTablesShare-Based Compensation Expense (Tables)Tableshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpense23 falsefalseR24.htm995635 - Disclosure - Commitments and Contingencies (Tables)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTablesCommitments and Contingencies (Tables)Tableshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies24 falsefalseR25.htm995645 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantA of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)Detailshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificant falsefalseR26.htm995655 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantA of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)Details26 falsefalseR27.htm995665 - Disclosure - Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityD - Summary of Changes in Balances of Receivables and Contract Liability (Details)Details27 falsefalseR28.htm995675 - Disclosure - Revenue - Summary of Revenues (Details)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetailsRevenue - Summary of Revenues (Details)Details28 falsefalseR29.htm995685 - Disclosure - Revenue (Details Textual)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextualRevenue (Details Textual)Detailshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueTables29 falsefalseR30.htm995705 - Disclosure - Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipment Sheet Details - Summary of Components of Property and Equipment, Net (Details)Details30 falsefalseR31.htm995715 - Disclosure - Balance Sheet Details (Details Textual)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsDetailsTextualBalance Sheet Details (Details Textual)Detailshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables31 falsefalseR32.htm995725 - Disclosure - Balance Sheet Details - Schedule of Accrued Liabilities (Details)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetailsBalance Sheet Details - Schedule of Accrued Liabilities (Details)Details32 falsefalseR33.htm995735 - Disclosure - Debt (Details Textual)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextualDebt (Details Textual)Detailshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebt33 falsefalseR34.htm995755 - Disclosure - Stockholders' Equity (Details Textual)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextualStockholders' Equity (Details Textual)Detailshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity34 falsefalseR35.htm995765 - Disclosure - Share-Based Compensation Expense (Details Textual)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextualShare-Based Compensation Expense (Details Textual)Detailshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseTables35 falsefalseR36.htm995775 - Disclosure - Share-Based Compensation Expense (Details)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsShare-Based Compensation Expense (Details)Detailshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseTables36 falsefalseR37.htm995785 - Disclosure - Income Taxes (Details Textual)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextualIncome Taxes (Details Textual)Detailshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxes37 falsefalseR38.htm995795 - Disclosure - Commitments and Contingencies (Details Textual)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextualCommitments and Contingencies (Details Textual)Detailshttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables38 falsefalseR39.htm995805 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details)Sheethttp://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLease and Contingencies - Remaining Payments of Operating Lease Liability (Details)Details39 falsefalseAll ReportsBookAll Reports arct-20240630.htmarct-20240630.xsd img267163886_0.jpgimg267163886_1.jpgimg267163886_2.jpg http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024falsefalse JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "arct-20240630.htm": { "nsprefix": "arct", "nsuri": "http://arcturusrx.com/20240630", "dts": { "inline": { "local": ["arct-20240630.htm"] }, "schema": { "local": ["arct-20240630.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 172, "keyCustom": 31, "axisStandard": 12, "axisCustom": 0, "memberStandard": 15, "memberCustom": 22, "hidden": { "total": 6, "http://fasb.org/us-gaap/2024": 2, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 132, "entityCount": 1, "segmentCount": 37, "elementCount": 522, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 382, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 9 }, "report": { "R1": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "100010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:RestrictedCash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "unique": true } }, "R3": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "100020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body",

"html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R4": { "role": "http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "100030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "unique": true } }, "R5": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_84f667ca-ad1b-45ab-b798-7dffeacf29f5", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_d98f8d99-8e77-49ac-acb3-6ab0203051a8", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "unique": true } }, "R6": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R9": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "longName": "995455 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies", "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R10": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenue", "longName": "995465 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R11": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "995485 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R12": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetails", "longName": "995495 - Disclosure - Balance Sheet Details", "shortName": "Balance Sheet Details", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R13": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebt", "longName": "995505 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R14": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity", "longName": "995515 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R15": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpense", "longName": "995525 - Disclosure - Share-Based Compensation Expense", "shortName": "Share-Based Compensation Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R16": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxes", "longName": "995535 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R17": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995545 - Disclosure -

Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R18": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactions", "longName": "995555 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R19": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "longName": "995575 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "19", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R20": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "longName": "995585 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryCashFlowPolicy", "div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:InventoryCashFlowPolicy", "div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R21": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueTables", "longName": "995595 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R22": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables", "longName": "995605 - Disclosure - Balance Sheet Details (Tables)", "shortName": "Balance Sheet Details (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R23": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseTables", "longName": "995625 - Disclosure - Share-Based Compensation Expense (Tables)", "shortName": "Share-Based Compensation Expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R24": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables", "longName": "995635 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R25": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "longName": "995645 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_e9439dd5-bf4c-4474-80f4-9e6a03bb5de1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["span", "p", "us-gaap:SegmentReportingPolicyTextBlock", "div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "unique": true } }, "R26": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "longName": "995655 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)", "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2aa2798b-3801-4032-a055-65de3ac61b41", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:InventoryCashFlowPolicy", "div", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "unique": true } }, "R27": { "role": "http://arcturusrx.com/20240630/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails", "longName": "995665 - Disclosure - Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details)", "shortName": "Revenue - Summary of Changes in Balances of Receivables and Contract Liability (Details)", "isDefault": "false", "groupType": "disclosure",

"subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "C_b426c796-f874-4c87-9e45-b633cbd1e791", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_b426c796-f874-4c87-9e45-b633cbd1e791", "name": "us-gaap:ContractWithCustomerAssetNet", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R28": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails", "longName": "995675 - Disclosure - Revenue - Summary of Revenues (Details)", "shortName": "Revenue - Summary of Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_aaa5881f-0363-48e1-82f3-bccae620156e", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "unique": true } }, "R29": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "longName": "995685 - Disclosure - Revenue (Details Textual)", "shortName": "Revenue (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_bfe2a9f9-ad71-47fd-8fbd-c6e8b820915b", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "unique": true } }, "R30": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails", "longName": "995705 - Disclosure - Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details)", "shortName": "Balance Sheet Details - Summary of Components of Property and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R31": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsDetailsTextual", "longName": "995715 - Disclosure - Balance Sheet Details (Details Textual)", "shortName": "Balance Sheet Details (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R32": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails", "longName": "995725 - Disclosure - Balance Sheet Details - Schedule of Accrued Liabilities (Details)", "shortName": "Balance Sheet Details - Schedule of Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R33": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual", "longName": "995735 - Disclosure - Debt (Details Textual)", "shortName": "Debt (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_e2e74ea9-2c96-4746-aa2a-e5c79afef371", "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e2e74ea9-2c96-4746-aa2a-e5c79afef371", "name": "us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R34": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual", "longName": "995755 - Disclosure - Stockholders' Equity (Details Textual)", "shortName": "Stockholders' Equity (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R35": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual", "longName": "995765 - Disclosure - Share-Based Compensation Expense (Details Textual)", "shortName": "Share-Based Compensation Expense (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_f5043171-2948-43e4-86e0-eb72c1ed8543", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_f5043171-2948-43e4-86e0-eb72c1ed8543", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R36": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails", "longName": "995775 - Disclosure - Share-Based Compensation Expense (Details)", "shortName": "Share-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R37": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual", "longName": "995785 - Disclosure - Income Taxes (Details Textual)", "shortName": "Income Taxes (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-

gaap:IncomeTaxExpenseBenefit", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "longName": "995795 - Disclosure - Commitments and Contingencies (Details Textual)", "shortName": "Commitments and Contingencies (Details Textual)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_64ee9048-62c0-4774-9431-435a10938e28", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } }, "R39": { "role": "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetai "longName": "995805 - Disclosure - Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details)", "shortName": "Commitments and Contingencies - Remaining Payments of Operating Lease Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_efef243e-cf99-4c1c-8f3c-6b0e1e53dada", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "arct-20240630.htm", "first": true, "unique": true } } }, "tag": { "arct_ADAIRTechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ADAIRTechnologyMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "ADAIR Technology.", "label": "A D A I R Technology [Member]", "terseLabel": "ADAIR Technology [Member]" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r41", "r649"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r798"] }, "arct_AccruedCysticFibrosisFoundationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "AccruedCysticFibrosisFoundationLiability", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cystic Fibrosis Foundation Liability (Note 9)", "label": "Accrued Cystic Fibrosis Foundation Liability", "documentation": "Accrued cystic fibrosis foundation liability.", "verboseLabel": "Cystic Fibrosis Foundation liability" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails", "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44"] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation and amortization", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r22", "r109", "r470"] }, "arct_AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "AcquisitionOfResearchAndDevelopmentInProcessThroughIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "documentation": "Acquisition of research and development in process through issuance of common stock.", "label": "Acquisition Of Research And Development In Process Through Issuance Of Common Stock", "terseLabel": "Acquisition of in-process research and development through issuance of common stock" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r715"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r54", "r649", "r902"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r507", "r787", "r788", "r789", "r791", "r845", "r904"] }, "arct_AdditionalPaymentsUponMeetingCertainClinicalMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "AdditionalPaymentsUponMeetingCertainClinicalMilestones", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Additional payments upon meeting certain clinical milestones", "label": "Additional Payments upon Meeting Certain Clinical Milestones", "documentation": "Additional payments upon meeting certain clinical milestones." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r728"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r728"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO

NEO Compensation Footnote" } } }, "auth_ref": ["r728"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r728"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense", "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r34", "r35", "r290"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r761"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r687", "r697", "r707", "r739"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r690", "r700", "r710", "r742"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r762"] }, "arct_AlexionPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "AlexionPharmaceuticalsIncMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Alexion Pharmaceuticals, Inc.", "label": "Alexion Pharmaceuticals Inc [Member]", "terseLabel": "Alexion [Member]" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r728"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r735"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r691", "r701", "r711", "r735", "r743", "r747", "r755"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r753"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expenses", "verboseLabel": "Share-based compensation expenses", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r319", "r323"] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r161"] }, "arct_ArcalisIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ArcalisIncMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "documentation": "Arcalis, Inc.", "label": "Arcalis, Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": ["r350"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r83", "r93", "r110", "r134", "r164", "r167", "r180", "r181", "r192", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r351", "r353", "r378", "r464", "r537", "r620", "r621", "r649", "r678", "r808", "r809", "r857"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r105", "r117", "r134", "r192", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r351", "r353", "r378", "r649", "r808", "r809", "r857"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": ["r750"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": ["r751"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": ["r746"] },

{ "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": ["r746"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": ["r746"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": ["r746"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": ["r746"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": ["r746"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r749"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r748"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r747"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r747"] }, "arct_AxceleadIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "AxceleadIncMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "documentation": "Axcelead, Inc.", "label": "Axcelead Inc [Member]", "terseLabel": "Axcelead, Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityContractMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "The BARDA Contract [Member]", "label": "Biomedical Advanced Research And Development Authority Contract [Member]", "documentation": "Biomedical advanced research and development authority contract member." } } }, "auth_ref": [] }, "arct_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "BiomedicalAdvancedResearchAndDevelopmentAuthorityMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "BARDA [Member]", "label": "Biomedical Advanced Research and Development Authority [Member]", "documentation": "Biomedical Advanced Research and Development Authority." } } }, "auth_ref": [] }, "us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BorrowingsUnderGuaranteedInvestmentAgreements", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Borrowings under Guaranteed Investment Agreements", "terseLabel": "Term loan draw down", "documentation": "Carrying value as of the balance sheet date of the sum of the obligations to contract holders to provide to them an agreed upon rate of return pursuant to the terms of the underlying contract. These contracts represent lending by the contract holders to the entity in return for a guaranteed (primarily fixed) interest rate until maturity, unless called earlier if the contracts provide that option to the contract holders (usually institutions). There is little or no insurance risk for the entity." } } }, "auth_ref": ["r868"] }, "arct_BusinessAcquisitionOfHoldingShare": { "xbrltype": "sharesItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "BusinessAcquisitionOfHoldingShare", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Business acquisition of holding share", "label": "Business Acquisition Of Holding Share", "documentation": "Business acquisition of holding share." } } }, "auth_ref": [] }, "arct_COVIDNineteenVaccineDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "COVIDNineteenVaccineDevelopmentMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "COVID-19 vaccine development.", "label": "C O V I D Nineteen Vaccine Development [Member]", "terseLabel": "COVID-19 Vaccine Development" } } }, "auth_ref": [] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Purchase of property and equipment in accounts payable and accrued expenses", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": ["r16", "r17", "r18"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r15", "r107", "r610"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of the period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of the period", "totalLabel": "Total cash, cash equivalents and restricted cash shown in the statement of cash flows", "terseLabel": "Cash and cash equivalents, including restricted cash and non-current restricted cash", "verboseLabel": "Cash and cash equivalents, including restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r15", "r67", "r131"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype":

"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r67"] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing activities" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r726"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": ["r723"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": ["r721"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r114", "r115", "r116", "r166", "r251", "r252", "r253", "r255", "r258", "r263", "r265", "r498", "r499", "r500", "r501", "r629", "r765", "r783"] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Share price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r266"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Exercise of warrants for shares of common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": ["r266"] }, "arct_ClinicalTrialAccrualsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ClinicalTrialAccrualsCurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Clinical trial accruals current.", "label": "Clinical Trial Accruals Current", "terseLabel": "Clinical trial accruals" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r727"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r727"] }, "arct_CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "CollaborationPartnerCureVacEnteredIntoCoDevelopmentAgreementMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Collaboration Partner Cure Vac entered into Co-Development Agreement.", "label": "Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]", "terseLabel": "Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member]" } } }, "auth_ref": [] }, "arct_CollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "CollaborationRevenueMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails", "http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Revenue [Member]", "label": "Collaboration Revenue [Member]", "documentation": "Collaboration revenue." } } }, "auth_ref": [] }, "arct_CommitmentAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "CommitmentAndContingenciesLineItems", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Commitment and contingencies.", "label": "Commitment And Contingencies [Line Items]", "terseLabel": "Commitment And Contingencies [Line Items]" } } }, "auth_ref": [] }, "arct_CommitmentAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "CommitmentAndContingenciesTable", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Commitment and contingencies.", "label": "Commitment And Contingencies [Table]", "terseLabel": "Commitment And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r75", "r204", "r205", "r594", "r800", "r805"] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": { "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock reserved for future issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": ["r53"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r668", "r669", "r670", "r672", "r673", "r674", "r675", "r787", "r788", "r791", "r845", "r900", "r904"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": ["r53"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r53", "r525"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [

"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "verboseLabel": "Purchase of common stock, shares", "totalLabel": "Common Stock, Shares, Issued, Total", "terseLabel": "Issuance of Shares", "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": ["r53"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": ["r7", "r53", "r525", "r543", "r904", "r905"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 27,042 at June 30, 2024 and 26,828 at December 31, 2023", "label": "Common Stock, Value, Issued", "totalLabel": "Common Stock, Value, Issued, Total", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": ["r53", "r466", "r649"] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": ["r732"] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": ["r731"] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": ["r733"] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": ["r730"] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r11", "r119", "r121", "r125", "r459", "r476", "r477"] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Comprehensive loss:", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerEquipmentMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Computer Equipment [Member]", "terseLabel": "Computer and software [Member]", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "terseLabel": "Construction in progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "arct_ContraExpenseIncludedInResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ContraExpenseIncludedInResearchAndDevelopmentExpense", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Contra expense included in research and development expense.", "label": "Contra Expense Included In Research And Development Expense", "terseLabel": "Contra expense included in research and development expense" } } }, "auth_ref": [] }, "arct_ContraExpenseRemainingAmountIncludedInAccruedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ContraExpenseRemainingAmountIncludedInAccruedExpenses", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Contra expense remaining amount included in accrued expenses.", "label": "Contra Expense Remaining Amount Included In Accrued Expenses", "terseLabel": "Contra expense remaining amount included in accrued expenses" } } }, "auth_ref": [] }, "arct_ContraResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ContraResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Contra research and development expense.", "label": "Contra Research And Development Expense", "terseLabel": "Contra research and development expense recognized" } } }, "auth_ref": [] }, "arct_ContractWithCustomerAssetAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ContractWithCustomerAssetAdditions", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Contract With Customer Asset Additions", "documentation": "Contract with customer asset additions." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueTables"], "lang": { "en-us": { "role": { "terseLabel": "Summary of Changes in Balances of Receivables and Contract Liability", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": ["r811"] },
"arct_ContractWithCustomerAssetDeductions": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ContractWithCustomerAssetDeductions", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Deductions", "label": "Contract With Customer Asset Deductions", "documentation": "Contract with customer asset deductions.", "negatedLabel": "Deductions" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNet", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"], "lang": { "en-us": { "role": { "periodEndLabel": "Accounts receivable, Balance", "periodStartLabel": "Accounts receivable, Balance", "label": "Contract with Customer, Asset, after Allowance for Credit Loss", "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Total", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": ["r268", "r270", "r281"] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "periodEndLabel": "Deferred revenue, Balance", "periodStartLabel": "Deferred revenue, Balance", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue", "totalLabel": "Contract with Customer, Liability, Total", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r268", "r269", "r281"] },
"arct_ContractWithCustomerLiabilityAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ContractWithCustomerLiabilityAdditions", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Additions", "label": "Contract With Customer Liability Additions", "documentation": "Contract with

customer liability additions." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/DisclosureRevenueSummaryOfChangesInBalancesOfReceivablesAndContractLiabilityDetails", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "verboseLabel": "Deductions", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedLabel": "Deductions", "terseLabel": "Revenue recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": ["r282"] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails", "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "auth_ref": ["r136", "r137", "r225", "r253", "r412", "r419", "r463", "r611", "r613"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "arct_Covid19VaccineMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "Covid19VaccineMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "COVID-19 vaccine.", "label": "COVID-19 Vaccine [Member]", "terseLabel": "COVID-19 Vaccine [Member]" } } }, "auth_ref": [] }, "arct_CslCollaborationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "CslCollaborationAgreementMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "CSL Collaboration Agreement [Member]", "label": "CSL Collaboration Agreement [Member]", "documentation": "CSL Collaboration Agreement." } } }, "auth_ref": [] }, "arct_CslSegirusMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "CslSegirusMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "CSL Segirus [Member]", "label": "CSL Segirus [Member]", "documentation": "CSL segirus." } } }, "auth_ref": [] }, "arct_CureVacAGMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "CureVacAGMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"], "lang": { "en-us": { "role": { "documentation": "CureVac AG.", "label": "Cure Vac A G [Member]", "terseLabel": "CureVac [Member]" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "arct_CysticFibrosisFoundationTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "CysticFibrosisFoundationTherapeuticsIncMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Cystic Fibrosis Foundation Therapeutics, Inc.", "label": "Cystic Fibrosis Foundation Therapeutics Inc [Member]", "terseLabel": "Cystic Fibrosis Foundation [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebt"], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r76", "r132", "r197", "r198", "r199", "r200", "r201", "r210", "r211", "r221", "r227", "r228", "r229", "r230", "r231", "r232", "r237", "r244", "r245", "r247", "r390"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Interest of the prime rate plus", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCollateral": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCollateral", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Collateral", "terseLabel": "Debt instrument, collateral", "documentation": "Discussion of whether the debt instrument is secured or unsecured, and, if secured, a description of the collateral and guarantees required or provided." } } }, "auth_ref": ["r40", "r46"] }, "us-gaap_DebtInstrumentCollateralAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCollateralAmount", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "verboseLabel": "Collateral amount", "label": "Debt Instrument, Collateral Amount", "terseLabel": "Debt instrument, collateral amount", "documentation": "Amount of assets pledged to secure a debt instrument." } } }, "auth_ref": ["r40"] }, "us-gaap_DebtInstrumentDateOfFirstRequiredPayment1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDateOfFirstRequiredPayment1", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Date of First Required Payment", "terseLabel": "Loan first principal payment extended maturity date", "documentation": "Date the debt agreement requires the first payment to be made, in YYYY-MM-DD format." } } }, "auth_ref": ["r10", "r39"] }, "arct_DebtInstrumentExtendedTermPeriod": { "xbrltype": "durationItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DebtInstrumentExtendedTermPeriod", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Extended term period", "label": "Debt Instrument, Extended Term Period", "documentation": "Debt instrument, extended term period." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Term loan", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r222", "r390", "r391", "r625", "r626", "r647"] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Fee payable", "label": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": ["r47"] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Increase, Accrued Interest", "terseLabel": "Accrued interest added to principal debt balance", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": ["r784"] }, "arct_DebtInstrumentInterestOnlyPaymentExtendedMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DebtInstrumentInterestOnlyPaymentExtendedMaturityDate", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Debt instrument interest only payment extended maturity date.", "label": "Debt Instrument Interest Only Payment Extended Maturity Date", "terseLabel": "Loan interest-only payment extended maturity date" } } }, "auth_ref": [] }, "arct_DebtInstrumentInterestOnlyPaymentExtendedPeriod": { "xbrltype": "durationItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DebtInstrumentInterestOnlyPaymentExtendedPeriod", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Debt instrument interest only payment extended period.", "label": "Debt Instrument Interest Only Payment Extended Period", "terseLabel": "Extension to interest only period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "verboseLabel": "Borrowings interest rate, percentage", "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Loan accrued interest rate per annum,

percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r46", "r249", "r390", "r391", "r647"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r138", "r222", "r223", "r224", "r225", "r226", "r228", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r246", "r624", "r625", "r626", "r627", "r628", "r647", "r784", "r851", "r852"] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "terseLabel": "Loan maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": ["r112", "r624", "r846", "r847"] }, "arct_DebtInstrumentOptionForRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DebtInstrumentOptionForRenewalTerm", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Option for renewal term", "label": "Debt Instrument Option for Renewal Term", "documentation": "Debt instrument option for renewal term." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r10", "r28", "r31", "r38", "r79", "r80", "r138", "r222", "r223", "r224", "r225", "r226", "r228", "r233", "r234", "r235", "r236", "r238", "r239", "r240", "r241", "r242", "r243", "r246", "r624", "r625", "r626", "r627", "r628", "r647", "r784", "r851", "r852"] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Term of agreement", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueCurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue", "totalLabel": "Deferred Revenue, Current, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": ["r776"] }, "us-gaap_DeferredRevenueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueNoncurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "totalLabel": "Deferred Revenue, Noncurrent, Total", "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": ["r777"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r4", "r21"] }, "arct_DevelopmentMilestonesAchieved": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DevelopmentMilestonesAchieved", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Development milestones achieved.", "label": "Development Milestones Achieved", "terseLabel": "Development milestones achieved" } } }, "auth_ref": [] }, "arct_DevelopmentMilestonesReceivedAdvancePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DevelopmentMilestonesReceivedAdvancePayment", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Development milestones received advance payment", "label": "Development Milestones Received Advance Payment", "documentation": "Development milestones received advance payment." } } }, "auth_ref": [] }, "arct_DirectorsOrOfficersMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DirectorsOrOfficersMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Directors or Officers [Member]", "label": "Directors or Officers [Member]", "documentation": "Directors or Officers." } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r280", "r630", "r631", "r632", "r633", "r634", "r635", "r636"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r280", "r630", "r631", "r632", "r633", "r634", "r635", "r636"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueTables"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r812"] }, "arct_DisbursedAmountUponExecutionOfAmendment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DisbursedAmountUponExecutionOfAmendment", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Disbursed amount upon execution of amendment.", "label": "Disbursed Amount Upon Execution Of Amendment", "terseLabel": "Disbursed amount upon execution of amendment" } } }, "auth_ref": [] }, "arct_DisbursementAmountPayableUponAchievementOfProjectGoal": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DisbursementAmountPayableUponAchievementOfProjectGoal", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Disbursement amount payable upon achievement of project goal.", "label": "Disbursement Amount Payable Upon Achievement Of Project Goal", "terseLabel": "Disbursement amount payable upon achievement of project goal" } } }, "auth_ref": [] }, "arct_DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DisbursementPaymentUponAchievementOfRequiredManufacturingPracticesAndINDApplication", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Disbursement payment upon achievement of required manufacturing practices and IND application.", "label": "Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application", "terseLabel": "Disbursement payment upon achievement of required manufacturing practices and IND application" } } }, "auth_ref": [] }, "arct_DisbursementPeriodFourMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DisbursementPeriodFourMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Disbursement period four.", "label": "Disbursement Period Four [Member]", "terseLabel": "Disbursement Due October 2020 [Member]" } } }, "auth_ref": [] }, "arct_DisbursementPeriodOneMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DisbursementPeriodOneMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Disbursement period one.", "label": "Disbursement Period One [Member]", "terseLabel": "Disbursement Due January 2020 [Member]" } } }, "auth_ref": [] }, "arct_DisbursementPeriodThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DisbursementPeriodThreeMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Disbursement period three.", "label": "Disbursement Period Three [Member]", "terseLabel": "Disbursement Due July 2020 [Member]" } } }, "auth_ref": [] }, "arct_DisbursementPeriodTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "DisbursementPeriodTwoMember", "presentation": [

"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Disbursement period two.", "label": "Disbursement Period Two [Member]", "terseLabel": "Disbursement Due April 2020 [Member]" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpense"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation Expense", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r288", "r292", "r320", "r321", "r322", "r638"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Dividends", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "label": "Dividends", "terseLabel": "Dividends declared or paid", "totalLabel": "Dividends, Total", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": ["r2", "r81"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r682"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r714"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": ["r725"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Basic", "label": "Earnings Per Share, Basic", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r126", "r144", "r145", "r146", "r147", "r148", "r149", "r154", "r156", "r158", "r159", "r160", "r163", "r346", "r349", "r363", "r364", "r460", "r478", "r615"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "label": "Earnings Per Share, Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r126", "r144", "r145", "r146", "r147", "r148", "r149", "r156", "r158", "r159", "r160", "r163", "r346", "r349", "r363", "r364", "r460", "r478", "r615"] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": ["r19", "r20", "r162"] }, "arct_EligibleToReceiveCommercialMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "EligibleToReceiveCommercialMilestonePayment", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Eligible to receive commercial milestone payment.", "label": "Eligible to Receive Commercial Milestone Payment", "terseLabel": "Eligible to receive commercial milestone payment" } } }, "auth_ref": [] }, "arct_EligibleToReceiveDevelopmentMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "EligibleToReceiveDevelopmentMilestonePayment", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Eligible to Receive Development Milestone Payment", "label": "Eligible to Receive Development Milestone Payment", "terseLabel": "Eligible to receive development milestone payment" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "totalLabel": "Employee-related Liabilities, Current, Total", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r44"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" }

```
} }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r680" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r680" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r680" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r764" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r680" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r680" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r680" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r680" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r719" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r760" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r760" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r760" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Equipment [Member]", "terseLabel": "Research equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r103", "r122", "r123", "r124", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r165", "r193", "r194", "r195", "r267", "r335", "r336", "r343", "r344", "r345", "r347", "r348", "r349", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r383", "r384", "r385", "r386", "r387", "r388", "r392", "r393", "r406", "r475", "r491", "r492", "r493", "r507", "r569" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name" } } }, "auth_ref": [ "r189", "r190", "r191", "r342", "r767", "r768", "r769", "r840", "r841", "r842", "r843" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis", "presentation": [
```

```
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-
us": { "role": { "label": "Equity Method Investment, Nonconsolidated Investee [Axis]", "terseLabel": "Equity Method Investment, Nonconsolidated
Investee", "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity." } }
}, "auth_ref": [ "r104", "r134", "r192", "r378", "r423", "r424", "r429", "r436", "r443", "r444", "r455", "r457", "r650", "r651", "r652", "r653", "r654",
"r655", "r656", "r657", "r658", "r659", "r660", "r661" ] }, "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
"presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-
us": { "role": { "label": "Equity Method Investment, Nonconsolidated Investee [Domain]", "terseLabel": "Equity Method Investment,
Nonconsolidated Investee", "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity." }
} }, "auth_ref": [ "r104", "r134", "r192", "r378", "r423", "r424", "r429", "r436", "r443", "r444", "r455", "r457", "r650", "r651", "r652", "r653",
"r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-
us": { "role": { "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method ownership percentage",
"documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of
accounting." } } }, "auth_ref": [ "r189" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text
Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r729" ] }, "ecd_ErrCompAnalysisTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]",
"terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r687", "r697", "r707", "r739" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]",
"terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r684", "r694", "r704", "r736" ] }, "ecd_ExecutiveCategoryAxis": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:"
} } }, "auth_ref": [ "r735" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueDisclosuresTextBlock", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureFairValueMeasurements" ],
"lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire
disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and
the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures
about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts
(as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to
estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair
value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a
concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring
collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral
or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and
nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial
statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the
effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the
balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as
defined) and desired information." } } }, "auth_ref": [ "r367", "r369", "r370", "r371", "r373", "r374", "r375", "r376", "r377", "r458", "r641", "r644" ]
}, "arct_FebruaryTwoThousandAndTwentyLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630",
"localname": "FebruaryTwoThousandAndTwentyLeaseAgreementMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "February two thousand and twenty lease agreement.", "label": "February Two Thousand And Twenty Lease Agreement
[Member]", "terseLabel": "February 2020 Lease Agreement [Member]" } } }, "auth_ref": [] },
"arct_FebruaryTwoThousandAndTwentyOneLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630",
"localname": "FebruaryTwoThousandAndTwentyOneLeaseAgreementMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "February two thousand and twenty one lease agreement.", "label": "February Two Thousand And Twenty One Lease Agreement
[Member]", "terseLabel": "February 2021 Lease Agreement [Member]" } } }, "auth_ref": [] }, "arct_FinalPaymentOfDisbursementAmount": {
"xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "FinalPaymentOfDisbursementAmount", "crdr": "credit",
"presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-
us": { "role": { "documentation": "Final payment of disbursement amount.", "label": "Final Payment Of Disbursement Amount", "terseLabel": "Final
payment of disbursement amount" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit",
"presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": {
"en-us": { "role": { "verboseLabel": "(Loss) gain from foreign currency", "terseLabel": "Foreign currency transaction gain (loss)", "label": "Gain
(Loss), Foreign Currency Transaction, before Tax", "totalLabel": "Foreign Currency Transaction Gain (Loss), before Tax, Total", "documentation":
"Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r379", "r380", "r381", "r382",
"r566" ] }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ForeignCurrencyTransactionGainLossRealized", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": {
"role": { "label": "Realized Gain (Loss), Foreign Currency Transaction, before Tax", "negatedLabel": "Foreign currency translation loss",
"documentation": "Amount, before tax, of realized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r545", "r676", "r849", "r850",
"r903" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits,
Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r691", "r701", "r711", "r743" ] },
"ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
"role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement,
Amount" } } }, "auth_ref": [ "r691", "r701", "r711", "r743" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of
Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r691", "r701",
"r711", "r743" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text
Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r691", "r701", "r711", "r743" ] },
"ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name",
"terseLabel": "Name" } } }, "auth_ref": [ "r691", "r701", "r711", "r743" ] },
"ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior
Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards
Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r724" ] }, "us-
gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"FurnitureAndFixturesMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
], "lang": { "en-us": { "role": { "label": "Furniture and Fixtures [Member]", "terseLabel": "Office equipment and furniture [Member]",
"documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-
gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": {
"en-us": { "role": { "terseLabel": "Gain on debt extinguishment", "negatedLabel": "Gain on debt extinguishment", "label": "Gain (Loss) on
Extinguishment of Debt", "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total", "documentation": "Difference between the fair value of
payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r4", "r24", "r25"] }, "us-
gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"GeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": {
"en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "totalLabel": "General and
Administrative Expense, Total", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity,
including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or
product line." } } }, "auth_ref": ["r62", "r548"] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label":
"General and Administrative Expense [Member]", "terseLabel": "General and Administrative [Member]", "documentation": "Primary financial
statement caption encompassing general and administrative expense." } } }, "auth_ref": ["r62"] }, "us-gaap_GrantMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": {
"en-us": { "role": { "terseLabel": "Grant Revenue [Member]", "label": "Grant [Member]", "documentation": "Award of money not required to be
repaid." } } }, "auth_ref": ["r813"] }, "arct_GrantOneMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630",
"localname": "GrantOneMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": {
"documentation": "Grant one.", "label": "Grant One [Member]", "terseLabel": "Grant 1" } } }, "auth_ref": [] },
"arct_GrantReceivableNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://arcturusrx.com/20240630", "localname":
"GrantReceivableNumberOfInstallments", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": {
"documentation": "Grant receivable number of installments.", "label": "Grant Receivable Number Of Installments", "terseLabel": "Grant, number of
installments" } } }, "auth_ref": [] }, "arct_GrantRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630",
"localname": "GrantRevenue", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/DisclosureGrantRevenueDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Grant
revenue.", "label": "Grant revenue", "terseLabel": "Total grant revenue" } } }, "auth_ref": [] }, "arct_GrantRevenueAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "GrantRevenueAbstract", "lang": { "en-us": { "role": { "documentation":
"Grant Revenue Abstract.", "label": "Grant Revenue [Abstract]" } } }, "auth_ref": [] }, "arct_GrantRevenueDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "GrantRevenueDisclosureTextBlock", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/DisclosureGrantRevenue"], "lang": { "en-us": { "role": { "documentation": "The entire disclosure
for grant revenue.", "label": "Grant Revenue Disclosure [Text Block]", "terseLabel": "Grant Revenue" } } }, "auth_ref": [] },
"arct_GrantRevenueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname":
"GrantRevenueOutstanding", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/DisclosureGrantRevenueDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Grant
revenue outstanding", "documentation": "Grant revenue outstanding.", "label": "Grant Revenue Outstanding" } } }, "auth_ref": [] },
"arct_GrantTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "GrantTwoMember",
"presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-
us": { "role": { "documentation": "Grant two.", "label": "Grant Two [Member]", "terseLabel": "Grant 2" } } }, "auth_ref": [] }, "us-
gaap_GrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrantsReceivable", "crdr":
"debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang":
{ "en-us": { "role": { "label": "Grants Receivable", "terseLabel": "Grant awarded", "documentation": "Carrying amount as of the balance sheet date
of amounts due under the terms of governmental, corporate, or foundation grants." } } }, "auth_ref": ["r778"] },
"arct_GrantsReceivedFromJapaneseGovernment": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname":
"GrantsReceivedFromJapaneseGovernment", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
], "lang": { "en-us": { "role": { "terseLabel": "Financial grants received from the Japanese government", "label": "Grants Received From Japanese
Government", "documentation": "Grants received from japanese government." } } }, "auth_ref": [] }, "arct_GriBioIncMember": { "xbrltype":
"domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "GriBioIncMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-
us": { "role": { "terseLabel": "GRI Bio [Member]", "label": "GRI Bio Inc Member", "documentation": "GRI Bio Inc." } } }, "auth_ref": [] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": {
"en-us": { "role": { "totalLabel": "Net loss before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes,
Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method
investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r59",
"r87", "r92", "r461", "r473", "r617", "r620", "r792", "r794", "r795", "r796", "r797"] }, "us-gaap_IncomeLossFromEquityMethodInvestments": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr":
"credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": {
"en-us": { "role": { "terseLabel": "Loss from equity-method investment", "negatedLabel": "Loss from equity-method investment", "label": "Income
(Loss) from Equity Method Investments", "totalLabel": "Income (Loss) from Equity Method Investments, Total", "documentation": "Amount of
income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": ["r4", "r60", "r86", "r164", "r170", "r181",
"r188", "r472"] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementLocationAxis", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label":
"Statement of Income Location, Balance [Axis]", "terseLabel": "Income Statement Location", "documentation": "Information by location in
statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r196", "r202", "r203", "r366", "r368", "r372", "r488",
"r490", "r553", "r606", "r642", "r871"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label":
"Statement of Income Location, Balance [Domain]", "terseLabel": "Income Statement Location", "documentation": "Location in statement of
income where disaggregated amount has been reported." } } }, "auth_ref": ["r202", "r203", "r366", "r368", "r372", "r488", "r490", "r553", "r606",
"r642", "r871"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxDisclosureTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxes"], "lang": { "en-
us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income
tax." } } }, "auth_ref": ["r135", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r337", "r339", "r340", "r341", "r503", "r640"] }, "us-
gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureIncomeTaxesDetailsTextual",

"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "verboseLabel": "Income tax expense", "terseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "totalLabel": "Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r95", "r99", "r151", "r152", "r164", "r171", "r181", "r328", "r329", "r338", "r479", "r640"] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities", "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": ["r3"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r421", "r781"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r772", "r781"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expense and other assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r3"] }, "arct_IncreaseDecreaseOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "IncreaseDecreaseOperatingLeaseRightOfUseAsset", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedLabel": "Right-of-use assets", "label": "Increase Decrease Operating Lease, Right Of Use Asset", "documentation": "Increase decrease operating lease, right of use asset." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r691", "r701", "r711", "r735", "r743", "r747", "r755"] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r753"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": ["r683", "r759"] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": ["r683", "r759"] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": ["r683", "r759"] }, "us-gaap_InterestExpenseLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseLongTermDebt", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Interest Expense, Long-Term Debt", "terseLabel": "Interest expense related to long-term debt", "totalLabel": "Interest Expense, Long-term Debt, Total", "documentation": "Aggregate amount of interest paid or due on all long-term debt." } } }, "auth_ref": ["r89", "r101", "r102"] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": ["r127", "r129", "r130"] }, "us-gaap_InventoryCashFlowPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryCashFlowPolicy", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "label": "Inventory, Cash Flow Policy [Policy Text Block]", "terseLabel": "Restricted Cash", "documentation": "Disclosure of accounting policy for determining where the cash flows related to the sale of inventory are classified in the statements of cash flows and explain the nature of the receivables, notes, and loans." } } }, "auth_ref": ["r9"] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalanceShares", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Investment Owned, Balance, Shares", "terseLabel": "Number of shares owned", "documentation": "Number of shares of investment owned." } } }, "auth_ref": ["r509", "r515", "r578", "r585", "r589", "r670"] }, "us-gaap_InvestmentOwnedPercentOfNetAssets": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedPercentOfNetAssets", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Investment Owned, Net Assets, Percentage", "terseLabel": "Percentage of owned shares", "documentation": "Percentage of investment owned to net assets." } } }, "auth_ref": ["r511", "r513", "r514", "r579", "r584", "r586", "r587", "r590", "r670", "r901"] }, "arct_IsraelMinistryOfHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "IsraelMinistryOfHealthMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Israel Ministry of Health [Member]", "label": "Israel Ministry of Health [Member]", "documentation": "Israel ministry of health." } } }, "auth_ref": [] }, "arct_JanssenMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "JanssenMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails"], "lang": { "en-us": { "role": { "documentation": "Janssen.", "label": "Janssen [Member]", "terseLabel": "Janssen [Member]" } } }, "auth_ref": [] }, "arct_JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "JointVenturesEquityMethodInvestmentsAndVariableInterestEntitiesPolicyTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "documentation": "Joint ventures, equity method investments and variable interest entities.", "label": "Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block]", "terseLabel": "Joint Ventures, Equity Method Investments and

Variable Interest Entities" } } }, "auth_ref": [] }, "arct_KeithCKummerfeldMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "KeithCKummerfeldMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Keith C. Kummerfeld [Member]", "documentation": "Keith C. Kummerfeld." } } }, "auth_ref": [] }, "arct_LUNARCFMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "LUNARCFMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "LUNAR-CF.", "label": "L U N A R C F [Member]", "terseLabel": "LUNAR-CF [Member]" } } }, "auth_ref": [] }, "arct_LanceKurataMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "LanceKurataMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Lance Kurata [Member]", "documentation": "Lance Kurata." } } }, "auth_ref": [] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term", "documentation": "Information by contractual term of lease arrangement." } } }, "auth_ref": ["r405", "r771"] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref": ["r405", "r771"] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": ["r74", "r404"] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": ["r397"] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Remaining Payments of Operating Lease Liability", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": ["r855"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetai], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total remaining lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": ["r403"] }, "arct_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetai], "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year three.", "label": "Lessee Operating Lease Liability Payments Due After Year Three", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetai], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "totalLabel": "Lessee Operating Lease Liability Payments Due Next Twelve Months, Total", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r403"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetai], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r403"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetai], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r403"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetai], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r855"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetai], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r403"] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Option to Extend", "terseLabel": "Lessee, operating leases, option to extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": ["r398"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Operating lease extended additional term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r854"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, operating lease, term of contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r854"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r10", "r43", "r44", "r45", "r48", "r49", "r50", "r51", "r134", "r192", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r352", "r353", "r354", "r378", "r524", "r616", "r678", "r808", "r857", "r858"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity", "documentation": "Amount of liabilities and equity

items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r58", "r85", "r468", "r649", "r785", "r799", "r848"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r45", "r106", "r134", "r192", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r352", "r353", "r354", "r378", "r649", "r808", "r857", "r858"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Non-refundable commitment fee, percentage", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Revolving credit line available", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": ["r42", "r47"] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Loans interest rate, percentage", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period." } } }, "auth_ref": ["r42", "r47"] }, "arct_LiquidityPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "LiquidityPolicyPolicyTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "documentation": "Liquidity.", "label": "Liquidity Policy Policy [Text Block]", "terseLabel": "Liquidity" } } }, "auth_ref": [] }, "arct_LoanAndSecurityAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "LoanAndSecurityAgreementMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Loan and security agreement.", "label": "Loan And Security Agreement [Member]", "terseLabel": "Loan and Security Agreement [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtSummaryOfFinalPaymentDueAtRepaymentDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "terseLabel": "Long-term debt", "totalLabel": "Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r10", "r84", "r234", "r248", "r625", "r626", "r647", "r867"] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current portion of long-term debt", "totalLabel": "Long-term Debt, Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r111"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtSummaryOfFinalPaymentDueAtRepaymentDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r6", "r138", "r239"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtSummaryOfFinalPaymentDueAtRepaymentDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2022", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year." } } }, "auth_ref": ["r786"] }, "us-gaap_LongTermDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Long-Term Debt [Member]", "terseLabel": "Long-term Debt [Member]", "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r113"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r10", "r801", "r802", "r803"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r10", "r23", "r801", "r802", "r803"] }, "arct_MRNATechnologyMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "MRNATechnologyMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "mRNA technology.", "label": "M R N A Technology [Member]", "terseLabel": "mRNA Technology [Member]" } } }, "auth_ref": [] }, "arct_ManufacturingAndSupplyOfArct154DrugProductMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ManufacturingAndSupplyOfArct154DrugProductMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "manufacturing and supply of ARCT-154 drug product.", "label": "Manufacturing and Supply of ARCT-154 Drug Product [Member]" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "auth_ref": ["r206", "r207", "r208", "r209", "r286", "r324", "r365", "r420", "r487", "r489", "r496", "r516", "r517", "r577", "r580", "r582", "r583", "r588", "r604", "r605", "r623", "r629", "r637", "r643", "r644", "r645", "r646",

"r663", "r810", "r859", "r860", "r861", "r862", "r863", "r864"] }, "arct_MaximumSalesRequiredForLoansForgivable": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "MaximumSalesRequiredForLoansForgivable", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Maximum sales required for loans forgivable .", "label": "Maximum Sales Required For Loans Forgivable", "terseLabel": "Maximum LUNAR-COVID 19 sales required for Loans forgivable" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r727"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r727"] }, "arct_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "MilestonePayments", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments" } } }, "auth_ref": [] }, "arct_MinimumAmountAgreedToIncurUnderResearchPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "MinimumAmountAgreedToIncurUnderResearchPlan", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Minimum amount agreed to incur under research plan", "label": "Minimum Amount Agreed to Incur Under Research Plan", "documentation": "Minimum amount agreed to incur under research plan." } } }, "auth_ref": [] }, "arct_MinimumIncurAmountAgreedUnderResearchPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "MinimumIncurAmountAgreedUnderResearchPlan", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Minimum incur amount under research plan", "label": "Minimum Incur Amount Agreed Under Research Plan", "documentation": "Minimum yncur amount agreed under research plan." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "auth_ref": ["r206", "r207", "r208", "r209", "r286", "r324", "r365", "r420", "r487", "r489", "r496", "r516", "r517", "r577", "r580", "r582", "r583", "r588", "r604", "r605", "r623", "r629", "r637", "r643", "r644", "r645", "r663", "r810", "r859", "r860", "r861", "r862", "r863", "r864"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r746"] }, "arct_MonthlyBaseRent": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "MonthlyBaseRent", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Monthly base rent.", "label": "Monthly Base Rent", "terseLabel": "Monthly base rent" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r754"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r728"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r128"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r128"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r67", "r68", "r69"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "verboseLabel": "Net loss", "totalLabel": "Net loss", "negatedTotalLabel": "Net income (loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r61", "r69", "r88", "r104", "r118", "r120", "r124", "r134", "r142", "r144", "r145", "r146", "r147", "r148", "r151", "r152", "r157", "r192", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r346", "r349", "r364", "r378", "r474", "r546", "r567", "r568", "r676", "r808"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "arct_NonCashAssetDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "NonCashAssetDisposal", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "documentation": "Non-Cash Asset Disposal", "label": "Non - Cash Asset Disposal", "terseLabel": "Non-cash asset disposal" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r727"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r691", "r701", "r711", "r735", "r743"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],

```
"lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r718" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r717" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r735" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r754" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r754" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segment for research and development", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r621", "r793" ] }, "arct_OctoberTwoThousandAndSeventeenLeaseAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "OctoberTwoThousandAndSeventeenLeaseAmendmentMember", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "October 2017 lease amendment.", "label": "October Two Thousand And Seventeen Lease Amendment [Member]", "terseLabel": "October 2017 Lease Amendment [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r92", "r617", "r792", "r794", "r795", "r796", "r797" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Operating lease costs", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r399", "r648" ] }, "us-gaap_OperatingLeaseImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseImpairmentLoss", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Impairment Loss", "terseLabel": "Impairment loss", "documentation": "Amount of loss from impairment of right-of-use asset from operating lease." } } }, "auth_ref": [ "r853" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetai ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "verboseLabel": "Total operating lease liabilities", "totalLabel": "Operating Lease, Liability, Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r395" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r395" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease Liability Current Statement Of Financial Position [Extensible List]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r396" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r395" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets, net", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r394" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetai ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r402", "r648" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesRemainingPaymentsOfOperatingLeaseLiabilityDetai ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r401", "r648" ] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r70", "r71", "r72", "r82" ] }, "arct_OtherAccruedResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "OtherAccruedResearchAndDevelopmentExpenses", "crdr": "credit", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Other accrued research and development expenses.", "label": "Other Accrued Research And Development Expenses", "terseLabel": "Other accrued research and development expenses" } } }, "auth_ref": [] }, "arct_OtherCollaborationAgreementsMember": {
```

```
"xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "OtherCollaborationAgreementsMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Other
collaboration agreements.", "label": "Other Collaboration Agreements [Member]", "terseLabel": "Other Collaboration Agreements [Member]" } } },
"auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherLiabilitiesNoncurrent", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": {
"label": "Other Liabilities, Noncurrent", "terseLabel": "Other non-current liabilities", "documentation": "Amount of liabilities classified as other,
due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r49" ] }, "arct_OtherMember": { "xbrltype": "domainItemType",
"nsuri": "http://arcturusrx.com/20240630", "localname": "OtherMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails" ], "lang": { "en-us": { "role": {
"documentation": "Other.", "label": "Other [Member]", "terseLabel": "Other Collaboration Revenue [Member]" } } }, "auth_ref": [] }, "us-
gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNoncashIncomeExpense", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": {
"role": { "label": "Other Noncash Income (Expense)", "negatedLabel": "Other non-cash expenses", "totalLabel": "Other Noncash Income (Expense),
Total", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } },
"auth_ref": [ "r69" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": {
"en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "totalLabel": "Other Nonoperating Income (Expense), Total", "terseLabel":
"Finance income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [
"r63" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance
Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r727" ] }, "ecd_OutstandingAggtErrCompAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount",
"terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r689", "r699", "r709", "r741" ] },
"ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r692", "r702", "r712", "r744" ] },
"ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r692", "r702", "r712", "r744" ] },
"ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs
Performance Disclosure" } } }, "auth_ref": [ "r716" ] }, "arct_PaymentReceivedFirstInstallment": { "xbrltype": "monetaryItemType", "nsuri":
"http://arcturusrx.com/20240630", "localname": "PaymentReceivedFirstInstallment", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Payment received first installment.", "label": "Payment Received First Installment", "terseLabel": "Received first installment" }
} }, "auth_ref": [] }, "us-gaap_PaymentsForAdvanceToAffiliate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "PaymentsForAdvanceToAffiliate", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": {
"label": "Payments for Advance to Affiliate", "terseLabel": "Payments for advance", "documentation": "The cash outflow from advancing money to
an affiliate (an entity that is related but not strictly controlled by the entity)." } } }, "auth_ref": [ "r13" ] },
"arct_PaymentsForMatchingFundsForRemainingBudgetedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630",
"localname": "PaymentsForMatchingFundsForRemainingBudgetedCosts", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Payments for matching funds for remaining budgeted costs.", "label": "Payments For Matching Funds For Remaining Budgeted
Costs", "terseLabel": "Payments for matching funds for remaining budgeted costs" } } }, "auth_ref": [] }, "us-
gaap_PaymentsForProceedsFromTenantAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsForProceedsFromTenantAllowance", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": {
"label": "Payments for (Proceeds from) Tenant Allowance", "terseLabel": "Tenant improvement allowance", "documentation": "Net cash outflow or
inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant
to prepare the leased premises for tenants occupancy." } } }, "auth_ref": [ "r12", "r64" ] }, "us-
gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": {
"role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Acquisition of property and equipment", "totalLabel":
"Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived,
physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows
to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r65" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer
Group Issuers, Footnote" } } }, "auth_ref": [ "r726" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount"
} } }, "auth_ref": [ "r726" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO
Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r718" ] }, "ecd_PeoMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r735" ]
}, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [
"r728" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount",
"terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r717" ] }, "arct_PercentageOfNetProfits": { "xbrltype": "percentItemType",
"nsuri": "http://arcturusrx.com/20240630", "localname": "PercentageOfNetProfits", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "documentation":
"Percentage of net profits.", "label": "Percentage Of Net Profits", "terseLabel": "Net profits percentage" } } }, "auth_ref": [] },
"arct_PercentageRequiredToBeMaintainedInConsolidatedUnrestrictedCash": { "xbrltype": "percentItemType", "nsuri":
"http://arcturusrx.com/20240630", "localname": "PercentageRequiredToBeMaintainedInConsolidatedUnrestrictedCash", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Percentage
required to be maintained in consolidated unrestricted cash.", "label": "Percentage Required To Be Maintained In Consolidated Unrestricted
Cash", "terseLabel": "Percentage required to be maintain in consolidated, unrestricted cash" } } }, "auth_ref": [] },
"arct_PhaseIClinicalStudyMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname":
"PhaseIClinicalStudyMember", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang":
{ "en-us": { "role": { "label": "Phase I Clinical Study [Member]", "documentation": "Phase I clinical study." } } }, "auth_ref": [] }, "us-
gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual" ], "lang": { "en-us": { "role": {
"label": "Plan Name [Axis]", "terseLabel": "Plan Name", "documentation": "Information by plan name for share-based payment arrangement." } } },
"auth_ref": [ "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830",
"r831", "r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual" ], "lang": { "en-us": { "role": {
"label": "Plan Name [Domain]", "terseLabel": "Plan Name", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref":
[ "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r824", "r825", "r826", "r827", "r828", "r829", "r830", "r831",
"r832", "r833", "r834", "r835", "r836", "r837", "r838", "r839" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
```

"en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": ["r719"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": ["r763"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": ["r718"] }, "arct_PotentialPrincipalRepaymentsOfDebtInstrument": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "PotentialPrincipalRepaymentsOfDebtInstrument", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Potential Principal Repayments Of Debt Instrument.", "label": "Potential Principal Repayments Of Debt Instrument", "terseLabel": "Potential principal repayment of loan" } } }, "auth_ref": [] }, "arct_PreLaunchInventoryPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "PreLaunchInventoryPolicyPolicyTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol], "lang": { "en-us": { "role": { "documentation": "Pre-launch inventory policy.", "label": "Pre Launch Inventory Policy Policy [Text Block]", "terseLabel": "Pre-Launch Inventory" } } }, "auth_ref": [] }, "arct_PrepaidExpensesAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "PrepaidExpensesAndOtherReceivables", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable.", "label": "Prepaid Expenses And Other Receivables", "terseLabel": "Prepaid expenses and other current assets" } } }, "auth_ref": [] }, "arct_PrepaymentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "PrepaymentFeePercentage", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Prepayment fee percentage.", "label": "Prepayment Fee Percentage", "terseLabel": "Prepayment fee percentage" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Debt", "terseLabel": "Net increase in indebtedness", "verboseLabel": "Proceeds from debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": ["r779"] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Long-Term Debt", "terseLabel": "Proceeds from long-term debt agreement", "totalLabel": "Proceeds from Issuance of Long-term Debt, Total", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": ["r14", "r498"] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Amount drawn from Loan", "label": "Proceeds from Lines of Credit", "totalLabel": "Proceeds from Lines of Credit, Total", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": ["r14", "r784"] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": ["r1", "r8"] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockPlans", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from the issuance of common stock under equity plans", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": ["r1"] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails", "http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "auth_ref": ["r183", "r422", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r608", "r630", "r662", "r663", "r664", "r666", "r667", "r806", "r807", "r812", "r870", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails", "http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "auth_ref": ["r183", "r422", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r608", "r630", "r662", "r663", "r664", "r666", "r667", "r806", "r807", "r812", "r870", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899"] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r5", "r404"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross", "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r74", "r108", "r471"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r404"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails", "http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Net, Ending

Balance", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r5", "r404", "r462", "r471", "r649"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Components of Property and Equipment, Net", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r5"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r74", "r404"] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": ["r716"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": ["r716"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": ["r206", "r207", "r208", "r209", "r284", "r286", "r315", "r316", "r317", "r324", "r365", "r417", "r418", "r420", "r487", "r489", "r496", "r516", "r517", "r577", "r580", "r582", "r583", "r588", "r604", "r605", "r623", "r629", "r637", "r643", "r644", "r645", "r646", "r663", "r670", "r804", "r810", "r846", "r860", "r861", "r862", "r863", "r864"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": ["r206", "r207", "r208", "r209", "r284", "r286", "r315", "r316", "r317", "r324", "r365", "r417", "r418", "r420", "r487", "r489", "r496", "r516", "r517", "r577", "r580", "r582", "r583", "r588", "r604", "r605", "r623", "r629", "r637", "r643", "r644", "r645", "r646", "r663", "r670", "r804", "r810", "r846", "r860", "r861", "r862", "r863", "r864"] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": ["r684", "r694", "r704", "r736"] }, "arct_ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ReductionInNumberOfCommonStockCapitalSharesAvailableForFutureIssuance", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Reduction in number of common stock capital shares available for future issuance.", "label": "Reduction in Number of Common Stock Capital Shares Available for Future Issuance", "terseLabel": "Reduction in number of common stock shares available for future issuance" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "terseLabel": "Related Party", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r187", "r285", "r410", "r411", "r465", "r469", "r519", "r520", "r521", "r522", "r523", "r542", "r544", "r576"] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r187", "r549", "r550", "r553"] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "terseLabel": "Related Party", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": ["r187", "r285", "r410", "r411", "r465", "r469", "r519", "r520", "r521", "r522", "r523", "r542", "r544", "r576", "r856"] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactions"], "lang": { "en-us": { "role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r407", "r408", "r409", "r411", "r413", "r504", "r505", "r506", "r551", "r552", "r553", "r573", "r575"] }, "arct_RemainingLoanIncludingAccruedInterestForgiveable": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "RemainingLoanIncludingAccruedInterestForgiveable", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Remaining loan including accrued interest forgiveable", "label": "Remaining Loan Including Accrued Interest Forgiveable", "documentation": "Remaining loan including accrued interest forgiveable." } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Repayments of Debt", "negatedLabel": "Payments on debt obligations", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": ["r780"] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Repayment of term loan", "label": "Repayments of Long-Term Debt", "totalLabel": "Repayments of Long-Term Debt, Total", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r66", "r501"] }, "arct_RepaymentsOfPrincipalAndInterestOnCollateralizedTermLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "RepaymentsOfPrincipalAndInterestOnCollateralizedTermLoan", "crdr": "credit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Repayments of principal and interest on collateralized term loan.", "label": "Repayments Of Principal And Interest On Collateralized Term Loan", "terseLabel": "Repayment of principal and interest on collateralized term loan" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual", "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual",

```
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang":
{ "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "auth_ref": [ "r136", "r137", "r225", "r253",
"r412", "r419", "r463", "r612", "r613" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": {
"en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development, net", "totalLabel": "Research and
Development Expense, Total", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for
computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction
other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or
from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r326", "r606", "r620", "r865" ] }, "us-
gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpenseMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label":
"Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]", "documentation": "Primary financial
statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-
gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ResearchAndDevelopmentExpensePolicy", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Costs, Net", "label": "Research and Development Expense, Policy [Policy
Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at
discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique,
or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a
plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r325" ] },
"arct_ResearchCollaborationAndExclusiveLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630",
"localname": "ResearchCollaborationAndExclusiveLicenseAgreementMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Research
Collaboration and Exclusive License Agreement.", "label": "Research Collaboration And Exclusive License Agreement [Member]", "terseLabel":
"Research Collaboration And Exclusive License Agreement [Member]" } } }, "auth_ref": [] },
"arct_ResearchCollaborationAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630",
"localname": "ResearchCollaborationAndLicenseAgreementMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "terseLabel": "Research
Collaboration And License Agreement [Member]", "documentation": "Research collaboration and license agreement.", "label": "Research
Collaboration And License Agreement [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r685",
"r695", "r705", "r737" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r686", "r696", "r706", "r738" ] },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r693",
"r703", "r713", "r745" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedCash", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": {
"totalLabel": "Restricted Cash, Total", "label": "Restricted Cash", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as
to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other
accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r774", "r782", "r866", "r869" ] }, "us-gaap_RestrictedCashCurrent":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
], "lang": { "en-us": { "role": { "label": "Restricted Cash, Current", "terseLabel": "Restricted cash", "documentation": "Amount of cash restricted as
to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial
institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r774", "r782" ] }, "us-
gaap_RestrictedCashNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RestrictedCashNoncurrent", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": {
"label": "Restricted Cash, Noncurrent", "terseLabel": "Non-current restricted cash", "verboseLabel": "Non-current restricted cash",
"documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on
hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref":
[ "r96", "r775", "r782" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": {
"label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "totalLabel":
"Retained Earnings (Accumulated Deficit), Total", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
"periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "documentation": "Amount of accumulated undistributed earnings
(deficit)." } } }, "auth_ref": [ "r55", "r81", "r467", "r494", "r495", "r502", "r526", "r649" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang":
{ "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]", "documentation": "Accumulated
undistributed earnings (deficit)." } } }, "auth_ref": [ "r103", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r193", "r194", "r195", "r335",
"r336", "r343", "r344", "r345", "r347", "r348", "r349", "r355", "r357", "r358", "r360", "r362", "r392", "r393", "r491", "r493", "r507", "r904" ] }, "us-
gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } },
"auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": {
"en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "verboseLabel": "Total
revenue", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "documentation": "Amount, excluding tax collected
from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from
customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction,
including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r90", "r91", "r164", "r168", "r169", "r179", "r181", "r183",
"r184", "r186", "r279", "r280", "r422" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenue" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with
Customer [Text Block]", "terseLabel": "Revenue", "documentation": "The entire disclosure of revenue from contract with customer to transfer good
or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with
customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill
contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r100", "r271", "r272", "r273", "r274", "r275", "r276", "r277",
"r278", "r283" ] }, "arct_RevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240630", "localname":
"RevenueLineItems", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us":
{ "role": { "terseLabel": "Revenue [Line Items]", "label": "Revenue [Line Items]", "documentation": "Revenue." } } }, "auth_ref": [] }, "us-
gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueRecognitionPolicyTextBlock", "presentation": [
```

"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of
accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r547", "r607", "r614"]
}, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "label": "Revenue,
Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligation", "documentation": "Amount of transaction price
allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": ["r97"] }, "us-
gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
"presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "label":
"Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for
expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": ["r98"] }, "arct_RevenueTable": {
"xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "RevenueTable", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "Revenue
[Table]", "label": "Revenue [Table]", "documentation": "Revenue." } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": {
"en-us": { "role": { "terseLabel": "Revenue:", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": {
"role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets acquired through
operating leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref":
["r400", "r648"] }, "arct_RoyaltyPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://arcturusrx.com/20240630", "localname":
"RoyaltyPaymentPercentage", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": {
"en-us": { "role": { "documentation": "Royalty payment percentage.", "label": "Royalty Payment Percentage", "verboseLabel": "Royalty payment
percentage of proceeds from net sales" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
"terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r754"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
"terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r754"] }, "country_SG": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/country/2024", "localname": "SG", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
], "lang": { "en-us": { "role": { "label": "SINGAPORE", "terseLabel": "Singapore Economic Development Board [Member]" } } }, "auth_ref": [] }, "us-
gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SaleOfStockNameOfTransactionDomain", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-
us": { "role": { "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock", "documentation": "Sale of the entity's stock, including, but not
limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction":
{ "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
"presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-
us": { "role": { "terseLabel": "Equity method investment, sale of common stock", "label": "Sale of Stock, Number of Shares Issued in Transaction",
"documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] },
"srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain",
"presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-
us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario" } } }, "auth_ref": ["r153", "r287", "r766", "r790"] }, "us-
gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsTables"], "lang": { "en-us": { "role": { "label": "Schedule of
Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Liabilities", "documentation": "Tabular disclosure of the components of
accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash
Equivalents and Restricted Cash", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] },
"us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
"presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseTables"], "lang": { "en-us": {
"role": { "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of Share-based Compensation
Expenses", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is
not limited to, related tax benefit." } } }, "auth_ref": ["r33"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-
us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name" } } }, "auth_ref": ["r189", "r190", "r191", "r342", "r767",
"r768", "r769", "r840", "r841", "r842", "r843"] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
"presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtTables"], "lang": { "en-us": { "role": { "label": "Schedule of
Maturities of Long-Term Debt [Table Text Block]", "terseLabel": "Schedule of Maturities of Long-term Debt", "documentation": "Tabular disclosure
of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": ["r6"] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
"presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsSummaryOfComponentsOfPropertyAndEquipmentNetDetails"
], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
"documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes,
but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and
accumulated deprecation." } } }, "auth_ref": ["r5", "r404"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
"presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-
us": { "role": { "label": "Related Party Transaction [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]",
"documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": ["r36", "r37", "r549", "r550", "r553"] }, "us-
gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
"presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": {
"label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based
Compensation Arrangements By Share Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment
arrangement." } } }, "auth_ref": ["r289", "r291", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304",
"r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318"] }, "us-
gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ScheduleOfStockByClassTable", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual"], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "terseLabel": "Schedule Of Stock By Class [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": ["r26", "r27", "r28", "r29", "r30", "r31", "r77", "r79", "r80", "r81", "r114", "r115", "r116", "r166", "r251", "r252", "r253", "r255", "r258", "r263", "r265", "r498", "r499", "r500", "r501", "r629", "r765", "r783"] }, "arct_ScheduleOfSummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "ScheduleOfSummaryOfSignificantAccountingPoliciesTable", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
], "lang": { "en-us": { "role": { "documentation": "Schedule of summary of significant accounting policies.", "label": "Schedule Of Summary Of Significant Accounting Policies [Table]", "terseLabel": "Schedule Of Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"], "lang": { "en-us": { "role": { "terseLabel": "SOFR [Member]", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": ["r844"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r679"] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "label": "Security Deposit", "terseLabel": "Security deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": ["r775"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r681"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "auth_ref": ["r184", "r185", "r423", "r425", "r426", "r427", "r428", "r430", "r431", "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r510", "r512", "r514", "r579", "r581", "r586", "r590", "r593", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r609", "r631", "r651", "r652", "r653", "r654", "r656", "r658", "r659", "r660", "r665", "r670", "r812", "r870", "r872", "r873", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899"] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": ["r172", "r173", "r174", "r175", "r176", "r177", "r178", "r182", "r184", "r618", "r619", "r622"] }, "arct_SeptemberTwoThousandAndTwentyOneLeaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "SeptemberTwoThousandAndTwentyOneLeaseAgreementMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "September two thousand and twenty one lease agreement.", "label": "September Two Thousand And Twenty One Lease Agreement [Member]", "terseLabel": "September 2021 Lease Agreement [Member]" } } }, "auth_ref": [] }, "arct_SegirusIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "SegirusIncMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Segirus, Inc.", "label": "Segirus, Inc [Member]", "terseLabel": "Segirus, Inc [Member]", "verboseLabel": "Segirus Inc [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r3"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetails",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r289", "r291", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "terseLabel": "Share-based compensation number of shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": ["r639"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": ["r32"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318"] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "terseLabel": "Common Stock [Member]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r7", "r53", "r56", "r57", "r103", "r122", "r123", "r124", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r165", "r193", "r194", "r195", "r267", "r335", "r336", "r343", "r344", "r345", "r347", "r348", "r349", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r383", "r384", "r385", "r386", "r387", "r388", "r392", "r393", "r406", "r475", "r491", "r492", "r493", "r507", "r569"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis",

```
"presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "auth_ref": [ "r184", "r185", "r423", "r425", "r426",
"r427", "r428", "r430", "r431", "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r442", "r445", "r446", "r447", "r448", "r449",
"r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r510", "r512", "r514", "r579", "r581", "r586", "r590", "r593", "r595", "r596", "r597",
"r598", "r599", "r600", "r601", "r602", "r603", "r609", "r631", "r651", "r652", "r653", "r654", "r656", "r658", "r659", "r660", "r665", "r670", "r812",
"r870", "r872", "r873", "r875", "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890",
"r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": {
"en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many
axes to the table." } } }, "auth_ref": [ "r139", "r140", "r141", "r165", "r393", "r422", "r497", "r508", "r518", "r519", "r520", "r521", "r522", "r523",
"r525", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r544", "r547", "r548", "r554",
"r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r569", "r671" ] }, "us-gaap_StatementOfCashFlowsAbstract":
{ "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": {
"label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": {
"label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
"lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": []
}, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis",
"presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-
us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario" } } }, "auth_ref": [ "r153", "r287", "r766", "r770", "r790" ] }, "us-
gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": {
"en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of
comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r139",
"r140", "r141", "r165", "r187", "r393", "r422", "r497", "r508", "r518", "r519", "r520", "r521", "r522", "r523", "r525", "r528", "r529", "r530", "r531",
"r532", "r533", "r534", "r535", "r536", "r538", "r539", "r540", "r541", "r542", "r544", "r547", "r548", "r554", "r555", "r556", "r557", "r558", "r559",
"r560", "r561", "r562", "r563", "r564", "r565", "r569", "r671" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]",
"terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r688", "r698", "r708", "r740" ] }, "us-
gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": {
"label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash
or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodSharesAcquisitions", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang":
{ "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Issuance of common stock related to acquired in-
process research and development (in shares)", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." }
} }, "auth_ref": [ "r52", "r53", "r81" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Stock
Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, net of issuance costs (in shares)", "verboseLabel": "Issuance
of common stock", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r52", "r53", "r81", "r498", "r569",
"r591" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang":
{ "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "terseLabel":
"Issuance of common stock upon exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised
during the current period." } } }, "auth_ref": [ "r7", "r52", "r53", "r81", "r301" ] }, "arct_StockIssuedDuringPeriodSharesUnderEquityPlan": {
"xbrltype": "sharesItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "StockIssuedDuringPeriodSharesUnderEquityPlan",
"presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang":
{ "en-us": { "role": { "terseLabel": "Issuance of common stock under equity plans (in shares)", "label": "Stock Issued During Period Shares Under
Equity Plan", "documentation": "Stock issued during period shares under equity plan." } } }, "auth_ref": [] }, "us-
gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang":
{ "en-us": { "role": { "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Issuance of common stock related to acquired in-
process research and development", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r7",
"r53", "r56", "r57", "r81" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Stock
Issued During Period, Value, New Issues", "terseLabel": "Common stock issued, value", "documentation": "Equity impact of the value of new stock
issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r7", "r52", "r53",
"r81", "r507", "r569", "r591", "r677" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang":
{ "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise
of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r7", "r53", "r56", "r57",
"r81" ] }, "arct_StockIssuedDuringPeriodValueUnderEquityPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630",
"localname": "StockIssuedDuringPeriodValueUnderEquityPlan", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang":
{ "en-us": { "role": { "terseLabel": "Issuance of common stock under equity plans", "label": "Stock Issued During Period Value Under Equity Plan",
"documentation": "Stock issued during period value under equity plan." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang":
{ "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total
stockholders\u2019 equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable
to noncontrolling interest." } } }, "auth_ref": [ "r53", "r56", "r57", "r73", "r527", "r543", "r570", "r571", "r649", "r678", "r785", "r799", "r848",
"r904" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityAbstract", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": {
"label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "auth_ref": [] }, "us-
gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

"StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r78", "r133", "r250", "r252", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r264", "r267", "r361", "r572", "r574", "r592"] },
"arct_StudySupportAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "StudySupportAgreementMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Study support agreement.", "label": "Study Support Agreement [Member]", "terseLabel": "Study Support Agreement" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r389", "r415"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r389", "r415"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r389", "r415"] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/DisclosureSubsequentEvents"], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": ["r414", "r416"] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "arct_SummaryOfSignificantAccountingPolicyLineItems": { "xbrltype": "stringItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "SummaryOfSignificantAccountingPolicyLineItems", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policy.", "label": "Summary Of Significant Accounting Policy [Line Items]", "terseLabel": "Summary Of Significant Accounting Policy [Line Items]" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetails"], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": ["r773"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information" } } },
"auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": ["r734"] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income tax payable", "label": "Taxes Payable, Current", "totalLabel": "Taxes Payable, Current, Total", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } },
"auth_ref": ["r43", "r44"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": ["r726"] },
"ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": ["r733"] },
"ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": ["r753"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": ["r755"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": ["r756"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": ["r757"] },
"ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": ["r757"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r755"] },
"ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": ["r755"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": ["r758"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": ["r756"] }, "arct_TwentyTwentyOneInducementEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "TwentyTwentyOneInducementEquityIncentivePlanMember", "presentation": ["http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "2021 Inducement equity incentive plan.", "label": "Twenty Twenty One Inducement Equity Incentive Plan [Member]", "terseLabel": "2021 Inducement Equity Incentive Plan [Member]" } } }, "auth_ref": [] },
"arct_TwoThousandNineteenOmnibusIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "TwoThousandNineteenOmnibusIncentivePlanMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureShareBasedCompensationExpenseDetailsTextual"], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen omnibus incentive plan.", "label": "Two Thousand Nineteen Omnibus Incentive Plan [Member]", "terseLabel": "2019 Omnibus Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual",

```
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label":
"Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other
than Collaborative", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-
generating activity or operations." } } }, "auth_ref": [ "r350" ] }, "arct_UltragenyxMember": { "xbrltype": "domainItemType", "nsuri":
"http://arcturusrx.com/20240630", "localname": "UltragenyxMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails",
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://arcturusrx.com/20240630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang":
{ "en-us": { "role": { "documentation": "Ultragenyx.", "label": "Ultragenyx [Member]", "terseLabel": "Ultragenyx [Member]" } } }, "auth_ref": [] },
"us-gaap_UnamortizedLoanCommitmentAndOriginationFeesAndUnamortizedDiscountsOrPremiums": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "UnamortizedLoanCommitmentAndOriginationFeesAndUnamortizedDiscountsOrPremiums", "crdr":
"debit", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": {
"label": "Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums", "terseLabel": "Loan origination fee paid",
"totalLabel": "Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums, Total", "documentation": "Amount of
deferred fees paid by borrowers and unamortized costs incurred to originate loans and leases, unamortized loan commitments and loan syndication
fees, and premiums over or discounts from face amounts of loans that are being amortized into income as an adjustment to yield. Excludes
amounts for loans and leases covered under loss sharing agreements." } } }, "auth_ref": [ "r94" ] }, "arct_UnderlyingAgreementMember": {
"xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "UnderlyingAgreementMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesDetailsTextual" ], "lang": { "en-us": { "role": {
"documentation": "Underlying agreement.", "label": "Underlying Agreement [Member]", "terseLabel": "Underlying Agreement [Member]" } } },
"auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label":
"Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r752" ] },
"arct_UpfrontPaymentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname":
"UpfrontPaymentReceived", "crdr": "debit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Upfront
payment received.", "label": "Upfront Payment Received", "terseLabel": "Upfront payment received" } } }, "auth_ref": [] },
"arct_VallonPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname":
"VallonPharmaceuticalsIncMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRelatedPartyTransactionsEquityMethodInvestmentDetailsTextual" ], "lang": { "en-
us": { "role": { "documentation": "Vallon Pharmaceuticals, Inc.", "label": "Vallon Pharmaceuticals Inc [Member]", "terseLabel": "Vallon
Pharmaceuticals, Inc. [Member]" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual"
], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-
gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain",
"presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "label":
"Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
} } }, "auth_ref": [] }, "arct_VinbiocareAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630",
"localname": "VinbiocareAgreementMember", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual" ], "lang": { "en-us": { "role": { "documentation":
"Vinbiocare agreement.", "label": "Vinbiocare Agreement [Member]", "terseLabel": "Vinbiocare Agreement [Member]" } } }, "auth_ref": [] },
"arct_VinbiocareContractualLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname":
"VinbiocareContractualLiabilities", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureBalanceSheetDetailsScheduleOfAccruedLiabilitiesDetails" ], "lang": { "en-us": {
"role": { "documentation": "Vinbiocare contractual liabilities.", "label": "Vinbiocare Contractual Liabilities", "terseLabel": "Vinbiocare contractual
liabilities" } } }, "auth_ref": [] }, "arct_VinbiocareMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630",
"localname": "VinbiocareMember", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureRevenueSummaryOfRevenuesDetails" ], "lang": { "en-us": { "role": {
"documentation": "Vinbiocare.", "label": "Vinbiocare [Member]", "terseLabel": "Vinbiocare [Member]" } } }, "auth_ref": [] },
"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date
Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r722" ] }, "arct_WarrantFeePayable": { "xbrltype":
"monetaryItemType", "nsuri": "http://arcturusrx.com/20240630", "localname": "WarrantFeePayable", "crdr": "credit", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": { "en-us": { "role": { "documentation": "Warrant fee
payable.", "label": "Warrant Fee Payable", "terseLabel": "Warrant fee payable" } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": {
"en-us": { "role": { "terseLabel": "Diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average
Number of Shares Outstanding, Diluted, Total", "documentation": "The average number of shares or units issued and outstanding that are used in
calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [
"r155", "r160" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": {
"en-us": { "role": { "terseLabel": "Weighted-average shares outstanding:", "label": "Weighted Average Number of Shares Outstanding, Diluted
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://arcturusrx.com/20240630/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": {
"en-us": { "role": { "terseLabel": "Basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "totalLabel": "Weighted Average
Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable
shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that
common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r154", "r160" ] },
"arct_WellsFargoCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname":
"WellsFargoCreditAgreementMember", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual",
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPol
"http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureStockholdersEquityDetailsTextual" ], "lang": { "en-us": { "role": { "label": "Wells
Fargo Credit Agreement [Member]", "documentation": "Wells fargo credit agreement.", "terseLabel": "Wells Fargo Credit Agreement [Member]" }
} }, "auth_ref": [] }, "arct_WesternAllianceBankMember": { "xbrltype": "domainItemType", "nsuri": "http://arcturusrx.com/20240630", "localname":
"WesternAllianceBankMember", "presentation": [ "http://arcturusrx.com/20240630/taxonomy/role/Role_DisclosureDebtDetailsTextual" ], "lang": {
"en-us": { "role": { "documentation": "Western Alliance Bank.", "label": "Western Alliance Bank [Member]", "terseLabel": "Western Alliance Bank
[Member]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year
that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding
and Unvested" } } }, "auth_ref": [ "r720" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482888/230-10-55-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481598/310-20-45-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "210", "Topic": "954", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r199": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB",
```

"URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",

"Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r345": {

"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842",

"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-15" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-33" }, "r444": {

{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35A" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944",

"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" },

"r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",

"Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-12" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-34" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-7" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r667": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r668": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r670": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r676": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r677": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r678": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",

"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r750": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r751": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r752": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r753": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r754": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r755": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r756": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r757": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r758": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r759": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r760": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r761": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r762": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r763": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r764": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r765": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r766": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r767": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r768": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/210/tableOfContent" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification",

"Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)",

"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-6" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section":

*"50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" } } } ZIP 58 0000950170-24-090905-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-090905-xbrl.zip M4$L#!!0 ($.&!5F?+*Y1Z(0! !NV% 1 87)C="TR,#(T,#8S,"YH M=&WLO6M3'$F2+OQ]?T4>SO]G9+7;CYV+33\M/\759 M^]&DGE6Q^.G@]Y^+G?&H',?B__QE_VWQ>N)GQW$\+5!Q-)V>;+Q\^?GSY_60 MRG$]&]B?'+PN$YHUO5='F[XO7=AJ+#8HI1U@C+-X3N<'9!N;K#"O\ M_V&\@?'2SR8GIU5Y>#0M?O(_%_E7T/=X'$>CT^)-.;9C7]I1<;#H= U&Z=>+MS=&HV,^_JHO]6,?]4PSK;9M'4U@.6))Q_>N+I9%_9NN3ZO E,<;_)+?>=&^MM/'%5:-0GKv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|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

*!1D0$MHF#! *>$ M6BUZAVI##I7^N-E4H 03X&D;01?BF;N!L0.BPM!(O#0D]19SGV("N[N:#&|_M[&[N;[U9+:T2*ZT^4BI*R3IC!'*8>L2%|<@8HI 0D41!=,3]/;OOB2IS66[)^Y!;LW'9 M;N&'CR>SZERI.8ZVAL^_S=N /Q<-+)XL/N<6KFBM/K)5K*]IKWWX@RT>M&OY M59-SWT;S| >;_'#P^JOFRGK"*5$;\.Q'6X,_8VALEAKHZ1@6WMO7V>=3U0=Y MQF=]-=[;N-S$[@Q>M]-)=__4M1_ +_%O7T= 0>KXO=^+G8GQS;|>)%-YE.)\? P;F8(9$?EX7AC%-,T M]U&?V/&BF\]'1*\(OO%QXZ2*Z#.@^;M+?7^S.^CKYDW_[M$Y'XU2\O9WF8R6+KC]8]=FBMBVOBY-I$28S-XK?6Q _&4VJ MC3_AYK]7WUN>6ZZ.KY=6YL*;K&#;MVL;7W^^\[!P<[M>[N/?67H+5?FOS8/_K:S^]?W>[MKQ>NM@F+!S75K,9]39N(-CO_\ZH?@A']O M@! <6++]]$5)P RGU9%2&Q;M5LO)Y)-]=W>_ "NL*=&](.S^V&/WE]S=[^|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| M>2[M5'JQRA@3Q+3AM%_&07E\6-25![WB^)!*16169C[B]?\Y.7Q1V-'TZ@<7 M-$.J\4T6PH%K"WB+-)\+XB@ M)!(1L-5.B3O:[RTC[L?#ICK?>)K#,? MAD&[N:[W_L/_A(*ME^YOOMC^\W]DZ M*/ZV]_:USNY?#XJ=W:WUSOCT@5Q]=SOQVOYB_;3(&U9,4G&^A86MBX.3Z'-$ M9RC* <5%.ZV+KJ"_77LZ=J?CU+O$3#VIH]1'J],_4H<(.]]PAU#ZC8=+O_R& MHT3]F)_DZPWMA;']/?F49WF-",+"*ADX11$+GJ\.@R0ARB =E63">R.$[8 MY;PGUL]W]_I6M'PB[8OCZ ZTG$+@*FF)F"(&<2^!))7*68&"*255,>H4E:7N..I[6N0$M:Z=S*9?QMIE@=VG'Y?YO//P\H]|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|",_=_|.\OO-J_"C/(IY.SD51]T. MHAFDK:>%P46PI_5Z XK?/-#XWHY=I]M1!RH7#X@(SA"7A.8;TA(%RJFA!@?K M33<1$UNSJH()MAE&L@"=VNFMLRO=B4C_.]8K.,"ZFPOURMW]L<3]M[]D?'"%; MX0/,O2AV)P^^ GQ [9NA=D8S ++C6VGMDWU< G4S]M8/M[8G\&;'(OY1>#9J WI/T#OBY^R<%6O**/K\Q>F M1V4-([8G^3[PJA&^'>\9<,?ZY_55H;)6V!C!&%@O!E#9YD(Z+B84DO6"RL2L MNO,I\^*NXME.Y8<@_2 R@,J#ZC\V 9@- 6(YA&+*5W?+%?F5E3?3* M;PO@,G3%@_H8P!SZ]!;*&F#-,7]T>+P.6GAL M1A9B*L=- GJDFI#*'2E#\ZKKQ-8_)I\5KWWWA^O$M7LRJ]_SE:\;Z>+,W/Q]?9K7LFZX;>+,GE M^@\>E-_AQ*$K#^$MH6+NWFI M 0(_?ZE+;_?FM6BSHL0I? 27>IS[!RP4[;A85P-;EO4EE>M*YBU/[6 3\I-? M7] 7PQR'.?9UCMW%^CP]37OW*I_ 4Y< ST/$#7KVXY_AP76^KZ<^\:=D0>&D MI3>. (*Z"03PR@BSU&.G$G=#$.(8[2DS>D,M?9G4YCG7=>6&/[NIX7"61!]7Z M+E0^S&N8US"Q85Y/<%Z#^7;]JFU??=SY*+3#AR3[AU<*O=?"&:D0I4'E="(* M::HEPA%38SSGC'?D5E_0R%\;$MEJ*;3'RN% J,.\AGFM7IX.%S*>5C;1G?2- M8*V;*"+,R717RVP3ZQE",)TV<[JQN [U@EFWY[2L]"TZJI]_1:> [\O1[PW&.8R> JG;"- M\(-QC^K;I]+K-";ZX6JE#?+K?EAJLPD>WIP=SNI!0=<*BBE?NXQ=#\;P1S;< M\?K''8RH.4B\;2YO@"A<7.>C6#CGD-!>(^X- 1U8%AQB/W!'*]/#\,DIPJ226 MN>P.-@1QD>NC^NB1$DIQ&S!.3%UQG:I)JJ!< C[(Z1/JO=FTD=H@OE\4LW'9 M-O_A8Y-G*_[M9']JU8"D: [3G$TF3&9@1O02 M.?LA#;JM"!O*3VWJK[S3AQ&-)R$N?@/CRH\7LQ_%+RB45:L_Y\#ZV?'X52CK MDY$]W?Q.NB;(J-#]%8 @ /7S)4\SW |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{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|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|[??+?] MX?W.UD'QM[VWKW=V_WH =+8%PG3W=;'S_] X^/"7@YW7.YO[.]L']UA9KE?E M=[?V=E]O[QYLOR[@KX.]MSNO-]_#A[]LO@7.W"X._K:]_?[A%^='P?K?MZ_U M5Y7_OE;;<8UR,LOT8S9I4U7]*A\1*(B35W/1E0>4)1G, (+^.0!N9S$"K*+_$ M\.K,!;*._[SX07/@=%+'C3KGJL\WY>=-MR7KF[9?M/7=IV?R-V?9;WUB&XO? MSU^"M\)%CXM4ZXR V=S*YBM>(.OB6T^_]8RN:_[-IA^ZVU]>3]O+BS=7/C+B M.>O_.*PFH.NC,:.EYK]7N6IE]^!LM&I,_N]I%OQZW2_5MFII^AJ%1M^W/O.# M2LHT/(NIP<[G]{^^H"^^/E.:ERW"X;5? 7/7R-XHIOQU]?&/A6G[#K!=+-S#.P#!W8YC7T<=C%ZN"D3.F80/3 MW("R^B"I874>@#5O0'_7+>=/C1MO,@.5-N3"(&WE=M CBT]V-(O+!=5_'I#J M&]/L R-UB4,_S<9V%K)7_):[WH<%&<3QTR/R>]O3)S39:XC&QLWQM6STH!TD M?W]6:"\.XF^'BYMU':=UERAQ_R<2_8")AW#O/1Q./)79#C3\%'?U*> [J4YIMQQ:=U_)L.6RZ:?'* M@7^??9:/N9MVEAO&/0K%OE8HYN#\)M0U_Y&C\C_940Z2^1X1WG+!'B'>7-'D M>-*OZ5XD@.OF^:|=[NF52+#*:3? A'AT2_B_E%]C&|9MY+K0F..O-1VVXY!0; M%'C2B&OCD-&!(*6I"LH2]2Q[T81TP\CV8_KUQ=;'F&*BG$7DDS&(>^*13LPC MZ7 D4;!@@WU1C.TQ#'A6HT-K3S8RVVV.0_YG^YSG-J=;MJI.R_'A/_+QQ(MB M-B[;7CY_'#P^D6;6>C7%S"$$'UY;$?UKR\0?&I/,7Y]47Z9;HQGQRA,IFC^ MQHO?J,1KC)I?7EZ<|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|-'%'4,BI6>-XA7%C3P@*A\)4G55A M?%M:5X[*:3E/;5%/)_Z/(_A%K.I_^Y.F1+UJXI*GIT,!H" <|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||EBIHC#O)@;FTI;2C=EFR) M"(RQ0)$3.<*/))XC_&".-K&DN3>Q54=9U M3B)LQ^$75[W\;3*;UE/XD,.-YV]_CE6\'VJ.Q/N =4)$"XJXEA0 "@C5V!B# M96#]DTZN)7VUTSO-(MQXE[]K\E]3CX%X+EC,.;@B"!\A'"*1:\15E#*$0(J3X*

*MZ@BND^GMG6]J=W.D:@WS]W)SW0*RBFO*FW>2\T*F6T5K"$ MG$FP==PTEU) &936":LYMHZN!(WNAT:#<14#6)8$"CA(3PD)4 M;"736PV-RC5-KRJ)?D\T^CKZ>.QB53#2T"D;7/9/VLDYN.PO*&XL))]X0A(S M@$K,+;)&:J2995HHKQWY*N_:'>5=8V1T%=O\W...!V!Z[EOY1($I@B6A $^0 M"H&!G9%SLCN9$$Z1,J]U8^49 "*UMAIREB1(A<|<$A;4E 6"6M MK4X 8)U$R*T8I+A<8V*%-1\>!64/40CWIN%Z/SN>C?()-9!I*GTY':3&<+=P MN%MXY9K]="]G;%SJ& *5(,1$0IQZ@0SS$AD2/"""]0Z.0?>CU-:CF/8MM6X M'!_62UCPNH6"FPNU&I8;_OK>Y45"UK1Y2F4\;E8G_>0?D'9#W 9%7*VR# M%A&!&NX03Q0C0Z- U":3F#%<>=.%#7'_R,ND6M-RA5DXGQ[R#GF-[G:'O+[U MQ9U^+\P@YP8Y=|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|_.M'F MEK|=^EU%O]_PC^O[RB<+C'Z-XK'*RC@/G,7QL4SM+!&GO"X19]Z^*P:TPCEW M)[^N-|"J&(O?X?-176R#715^<._[LBBKI_+'S[W/D|0/RB\#@=_DG'B0@X,< MO"E(_%!(S9. D44"P5O QTV"3/JP7(,,'=AC8(]! O)Q[E-+\#%@VB>F"-JUCCNYF% M!]886.-YLL8@-0;6&%ACD!JJ ?6M777USLX^_%3',_BQG,K'_<#B//()SE, M[+%-;"#+86(]G-A EL/$>CBQ@2P?Z<3Z61WB\IHNQ]4^RL2Y6SD>%XQ!VUQS MJUI]?[@E^HT)7WWCK1>VW4JO?UX*N'T*]SH%%YI%QE&DA"..@T6:NHB"C4Q8 MA2U77^5+3%IRYZE& FN)N"$..9-+G3HLH_(!"XV_SI?8L->;:G*\!8WE0?Q7 M.3W:FM4P\5AM?_&C6:XWM5G7$?*

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|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

<:"B!%K:53Z2|NNK^;<^G%B1TT[D+\!2V?F_CEFEOZN(V_N)WR8 MKOKV,Q(2%0HK%-X+NHR34> D$*<2H L0"9F@%3)>4TTPXU2LI8OI1J#KZTD(M?(ITY9I758'J4(]J.SJ;4@PS(P0R2:=Y^V8'^I>2(CEM-&9N1:3H(>[0]J39 M.-_40:Y59ZM06*%P7Z"0&I.LIACA(%@V0 6R#,Q7ZVE0@(8"KR?=| FAD*@] M4@:WZCBM*:?PG$R?/>"7$-VT!V\9C#[-!LU9[B5<7:;/A6VJS+GG+FM;-WF*

MG<.ORJN55RNO5EX]S$VLO'H0VUQY=0\V\=GSZEUA_D!9(!HYEGT>021DD_.(MRR@=,\EAN]*1X$$]$L';;+(]#;O1F^N69OOTFLP0= <4(6.L;\2FJG2?!7'7 M/+('L<B1U[>Y0NSM\1V,;)AVU02#/?"ZZ-0;I2 TBB5%] MC5%4KR5;[-WT+$[>CD?CZZG)Z^VTR_N$;RHS;&\:/3P3B5!1L+@UE 0!\Q< M2!PY8S7BG(%:36E$-&&A#(_>V)76 P\JPMT&"K(^%9LZG[:B8$7!BH)[BH)& M&NJ]Q2@)!2BH14 :>X,RDO$4N#5NY1BN!Q7E;@,%=9_(3? 4BJ"A84;"BX)ZB M8#Z&%1!,(18U7^IQ.OL@.S*(YE,A\.BO6!78_.=X<#[)DOWF:RM%)^12*GH6='S:=*3

M,\6BT(CP!/C';6SKZ021,;CD%&=A'5[<9X2>@O2-VJ.LBHJ>%3TK>FXF$\"J M**2AR(B0$$]1(ZV9 BW4.FXSP@]29^0:KC7S-X'<]K[R?CSH,D\ M!G16W*WPNC8X]%()'Z, '5Y8Q+6CR!+/\FD^.!$7 M)!%K]#D_ @Z_[B96ZK!0L:*5?"KX/?HMI76>F.M0RH0T.:T5 !^*B&))4U4 M14"RE;*)A[N,-P5^E-2:L0I^%?PJ^'U?MD%RW <9$0:[%W$;"'(Q.92X!3-8 M,>/<"O@]W..[*?"3^L#LWQU,#RXC'HP"#.0%K-+MQ/D-A)VO0IYQ><;R,^?K MM].^WBZ9N'IVU\L](AF;@OCF1O&IQ1!]W.V_=MF9-'MJ_#LI=&6#F/G%(.D MLHAHQ1 7+'"%KF4/8"TQC\&*E8[T#W'S M]OI[ZHOIT8R'(KQ);]?!6F-VU M';\PNWLP2P-E1EF+(G<)<6P%LH89)*44F' 7M%PY!_DA[N.-PJR@?;&E,%J% MV0JS%68KS'YO=AZ16B@7$<9:(2YSVTP?,#+1$VVT4FXU. ^|ACN]-PBSG?;@>_94>B%P7 VC:%ZP_>K.F!M0JL*I/LE MJ$BBF -M'R#=@=[O!=*@MR/+K=(@=WQ0*X<)/L2+_<9.1H/1I^9]G)QF5OXY M,_)UP02_QG ZM=/8O$O'YW$", IZ/!S:25-N68@MO"RVZ'VEUNWS9]1$&]Q% M(1"P>Z*BR$4P@T*0W$06HN4;F?_K%KZVN@+XZ-9^?[7\]$J,9[RA56)LN;R% MA:0TR FAN4&<<@S"PFCDM.,T:1XD68E[/L0AOZL20S%]D[#9"&,)<6UA+@(L MNB

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|W$RTNG-O2^VHCMT:$YYS5AGJ+0!>^VM_UQ+5]MO:Z78] MFU)"0X%HA;D'V6)HFQ30*3**@:RD#O88?K>0$$?HN?;1? =L39?!=M+J3B MX;;K/EP+IF)ZQ?1GA^E2*H^=9 ") ? Y@5%C)*6(":>9%DQHNE)?]1#/^18Q M_8%^](KI%=,KIE=,? _Z8'K(77P6*9&X;RFE4R%H9D,1.!.>MB'JE_]E#@@); MQ/0'A@@IE=,KX>7U%'V ?RW,H_QZC^%+^/.!$[ABR.^D[1NC^>KK[UB"CV>Q!R0*Y&A' MEX/1I]YH/(4;[00^!J: RSY-[+!W82?3WCCUIF>QB9G^ Y!NS(43HR*M[13^ M2(.1'?D!7-[D5]KG\(;F:&F)\T]&P>>>']H&2/C"?HIH- ZQ&PXL0/ZZ6^IA M_(+"8!(+P;Z Y9B=CUZ&07.QM)|>O"$%PM"_G)/:B7T>>XWO4;RL-SSGWEOSA;1MK(U;0C-

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|"@OGKT8/#@\4!FI,E)EI';E7L8DN5O>4 $A>PB)0APH1%W$H)]^3#P@,3)+? I<6FEYC^8>2& M44P;91R5"?GD$B!2(,@8J9!R$EOF5%1IQ0QUGJOC1)*T ^KQ4RD0OD)&/> M!1*5V:89JON";.(RV>DUZTWW74]!ZO=LGSS=? CFV6H[&GUY&Z?U0+6]YZ4- M2XMU37;=?;A+Y0"M6UU5O2>?;>79RK.59^M&5IX]|*VN/+LG&]D;GI1G[6W6 M+)@@%4-

!>9K3!6R.I6$4#3Q44F,T63U6C"89C(V(.,H03Y(B$W5$3J4HG/0R M6'733P,V;GMLS:]@Z[;T9RSG,A>I0U4/W,%Q0J*3P6*,A 2E%2(CE?8F*";N 4DQ@*+B.9\$QI F *DJ^$@#HS[9E3/1*RAN"Q0W M71A0'=F+6GY@E?:DK_.+.&IL8:OX)?]\>JX/[^3#;SLFK:G@_^ZVN.N:>;&3E MV8/9ZLJS> [*1NV$7;KID3W#M!)%(9E6Y-EW]6P;'^EG50^1!!HB&@&ECGS8&5[#JAE5'!<2FR,NBGM<,#: M.;X04PXLC89C#ZU0JOML5.^?->R\YLY MGX? U==O19G/BZSZ=W Z:BPY+^=_%]=@A8JA&?T6/'>>6BAX[2PP'H9"%().G M5* @ D7<8X^<50F4JQA-(LIBNZ*0/214;="=41-TY

*M!*F(NK/$4/6QBAX[SBT5/7:6& Y"'R.4R"2Y1B)9@7A,$AFM/.)$8VPTC!TQK?L'= D6%Y+4-$D7#,0B' MH)%5("LDX9PRK:/1*U5L1B>!D^8H!)Z%D,% (:V.0%ASC*#'AAF_W^ *S7S5L M-1=J3["J]HW<"&AA;@F+5J.(J1[5.H\L9AAS078(!K%Y$#.QU9L,JQ$L'J;(#?:-:-/7RE':).:,0MYL@E MJQ"7"@MK94K&;._X J'ILIX053%K!S?R4#'K6?=.H98K&I1'26&P.HU6R'F2 M$,:1DD12X'(%$3ES@MFDD*7<(4Z%0TI'@"*)/$F7 JA^3W!\@>%]J?>] WAM M*U4Q>W9.-

MK#QI,%M=>79/-K+R[,%L=>79/=G(W7"D/&MGYY,()++!.B0B M#TQB(@E9<=-P@9GDQB/'E$+<,HQ,B@P>(7"(VCLNPE8;=1/5IZ2>DEM!<8=W MM(+B,P)%F?(QX1$Q@0'@&7YZ-V(7(>$ZR==>XF*$H>H\%<(TDSD"K%D>'Y

M'$F+,&&Y5X;%13KZ07[[,=^\M,+JKC:6W%5[>YGO]659_=D(RO/'LQ65Y[= MDXW<#;-

*PPX8;H\PD(SF*BEC$J;/(<9(/+XA4)L:YM>FFX>:-4,HKCZ1G,:=. M$F1"5$@Y9DSD7FN!GVE#8-/GN7IW?RS "GL5]JJJ4K=Z1Z96>;:J*@]55;P* M0DK+2Q(F)H=K\%3UVG\LJ>NPL,1R$1D8H$RQ*@BS5$7&3 MO0\X9_1:;QB.6A*.UQ$H>;I6N1QOL.]$1=2=0Y"*J#M+#%4?]^BQXIQ2T6-G MB>$@]#&OI.)"6J29-8@3YY'!*2!IF-7&8^.(6$B"1Q]=\)^S M4>PQ7$\N6"-#T2.:.2J.9VX8#T\JW3[]@Y!+0GDNK:(X%":B6.D3<"(88]] MM382OY*E('S *GF&%,WW4!.143P@+:-7C-"(7=KF"0BJC_D&V[A]E5:>E?39 M(+-4]'SZ%=E^H\L*HXN6OH0*P$OD"$V(2\V0YE@AZD+D)$E.Q7I@]#F>R5 ! M="?

*AH@)H!="= 5#L 0UMI"B6V).A#%DK$K*<:Q:H=(S[FP"JD_<>1.$UBL^[492Q8A(D.B(<8D -M&$E!<,3:,AW7BM'W:YW# M">EK8PX/K+?? =FPW.;JB=D7MG=%]E8V&&480(RIE7*V(C-0$]%@?DY*4L+"B M^\84$^6@0QD3-9]/=*)>20=CB0*0-Q@M^<\$+HO-GD,T*[^Z<,#@/"OA=&7 M7S=)SU=<\TWXN_'VK[[POO/.TRL37:S84G&9G4W'W=;FL0Q&G_+@|^5H:"_ ' MLRD|_DL,+]M7$8R/\%^Z&X

+A_:BB2^:>&$G=AJ[52@/S"8>^_57"EE?N9%7RON]R[RH=?[/XNH.T#:+F=^#/X]2O?0SJ RWD;_[C!_I#W=/#G&PEX/W;TX.: M;"7@K>WI?9V+?[:*AP-+|,YUN6HD4FF\TO@![NE!3;82|+,$Z8_C:<7G:EM7 MT'@,:,AO@,9W%3#M!:R\:KMFE7#!PTCC/N4ZN(!JE5>J@/T:)^0FBNAD=/ B MMA+X#NWI6LU\ [V?GLZ&=QE")O!+Y[NSI.HE\.>^AM'I0U2>P"T83K,Z3)SI] MUW+^.!CUIF?C66-'H?EFDMQ!8\CA64UMA6NUE]8B:7>Q94KEH^VHI.<@=J:5 MCRH? 53YZE!>O/?JA,E)EI,I(CV&DUS$-_*!*I,I(E9$>Q4AMS4GEHZV[9PZR M3]SKZ..YBY,>(Z57'-UXK[BU%>W16L7BT48B(:)Y0V/-F5!N _$"RU!F + M"7",,=)2122T((X0A:,UVVM@AG6?4UDQJV+6SFWDH6+6LVX7IC#E@4F'0.O* MQU=H0$23(I(!<"T)J[%9.8),,Z.B8 *E:'2V5 $1J98(*T>\L#Y(L]:>N/=K M%\:8[A-.]@D:M|\(K&+D+NSH_F'DAE',"*:B=03)Y"V8E)XC0RQ'DNKH%;8$ M*[:"8F"M2@67VT# #!76Y4:)&JF04K0^49/$%LU0W&=D@^];M/G[I0! M#T8!QO%"P ,?B(OS=2C=L?)CEA^+:XKZW8N^O(W3WF#DQ^>QRHT]9J8-BXM# M.25RC[>Z\NR>;&3EV8/9ZLJS>[*1E65X(?M1*D@==@;>1 @Y10A%GN#'&,&\60=,I)$0)"E#...Q%N M@I1U!NYA M' &>(A %S)'.ZR/!'/ P]ZY3"&"E([XNG]SLSYZNE=%+LC9YN8 M*U[.+^*HL86)XI?|^^;]OWN:: [^+!5%/=,3?-VJBJG%[S[JH@R:8P|(^=W$] M=H@8*GI4]-AQ;JGHL:/$3"">:A2L9S7A#E):#3T'$]J856L\GR%H!<6PTD8BX24 D$B@^[K 4.(L=_/P-A*S M%M'JK88J7%6XJG#U2+AR3KAD,4J$@XVOC)[G5$DIM9MQHRD0KC#*AC M-CK$)<"B@P#E, !N#3QA+YH*BVV\U M1+7J,[U7ZEQM-50QJ:*"9B M"H18AX0+8(9:!7H=SDW6M"/&@RKHY?;.4$9-G_(#U^MJ K*LWNRD;OA2'G6 MSN9H6%!

*<>J22D8@KCY'5UB(58\#2:4GT2HJ3E9Q1IA+R,G>$QE8C(Z-'5(1H M*/PMV$I'Z =V"+F?GUG0OA!XGSPUUDS*2.10]#W!/BL@JJE (22JKA))VQ7==07%;H%A;YA]$ M(Z4JKO967%6[^]EO=>79/=G(RK,'L]659_=D(W?#+-RT-RL0K9-WR"L;\I'9 MH(TF:1"W5-$8X+^TD>F5GFV]BH/556T-TF)))%F$124(S2U!M$$E>"1D^- M6.EM\Q ?[*(XJN/$#YKR M;?OQ^")38DW-?BCGU3YNM8\;EE%+KB,2W%/$/5-@8@8W MAD,G$G!8A_.TL,!Z&,!6LYMA@CS 4H5L:#3H5I;MA*M8J8ZJ3D.B)!51G;70ZJ M9Q8|^LR"_YR-8H_A>F3!&AF*'M',46$\<|-X>"+I]ND?A%"*0I 85$214Q P MBAFDK1.(2,>(I$0KCV*)4F,=SY)D$?&()ZL1(8+@"R28B#11:FW???!VIKL MN4$KSTKZ;)!9*GH^_8ILO\-EA=$YC"8/+*1:R0H3PRS$"->

*M.8SA03#Z']CJ "ZDW!1 ;0"Z,X *--<:FP3H@DGQ'%(2'O/D)&6.&]C\GX% M0 4)&D>!49 YW<@0BZR)!*DDE7+!6FI6CH#@9PE_/G# <5WSS8$6DC.:KK[C'3Z>Q9[UN468'5T. M1[IZH_$4;K03:[AB!][-+'#WH6=3',EUO0L-C$3>LA=Q')OL5$)\MHI_)$& M(SOR [B\F<('I=+Q:&F)\T]&P>>>']H&B/;"?HIH- ZQ&PXL0/ZZ6^IA_(+" M8!(+I;Z Y9B=CUZ&07,QM)D\8-M^D*LN!^FR>TNY M%<51

*)K]DECX7EGO_,>W.V'"B7K6G#V#;!6%_8 MX9_VLGGYPU\7F[BXLMV"PKBWK_]CEGGS*L4:UO06+.F6=)-3[,BHR"AOF[/? MTW#\YP.IZL]VQOS(GG4LR?&'5Q]_^_#;:>_CW]]\.'[_YK>/)ZL.>W]_]^OK MD[=_.^V=O'UUU#M^^[IW\O&T=_K;SZGKYYW8/?3M_]>O+Z^"/_

*M]%X=G_Z]!\NO[_[[*79V)U;BQ]G(S@*\+/RTQ25X4OC+DRNZTT()6RI4M[/I MN-,6\UBR6("AY\L1";Q# 3TX$L,+]M7$8R/\%^Z&V /A :BB2^:"!H)<&FW M!L4H:)_]P|WLK<^#9N &0U"F7W3WWY:755XG]9%B["]S07?+!>2(,_.U[[_V M'3TB1CSTYNV|>+VM#VXEN=6UOV%2 .7OA\-A[^8%>YZ_^8|?Y]?F>-W91-W M0][@JJQ/'MS9;GGPI?5EHYCRBCA50E?6N(TUOEF*4%GC*|*X MF(>W5+_ $B2_)6F\4?-XG=3V[B*"=9K=Z3G.\GDP'<1O]BW;C578/A8|\TG6 MB3VWB56R?*83^W[I])U].>^3&K&[TNFN!7T;I[WAN%E+X\SG34!K;%B[Q M1J:/:F3Q/.8C\L#@U_?E 5FGE#*&H*1X1#S@B+07&ADK+#9&),U6&@1$PYD) MN6EFXKG1IN)(X\21B=)BYIP(<;O'$7+>QVSK'9YW@&'6DC19$7!W-K0BX-81 MT! 9&#,*L2@=XEX FDGBD=12X1!D=&RE7YW'F% 1')(<,0)9X":T2+ /YY: MV'G+Z581D/25D14 J_G$>RQ=)I#;SKN32)\Y0?#V!O-U>W\:?X]IQ#U?ISE M;,G!Z*?>Q63|>9!#A.ZR-[[%3?3BH$RZ>QKD.X71FS?3#VRZE83W;T_W<;H; M]S\M'^!2GO@0@V0YV:X\Y*YC8795LKZ.<(D?M.>5VU'HV?,QS/A_R@? 5A'LN M*NF!'5*V=DO+2\9U,KEM@D^YL21&)I^]HC7S5F+C"2;K\#4ML]OQ*!PO,=N: MBL|(7Y/|\C=MGK8K1NW'/NXW1LE$D_^'(:Y1ES9B(P$H. (D1$FIQE*N')WX M$&_0-C'"*D0V6QSX+VEZS)ZC]MW-^OGF]|KHDA^D+ M0@]<=%1\.LQ]W&]\LBZ2&)A!C%# &F4D=&*!FEN>]CF(^|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|;UEN38Y@W9=TOT[*]@IO1:]*5+_\#CJKU@'P25]I M$+=< .!PBTB@4@22N$QXLUD6ZT4JT1?FT$WSZN3=EGH[F<5KA3M5;NPO5U6Y M<2UT"-HJH4$CJO+91#IYY(A)2()@P)3RF,2&\A_F;/?K%=>M2730OF2UE64% MJT/,.K6>\X[6"W[WC6T9O5|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|'-SU9G'?P:K$ZQV5QUM03(@CO$N5\S<[A=6"N*(77>%<_FAQ M7E.KUN1<*YM+CK*:LL"L6U(>Y@W,SG-IBRTYS6!^YN2G;(S"\P97.5N=PM6E M!\&M,/EP9P.$<6[-E6WTFW!67IH[&C\EKDVOY6N$FZT2=[*)LB'>42\3$DI(MQ(54R$;"D%%4>1!8E(;5=DD/:J*\W 3Q[7@T/R=D37L/TQ>%+2ST(%B=)WN5AZ7KN-F>$?"T0O3%QHZ[M=4(P&9Q&EEN&.,& 8$8E)&/R,EAF'7^4!WG1%]"?Q3 ;QG=IWO[W1M/?CYD" M'^5+?FQ"4Y=K=#'/V,]6RU?S%\]?T2^_(6=3<;MS"A8\-%^.AO9R M/)O"#GZ)X66[FPH?*

X;]TUQ<3[Z)+[J,U&YP)5^\??0/5X. 42Q2QSX/FD&; M(_ZB>\JU2^':L,C)*F^6Y$C^):>6?>TB1VHCD I/*_E[D76YO;]Z+-\,L?W X+=^W;YS@I&EW=['T*YU1GW$#KYRM*U MK(K93BS>^]FKLD]EGVOJ:F6?>U+7-T5_43E79;^'Y4C^#ME_IWIVV\AO; 8L MV%-D\S_"M?+]+BOQ? L1XGT694^BMI+')E2K:^=;@>_G!H_%7UN')Z>.NV?[; MGF[Y^@_L\XE3H2PRV.50FA;()@,FN#96..H\)FOQ-=]N>!]/7]G))!>._U>N M@+W3"\FN>2'9M[R0$O<9O=OY_'R)?]W,_2QHOL)>T*'98Y 'A*'*-MC)(,^E0D#$P%P13;#5F]>CDC%??"--_G^00 MH@^K407'?I!XI;-#V>GU6_^",.\NM011+"L D$M*<6"2(4"1%1:)<.2WH\6E' M%0LO3"Y%O!\R>$0|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|?\N:.N]/K&2FEIL79+%?!; ZGQ8&;-)C?] M>['Q4P"*'MWWC.YZ"[K_RTWQ>[Z)/81?!^%75NKNBB\STDFM0=--'",NG06# MQX(9 Q8/]RIB'W;B=?P(>#2:Q8S$N?%NMD[^3ST]?0U\-(;Q] IOMN:FL:*Y M$5]9JH/S+3Q\B[K2FSOC6FD,"+)[K7_AO'? *L.LEEX75=_H'3NSHI+NO+1A[M:L&Z]G'6=OS.-[@:ML&?CF"R)Q?%[61'I3^=S68LB$';MI:<#;-@'[2M8W+! MV,N;@+I'3=LW<6DR6<*'ML-7GN32<%?E>UV6 MI9X.VT*U7<_#Q>]D&$N#OOD@NP_F@VG_6HRWZ|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| MOYV,SS8=(_CMFQ_.0CTZR84KX7_AL_VVHQ,%7 S,O57FW1\7/,R!TQ[8>F![MG,#&@V<69P@$T-)%8]KO6X=NA;VN/:+BN"4,LQMP2EY!3B#'0U%Y-$+AEM"/66 M6785UX(P2D4B$!$^ :YAB8R7"@GFI>%$*F;T >&:'E!S7Q5">F#K@:T'MD,$ M-J5"%$X0Y 4+ &S*(L,#]&$ =I)8(]UZJ2/]" \6M#I+$D:<$HDL8P*)0+$, M\&=(:^>-]P=L6@PTO:]N@8\-V.XA-;)W>F[GN?^T(R#FT>,7,_>64/%D.>VY MBIE2#($^>B6CUQN?G-[8_$.BAZQO AE#AF;Z_UR&I'-KCNC+]"I8C7&ZY] M+#/'".B'$=<*K@';X*T9 &P FOIU.&HBT3A7E?LP:S?TJ<$9Ku2TO-QOZ6/ MGX^W=(&G'C.2!,*:;L2M4LB9F% PR6MC=/ V755*DG2,)B603H:!/9HAQY-& MR3/EG9)4<.QX@PU@!I3+G(MXYKJK"/'BB0D:$8]SC2RU&J$N8?;@F0TXL/!,C)06O=PUL-9OZ5/'\Y2#)9@ M[C*2@6KF@TJUZ/N4"6R^04L:#:B8)8[PWR_^O-CR2O_@96ZAGIN MLE9/5/ZYR)EVWB"C&4'<6E#FL: H16M5E,X8LR;_DI;<>;J1P%]"_",..2,I MT@[+]'S 0A^0;R(?DE:W:[NVC<(6-?UVPXV+QST:.=]C=(_2/4H_8$8H%UA$ M+!!-*O?_)0DY02QBD5#+O: ZKIWXYMHS(W*OPJ@ V5/4R&#"43*4 UJG9_) M@VP&XI8!L1ZD>Y#N0;H'Z;V#-%8.)V$8*8,I("YCR#(GD9+22$\U)7$MCUEC[93U'$!=)L0#RS5)]$#,.!NMGN? X91[BG[2V_ODIMS7'WM0X^;7XX]OCGOWWEV3"&_; MK/ZQ>.]N[9Z[IOWFDW+.):>$Y1A103SBAN="F2H@]9+#3!$74[CJG%.>>R43 M0]8Z@;BB(H==(@K6$D8)M5HY-FI(_&\=;C9X^?/7[>%#]I MY-@;P9!WF",.0\AG%#PBN4E$LL(G)]IBIU&1&B4BTEYAP-QDD4W:(!,%-Q%3 MAGDX'/PTXIZK#/?HV:-GCY[/$CT#P]2QH!$V-M?0] 19H@Q*RJ6H@G4*FS7T ME)ASA1D2*M<<\5HB*W@"9902ZT5BT1S06; <&;[GOCH]? O:XV>/GL\1/SAU- MS@I$D@9-4C+0*:-+B&#&I2&*:>G7^Y*QE)C2*&KE@YP+8+T'JRAG'A-] M0-8[&8C[/DO[U/'S+X4$G_MYVY/E9)O'+]D.IBQ&TT\P[3-(;R+F0*0I$95' MAF()8LYFUXGSR G/O0=; >NUTH0Q8I_-"&0228@3BY%QD2*))<5"8B/P 94F M?' G]://#WT\<'I8AD*/HL\513TSR;CL.)%>(YZ2 F-!&B2C4UH'GKQ8S\,/ MFDLE*,)1@+$@N40Z$(:X2D9+&)A-[']0](%=U3V&]AC:8^BSPE!FE7))!)25 ML("'E" 7>$!$:-!"N?+2K3FL-2&.4A<1YMG)K;E%6LN(1'0&XY"\)P?4*,K! M'=8]BO8HVJ/HLT)1[931*5DD<&XA'Z@!RSY*Y#S'6$HKJ5H[MX]=H"12A[3+ MY;E3+AM)HT:2J!!U2$%) <3@H^N!NZT>/HLN.:_C=PC1^F2_@^QGL5NWA[U!_M69K0LK>8'PG&_O0=ES&A\/?#>DFO#.:[+]_F8#Z-0&G#X?@KT&EU;B?V!)Y\ MVE3GD_&7.L2]'K6$V%9Z/+&33-#5%&X;V>EL$L["M7Y;'(^;FU3N6;U^,S ME,A%:1'G7C75V;B95@U,M$Y 9Z/IE0*2^0FMB]M.X,=)/(.Q-4?+.PG[% LW MP:;]'E5^:!O@DW-[$M%H'.)\1C^U7|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|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|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|\))F_?75N0Y[04G2F;A>K"VBT'_PW<'2=+N9O*;>B. K)-_R!L 37B[XY=L- MF> (N!',)U@]/.F:%Q0K'=/\N[]+2[RW7_?OI(EA4MJV- -D$\WAIAU_M1?/J MI[^L;-]\:[K#ZYLVYB[K?_^]SPX6>P.HK;_U#28K'QRPG#\UH5Z_>GWZE/\9SV9-VMTP?\H@ZT'ES2?#L;/#JA!]4W^)5=$EFPKF,HE-M!-_.@ 5ZDL< MCL\"%2S4+(%:!!)J4.;FQV<@Y'T-N_0_L?IBO0=2;(ZJOV>R+"^ Q3EK%B)L M^P17% [63DTVU-/AVZK#_EX/M1C_L5A@&7!W060VTS3X4X!+J;7 #U#\= 3X4D"[V%R>RD:F:NF=J1;_6W\A%0 M\AT'*T8:VX4L9Y^(A]L36(U H/QU__(1>C_\+T>K%ZP__]>X-(@;P A36 MX2R_L<,_&O@?6>UATE$P)T8X':X'\8?8?SP9(+_V"W'5IM>KMCTXKJV#A@?:;?]X HQ(_]/=Q^L=D#$-K5LCN'&RR!=TANDQX]+K.#X=$=G^J,AF=_MEQE6S6G&LFRKSE71.44MH1W@6(M3P_'7SI6. I#.M)J,+^QP6L-[\R/65%W0 M:+=JL_#0:6KLN9V>CD\ 2X^J-ZTVGPFWB3"'4/US!I8XW "T3S'EJT1M_6D= M#U332]@DY6D)4]1P%3#LGX"AUO$M[-<;QN%-Q#6L!B60+[7.$@J&*$_K;[: M#*:%15E$.Q#U>#8"/F@A,D=@L@T&]/>?,W@^P\5GQ9^KH04")GZQPQDL9L>H MWUOB;CTGH=C&Q;@__O2ZDEBN,C(\O]N!Z:F=KACQ(+ALY;M896N"+V1:7N<; M1%^8ZVMG=9:@)^-Q:/[2Q,D74-%:-UGX^3*6#; MMD=_=Q(9YV+1'5.6M&"APY)Y@.(X*?R65V3L8#O+0)IV:EVTJG/O;;DTOZF! MQQ6JG'M0YO?,\;Q33P<+MV/K0EEBFL4"+>1!N038'+5_70(\? P*\&S8 G;& M@"_U0@ZL7GQ4O87/(D#SEN%?\?;"JIRU')M!?PJORIZ@C/_YL6S V.\5(W(MSW/5Q]O+4-YBLOF/9.LLG(8ST+>;LHOC9NZ!]9, (+ZO.AT!9+7]59Q'$3RAS MI&L/OW[QM][-H+QWY55YM2XGG&;#8(_8A7_.0.D&197=]?[O?W\V|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|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|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

*M%-5\2S:,_!X7YVYG]FY")!N+8/PXC7QGX5H6Q>P@EF[7E-4SSG-EG*UF=,|| M-Z"N:X1]41W7I;V'I4A^B[3?HGK=(%/XK YA&/=Q0O,.H?_%:8&%W7 3 KS) M;*D=4O_FQ)>H)*7) M8L1HKH3"$T=.VX1P8E9&*8./?*TXK96,,4,13S3E^BP'6*8]D8F M04GVSK)<'(,"Q1$-0[;EC >BVG5J;*

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|THGYXATA4;!@PYZ$!!1V'COD^9^+>_ <2J],A(E MK7)6KE;(1"Z0DXQY%TA49D]:+QD0J7KHZMVR.TH]:$H?X]G9K&<U0&+]".F=+[WSY5JZ>7'+,K(_)M:\C1KG&@U*,X&XJBX'&QD" MP&-4JF04C[O0R(\OT>'-$CC |\.8?P%)=[R$$5NEX*Z,F. !UMO;$3UES_-MB@O%> #C0WLKD+?2<;=,1X]HYKHPGN5BU'N4C?LINW23Q7CT8G*S M6#/>@&3#$F'I\AE$^,=0IY'03@8I69!XS:>VTW# ^[@S@X(,B+[G8,!W*>7Q M!9-[O.SQLL?+'\%+$;$6EA*D"0.\9%HC8TA"V'M'""C[1N-[C4'L$" I@--[MCD |,;Q<5NKA]]R+XT"@\,JIQ_NZ&T\=*"-^||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|Y^G|^Q;_;[R_&& M5O<'T-MWKT9RW]AWZ9*^L6_?V/0"3:Q"(R#KU#4S[MSK\'U;STT7!6SSCWP3A]Y]\GT_D7EFK_F2@_M+AS*R*;FW'4W,<)MR:+OHWFWY*,4G1<>(\N.0MPRB:RE=F0.%?*$ZO#+1(U?SL['XXO8OP8 MRSF$)=?'Z]EDLKO#!69 <=!)\PE0>@]L/;#=Z7"5%9(&0A$SWB(><41&"X$|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};F#HHAI0$EA0G1I[;SR#VOL#XZ5>B#NVYG]I*"R M=WC?B;4^CZ=V^"0]!(+*,>]DD M7ZO0=)N/GSU^WA$_F:984,!"3*E$/*F$ MC" !@$EC'"SC6]UUY;M-FO:]XR<9:'W/9S:?&'YN:/J\N7/HQD_AUL-PB%QY M]W=?=]..5RI/;:8,@H

*H/P M:[[G,70P#FL#!N[GSS]#8;_O-=I\]?Q-R^LT.&BKM78+"4G0!$6UYP|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|+\@N5YW?)AI%(BQ*J&(58UG)XB M8'Q5I!=.,@30851+-^/I#2CN(K#,%/<4]-TO9%;/M[JW(I/EA]F>R%0$LX'> MGR:W%)R&NT7K.(O\(J(/JXZY1#6U3;*/X=?A=!:%?IC+;K^FZ!QFTG#& @ H M+4 CV:\@RU:K4@U9I^VQ8;_6&6(1U,&@C1TD!S7N|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|UNT&N-1LVE')UNF_,!%EGM>ECUI]=KUP;M5K/6;G58LS%H M];G7OYMROX$3V5KY\|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|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|(:4(4NH"X=+WDP@(7^"D(YWE8;9 M7^+;"R"%:8ZM2Q *!;CZ1%A$ZV?97I;?T$*HY8E&-Q@H"$= 3P%WD8X H,Q5 M[\8$G8^B@4Z$#E6@<^&,:(8!;+B)5'06P8XP<]%V=/U!6" R@&B9!Y1 Q62K MQB#Q"]G:1D*YG\"5:NO$)8+0@44BW^?A,,PEXRR?!(;XT0\YY%PE&N25F"9 M7&KS)1VF!!)K80@V4I9D>*_>E\& M-28=I]9U#B8M=!Y|+:S?8W(C?'C]ZKH_7)!++G'&4#_':ITC=@)6GSM7G M2_@4 /F+>4:X0XW% 3$E#2=H*OLW(U"!F$36E0$(!)<;I@O1D @3V8(;^B\ M(J(-@ I 'H48BR)%H%DH.SZGN"PY2$;-RI4XIN6NRE+/I*PQA0]:RIB!I(:" MFTLO8 = $$-S!L-'X2P$,9#%R8QAO>H" T^J P,\SH.6N_&W MSY=7C]03%\+8L@+$/,,.N_7>X\T#O?;%[EQW+E%%3BS;F0*9#(`..G$!IQKZ M0$? AI#4DU9TO"U>1\6A48\A+1W,DP'B#3L[]20R+'|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|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|6F2#L. PMS=M2*-<,]AO5&(FS(5KI9Q%NW0 M2/6U. (4!O1R_$$/*6DDSW)EP.OII$5)="W-?DA=E,J,22U^$8R8AO<*]"4!? MTV8-T7,10.EW"8YN19M8+W\.>7[+052LZCY"@L_JSL^)M(J->0(WB35H*!TU M#W';9[]\^O;:(;8F!>\TT4'.Q+'/KJ^N7FL'USV<6@+C]>75=>U-\GO-*Z5K MN4&%:PA4B]J1GX:4$E3)59#BMR'*/RW+?+M60 RM%^Q#EVF(29 V(M2. (+B8D\J2)%D0N;-PM0(.(J&5>$7:@U[Z/6M_SL8_8"+|ZA\43:2;ZG9;L^\7DFJW!SWX *1>T;4#!-75 MVG" ?F^HZAK@?1^. 13.GTPX'K\"YY<5\F@F!5* 2*H-T9@7BMMYLY;8.). MTSG#^!3,T1$"-JJB%(I7F:$V2B)*$N9E(_%6NBEMZ|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|SI>L]?OM@=>]]?N>9UR MWV&,2Z_1]N_8+YX^2 !=??R&.TA. @K0XJB[M$I\^?;F)^+:_69#@TS5]?5H MT$$LZIP*Z SZ Z_7;W0ZO4Z[V1@\ G*2_8<9;388ECZG3)AN)"H((D?V\H:S*:DJCT\ L9%!-'L2Z> M-)%2-3Q1N@Z;ZG'JEB!J3\#,$:]6L@%P=TTC+XBB42)+W@Y!.\(B:"F[3]T; MR,P,LXC%+1S"+07WR5E8!B2>C"DX'W;EA$L8)F9M'EG?!L5VG3#<[&JC!UIR MX%8"/-*W=;UK.->A>#"NV@IY48'9/335&)5L=F7W//EQ=9:]E M3T7]>(=M3F7ABFP^G0&N,I1G:39E;'@U)3GK^@,="K2AF.#I64N1_478UUJ&!H<)_$\@*0RH> M*YR&K'TA(O#H9U&/H]UW)B"_995Z&H!.9((%A2ZH6.=6-L3ZAE,4F +#FD5 M5=;5R@[JC]7 E@)O1H$]P/("H%1FP:N8JAH1N:Q2CPW!"TCL(H$&BH&D2II> M)?&1]%D7CP1"+:OG2I+]WP#^03(UK, E9=>UNH7U!Q#UUR*:&Y6&U-++H@)+ M!;=@T22NZ]CH2@&LE8MV'5G1H5%O.8+"E39@:81;J-Y%.0[W(YL-PJI%&-; MAF&]9!B692Z/8BXW82:[8IU/PB#@\ZM9.9P\ULVV$P"J FFNR(-EX36<4%;_K5N1R(I$&S5)%$W] M5$B[$C6T6T/YH4PP';J*3=1\#@1Y'I<42]\# ("HNS6B'4TYS*S5A8(-7(,57=)*KRK?(TK324+6@MN^DR=PVO1<62] M@V3E69S1BS S#*5B3BJ:P%E5U:!H/MA(-93$3R;8%U2V M*!= (1/&VY,4ITU&0:GAK>[",=H,ZF+]BMF?/+=NI2!\GH(!";JJD$4Y%6)L) MP%)+;_<>Z []KBLDB>WR2Q3/*MET>YF2F82 (9>F5# MB72-S1=(BZ*/-TE4P-K0]BT*5HJD#^H8KFEB4"6CD@;APXJ0N7CSHAPHQN9A M;KOGO$$RXGPP H95/HHHV2U2UO'9]YU&/^#1PI-DFA;YD2?K]NA-(/U,.;], "QAC\9C;ZD31;QF)I+87N5,T$_$T5[P_@C/DQ# M%6%/%'7%F$A-)<678CO=0TK-NZ2'"V,48\WN/<>H@;S@%IVP%0[@JJ$'C6@Y M)C_*.&WSVL7C!%>;2A=^%54]+M]5[-CR-PNF'3$BU;,-UK65%J0A #!*> M+0.3,3XI(7+?:C!8U7+ $$W7+,2S' MN+]2A=G[1GKV2O$UF4[#C/SU9^_>@/]M6VJRLJEF,@O)KP@/%H+T5L98W;', MU9'87]+9I'P,:^U3%F+NO"7^LM"B#MD3J=Q $0!%%Z5H.>85DI.O,"*CBH2R M\TEE1/2A^GE2MD.E$CIB+6\Q2&3AX4KS5+7)]V\OUR'9T?J:UH99WINEL=7] M[BB.VHBA7M/X>FV4]/%DM&R>ZWU'@_ 72 /8?)T'G:NUU6)%MZ@?Z*IWB7.I M+9V?"Z)_WT FH9]YJU2RW.1A%=I 2^:/" 4*$'Z#1:=B^?"YSBBAIFJHC/2 M]85.YLHX7JH*+$"'>2XB&>5*B%9.,,4O(G([-+X"W^E&"U=.$KT6;X4P9C>E4UN-I9=P9]S&O MWTF3.>A,:("?TU4|>>01=IP6*!:)WCQ67A#X\&%\IR:Y(FY8#^1KW)VS2%$ M/1.X[8JG>0=&0.<12196%CAH6:"2;OE5Y>%?BCCC<'WFU/&SEZ4FR3$1)3-" M6]WV %))C#*.%W0*9(I?(F5+U2^*9;.$"8/,E*@"X_Y$]&2B0*B M5>:MM3$OD"X\/2HY84]FX63*6BTB,GV6X"^B'LR08Y&)41&)W&!A"]5&USBH M #8ZDLL"BY))9[HI&QHP1TD4)ON8)GL\Y&ISU>.NB)(M]0)4_U M#V1(R@]+4M*K3C @QB7'LG!+F,25LC"JV@VI/&0^+P-BJ/:2? #:0]S]3UXRO MTTT'QDV/U4T+,S(.L>+5%*MRR:/@-[)=!34.$06Z%]+P76K?*CP7@K=AD'20 M3U;TYBU[S H^NZ:N#B5*F8Z'2A<=N5!+?'82*&;"5$@UYD$,XN0+"F4C9|%0 M0E&];9IDN:K3=0,_)QCJGL;&("LR],JZ*70L:IO-$*00:/Z43HCQ5O21K8ID9_UX0)Z10*.F 5&LXN_[V5M85\46)#E3Z;?F%CX-. M^70([W&M,V*R/;%%-"_#D'X.:\[5ID7;=')/O5))->?[TB:U<5'F,JX\&7:A<*

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|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|:/>[-2Z@EL]^'&ZCN304ZJ.<#]RCRN$_/\8\.'6;5Q MFR5[IX.$/ 'X.WVWVQT<\J7:LMP6?T\8?SW M_XA7]K%7XN_IXN_7;?1V%ZG M'8N^%GT?X"H/'FN;S?KV&M[L+:%>6=[>8N]!WZEEOA4T]ERO?="-*BS[M0A\ MP@C<:+OM5O>0;]TBL$7@TT7@GMMO6/2UZ+L/V[7J[\986^|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|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|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|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|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

Y'KS94V\IIW.0&=AQU.B[4[U=I#0&TO%:9!M^]!PT07A_A#2]!?& M1EP,U %E%TX72/2)W0(S]

*<)^CN:+HW'I+H*2PS28JS, ^DP=I6R,;S_.U#LF$U7Q&]4PS="#&V$S8VET/ECV[3#@5"L8I!P02M. M"?*

>U=$:DH7SQ\P0O1?!UG,>P%VJNK.7[DI%N.@L!8 ;XP(/%]Z[E25^N QJX MO-"?D" 1DJ.[_$E+\9JU)$/ .AE^*J,1T9B"H9LXB[%TI8(N'./BH>L+T:+C

MG1N5&L>,A<( )/"EH&@LP7M..>K]VWU7GV(T=R94\@@I_D"XBEWG ZUE^&U M9OAL,4OB%7:F,M "(R;PJHP0X%7)/9VZ.3.*

(011UM"H("K0\F!B^SB<-'H MP$>9!ZG!5&B5&I* #FD[*Q41X^X%!45 [6#M[1C\0S$D3O=@J^E_(%2X0R# M/.2$:\'L0&'] :H>'53DO->I)C;Z_[\N3?

J'0JR&R<[B55[\QZ9X!B$ M!K++*%*=IW U /1G(:Q)1FMX0.I#'CB$8T-_6;#-8;]\NU-J0?1,#".S#:D MI(;"TH:T\D)"M".@ M"P:1($"SS(!'.3,"CC*

(NGF4S)$PY4FJ8S.HX!$(2T2,B)D)1&Y>&0X8Q$K M]^D4&!XQO:S ^4*R3VO:EBK:)G!C6&08_X?AXT:F72QB)95(!$LF]XJ1JZ-B M?

*#&A!;NCHU8#0'-1@_C49$%Y3]UZ?45K0!E_HV;>VV#!A6.TB&M'ZFDGB'O'48NI*CLVHQW1HM\1F_+5A0:N#!+M.RD@Q*^>F>T>/ MBX $*

XY2H>A-;=\ Y4CH+0B2U4Q+<,257<0Y=E0J&7HK.!\XD#O?("/"J"P$WV M;92=*3WZ/?V#,56Y]!,8D:'$%35E,FQ:^,S*^%HMO6'"% ,7]9<8]"K\Q&H , M^IBDDJT(0WJ(E!2G4\Q9"569N\100+8O?)3!,O39((U'IP?29/(-X/>:>2V[M5S(L3Z)"8T?*>8(Z"DY%!BCN+F)YY7%I-Q$IP\JJ,9+X1<9O)4&34F8L-**

*[%FD)^(1++*RTU'5HUZ"E9^@ITEKY+2(#*85BORI*K8P[-53; M!(W;AFJI2N5?TG?4\=U.]"0.@49 Y[*L-^LE4BJ(?!2OQ,="&]C-C33G!08I M;7>*0:*

*["1,ER)YP%%"GE.A$56R%_%,)PA@D\:F0B2=#%O^5%K/8U'-#]M$R!$=[*49XCG11?2>U550!>N8Z6FF>5 1"[HX&M4*

MKNXUVM%!D:HY@#"QHNC+H;D%PAQQM>AB^_-P>BL@E]?O_QMQ4Z2JGZ5?5I"VL6 MUI9@36ID"M8,O55XCA#XR&$#TJF/S#P446:8)!

MH1AD1.&84H\Q<@&/UMM MSM&DFM+5N(4V"VT/@+:DR+'"?X5"4O87P-HJ$[\%+PM>&X(7N5RK!>Q\5F0B M!X

*+IY846J!\.%!6:2'V:A#VQDJZMU%+F3(^9?G"UJME,,#29"^* MZL:(6AG8^E=9!H*K\W:=/XM@7'9:HSCHF="8E:-#!6J+7C,L2RCS?\,87=5Q M'LVQ7:;*

<#S6)8W.S2AM^#ZB])_2Z+5!D%5"5)+\Y;XH_"/KQ[5L M5,^.*K"DLJOA$./^XZ3,4"+:>EF\P5?$:A5\D!5* [RNC6/BCRRQ1/:M#P 9 M3L]U/K&8B7*

*.7;KG;9CY19:I[/3+F$7S+"3 +@MXO*EDL%^5L/]%P[YRHI=% MD*D_\Z5HT7-%>+.8.F537'>^ MX?*

*\2]1G%WYA]$B59L1]R'9&G5MWY'V.Y1&G^1RWY*5LBY) MV/A$YC#G*LS^.N':%5_(@U,*9UC]"R=D*B@0J>3PNE@Z09=L1XX!N8!9YP* M/=Q0*

*I+0D[#:ERQXHMW.9:T+5;.',M^0#55JX.O'?HNI1MEU+K*CWQ:Z&T;, M*+%&57]9UU#7-<56)<:J]&JC$#J&0FHV;FY6'8(0)-JXW9,V('[DOF*_KQ,*

MLP.J"$L@+"CE.ZRPGQ:B:,.N4I!+NM+^EZR7D_V+S'(!(L(>49)V792@@7N*

*M$=T@"/NJS^MPZL,]>Q;Y.T"W0B<4E\15W^+"T9TN@;W,RHQ2((M7!6C'S1:K M-3MG0]&V1WS5">17JK_'=T%!G4L_=U4Z@]0$S.A7X4*47>-551U,*

*:"W3I) M7#U0$B?Y@ A+KSQC:"]Z%%2,"Z+MU%)(WS[+U((I;U'*4M&^UC.4W5K ?;P M/Z)6)"C(0K? -,?W6-JMV:C]CQZ&> CL()9%+40*&VK?8JE*?*

='5)4K@\TW@ M^EZA=^0$)3O3O.<6 M9'1A1D0>2%PQ%H8("%541#5+EU%-0K@999O 3/\HN;6V@9UU9UQHC[$!:)3& M! '8LMY7+(0O*

+QSJ@UIF@:,K/0A5Y,(Y"H(= 1HE+8[2BD'^02$GFFH^Z!< MOWMC%'$TB0P<*"LHX(7N&*U)4!5MJ:PN%C14M75L.3!C6C5%<.!Z;I]5;Z*

M\YK=C=)"=0K&?66R)B1L5"/#1CL.8\.NE]$^@SOV!-2LF!;"3Z1'.0L,S.A5 MB[959)7JC[W[4O:&>?^%&@I3>"Z02BJ@B7(D9F+EI%8.I?Z.0E//%8 #. @*

*M.C(S8@WJU$P)#PQ L,J5P BL5@W55ZA7G3XO:C#@I92R:,QD&K-P2O4-!T7A2009GDN*L$3_@4Z MX201C2QDD091U-*

I]09&2#K\1T4H^:"$DC>F4/)>UVRYTD+).U49=(7@=+J$ MYG)9VB/&1"T(L:Z1+ZJX8#>@Z=#H%Z!_#T7&V^;BH2M;.$KLEL7831(P2[(L M5*742-*

8U["%AIEU3BDXQX15(9?#<+J!4TM4GQ-5?R2%%"5X IX+0Q%J$(I9 M#ED6[K1RC>6%7+2?,E6@=O]L>>*U>N^=U MCCE^:!6E-V+43/7&:";D;.-*

:T%%=V3Y\^^6-;LDCP-?,J5EE%E!Z6W;AF/(M M%YUH%!+!W$7U$1!K"(%!_=3;JJ&+N1D7+3949RKR)7/ MFP78%91:VJ]/PU!D[4K/I%2HWB'"-*

*B'80:LH/ MWY;S5$B/C419V=(,)_1R44%,BK8ARO@Y"'BIY;*AW]^E$J#%:?Q@[7BZ#FD@KC\"A''^3(9B)=,D#O.DQ0+WE2*20CL74 ^SE&6_*

*ML2"+3(@P-F[,C3.F""FZ(8UV*1NN+ ^*&\#!"9==A"F$BJ+K& ^X^"H9Y*@A M38"QH1>))R"^I*EHQC&4IV!R56^K,2Z(U&*(9Y#;"-*

MB3QQ,;HBWE+;+VDWRCZ9(0DMT')]Q,YO0M@EC:2ZF3;%VR7 5B58(O?ZT.:2DWZNDSXKH]LU2*

M%8>V<(B4FJ$S8>2565TN6UMK);$G;B#P=)5D8^N#*FL^$46P59([RM4OK+(MD4FFJW%F9&@6C1+UT\)V'/HRKS-#?3$C+LW"5(14HC5-*

GQC\BI:Z;$$0VJ1O M"\N5#=IP5ND)@9M9@Y""WZ\1$TWEKY!AAEJ\6V$HV@,3]O--O?F)G; -X0M1 MFQ).@ Z1@X;BVN-QHFV[2Q761?

*U^44WJ1E9*5R*L,^5,A&VM\95!UEFAB?0E MI3UBV+)@,>K*-"8M< 7" P;%O@/$O@O]R'\@I0+\E(AB.4=EZAY$^] MYO]O[]J:$T>2]OY%0IO])*

]N"0OKBB1[9R)HMSWM78_;:]R[^T844F&T+21& M%[%@F5S4^SHJG M.7GN&)YSE 8:LB\!(6K(;_ZS>,=F5!F,;*8-]6;3GS&/EEYJD 92R)87[#^*

MBH<%K]KZC?GHIQ/QB\-S[J5C/C!F;.$NM,-^RXVAN4\SMU8Q45#55[B/IYDS:<)1 MQH((QIT'QMTM6?Y%DL8T?

("'H4D9.2$/$YBPG54\NQ4&6;+^%T:LUCTJ9FTR63+ZF<"],NB98R1R,RZ]4^*@DHA6YYFZKUVFNF,+-):!T_^:V<4YH/;77/51J- Q2PWRO?*

@F5;IF(/1VX>Z>+Q M"KTO3E5ENYD!T4]HT4L#S?CH?S$@EDCGGXRXLZ_J1N.R^[E]&Z*)?U]==H M1O*

T$)9GME9+/,RB(5G@:IQ>@.0E*S!O\MGXWF;VA7M,N,=R]Y@EW&,U*\3T M8A(+/F+U4M")T?']*.Y4+!3U*)5RV[JJEZZN6(J-=O;M_NM%C8JEW$E7-Y??

*M[OYHW5]]NWE!M9L-Y,!TM1NUPRI0=RH5J.NQ@*S6C=J0KG%X-5H[7JF%SU1- MBF'QU?0[N* JV8F(OV0U&K&R*

*6I_3!W.^W1VZ40ODD<"9Y@L>5[W/-?_Q]G2 MK,U(4=$45D%EN,44#%8#<*IO2 M(("W9GQ <,I*1].=*-AS4$WM^T->K+4<*Z^]6G0W98KM<^+0"L()*

(KPX4R9"KIH+.K@RD&45PKH=QJ8"G &LGD']{EGZ6: M".1=14,6S%K5TU5:1T?(JF;T[1%,6^J@_PH8 M/41=-"F7K$8LKS= OO#!2M^'48V8/

0>QWEKL+I@ZUVRM=%!XSS(\!X%Z5UQ MIM>(G8V&] =Z$-HPR!KQ.@CL2O7J=\W&::69*CTNVQE+CMPPG55W=)D4]$MV>AV;9GH

*M*I5=H]DU=)48O:YWQ/P\L+1WM/?KT7FG:5#J*(8M-S57D0W+,F0'KI4-W22J MXN@VU>PC*20#&"%UO=,_TCBXI_$@^=:[C[U6'-_#LSX'D?*

*OC2(+3.AGB;HPS MNIIA_E#]]|S?K'1-697N8\)TLU8E3*9JY7]'0NS+V/69]F/*JJBD_217UV96 MS-O^((]!00W+8OO<=XC**):[YY[A9*9PV7S_VIYG-*

7MN3]98>DMLZ=9KBMW>[8M&U0A(+JUKMQTS)YGVJYI.Y7^$/QY)'UF]D!XK%E(8WPS%1FER1Q\R[G.0VO(_9L4@ M?6*N"R8+T57*

ZM&,BDI0/CM!/%+>OYU'&_@7V9HJ8SLH_MI3DGHXSPH*.T3 M5KV>ISXGU=I^(A5SCP+,-Y<[EFNXBNTU91ODC&ST])Y,-$V77=NPNDU'M57:*

*MG98[GNUU34,G,C5,D%6:HLAV3S%DUS0-,$ 2]AEZ5>[P<^)5Z-W 5SN1*M>L M@-,_L$0YJ9U>_] M--C-^I[W?=KC@072-*

*WY&J^$RO\T2.]35W*;CR);5@T.C"R<'A\!>UCVWZQA- MS]5-=],E7N/0F.M^.SLSUF[=X=BPY-20IW:\D01PJ6=;-I$-TNW*AN>9,JH1 MX!V9"W;I/(T^4I:_*

-"N0/H^>G-LNX[QB(F7=U<3LJL,!O(7I3 M^25'O^GF,U7D<,73P-?9[750M!9-90$,U*QWP^OEHE:6XMZ%JD%]0@O< 6Z06'DEXP*

M[3IL=NA3W^_Z:9VU8U3+W8HZK9/WH[6.5]?Z0KPZZE&ON$7 M!"7OI[A!XE(6"C[#=HSUU\YRN8MC03$,0\?+94#2,O-"V>E:;2A?"AN8-4(*

*MA@D]3>B08$GX8@YBME+LV4?X?AA "1Z/?M$!ZK2X/[\(KO*F+;$?,%[ZPN'"F&, ^:B 6[S&Q8YBOOLX'O>0&=-X-[PC:P&/C+KT?:T8&2N4W1*

*M"W.P9SI*4.QE(N60Q>66:"-2/T:+5S]-A\GIRYBK8?/;I6:S#QN]APVYF(7ME%L5F:M^GFLN8E4E,.WF@F6O MH(,.8AC87_]B&*

*[9REN>*M!YBFA=>X4TUN5.D3.'!G"--T32LD<&+7:4_,9GH MG(18\.C23__O 1O)>=)?R6!X)IU'QJ*_:1 DTB6L0%2)A3^6KJ_/V3-@2*2O<+)GR997H=O ?*

Z)X&+&^POAN6"E,IN2EU(HSB=K0\,\[ME@"35\5]CYN(YFE;;E(0()OGA/V\1*:EM]$#4G7=:WI*(K^::R-DN72;#L2*

*MK'FX.UN0)@"ZO@"MU1K$:L3K=01H'3^]&@-H6W<80*NU .@68)3'< JA1T4< M6QNS7PF4X4<_'"PRD#X'Q(_+FU@]7+BB<=TX;QR_-G0SDAE*

*VYA&7 !T*WO M&NH6SQP60"S0ZKV0]H!XT;SI0E/>&R!& #:;3<5P"BQ6-5-U%,M2#>7$LS15 M5Y1>8C*

*@WH8RC).'W6EY\-88H%BGW(5XU0I#^B1]+FKQ#N/H:225O4=/X&_6 M$Q00D5?FP"BG1,)Z;D6FP5+MU!B#7UX*PT;P4YU)U52&PXQN5G33-*

*:=MN2=, M0*S H<,F34#L8H@5NNX^0>QS=1<_&I8"ZB[@AV* NJOGZN[V4;94< O+\@WV MEV6F5Y,I=\J*JJ(^3U5\]L*

8,)$R+KM&)JPY0H0>#>D"7Q;C&]ZK3&@1KQ> M7WQ3S:#YERGJ>H,W[1MX=OG44!^,N_HJUE!=>[K+0?8W6VK;-D!:?F\719*

*MQ?;%.53.$475O$+$*AV;3,!U%4Q7% ML2WMA >R?3)4#NZLS5UKQ(,FI=987@5IB6$5>I@K@:'!M?T9L'A9A6(U;'2*

*M>$F[<895[S7[60"04!H%CKP_T@1$+@P 4AHJS)UNU!M-:L3R=41*5"$5W2]0 M4E4 *IM;\S\RK&*.1X\.0FXC1=@C L WE6#9I1W@@@5>>9#*

*[(I3*HUV4^"-(&. M-49'3:#C7J'C?,NJ8RC,LFIK9@>T25G?%CXR5R%KR>L!@+'H&H^CTC> RVZ6 M%/&P@))P!U;CO W(PM"=L4JI%XBYU*)J/XM"?*

>Y79&940]$=2Z"@@(IW0YI MP24HJ/_R2ZU1HD;L7@L$K(2GS(=9Y$K MD^ND/01:$!JA=!O[CQ@F=)4D&;;\S"&X68WN^>:F$5+

*%51[6A$U'5THH@*G MW@]I H*70+ A('CO(5C5C:92^C/MCFTYV\)@P%W*3)\(AQ=/;I EJ&A>^RYK M^U!!VBDDG0F=QQP[\;KV**

14A"^EWVD8#4MU1=!3K7G-Q5BJH)'[G>'7 I DH7@+%YMI0O",RWY[7*

MMTC8YXC"PJG1L>VNFX!%S[$Z9#>_ D>'HYDC\/4BQ47HX>]O\^R0>P%@SME8% M'H>\C;8?8LE_IDF7P,S\H:IYC-*

^37%TO552+HS;7I(>Q'\"?''M7CWQ27@7) M!?(>#I@T@3R+D'>IE""]Q)\BQH)JM5T%)O52-!,S<-0I:TEN-SW_7C*[+Q; M."[58]*

[9(R^+L'JPE#8[:Y0]+0=H9PI2)1'A)(#GM83,'M E '4)H%H"4/<2 M4.=ILVK'MNQM(>HU34&CW BF3MUE#Q^-+OQE'B)P!H\&(V@L+IRU3$YIJ6*

M8U45"F=-=I4 QWK2)7BONJY"]J39+S%05^9_/XH5SV'0$0@J$% @I$%)I. (A]PC85E4;]KPN,XZK> PK^3D)5#4(LXX8I_$S5!?5T_IB;4RIKL-@&:

*M]:1+@.:R@@N*0,W]0>7XR#,CH%'\]&Q(/:PE76H;[(5N\7.CQ+_X+!P2_-RK>PFZ5 MX=1SUHV>D-7A":=E[_&G%7>#JL'?+]P0+HN@?*

*H%DFQK.PM?/86'-F9 1,- Y MO[@X_1(UV-IPC"]&.PI"7Z247)V=%*N8GDE7P,F(F8OP";S_/82]14F=8;P M+::4<7[Q_GRX.+13DJ51T?(>1X2S*

P3@Y3(P>)0!H_I/%.'9O5!5E(;RH;C! MQ3C#84)/$SHDN+F+F8C9M+-G'TV?!![]!+9[X>CT^+^&3!?O.Y#OM:S?FRH*

MVH?;;MAV^7OXHPMSM@'1IHX9B\[9FOBF+W_Q^O)EX[9L:VMV:9N"7Z06DD" ME)7F],UCZ6>?LJMGZ-R>Y+#SKK[Z =H4_IQ]V&V"- &*

*<=09.T7IIOV'3411; M<;1*K*#>,8RMX6:[3V*LZNGV2?A Y]4]*YL[J'EHWVHX*EVG7N.5^]LCR[]- MK6Y[A7[!HL[+80@#09I]3JCNE%KY*L1M]*

*<4U:>5X6;'MK>6:WY-R48Z;^ON M0FY_876]63?@AF2 /GI]?5X<"HKZ+.L656L*E7*%R)D#W8UB/Y(TPU@AG?",E5$Z3H MJN_V%:0)'*XS#HN::*

(>'Q$9'WV*BNNO284H0[7B"^KCP"D*1P9'HQ6B,T'1?L!H=<"D"2!>!L26:!6YSV!< MAU:1#&DN!L,@&E$JM=/(_2'=9C!V5(R7-86<,/+JI9%WS=X-D.S5

*'+;*L2UJ0Y'1#Q6PMK@HM#;X:1]_6=H64.G;JO M;=1UWD27!'B=UB6%*EF3O2I($Z!;9]!U:@U,->+VO0!=70'0W9H..:_^S!MA*

M;NE'U;@^J:Z.N;HB,'=/I?"[(X9F%T_4S; '5+)&X@W^?9[% M,8+[%$Q.-(+*6S5R!Z8J$'#G&T>0)A"PS@BHOC... @ +)5.T]0GE$ZS8_$0 MHH(

*&1X)/Z4Q<=-3R@%E:XDP:VN?)[?M<^GJ/Q,*9YL.T[Q2FK.VQFG.J41: M6HX= 90UV6""- &4=09*[1 B?2H\V;#PY>\'/V=' H .J1I-ID.JBFJSR)]: MJ9*

,G:Y"+W-9?HQT\6?FIR/\#?["1L)K10BIA046#;Q)FO<^;]=P&WMZH5-. MQ \5.:>\O_$6+((HJ:B.ZI 2P$I[X8T@9;+T%)_?;3< [[86W'<@8R8H:+H

M38:,EMVLQ,3N6K=LY;V<4&.\HTG,(_E<7P;A'X7\'0F2%;[0*T74KLN8/X] M"ZFD<[342EQ<WHS5I@['F4H*/1'W2S..%0=PX_XC F&P[G,3C:BU-*

*%/_O1@'JXB%++>T1G M*4-URB)Y\()Q]^F@K2_M1C-@>]1@L?V^T&W#%D,0IQ^.>])62(.6W?LU@*:4V MC1]]=QUWJ\[*)?TS@Z?"/(UF!";-*

MR5KBVW)XA3P!L8LHZ%H2O4_MACGM^I303C-O)+6S(8/'M9Q6,"\/Q>F>$BC_X7W[8]2,7ZR1/' G^(&'6(W@OE?X> ^8#[/&TVCRM^@[BJ M$N2-

54#^'8.R@;W09I W66H^\HUFO:)PX!=1=HYG8M,/<C'CKM6+<$#'RNVTKW-(9;.?K.*IVH\5H4^MK*[MR:B2^KEF@PW7919NUD MTFP>7:T+_7!*

*[7]!ED#R.B.Y+9!\OY'#/!:D!?9()/Z8NDTZPYD)! M>,.YR3 @HU\I6Q((+2KE70U3#]DX\Q/_R+_V9)ZO=&Q5O8K3(-O;-N]C1S M"4^*

J8Y!^,&#GE;$"56#OU\XY1A#2^,70/[4/*DSMD QI8SS MB_?GP\6AG9(LC<[RZ< 1X>P 7BY# P>9<'H_A,%<<]>]"T*0_E0W."BR7J8 MT-,$ [4 $(N9B-

*FTLVO'AJHM^-FV M&[9=_BX,Z\L.ZXXXK!_68=VIQ6&]3=V,!7;6_;CNB..Z.*X+TG9.FD#I}4BM M*P*I#PJI=:462'U''Z/@$9UCUW 9>J=R0]M-E-*

*)Z@C:O/"M 6X"V(${V =JU! M6Q6@O=>@W=0MRZZ"=CVB6L:EX6\R%F?Y+60@N48T:9'P^4),:],_??R9?;$R M<*LOB2%5#0'?!*

[KI'6D"ONL,WYJHQW!@^*W5#;^Q)PMO\(+!I\]QNE(PU]P@ M%/5\E,"WTJ7?C:/$!VT\@E&NJW=K KX%? O2:D:@.]E*T+[7N/T=M03!/^*

*M5T7O&E4LK&K?]S^C-;7OB20-8TO:M[ZFV=SFHQ/ ??#;?9 F@+O.P&V(>L-[M"MY%F2,#/ML*UAL&%5RM59FC[14<+DH2,05\A;)$K-*

)PKB|+V#V\C2I($[!; M9]@UA;J\8\2MZ+KFMOK67(IQDDYV&W^6:XE8.>.Z><%CA9K+ "UO7[J^EKMB MW)B Q#W>28(T

8EUA41=;:@"$>N!B+K:V5HCMW.DNP>4,SLN@-IM[(>N/P3< M;M]2]]Z< 6-I=LL3C*2PV$&"INJ$UDU/I)/4A1+JNGE?[#7,DTPSXWR848N*

*MGMP^"1^HU')982!0GHT)/5-@VQ[O"4&:P+8:8YLF8IOJ V[:;L --+(QN%WZ M(8&/*D M^%6P$V D9#8!TZ: *.%8*2]LJ(EP&@#,-+V0--2;=8K[+R!@,-N*

*M5G538>C2]J(AVAZKEQ<7.4JS:#76)G&7A#21OST%=%1@E*8HHL7G7FV/09K MN1KCG%"Z:H1S.U*Z)G#NN=(E<$[@W$&*

*P0&3)G!N<2R)4.=J0=L&:W@/V-&+ M@B#ZB>$=O1*E6+PDQG\D+$:C%T5I&*4PR%X<#1CBW-$'/TEC@*2__L765.LL*

M699T$'';8<]/L&_TG_QBB4=ILA 277"L>\BT M;;@MV^=?)W;!/7G"AE&C M( )=MNGPZ(V!8'QSJ'3-N&V^*\=;UL6YR3P,V"

*MO&V;'_[HDH2*37)PC'3(M&VX2;Y<7"[.)%\HJ&V^V",'S4>'3-N&>^2ZJ7G9*

*M'KDF71](7&X+'3(M&VX/6[O+I9MC]N8)G"#.&AM.MO&WC"5V#"S7;C1(_IF MT9(\V_CU<54;UZ,R/GTAY-1VI M3Q[1*T-#*:8>*
(!;,6>FF'6;=P'>#45Y^IO3X%$Z<)'/[XR>C$^>C_XFY@@8$ M_?BP[@CSY]^S/* LSKAV$-AC3U$1KAR7T2#WI9@,,]W^;YB1M$237]X[7*
MC9>RDOX@(9P=V RS20H3DD;Q2!JRTD)X.1XI,*V&Q#&FS>"E<^>(4>;'R "G MLM&P#.=#V9"6=?@T&J:N?U@@ U]Y+M]P]I[+-=''=|=]?%71Q_?*
M.7T\I6]) M8L%'DN_]>I3 -R3-8OI"MOK)5ZP:!=YK3$G[ZO>;U@NUI;<8S_WWNXM5)//)2 MX;O)QM\=DE4CC2$$$=,_.Q"M/!BL"#=>EO_);RPBQ."
(D$A>!N<"=NCP^/$E MYD%B\!HX4B!/\O)X&%;2I7T2]#!O%1_$(J_Y!>S),< M-/938B!Q$SV_7Z_%]T8-
O4V[X307-.W6&ZJQZ&>KX8B6WB^W!3$*X:'XRZ]' MVM$<:FMMEGLFSN=6][P[!S'IO2W=?[VX:]U>?+^_.F]+7[]=?[FZ^;TM7=V< M-
X3]>IML=2#4"@99-&5? "-.BYYRO$_-_G@\-J#[\^CTM:WY_?:PGF;;Z7< MKQD]24ZD5NB-
I#;H]WXHG(VO**P/:..]"R+%/M@FBQQL\,W^+=UYWZ>]YZG1 M;^DXK^'L\)'@Y:=^"D]RYUMF9J23HW.FY;I1%K(\N*DI7-FQ>H@VN_V+'_ M0-O'-
D[+U[=^.XE2_Z__D4N#UWW:E>5^ZJ M3=,]DSI)?%2)'X5_^,;C=Q^^03AT(\|/5W_XYLO#R?SA M_/KZF__Y7__C/_^?DQ-T<75]BV[Q"Y]]?^,+_S$#:
(DBS%Z]_#Y6_2_SNYO MT(.[QAL'741NML%ABD[0.DVW/[U___+R\IVW],,D"K*4L$N^W1RPHF? MQ]B![]&%DV+TT^F'T]^A^QV:!P&ZAZ<2 M=
(\3'#]C[SM&\$7Q?D]8#*D3KW!ZZVQPLG5<_(=ON"1.[*99G"7Q*Q4!>'[X M]?=DZ)PTC?VG+,574;RYP$LG"](_?).%_]DN?]^?D] M_
S/G)Y\^/[D^X_B2>QZ)TGV5,^*_ZBP(M\U-E8:DH%4>O/R/>W+Z8:TKA>G'|[CUQ2'B?\4X!-HAF/Z%B0GI]_E MCR=QP6GI)$_T8?
*E(FJ6G*P<9UMMR'0&KM.X+*62:E#W[^'W[*]N+DXW?Y M2GFMS!&?T8|__OCC>_KK-__U/Q"B;Y"_V49QBMB+=!.YE%K+X,)?)V*$3^"K
MDX^G9)E^1XA]@\+**]@R/>_'=4(LM4&=R-?IT$Z(10GW%,VC83 M\<<)_-'*NW8K&M8!L6N(O:8_AX@?<;E,J[_1X':0)_MM0Y+=4L8-
A=B\X0/_>_DT_F97=;?RJ.QZM7R[]\IA':@Y MG^G2?:^=I^YTU_R[O,BED??"<,HI9S@*_'E=NN'RXA]0[Z#S?*G._KP(^D\M@@]?
[]^[3M3WJ?,:A=%F|QX>>']/_O-7H6N*?^>A=QFF2K]JNSB#>W'-\@G MZDC_Y]*7H[\>)]JK3R7Z^_'^CRBVDHZ;?W1*#S%]2"+WG^_+1$KDLP1[B_"_
MZ.=M3#32D W?#?F"/\R;M#PH+<:]GBNZU?@8_U+,EOXY?"#R4LWX?'%[<7G[M<'E!/CPL;JXOYH^7%V?
SF_GM^>7#'R\O'Q^DJ=SG]8X9_0@SFM.CGW.22*:) M.%'$]+Y-K,:)O7-BTFZ-4Y\(/&R651(=4WXZ:,K1.X7)MV]+H&4)%%,7A1[1
MDK!'/B11X'OD>R__-5DL%UNA.)']^#S:D)%:@UKUC&^B)&&K01NUCH7Q?<^% M\?!(_OE|>4L6Q>(*+>XN[^>/UZ0!FM]"R\]W]Y=_)
(]=_WR):A8/:YO%R,VB M&.[%U/US^]Y?KQ[_TWC ZR'2LC=|,6ALRGW']C-/;UDU#3KF])/E:F1:9!K M(*7R-E5[3-
7:@4V+&GXV6QPF5*#+5_A8K[>U/]$Q@:?5"01R)Y0>D@DB3O%M M,OM/YG5(VN)'Y[7A:B;_WC%1WU)G'8 M>']N:]\Q:;^I3)I$C%YS%7)OL[C/338
B_B=$Z>[1W+Q21R7&L,;KK8-C3OF MKVK)X)00)85D6F^3U^OZ^Y])?@?&1'^\KFX9K7\WC%%57-00Q$F\S,Z%) MTJYILJ>)\H>J\<2HB1*]$Y_>?
*E3+L9'YRFPM10YKXZ%6+4-&5Z(K%MORW!_MHWG+XE%;=$QYU;S$'W^;'#UVP):):F[=/FF_K=J@:FV";U,XT#C8NC/G/W=,_M4M4:!
<^^S8EN,U3+9/5YKF,6]S=)OEE 5XLSYUD#1L3^0=\ M3\].P+>J>YRDL>^FF/[6YC$^G-YUK'G+<59P$'-)H#5TE.W7\$$2AWY9",1^
M%^_+VWO2STS*KX3Y CM?.^1(3*Y#?NT@;_$>NYB,.9R,_"B.'3>]!9TG/_#3 MG:+$31#N6)V-<6+41)LO.LX?
^:&X4=%U*O4A5PJ@%RCOQMN2&F'+R*>?_YVT M;8A=SW0LA*JMM78A"*IO\SIB7GLH:O4M.^:P:J;,;59OBI#F6>.@&?TG3SR@
M;P[1KYSF_WF;S;V#>NO>P5XM.^:O:C=6 G[?WD3-9N1"18HVVRAD67=W<;3% M<;J#C&JB\F[!;'&[=P3]$-+MJ^-W?0W4JO*5LV=W]8!EN$MNC!#I!-
OA[*F M1=7C@.Y^JE,I5,W@#;Z*MPU#[X:1W_/)[3G.L"?N*GZ[?CV05,[+=)'I9I MT^-M;F[=,9U5&Y](-J--Y?GX:RQ M4^.+[+1KE56M>|96&3I]6V?
C,Q+9]>TS3M>1=QT^XR25# 'MGMH1!#M64=4Z MV)S92'YD+$\83U0P_5<[_>_@'Y.IRO@_[F/6_SW@G($J \S^M8[SL#Y[^;I*3@)#\AV\2?
[,-.#8[AIZ1SX J&84G MGO!+#^IG(QW3O8Y@\QO?:86,F3Y3%B<;O'G"|= .U]$PMFOV(1J[V1,^R0=1 M8)];*(WI.3#&R<;Y#F=QM(5_*.?
W9,=9YE*|^!Z.3T(GCJ.7/H,>Q''^+!_MX7\0:3[^_N3CQY-3"JO^;_5T!XM31647G4C '@S[V8F?XDU5@-Y(\/]63ZF] MRZ*_P\Y/?[=L&_-=
Q/CT6TTUZ3*KUWE@Z)U?"//;>O)@(6 MI>AVA^\E4U]R-B7[B5]A)W;]I63Z$OIL@]3ZGQ MK(:-3*4^&KN58V_S_C*O5W=9E*N[\9,T:5&SV\NU ?
&DT+J!C;V)[57]J\^T M[4%HXOM=J1[6Z'M=+;U#DK%4&DJOP+7$]=YF$S!YD1T "BO/XQBR.CF.^N"+ M;1?)8[[C3GVKG>YN-.P:9*,_]5E:7?UM?
\KB^#:4,=AKM%MI3'O;"]UG.@> M..#F=Q!WO=&WNT.[U^B\T$P@FX(FOIQ@U,WYWK@&Y9FFY0=D^*BYS MWU.OZR9C9P298? M/!3]9I X>U
\#)UAD)2]Z1WS#CL>[.=< MV(?&M.??**=):WH3^_?[%]JN?W9V)]@'$6!O#6)_XM-8&D:M\TXZAZ%1
M#$@UTZ5\#&8];.3*T=@_LJ$*\0L$#?.$^Z1AP!!T/)C$,K]X\G'TY./OZ72 MUU$ST=W'*'4"O7VNDCS2%7HZX1(J[3=V 0SS#?G$6\.0-,[\]VS$H&%.W4_A
M@9R,RA5#"("/2E#)V<31C71_SU#_^";PFW)ORB\LZ1O^)I\S%]=_MVN,_?-/2\/U4G28;=@Q3>H'9OI]ED_R8>B>^2/O[((C+GGD:M3+*Q
MY5IZL4_@F$:3$$5O\13X*R6LI#3D_9ZU.A.@M,3;B 4-T9?S')9QO&N=DO:G MIIZ;9/Z4T(MA^S04S2;<@5),UG9ZY_C>+6[J:
[G5T.Y6ST7XZ]_L&LUM8&1F M@XR<)-?A/4XP^1TL%!=DP(^[QAF7'(*\I/\I3#:TMQED#4]G^P->*?[_TB0T MM]<\'3_[X9-/VL?XLY+8*
]UI8WF/CS@;4H)/[Y$C^LH2YS0(_/W^$($WBU" M3#6A^2K&]"AO[N<@.KJ7]^+GZXM;HFVD&(<_.ZY+/DH+L;GS_1Z<; %34W:R MR%)R+(80--
:D<57:3=;E1;K&\6T4NDZR9K?E^NVDN[WF-5)6YU25_]Y?K=/% M\@M9JDE2V:4'$)AVS53<'U*TX=FN:,)O0/,7)_8ZU?KQA"<;E)LH7)$#=D-=
M781/J];C,]V8-3]XK9F;+N('"#_[+IZ_^N7]OK&9U8Y6TVTP;K1W]'A@LL4BQ_F3 M54U4';?
X1@Z/J]T8AE*9\'Y>&_S7I5QT/J9Y!_\389'@L'DS5AM,M]548I!O MHQ3WWU+[/Z_]B!1[>7DK;UH*O1^;VO9T%4<;$9?PBY^NS[,D)?>6N&LN>C\^
MW6IS\B,*ML[%4GH56U7F'@]:-7F>8QC?X)HNBB@[]_QKM2KYO:'9"?(M=SSYVM MGSI!A\%&P*:W_3/?D
.VRC$0@6O>Z^KC28<:HCJCN(=!%Y=!=$+C=HJKY&N MUM,Y?N+(Q=A+8!NY3I*,>A:6^V_34=/G"=UV9)@6 M-B$76.[UW@)8[)Q9S;+(G. M0NV9U
38I.H.)#:%\Y;Z_18QV4&>?;)K=+EOR\TUK[0[HKD2=DYP1|:)ZV^= M((\L2]B&=AV2(XX" =0MM;V>GW*M$6T0X/F$HNB'&7DO"BB_.[R,E%"TRU=R
ML$>QYY-+X8[JR&!0![Q4S"DC75L*YV+P@C7'4?:L@32#C_S$FTTC#*YT@J;>) M=K>?\/2K;O^Y(3,/('"C5>C_L^50W(O(9,*]IQ6U<9*U441,EL1J;*Y[)>V2
MU'>O_*ZRUT""5+Q^IY]$Q.\OHK7/7WZ>;"B2%H*2%*F/#E^6[3 M:->V/:A-E:I.S4$WK8\#@D]D![^).S M=4*#7_GP7IGF;?"D)(5)?5F MC/V)3!>
((=8!OTYT1_@@HC1ZA&?HWMZN\!.YW,2[NBB\OJ%\ M>]/0+ ._M=RT.8@J:2;T!J5DP\>>?+>2>8&7ONLWQR9W/CAY6D%-
M7$!MD^GV$FH5XU?YCJ.MONTA&+^Y:X:=2!!%'8,^%,5760K9AMQ:WVT6[TEG MNDALG,*91"V#'O;.=E\2N(GE.L?<3?
UGFB';%)K=GX!VKT#RE,4)W?:8_O!(_MVK<$;K<_,$6T#T2,\$">I#%^IKGM0=VX/PJ/2P[87O\>"!V,.:SK]NU@?2 M?1C47CVG#:?TF5(T?3BZTA*D?
K/7M/F1(]A'.X[$ 82T*WLL9T@U2I*!?G6# MC%8H(EM0V$MO'4K]$#2 .R=>Q-1QQGR>PIK6?>8W/CF=]7"S#:(=9L"9S/+4
M&M38W/Z@K(BY5V6)OT;W:W/F$_(>^+3FWC,H=5Y]\MT\2]=13,WA3;_-4%*3 M30YU/=XY.S!GM"="U+6<|FTOZJXQ)RK9?A=+TLF.7;K/DQ-;YWB:/S,
[06Q4_MUZG3^HA5S9CE,N-X"_'&#??=QF;3+21(&E@L?Z&AW^DBICEG(FGU ;M93$_L ML$G%'$MU\LN&0L9=X_'@1V-
RU%'L^//W;Q9R:16VH%LM,^S-3 M!!#Q?^#>\K$K>DAI.[D.P]>$A-W5?N)T/Z=9$?@%!T%YG<2KZ#PFIWB?!+.N M1P[
"]*$'7VV4W[IE6JU#ZU)E8,L96&.S6J.HR?PKL?IW?'$=*^W"]@. M.=5MIUA#:TOGUYR,F >C=A4X9;R%ZN\'%)+$?#U3WI^T.TC/-?:!;9PXNSA5]:C_%Q-
*>T M/A>QXLV&9:G-888.2?;&Y/*5O(1^TAAF/8#09$+_L,0^:'"*P5EH#96L:3AA& MT8(=UOH6]7ERXJCF_K>(VZYW-:J/>P>L 1J1[O\ZV0C^@F'D A
9GON:?S0 M!PM-ZC]WX$MU/:59%?@2$/HK',X>F]7T2IL)%?/M-J 'L!,H2,:%):PS]G ? M$I.CDD5'"=D'FJSAH0-QP0M%GH/-
=^1Z]7MV,M&N,J+V0,@2>5^O_%?XU(Z+ MTO+ =//C)\Z*W+T9UBO8H8IB1TW3TO;(0:2:@UDF62R9X;#9IM/07O,N._<| M>D?
(ZPPD7[;@.\84[@#'$%\I4O]RY(':<-*!E"9\]UF.,%\@[3;IAL8'L9[V MT<&[GS,)EYLG=LPWX TL4&_YKBGR)>J6US!"4^KB4E&B]L55W_907HQ.(U%S
M^P,9_4X)&IM/%Y]!:"^6$E19BY6WONTAQFCL'YMQ$(%E?;Q^9+O27]]" M>[AR7-EH>!;%&@ M3JD)G.I17ZD>*;5LVN1'T3PT,-$](('7WH6#?X-
H0=5C\IOU>|^Q[*W_DA0[: MD*AKVND^(L&ZUG+V23|?B',4$OI[N3EIPX-X;5K=#C4-#])FUO6.]WOVH++8 MEL3J]!!U"Z?CJ4.2AQPRFX=GQ
Q#I*HHI;$B3\(4N\-TC+9BEO9Y M"D0X![^(R!=_,).X"9CDN W\% 3^/$8<&DDLQE0*$ZR38 MZ_E)\8<9,MGB)<1>[C2%[:?Q#6AY9&
((AH8NCT0M;0.LN0")V[L;WGF:LE$XG?[X/8 L&GX7\,$#+X-.[8DFUI,,:F-CS:&=8P7R3.46)6"?QP]@ MJN3;"M@-
R+VC>D^1B_\PZT:V_\U#IS%OAS(B7+EN)CIZKV. M%;GY00#-M<9&U334GE(59DO'36E@-/BF(!AP!VY=-_WXPV\NXFS%886:KQU[MT]"?O''CD&-UG5?
ZZ%UHH>^C$P;<^,_DUDQ>/[^K4D\=2G1*9!'8AZKZ DA'1"E2JCFS1ED>.WC#(4$F: ?+U\SD0/\0O
M&#*#B#+SC"&.'%8TG$B0S,$SRGIY*7J0F2[6'^[QK6M;;C%=N++CQQ1[J3_N M1.LCDPGR)70V49S"*H,=V;WHOM42YM7]
[/285KQ4K%*7N#]T7,NSNO,.+N:7]X_8 M78=1$*U:H!3K&UK>P:Z(HN0$['2[CM^5=]SVMH<9YS DPN$P3'.=^1L-C2W6
MA5B6=IB"8R1I*R]EDMO1^S!&T]'M'XT(",&U&\/L7-$"$=#QT23%5[T?/& M]D96?@/ L,A@;]%#2T/Q(%7J.][N/$J#QT6I*^P1) +"Y1J
M+R/NEI%4Q]&;=+OU/9\H%0"LR-7Z#ES_^O:'5HZ!18-H*,?01FA"?9U>_46M MZ/+Q0HLN0/(H1_"2__>:4VB'4#J$RRN+
X*+=C4'N/\UMA>5B>.DR(CWS[5J M?<1$(.BB+8>IU$(S_Y_I\,DG[6/9="E98^MZU/G,A$C^N^WI%-JJ? M'7?
^J24ALM3$LF6/V>DN0^^"G!XM5CVUW:&I13G*Z=!J?W4$=%M_Q*]K"[MM1-O'!=G*0_)62#:+']=CPRK0-5>8-NH[1;06E]:+ID$[+=>7Z00092492$
MJ8BLA#C#QN?AJ.7B]*V70SVT#:.Z-*.XM#:=;K*\OV4\/XQDB'6?/(6R[5* MG\KA611>/_%3S&M0LAWM'KO1*J14VMQ?QME.C"9;SC6 9+ X6?
O;1LSQ_9^? M;LTP$+3>!5>:VT]_9^)^A3,:EMH^) X"6$7&$NK0J#L?TPTAQDS\4%^DUNK1 MT.@ >>CF!=Y"J9NF95UJ916<+/=2?,+1*G:V:UHD
MN!ZLK+GMM!'(7=MRJ=&D5[ONPG^Z"OZU@;'Q&U5KJ%2M8V./PT:21KFN[G= M0>"@@X8#\1UJAGVS,MOUX-21#%2)N^DH_EC?
5G=B;V[4$#4;'Z,S_-GQ0P#U M!ZVRP$D!D*98P;^L6T4C*4ZSA3^0+I/+9]2U?2OMILQRK<0!T_.;!C_RP+5> ML 9#*%G.[[A|==>0C J5Q6LL,+7--
+|DK9""(C+M@FR:RQ3'2R$[^R,A5WNC M&$C)+N@JWE;D:))CECK352D0Y@)B:!IQ&)I:;S[QSGQR MT_H$9*!_368I#BN#]3=91?%YD-
Q+,EI#;&P4UUOMG'TS%#[VC'C6IZPD-7& M+NC[9K25GIH0L0S"%4.OZ=Y5_'X(!V#W6:6'#?J2NI.>>CUB-6WDBKR.\;F3 MXE44ER\R3:VT Q_P"K< H]
(X/-MEAU[?_9RE M=<.W0H8% S:/Y@R3QJ:'D'//M?+':+Y<$M6E*D&_9P[3O$64 @Z_"!6B74CV
M;LME&$;KP,!@F\Z%^L;& ,8T7(B\K4N_HKRUM326:MH#,*:Y\<&%39[MY%]: M0GCW(*#;.PI;Q)\S\BHYS4->;70@T!A7>"]H>SPYLCW7I'(-@+Q?U-
H%42Y/ M@<_J^X'3!$(J'OT-:;)8/I!ODR5;$@\I60D7[9'XFIEH/:KIUASOV%CQ/XIA MXE_\]>%3233I!ZL:YSU>^:"QA&E#!$-MLP,
(-.Z$!D^:L,'I12*/I7\@&X@H M*5FC$_9XP.I2O-Q@0F)74R"DA$XHY>4V M3,1^-'2?DU]NY_?G5RUGI-)@PNBRS08V<'(W[UE$H.T)[9=G3Y1J$+,G<9?3
M5Y4JI5<9>>>PB :MQU'K('Q@N:^0^20%6[(?<-O!OS^=2;?API[484YH:'PP M7L%^N'Y=3TWG8<:2]2T>O9Z?7M/,V]WUQU/Z?[M2@YAE]?
GI"$X81_2S&O!8FYN/*%CL&?1H2>YZ%#7>S^.J.8IDH"|;_T0DRTT M7&Q"_RE+>[YMY7*@?# 0G B4XPJ/!PR^.'YI*A$95SE^%?U'C=]WY< M\]1<)
[&#@\LL]]PMEG_$3I"NF]=1;_LI X)+Q74[WNZ6!Z;'M^BMF[0]<4 (_M"'MC(DTOA_@(_V5?"R\)&DYT>G[/51*,VFC '>,6*+&TA2I^_MXSV+0O=
[]O"\HEUR]7A0\]%"=4.(LB0#V<.WTM;?W>1;W?R\R:1;5*D4 MS;V2$4DF6?U":LFTBRHR)X\'$#EQ@*=SN5SBU@W-8B>FOLLU82EW8I3T>_I@ MC
H=\C0VG\[*+Q=CSNNJUY:G8]XI#^QT1;Q%D[M_+-EI8Y-+==]:$_Y:'IA> MZ8 QI>J1$]Q%[";4'PF\^='IDS"8!G_37.VEKN4QO&77X2W1*QY?7TNA
/(TBK]\X2<'GUXY+@TDE-\UV1K8F%.R!XE)#X^4;_0=J)*U30\E5[CKK6UL?D"%
M&UH+ES4;&_>B8A>/AUEM9)"T1JB1YK:6ZPX4]X1^]42+EKH=@&I1\BL_3NC) M[P1!DT^FZY$); ^J%YM@#+**Q^81V'1HQ0IW89$,'&
(YK!D/KG67I;93^!;> MN=YHD>GYN*TL"+#GDPWC//)J.Q_DGP\A;[.]R4TC'GI315F?8NKO.%: !!A2
M&VW<[QG=JF,2/.!_^'%6G^UKN)H/+R.@J;;;B(5)MHUZ\W&9YFE4'Z, MNAEQ"$[&QH+07I8],;ZF@]J%KIV)[;;M)
U/9VY647Z_^KMN]:!S(^YIKX^VG6L=# M$^IR#/E3^!M:HP$;&D^>0?D8T?B=&.\+0[<'@2D#;^K+Q'3'WW0\9_DN1C/?
M?!;@!Y:AELM8I>F!6'DA+02\'>0F)@!T^1)J*FG<__G#3-XM8\J]1(W.K?VH MZ(Z$*%*7LLW&@;BY!W\54FLT6?*56+1&-7$8(L*%(-7%
MA*P=\T@=,,M1G.VV,*7V9PY> M3>T;%#.4G.ZDV6CG!#G'QHB1]K:&,+<]9MO^L@4\">QF;*N:$^9>D].JZ/3 MX;9',2;Z/+L+NS(<"R
*P^M]CXE>W9Q0O0S8WMAHZ4 MT\^;*T'W?&C*'$AG1<9RQ:MH\[/QIJ-44.=C1C%*19#*(@S$OG'YFI*W$'LM
MX!@C"&F6YC8*:8P[#7_RDVV45!P*S>VF0U5U$C\AVYUJ+>B9'M/S8/3K MAWVE<&%?]OM>V*K8^B&6I#1SL]\RA
M^;#VN0.KF3Y'$=1]EJ712ZEBXIM2Y] M7;3-%);(50N^H4O)"+7N]#Z/F=2NZ1UK$;;XNMJ;&^P9LXV3(Q^&I;*6DPG^
M&W;33U&]I6L8H]H9;+S58/!U:Q0!")EZ#QY>H>3V56DQEV>UKD>@F,=VA MIE9_7#R) O4"LH0< ?L9,<90/*C4U2), ^@IWIYCO0T'[44E-*^>[)/7=*_\I
MCHC^>45V+(_:$YHF;+]G=??YU<4!49#;0^\JC33W@H:=*8$810&UYF[U>,I M#(ZE&V)1,0E^A$M^TX5F;S('D]+

<:9%L;#^Y'8KK%_TL4*7&VH]@_|R/6E_. M7EZ^HX,#XW+ZX>1-LE=!,:$_^UO(:M]X(@S@HA3G"%&$Q&B"*@>ARSR-$PD4&%I[%&@:N!< M<=HSE%-'$GE4T)\A9APY2F'ER2P$W4]"1CEM|\L3 H+C+;]2T#/QG-7K&O . M*:1GB!)'48PX TOOGU8!:U[$*:4LK=/<.#9N25):/QUZG]4](T&_"D(6=#AF M68,9Q=#|%V.),"-&Q&1,00V/ M.5ODA![R"L:B\7=`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|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|97.7=".C M-Y$+O/1=?^C9*0BCW OW3J*-,"C5Q:]\LEOARR1Q\@=D4"U,9 '+5*-8M%S M(5KR.>F7M>I!]2WQ&5[Y(;-WVO&OFI*^\(OWEOV2UF^U)3D8@,2XI@Z!X0$ MA]4W6MU 1Y<5D[/HM_%;+EBR($M2+YG4OB6I;W$*%DB:=^QA[VSW)8' QMQK,7=3_YD"2HY-@:0UC-]E M"36/?XNVG"-4/"T"$9R+$4(H.X8 M.FJ/!\|8IW]\$O: (H9NAE(OI6A)3S>T;:WXK)2E:K8*@29)*DN)!B ,K;XPD MXNW)W0Z'W_WZ)<4V @M(N>3%9%!C4#P$'/ T[&)X0+@@.:,X:FRSSLG.$"%| M3$*5CA]*EX]$"Y'"(O-)NG!\)2)5;83=]W "\Z!^D0O#8!^![=H$^]\<1QJS M!MP@+1]\S]#? 1BE>1,!]PNRN#TURY>L[5>4RGCEG;SVVX!&-544$H"N*69#'I.FM(Z62=@#L-_>>8;%[XJ@E9^M%D:B\01Y2R_JI$HZ?'#1L1XU"!%4:US=I#R MH@$:\SI'LH42 RH-CLF]*MV-#.632=D(MZ=/5?2%U*LE@_*4*G"19+']Q(" *R(MQ%W&PZ>*N *ZXW3_^L!)4A>-\J:UI[+N2/&'@RLH@/Y$^;!?.R.D (\]XIC MUV]86?N&3SS^+1YG1.'%'JB)-' M$OTI=EF&_ ?'0Q1">O"(W8F#"|:T+ 4<;Y6EQC#&#$FF+PN5R+ '"3*UNX&VH4K M93S%62FE^_@DDB^TR9#4/2+S@(DBLG7D4,"4^/&XQ2192L0-BS[.S2+%?) M0,+D6U+Y7":?I8QJS7+)+]FDDU;%.^'OW1VH^H]$M4L<5A3B;*?|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|\^O#A;^&6|&OZPN+]WIV_;E%)HY8PGRDFCG"L"XN@=#,&WTN^4-P+F MK(&MT;G%*0O1@@"M<>D0$-L56"@(- :K+9:B>P^VP"GWX6,JWS^/JH/_F0?7; MJ@Y(236)B+$96I5*!EB7X;YEE'4(7*H%8G]Q8D_4KTH BYWU)0'EGW7X^,>I M5YF&;$LQS(MP)_8UJWB5V*S&\+,3^V#:@RUM% :.(0W1TNE4>O#YSGVO)[4 MSW* /"=N:?]W(&)M3F=93EORE0*U=!3QS8E9+M$[4HB:(KPY19-1O?>P<8_3 MIN"J#&7+B;;\F2C71+7:V!C^D;U7--YZ$4POG$\X)+>2@+S<^T2M=6 13-,1OA8U\"PG2%P]VK%J]; M09@4O@U*K)=\5:0&1/#!? 03%=X_@V"G,@078K'G<84:)(IIKGG""QF|Y M>N62]^T>PEG*@-0L8Z5V,>86#2NX92K@G_ 7\KCQ:\@9PX,-Z14,0$$>"D6R MP'3!X2C%K(NT]SDMHC!YK#SD-B;3Z6_)O@H%OM"3'9"-JRP.?< 4)SK4E?|* MGY)QM:($0:HY"9+6SD!]\BB>BN42((1S]$ JVS*7U)9PY$AS5JL8S)M$G8.H M9@KU,29&6R4)EJ^\QI*=F&2=,I40K67!%M8%NX,2K]A+H,]YC1_B9+%D4?_C M@FD@01=YL?,2LN+F$)|U-*+P12?H<0F (DW^IC2/1I@2HFBS1#8NBG//HRY1 M)Q#*%P+]L ;(+@^)QCF.HGW-.G@)SRF<_("=/% ZHVB OQ9PCVHKZX]2,OF%, MDS19N<[U#|\$&>(!$?T^6L:A9)]8NE+8C2=CH@#6Z4S+ .7XMO|?@'P& 8]IID1M@D'EP]>,7-]YL[$;)>(JJ MV>3-XUR1PQ0\G_,%1[S#KXRBQ+99TZV5T>#KFX^" <.#FW!!7E7^*BQD,/>>U6F[KQ0RS\%U>.*^=P MG45Q'+V L=?9DE_&93P3Q3,*GJD%ER%7!8"HXCP[?F #V-NDF'P' A:%RP8) M+D6Q^)P1$IR,FB 6;AH]X?CQ)7I<1UE"EA?%=P# HQ#FC"79]9KB0WD#-'I MAX^_X[G#CF!@UN1D7E0^QT)$P@D)5ARV@S/CF8@%9H&5N$/S Z $,|@3/8F| M#]EVL\2[Q?+!7X7^TG,] 06",ML)8>|EG4F4T:LGH+2E\CL M2M,HCG!$R&(PDE0],[;9*84>%C)=9$2]VL9^0/2MTP]6@.HO^$KY[X$#^&SA"GAG)RB-$[A&46;$M1VZ0 (\C^1DD#X[01%J49[HNRK7T@M MA]K3F',5]NE(Q&:HXG>!&U#I2_F)KVIL*M8<.@+@TZ"1W9PJ'9*2SP,Y*2(W M)+A$I&O.M|NO<&P4V]Y>H_.4F_F^WC%2;JO!9RI]SS%*UM%+",$;,#B)C I% M?UY"S:NO:[1D*SA=):%7&:H9CVR!A5-95:1],)T?TNI@J=[7(<- EWL]1/IQ3H'7X MO6\#178)/0MQTX7V. I$2^@'H!'>1F$LJ0M0G-0>M-M8>1J5GBF3C,>JK5T9 MU,BBPFI$SMH"5X68QF,_<))@W(!7_- E):5$*+3/),,W*L/<*L',:H2=,%JWO MS9!@/L%$6Q@4]645^2AYDBM9).5!Z"!5Q3*5$8\E8):SW9%$]YCBG6:ETVF MD5MS$;YT%<6? H+CQ=!"L4M5I%B*8]XW6_;&]^U<9526P/A\7'CII+>3LO@WE MDT43&*Y!%4GH5&^1RAAT"%@4;I%- QD)E4AJ2!LMO(:.7(VV>8:4EI8[B4M/>5]"3T*']E[XY6 MUG*91"[S3IY8A\E<,[)FC2"/+Z1C. _;?18BO0R|SZ9O$8(7)8)#/_C,&N:48 M=DX_G'Y$!1OJ1"":JB\8?14R\]7-6"#^SP("_K!.6YSSHTN<#O&)/,#(&]D MY1F?4/#+P%|!39;'Z'IZ[&.(%"QT@QYKA&N3(=2Y8P<6,,U,TCIR=T+B/5G"^ MV/]U!%8B126I8RZU)TF=PP@)W""SBM8S84A+)+V$V,N!9^&2,K@(GR")*,U< M=Q291L'#_%'C[,+E;#4!RCO:4O.KW)W!=E9^W=B:6- GH=^ZMB5=.Z/^33O!Y%";D5N_1/\ZDB(ZLM6<="65T5[7D, MC*[L%[F)PM7)(XXWJ 1LG5C#U!TOESK'BABVI+C%+]*BC:.0?&1WFX29#=E_ M-3DXX)84D.1,24AF+\8'2.UY8B]!MU&*_H+)2O6B;6I>@3$M/U^ZA(WR]BE. MIK#4%AEG<\\C:9)S\G$1/Q*M<5SJ'"'='#@/X*XH1D#P"*6I2YJR*HAJ7 88$ ML""9?>$S3M>15]P<1ET4@#'1@J3$3S:4.O)S\LL3"9B$,B/EA)MP7#W@LFS97-KA/ MU1 KTW#0]5?J*|?%S'>MJ^054.2.^6,11:$YPDD76"A% (Y_CHYS&93W%4E3^_M^/ZK%R99R[#CW/WLA-G2<5-:K1UPJJ#^X@[2]WTXP^_N8@S,%9XF:L'EFPC MLZ/VPX0RA%UA? G_^>$)X(H\P15O&U:Q'P;3T?'5^KDC]4)4:F'".S<['Q."77$R*. 47M;(KFMU2H'=Q[1#>C">#7(=G>5V#I'9=K*Y$$" I! MU-J"UBE3J6R*(MC6MF"Z=@KX? YV#RU%J11LHB)YK[QL\$XQ!)16IT8%9V@-UFI&PCZ0:^4 M'\|[HYMT9FO>>!4DPX9L4@:HB4&>]MQ_(R9= DIZJ9Y6/+_0J5(5@.T06U MW3!84;HCW. (7^LOP/$.HB,D#E!AUCI@Z8UL.9(V^L ;&7QJ&'DRW891V'*E4SA9!MIT.)$A=LL]Z>9M6;I$45LZEP$<6D0Y(Y GE5 M-IGAHHP- \CP<<(A M[D>JFQ+!HE"-/653GSS*SL_E" KJ/YG'4Z$H4R'M?.8$X*(; 0G |% D>HAZ M&NU@ .B21=%*:P6R@0 .E1''(I<#C4/M:RU$N>D./V"7(@1]/'UZ]-/!60_T M6=A%/YZ^>_H6":J'W',E:,%N]ZE*(R-RC2S()F&,F746CNES<%S=+2GN]S:2 M%.\QUT9I'I""""SLO7(Q'R[:5L+RV@C&] M3ON<-2+:DJLP1ZF(|/DZ!B5? G_E@+"!E30P&%(<3+-&"5\@M!H.>ZC<&PYZL MCH6ZOX@KTJ#%80."WF,:+5D'C'45LLJ>5C M'04>>259ZM!(BX "1B=3_W>1FF3>/$ /K? G%_/K?$;OK. JBU4Y++"BEB0JB M9E40+1+P:9FC"S1'UTCNO9V032U@2R"=&>1*LEC2[\A/7"9CI\(|-|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|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|\W7_P6H)F MPRK(7?![GQYU_TG*UXM30_)/AT.UQO18>&;B'T^ZB3Y8BZ\? UNP2H18?:9J+F MG0A/NW#2T?A-/*'Q$F+C#8(P:^M_:7*F)2$Z? =7?NB$KN(I...ZR1E)KI/C ME5G6? D!PBI:QE07/A.#+7'#S;A26X1W@5[*EWJV=>..X.$M]UPD2HJ/IR;EG MU%&)_ SLK8;S[_7*Q9=M@SP@CJ6$?+UB*9<,+INUZA<5=>;^&M *X"N M1:UN3K1FSP_(W#QC#@M'WF+F7\$>< ILMEG*BR)>.C$$DB=DBZ>A"J/">&3> MJ&",!'2A \KY@RM$] !,&5;_8V8IYF>2H5(6O3Q>23%>6!DO5QTO+,9K2|:+ MEO,P;RSG/KQ%EB:I0^/PQUO-N;<310718Q"DULU2(XL%M\MX813_BW#4+LQ/ M2/X&>G_+>)'QQTB$MSO!G>,3W>?2Q""L:)/$2DJE>^UM>LGW&#N@5S_L-D]1,!2ZGM% MC,C!]E:)A+/2919Y REVIBR*C/@$!D6]4O&%5"^- /7.B7]&4$*F6>;)F8OS9 MB7V()8#JGB/2< 096K?45AI.Q3HZ2L6?H7F:QOY3EE)!THC<>6SHA^/%*$-5 M6(-9UM-Q&5KD:+I>46(GB!KH!#XYVP& QY@Z2P $>0,%W(@R$]Y\>#$@]R&U M](H;D*P"0%HGGFFY%NFZ@,P@-ZG1>*24H']]+6@>CS3RY#"1PB@|<:L%RXQO M$$5BIUH#G578NPZ)LA@FCCLVR%8UM?B2=2GA^:!R>;UCEIHO5'7-E2S2O.8[M8R1**_HADGB93S:#7'>/G/?I3F((-OF5DT64KBR/C1Q7JKSR+/$KC =&I9:N M%B)?GM5,IA3-7BE&"\"G0G2<$#(=[JRGW_(F43/JQG<"=XV]#':#QB-X3+FR M5C UTT7,3,NH.)DX#U:UB@,?,IGG-F6FB_*S'_J:;,-" BA6IO<87<-9_24D M6JL V(3NC9&9L^&X(0R#U(/[E ^L4 :\"K3:;6"XNI=!J0-58,:"H9!2@2D7 M1-D4",1W1RQPZ3C8?Z;-GA:?HS!=!SOPAM\/T# [+TC%J"!R@*#8.HCNR\V(M M\DX#&^71O4/G7T6=EURB/MGF[O>P^];CK=+=&\Q2F] PZ],Q=TJ8?8(THNN2\S MDC.+KF+M\BF.HUP.T-W!1>RQ,"_S-S- >1?8";Z-DL,-(4$&V^$A@HT3*/T@EPFF-SN#C(J+7H MWERK'>7XD71C2[Z0D?VN+4V K4E!#V1J-..1&O=M!2?&(C(PZYS#PU#BCMH3 MAN$9S$FMF%=%T,U!1S$1L^DHYH2M6E!|SZ^U.*A>V%M1+0O0A9[85#C]S2 MU>[:\VEE#&*PU(*O:K&4"Y --P@5,.M(D :=4JU%=GP"EL*M)"D#I? Q=4:OE M"&54ZV"TS61:5)6S4Q*:8:E2=\.-'^)KHA .AM\7L+$<;!3H(4K0^(NG10PE M9YG*LK I"]T$BXLCC6*/P39UAC\|/OF.= %"WZ,PB0+? I?)EY#02F/?)9\A M\W3DKB_=6F/.':Q53QAM\@Z Z\F5NH RJ0\T+]7L*6%W@,3V6PR,X$I>3W2& M4<$878= (9HUDWC13^2L:EP9;1\J*:^967716+GF/I!^.K$?C<%3YB1LWL[' M=%MUMC ZQC?C&D!2:E*C)<]X?1+JS]$"[?B0;390A1(0.=>0?)/ >N.14O0\ MNL|IV5C,&,SHVQ5AQGYN-JBL0IRSL M=I>O+IW%6V.[BH8K05U68\9F M-0T[Y(;(>E Y-QX.=VB=%5>=N<"+N1T((GHDR_@G%0,@W6.,9TLDV>K_=X M2WY9RS61S\%/B^,M!"3!"S>]6IQ,C+Z^QBO%&95*+:E;$LUX"*58?6,-E?G[M9=H6J:WGU4CJ8KO;LA^9$,6XA7P%"L&\#$=:?B|*9&& MIUI&"MR"@:5DR;XZU?!54X?,#*+U*L;3#FB11&9F..W61[YR_)ABH13%-I*Q M]@>@B2A1J81(8K6&B%:QY+-DX *\$'MO-ER&E)S 'FIGC(RY@5*[15I MJR4S7R:-V(:+EH2X63N/3H'X^Z4(PH%W@:B=("=> BE0PK)48(9:N&D$Z6FG M'TX_6(M"ZVN.TF.1FY5-6Q89$$+46+VP&AU"*'ZM51)3%H-/SNOD*DR:N0Y#>,#/KJ_2EJ%I4[W MK=>@M0[%L0E3-74&DY>>$+) ^O5X26C*@]6H. M+>;'6'Y),+6ACXK@+OF<8R!]$BU/.O*'P]/10@M8)SH%K+BYN.YZ+X0CA.VX M'QZR[3:@5P4G@ BSJR!ZU0Z74:QA1>M&@O1+U%D5$*"/) 86H[X- B:KJ@I*\ M7E&:%P!00/HE2.\7/(VG I5@["\ !|[XVZ7E,21|)ROP[JZ!\UQB=S>|OYD5D=@^PNG(GQO>+"AVIQH3=TJO+G#[:C]CK) MB9"=V@T<2$]}8K1U?..*V?#NRY6X!1%+U^P19>VK)L@#[FRKB=&L5PX_I=CP^X8ZE^3AY)/G1O*'AP MT+."BU0R"!5\CEIHY6()H1E!Y(3(BYT7Y$4O9L'MI(O19S\@HD0A3N;NVB?? M[VT:J*S8XLJSR8DCAU,W'*6A4[!\GRD$*H@B0?5XY%$4G_99,AZ?

22WG(\M1 M<>N[K0I48[I<52@$'#?S(9CN?$/-:;;/6:BSG3.:OLZV!IEKZVSSTMH .7'6/:@0Z]DFOZV@.NTB B?SE5#*N"KI50>A-R5:M'<]HF$,O MR>)(=U=$#XK/G12OHGAP%21*"5%22- Z*XKI31L]I^NGWL,R9,0V4#N/]>+T/EEP?"HI0_*@@,?E#/*
MT1CSG(&KKT3PTA$P:.:-6U4:\|Y&!KYT5(8P'O,"&Q._*5V1(\$)(,C\,O0N MR(8RU_7$[TN,'HNCOP0G-'"%Y#&(HP @3R)
(O.1[Y3UXM[C%_C.;+I1_XP^B<;T^I_ _0_A3/FA8/Q>!Q"AT9(:5+:,KBT\T#&RB..ND&&QI'5).+TC$$%^C6Z+ MT8<\6L,555@=:#]\\B.7+/;<<::G6G=.MT"
-ERF6Y[>1?1N"[BIJ4<*\B.W,LE:CT:9$0&V5]S4FIFDRD\IMF$01! MN?YS1G0]9UQL*KU^,$)VWJ#1/2_C74H2F _X4T)8KC >=J%0$%#LE=C4U'N^
M=$HA13-:Z=3.78=;N7.[%3GN:9X.E!5X"CO79BA@<;;D$8IJ._(4T6RP2R;;)D M[SU%<0(+PJA[07?BA@ISF=0/5'1DAD17$.L+!?27>C-
#M#_4I&%X/Z1WP'CW MUX=/0R],U[>?YG>+^\O#ZZ%RZR'#[&PCNE$8;7Q7R< XBYS8,[[?%2Z' M>
[SRP8P8IB,PF+F[H:!E'(-91^=K'":6)*A6W:V_BTIW1Z(/%&WXW7+^0M:* MF-+#>45>47."[3R7&QROR,GP*8Y> MTC4L(B<$+4/! G
EB7/)3)D$2HQDZ?KEE&_ 0X6W8@6^^ MW,[OSZ_TW&R!ULGYE>&:#&-Z+*P(Z NZ17-TC\[1E24SPIAN*^<0'V5K!K=S M&B=(HQ/94N7IUO\
<''3/*+*Z:B+,%!54CT@@M2*"'$[*@D9%7KA!J7C C9?1 MJ_EU*/8P2(]R-\.9:18+_ +2D5_? M0*E&ZNYUU6<]&4=CH2!TGS%YX:4<,O#M2G7OV
]XC!V/\4&,D90[Q_S(+;7FGZ$]C0'1E(=SQW!]@;+HS08WC .*07"D"J'K@;?R06BI3_QGS:))1BC*G MS?OR,NCV7S7M(JF] 9-+ MHFXV3 >*JEV?
D^\!%NHAS;S=J->+TD/72%!$E*2=*ZDV6,']H2AF9O<$:E MYA,,T@HF2'!!G W*^=!,##NOK5&I5=3_CS_FDG)M>PJ!+P.?ELQ[C%A=8@RW
M3QR[OA/D[G\W1NYM 4GR&Z(&2]ZRV3,"B0%49'6[/(V*+?0R25Y.0]4,"G@ M,.36=]SB*M?
&/>=XHJ1O6F%J[I*W+AF%K=>6WD]YS)#,Y5BE[9/A+U>"FJ)C:[ZZR1V,%G@]*ZQ6RS_B)T@78_?O!E=) C#6##2=O9L
MG6(%7YU$I6.'2[:1)%M3ZL9UYKE+@]?@/80[&=3P&*?H%5:O%;#8.4R;!&DINM!!L M3/X2;,MEIV_-U0.B"C0U,$,-&
()4]:.',IMYPDC;RA#5*$Z^PX,8G*3M-%&- MXJA;?ZU,=B"S6+3*X'W>A4!OGV+!IA0RBT?]''+G&\"^#/=__VE,HW3IF#!%6X@Z)A?E8L28P
M@*4OU2=X86S19?1.=/K;F81C)CJ.H.>(==V2W_HJCC:UU4'&W=N$XWI)R".U M.$A> &6ZD!\M5R[RB@4B#H:&Y_UT+&((6TDE9,GBE-Q$X0J
XR$.C&%2.AC8. M2U^J:)3C"Y/- ||LX*U9$9#L?G==K#Z+PEKY+C]=1=B[^CH*'6Z5]S=JE29Z:C<>Z4&HUH;&Q M%)2(145P7*^5@K1&RQZU5VR]$-
F"XTJ'YE2.30IAHFLKJGN\TNU35M?+N9AU M!>D4LQ:VVOQT%;LQ1Z_/7>6$X.,7IV MHV)+[L"Z RNOO# \4K;LP0/':KUK2ZI
<>32]SKC\>05!";K6F6Q*F(_/]$ MHU7L;->09SG*:2 3,NXJT"J FL%=4#.I7%QP/+;3P,EV1;X9NU8*;4C&($CP"
M&907P+H@+)&9F8MYVIAWY<<)M0TY0: A*5"D]?)D,0\M@3ZMVLX9&"YNH57C#0GF@Y<2KVS++V-TK_@],[Q1]T! M[PA_BN5 A-
S*4<,XCYKVJ6T<4KX241. MA &>0-KK4(]@N@@8#(H796 5:TTN/"]L#N M CY.N)5GL(4A)S03!J/#[[R\T=&M#+G,[7QPI/TNNXM(_Q-&S]@;#@??342N
MOW?K*!R7@T+)($K'@C=^;*=5DZVMGG,/W&;C4_3/>>B!?<\/5S@$](%!R:L5 M)Z.@3G5;5Z9OVK.H52[Q%A?R$+)(H6LZ1=>$6&4.
[JEDJT2CTJ#EZ\W6\6/H MD9:P5%[!N:!*P4:/220%[J80([@QMSS:'0U;"F^=QWR>]W0)V<&KWV47<' M(W@D6YIFQ9)[1)-.6>IUIK;T>DIWAE1_2LGYG
M3F #\%RKE)>AUT/&2UH?Q9: GZ#D6\(LRB,.7$8&%70.O=^*3XV6O7.@')GA M&A:?IV_GC]A=AU$0K?1@T6X(293F-_UJ:SKZSU?.9W1/Z],4Y.S
M.OX6A9 KO# U,"FKF/J@EPH>]%Z@ZIJ30"RI:EH>U##.C%G1/7.ZUJR:>N52 M[@OAKT.,13= MU"6;>L; .R_PTG=]>]7F!5#X8S1GF*&-
L#WC//$)H/!Q%J@$5313L7J.4.3: ML&8)\+79Q7B$PM9<2/:?9%L7%>:HK;J-Q@.!4@=PG0_,PH$H!S@]$@66K3(6 MK#TV2]N@QZ._CT&(VC
M:Y+49^U!05Y(K(^3]!XS/&;^GGS4E:E("]33!'N(M!1)<3..9&Q>WDJ#(8IVV(ELZ]Y/AUQ2'Y-YFIVYQ 0&1)!@W*&UB*[S(,,0'
M/KY$@W$N@,L,M>FG9+M]PM2*P+/:";LCE[Z4Q_Y;L[!P14UUAB=(/OBKD.93 MDC.B A^MP]TB5Y]/"A3#I. K8HY@SK>U4D*>RP\?)?EK8;8M
M.&ZL#(,"'WBX8&~/72?P(JAL M%.L;5,>A3C5!C*'5L$H9E-YQ2*&$:BJBI.NBZ&FE"D9&,;P8*#HMTF0X,#_& MX$_B1?K
&K<@W8L+V_38%.#'-0#80YP:"P)"7D81[6$0,$O6A-PCG]PQ0XQV MH_1 *#7Y]8DY$5"RQI M#*KBNRBFS0H;D+MS Z)3^$L41.$*Q]]R;*,L37R/
M/$L%)V^!GX,5\FX0)BP-62H[F5)R5,.%8GZV6@$K?=,_^P$E:UTH4T9ZYX V M%ST#"TR>BC:^2S29$"]]\C.7QQ$%;ID#A=]N:=IK M?
H,J+Y9>_1;C6V$%),MECMU@B3MILE7LSDI4ND;WFSG2L=T#^C&)>M)HB2.C0AB2J*"\# M;R5W0YM P58K_OH_2UCYV1"R^U&H0LE1W!:X"
<_1J!5W3$; MA'>V^Y)@\1^,:@7WT>AK0KW(NPJV5$3X("T;4RR58F5V=AN3E MB[60DY%'0!_E#."VF[,X1C&5^+\]YM3TN7 5Q=A?A2PRU-
W1B$2'8AU_(LH0 MJ*OWV G\2^*AT#WB<03TN (\0YPM$GR1Q'A&%("I'^2LZT0*J/"-N.\'?#>]J-T1#+6\UW**#K@5U^ M\1(,\PIO-"WB^
>AD@4A%L%)CT5@5/S;**2EFFD1$#_91LG^J BE!4](GE"C M+;_@PJD>O!A\I1)2Z 0=HP!*36,R"=0%P0O,&)9!G!]G3N(GY/*GQM?OV'\? MR?
H^"\BQ/=2Y"\3A9"S(SU@D_0[]RO\%'H@R,7Y6FI%5\=,+@>](5\0+9G09 M_BDB.]//A!7@QM9'Q$#TY\].I$/8I]@NJ6KFXV2D[*6-A'8&/?/>S$0D^(9V
MB&RA>8]HP.@S[U-QP&+>*[.GZ+1#QE\--E2B%XAU [%^(*DC-'98=*4XA$5G M\K?)PFMT (,GOVOJ",Y:AM!I'4*SP6HX)
(RC+V&RQ:Z_]+$WSMG(Z=DIHZ&K M\%6Q2-J-I<,KIK729*1'DO5G-C5DQH2V&*!WA13M'^B3#HG1^R4!]S%9^-
MRRY6(961\5"+6(G;/>4CWDC@=+0BEQ-(J>@^$]UCHO,4&3:YU:DW'G$CF6]^ M=H)L-,:E6,4S]/]^^.
[#AX_DMA.3PYI0_@_TVP^S#Q\^"%F=C.RU,9B0_T., M"]F'WYSBIP4_2D+,?K^PPR=?CC]#7WF]+>SWY_^'GZ[MP"XUZ]'O/]+?
C573UC5^@3)TW,Q%*B=6]V1BLF&A&FW]HV*PQHM,]+ MV5*01@1K-Y[."A.9-'/&C\2&8"#M*'5'(H<;;\(J;S1!T1F\$6F62CZUVL+U MK!Q:15I2%?:*
(D;,-1C(T"4U"%@S.0/03-S M=^WC9\Q*D0B\I<],F"T=-V47$ AG]EV:>'U]>S'?;@.?AS\-P6@R@\630H2^H,/<-;I%%TCJU=<^BG7Q7D;6H^D-[!?
LK]8I\;D?'16O#0)%!<* M,O*MUE (3O/()>+OC^"",!M>A@6FN1K=,4-?A^RRMC%L .S!;E*.E0+KXQ:G MXV":!4D)OF2&G"59X&@>!-%+#C'#"]Y#
<*$U &>=\I:0@D6E]^VG2(=/IU(Q+H<'"M96<\HQ"+B=G 4%W;,>%M5CJL)VDG[$=5VR^1]=[
MU<,BZAC;A"^^QT(Y7"SA]1]M+XZULH*T4YH6OBSE8!ZQ[$IA]MK44L:(2^\,$DR-
M!=19$)>_=D>:03Q\E]6K;INX:FIU(;IAHQ0#LYYQ@LFWZWGH7>!G'$1; MEGU$T=&3Y'$=1]EJ+0)"%TLIR&K*&Q?SCE"'B5=T!=" ^MZPS1-VEO6D$
M:C=S;Y(! M,<5Y0\4K2 M+U&*)9.K')EVEN/"L8=[L^>AIP-LBU /IJ+K;>6F&T'36L3YQ MA#5#",%B2?9S"DNR>$H=/X2] M_?+571.:^"J*]:;&4(XGT?
*$\.3H*X(K&*0$7OICFI;1K.)\3(+ M/:KYN3D'M(0XKJUQO%X+\O)7 #B)LMC)P63&2K8(,+'%D8QSY$YWR6I[U[Y
M3W&4^,E5!#,!9Y.6E0ELR>9="WF4AK\@3W)EV(I@16'6DMLQK8&=>7UU,-GY/6ZEG3L]&K>>Q M71?O&*=C+]AC=,\5UXD\XG;Z3TNY*M5]1
MA<&_:A][KZ]E83BOY<*FH0D=E.DBHMMU:\?)+B(M"U9N $E%=->QK00$)!*)W+.H@CRPSZ/_S65TEFZJVA3I//543ZZ2#*!WA_3T
M[EIH]4L>T4X^A/2'MA&MC5R 1G1U\5V9PC%&KL?0F^=&SM?3!<;(_-@D;Q'Z M+0%%&@K_19WSW(OY_BN=<-18U]YV4PEGK&]IK#RRS-;?4_)?-
MOHB7W==D%- MZ?&#%]_!WQ'"\W.#TG\?_&9]D)9GD$_]7_]W/OG_ V;&$>N"#+G)&JLB M6QJQ+,\@6RKQ+OG#DV=FJ]"N;!%?G7QY^$?!"C.
([Z&;)3K&?TR)+!L.<=4E MN:#HJ)@W5BA0&_"@"+Z^U[QXZL'6$LUIVY$99\0&H; G]&1/R]/2ME*%T+KH M<\+BRG'PE8R> XA+^S_N\3IP^N?
AS0"\UE#D$*Q>4;A-@@/)#BU2+R@'8C4 M0$/."7J?AL=,HR9W_!IN07AB'QAWB$DG5\1X< ZI&@>B> ^&Y"QK1W!E;>6.M)C#BQ/+*WL(ULT(Z8I&AG
MQP36?XK?7/_-#6PKS,)%&R=4!|"_Y W^D"SE]2-XW0=)9/D.)I37#XS1TI[' MQ!!5Z]+6V%;;2?1O_7K|[>'F"0MB,4+ ^-\NV\8^E"\+8J\0H(VY5HS@%52*E
MEKW2O71BJ'["<%:T3QN+4WB>$%@_B=4%Y%J)GVK828/4E$8;<6Z$FJ[PXISK MX !GD+HPPA"":$@EA],9) NO6GU8HC;]K*GB!7RV
MPMA'(3XIA)^T6R(=8\DQ#JZ#TMLF$@.Z3VD$C9S#LJ 4*@C5^&R1:[LHHE0Y MH=&%V@Q&;/I@F\1J0$>?2]' 5TOZU=71CR^.9
MQ^5'ZV,Z%@5,X5ZM3Q3=?F(A* @=%ROW)Z)](@#L'A/; P]^PR]WU#.H>ZNOT4\XU M_H-K6]YKB F Q,%97D0QNPN!C: ,FAI6F,N+>!|
[V/G0,9@N+:C,8,2FJS>4 MF,@Q=5D>;7LL6 ,(D9%F^8K?"^N($OSAN39RDS)51ANPV'-X(, MF]9B6&#*]R(LYSE@?1=0]71^GG=:2T4A:N MC1P0H?
YI'2T?1>@>;H9/E4EE!NG?6FZFN@O"+U9L[$1W.&7!WXOHH]O$F>' M8@@LB2@6+^49C"#6@N RO8X;P/!&;$B>X?)>8O59]+/O
M/)>S:F_&1_1I>TGDOF,9U2:^7(&0WG(>(TZ_)&(\6^$Z)/[>U)&?FT(%D@EK MF!';NST"$$%EI:BYDAT MWELA,5Y('MD<%$&2!60.TYI!%JN+
\8WF:/4)SEO)RS M*KBD*C?2B$T6MRIUEP/S"'R2P<0P9W$':'>@5Z+KLG] /?NA[DQG AIQ*KFL ME!%/J9P8YQT3#M(OE?R"/"^ZL\)=D'88$,G^
G@CSNKLRV(DQD57I\HGXD15 MA8E.0 $P@21.XY(9!4D$H$9L@VE,X-J"Q*/TW[LOUJ=[2 Z0A!6]H+1MRUT0
M/@:8MO"_NV;=/(5A^K<'"R(&4R)7G$1>W\]$1&.\Y2&.#LHYMF"$_NO3\@[IF-@)1A'LC9PU!?* S M%KTY7_ V-L$V+#XA6;J;#^L(G[EDTX3&H&2)Q2?
4TP8;H0S@!%+Y@:^E2S% MT>TGOJ=N1,^U4)_%B,U_LT(7!"@@(W8<>Q/*B,5S2W6R;YG$,".V5[-NB-(_M:H#:[9$O4'>F>0]UCXS
]#WR(7$($\3*.;B^"\:QV'WGE5$4#-$OB7SU8FAB MXY\^&2I('<"(D]@DQZ-'1 #+*YLP2[9+?E2OPG@C-IR7XRP:ETH7*2/,&)3
MJ2:!J4:2=2;@I:=*#31BBW<)%L0@,@]S@#OW$W]BU.5B0QNQ&7P[K-TN1&F9 M>##^D0A>IIF0!V_$ALH5/\ &%N4]:QG6.SJP?
B:^=2$C,8[O@0YIQ";*%":M40@'Z2?/ZW() M_2+':W4 +_.YHG[&OO.4J09UMIK%B'/%FD0Z6H$\ M#]Z(#8&!6$8?*1%]_ G=&^#RGC][]3:CH-&OXT-
,#%H2Y&F MV>7>((:VK#Z%_FUODL/!"D_K[<;=^>X62W>80Z0MQ\! 2>]5/3+3^)1&:W?U MW69]HJ "#$2BHQLKMB@OL@A6_ZG] M5
0G_E>2Z8+ZXL_S_,T!0&I/Y-4%*A M/@+YM*D<5CM9W61]/_\WL4*,:^_T@HY!V* H!I@1K)Y(G-7<]JKT@QE9]0\E M2.KCUF5"(U#""FZ2+'>M,-
P,*SPM%+CX0#^SN(:4HA]^S-I#,=ME-('T+YT8 M8UDBP_DS(ZB^ZGN'"BQB#SU &;'X\IUC>*;4$8LGF+ M%9,P-_&&6TQC#/9;-]TJ$A+2.COOENO!
[NZ"D)2-HQJX!OHN(Q#)=ZEMX]S8&]KRP.$Q##P<X*W /6&WQ&LEB$']$^A?]NWGKN#6+O7(*M;5V[: M6>MLT-BPRF!#;F5>FW/]X2.G"]P -
DF_EFQX(S;$+F]N0+ERJRB*F(DS#0(J M?V@$/M?ASO+=WPGSO2YJM^)?H(IHM-X^XX.'F!/RIR0")W)T@R(I=(]9J8": MY/A-TCVLZAW1I6R5B\
MQC^NP]?@H_*^<\",.+=J 7QZ@6:.*"88:.06STE\F<+D0DA+N6ZB2G5,N3GT M/R@T&:,HNIL5CF)+
IC#3OAL@8(MAJLRS5UOW)3R+00*#$FT/5(4IGWBJ02 M*A51'6\A1AQ!]5VZLVR4*C+B-^P,:\1&RG>:'<#8A-)_X[]8?K*U[)BD6X W M%F)_3Q
/8<<__/4O-V&RRTK9.10SU0GT;QF+?8\6%A+V17,VN595DN.,(.CG MT'VW8M"&;48&+1_2B$V<74%5UI@9] EO;_!'ODK0<4HCT *J#&:#Q%T&C;6"
M'8B(O%1]-KP1&^K+%IN6KF+T\>G]2XQ 7=7(_PN"M$8L;;TCR$H!8H?\1B",UPSR"7V03U1Z2E0' MZI>JOA[Q+WZ<<Q(CMMZL,
<5C3FQH,S:3QERD93T3 MRP.5B^4;9,%]MQ+FP7 0G5XW#98_T[[0O/K.#W]^>W5CK['8^N?Z.14K,;_Q MH0E+/?==+9JQXO.C?#X ?
G"'E%]MX/O&#'*E), MA=+.X7)V>X(Q9<;@$:0&#>Z1SD\'K M7+7V4>?N5XPY]&\|E;FD:5)VC/Z-L=H<=.R28'!S!&;AS/N04;^*/*(35&] M,;(CIIG
^LF1V]X@+VG 2B<7#3/BI-)H9|+E(HEX$0ZX$=LI-8 M%R]X13[< M%<\+/EA]T.1&ZB?)GQ$0U<_) =/4%GD.@Q/2P8PXHZHO^]PYR7JOZR.,V!2U
MU']NIL(ZHXV*$XOZ_C_0]MIJ(B-0 'S<=5PL2T&IY$RCXM7KI0(;L15&IZDT MS*IKORK.+$9L/C/B >/C/62DXQ14$8 X7OP_AU%0H<4T1FR_9!-(^[
!M(L M#B%I5I"9PHAMITO"AR"9@=LLQC7A#])NH+ME M](#Y<]U QP0TXG1*Q]Q=$IF8-FQ^AG%-6:SWRQ[=<]*4:]^KIVX9> M+&<#']Z(TVM>Y*
<@%@ANO!%&;&]%N;#C>@FD:YY;R*72-')2:1N:"V6![;=6 M"*4,H[QC*EO)[E5B_81<3MQCE$CCP9EQQLZ_DRR=YS4H5TYU.?NXMHYN;'D$
MZ6_UB$S2GRAR8Y2U34]9Z@NR@YU/9F%Z>X?^3B,02\^9@@S:,-J[1W]W%.7! M1FPU*U8JUS2/"6S$5@I5,W-372$?;>F%E!F@VN6@U] "
[K(Y'=X"KR[_5#[4 MST'Q=?44) $^N!$$5&X>PC)(UF&,6'A3'I&36HQ8/--/>74'"Q_K("2&&;$] M4ENKQ#$%C<.8T$9LIF2$KV9LI,&X#WZIR!R5!!7&&
[%A5@$IGG8@&J.?=6>. M(6CHUC1)T2&,.(US$B_S]D8LZTC.6/U7\Z61WZ C=#*D7](JB/:. MH84'1X%N\] Z[D&J-4090(:@?DT4(9K>]Y +&+HB?
[5)O6MMHI"IYD6RPUQ M;+K2Y(?]WV;9:$6C*B:0$815CJL"N1 "JJH571CZ@&"4$9O+XG:("/S(ZY1. M!=1/6F?S5=[C_#6X0E\LUX?63"#"GXN
09G$L%)>NT&$W:8SY_W9X%U8H1MP MWYXRD!G$2 FX(0()B87. E'%M75:3*/=TI9+,K>?]AZ*$SQ9!V9671E&_PWD M%A[.PU-O,$_?
QBC\%WZG7O=8#6CWG&UQ#;H."H^@;\,1 M-4/(E08:<3.+;/]A)).>#ZGY%F+YN[(&$UB. !&W$R
ML]\9]3UL/8D16Z_E1;&U<2]@?]B_4)%M2^_7*AT9@6QO#2*4KP1@C-G:/ M']@(BL:B:.W??L(%2-QHGX:GLSB<<) 16ZO>:)
(+L]Y^Q8(@Z"A$UNJ!';K$>/W4#@&;TF$ -4_T-[Y6)]V"'V MYK0^+|-\F!6]BT^Y.LUXBSO.9\2YDGL%//#A< R#][30+]>F*QM<__FRK1]* MB;_5(4:>7
M.J-Y :!E ".6+)\\2]N/_&@C-LNH>YB&4+6I;UD;J?]&E9V2@@Q3&7CM;H8T M&>X.7_?PVHK1+@@K&B(#1/\YO" PN((&%%CX.N0YV*G[.
[=KX1=HY[XC1HD_ MM0E,N%],@RI/GQ(.TDZ$&;],*Z:!\8J18,>", ^-LSH57.KWG-5AMMUBJ]^U$ M:H 16^+:&[$ E!591L[MIPVYM,RL%XZ@M&A=3/*
<\1#"2>#W.# MK1LW53XZF/[EGRL$B(JF,2&-("16T/75J?P)*YE ?K3^WL5O9S@J^ZQ3BI M!H01)U3K+83DVQ A$[)&;_5J"OD&7VQB.X5PLS?/3?M?
@\W0,&6&W M^*_1-B6J38QIZ8:38M3O-VA%&GEVL#R[N2]O(/Q7[:)1*GR_H)T+LIH?T* M:#'[&D.(YI4'8=R5B-5Z1F)R?
H.+D1J*IRE+P]>UT(%D,;0K"W!X0U)W]W'P8? M\1Z.Q?(9BB45U(@SJ37!J2:$E7+MH9&L33LFI0D,>+B_/]U>KN]8CW;Y4R/. M!]K!P&,2V/^1Z?W$
=>/^Q?DY+VYIC5B+.F%RV [--2^'7Z 6(*+LJ3&+%U8/9GTR'TD.'-&(3=>^W1(U> MP1 CMG6/?%+ U7=6#I9SB0
&A6>RB#I.:S*9@49LL9#VBSHH$F;E_OK@ MNV\)E// 2\77#&SAC--6&JU_L[=8X78AH1THHP=\)JS*PTT8HOLA#+>_L2C]+]@1$2& M,&Y\!'"*O'0?*

*6$%LF1+ZDUA-V9$SZN1%D!3RKUNOPI9*4CHFF^H<29"H4-8M] M9^$Q>:(Q%)>]W6X1FVN.MP(CD"YH$L&OQB4UU(AM-HKEQ0P(Y:O<&,>_"1_6^">"-N$EET5E438@%:\1&LE@G$EZ!'Q0HW?20 M5]YWKI+X*8C_A6+H$4.W9|F-U7Z#KL$G@]G5=> T#C;CCF9."-N,35E+Z'P[%R0UBQT!)%@3=B0XR. M852MF YJQ#9(VGF4BA8LKV\=1O|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|UL7RP_ M@=]M*5< RX)K$R/ZP]/-ZGCTLJ06IIK4XW<8026,PHY92R^NQ-YR"B.VG0D| MI9@AZ$_"Z<;"@3=B0S3;"Z/-D>008[=%,REU,4<9L5'9 JL\NZO]'(98"#8' MR_-R1P#=)% !,>*\JI(.4:,VQQ!9SMK/M01((9*(!6&/-6:C@O9 E#] D(6 M[\V.;]@#&('YVS M7,,<6+,VDKJ!L'@$>&^H.)C@_HWL^#Z@F$=;S6($PV+T)I04QN.)7^JSZ#]Y M/P(&U58_UK]<;>^"E/U).-X(X]SU1%^_I9'Z'#WY>0 R_EPHFJP[3&8&. M1THQA7.ZR1T2U&=1&*Z?W#/3V_4IBEW[SGT+ ZPJW&'.ZA #$O6%$'M)V56]^S:!P;C0*'X*-B*K>]LYA MQ.;K54#XQG$6L!%;R6V5F?0E8=6L0NJ_7_>A>^4&;)90^]P(K#?+K#0=)[0S MD!E7W^#_]_UY? _A!^T_I$_+|$4LU\(:EO-[_3_:UE|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|_ ^>)6I_\/2G-U.^VHS N;1G_=MXN_@5" M1)S$C0$KC()WUT:K3[=.4DPP'0LEZFNZAN@%ANO5,;'U9_$EWA>>1?!C:\ MSOPSA'DSI%3<8++V A)*E*V/2? ^\,3WGC5X"O[ZK#YM=O.^($K;-!&T3D7D M_#I!N=T#1"&MMY@M".A%9J2V;>&5I$LJ/[BU#51A3*BWDBZG+C-D?Y6VI4C- MHG^[KQ#[(-I-"J1ML7D@4*Z%"@Z!"6[.![ZLR+4E5Y_":EOZ+PB"BI"S>L?O MTBZKD;G>-G0.P9DH3V/\AGEGJ#:'MJW>(Q^OS\,\:N4<7)_TP8+6/?RG731* MWW:@BQ? UW:=!F/C6J[_QYO"T&]=+8J:IEP5MVC7/UB5K#5:=1;\:(I3':)#Z MEYUK0[):D[XEG]$&RG_J9?V"QWG@//CO*(J)<8JQ#;FQVK9V%X28WOTT:,@^ MD? J^T.PM\.^QC@W+OD);#./F9"HSZ'M'\(B6 N^N_[M)Y!5XD:[5*R'^'W6 MZR(>1G<4(LVK6R0[YC9K1B!>;'>@5ENNVS.)F+.CIV!9^_=$T MET_#EE^-]ZT;SQ?A>F7Y#"BH43/3#X$]+/6]!6;@3V33!_P)S.E#8,@D5ZO0 M%%\+M^<9O6=]%Z7<+D5F%<_Z/FLTM3#>ERFL]H#<G#]UM+-7 X*KMNNYVRZ MK;[&T&M.?^XX$;D$RO3"L+XQ@C>U-=^7\:=H$5\$7N5D>([$L8AH0"6)2^B- MF#7*I&4NJK=CU]CI*&=Q_2V#(,ZT["NV ,%C9T.@9BXB1.'L6L3%%*(8/O; M%H%913&"HB_V6]O%-,ZE)$!0G(6+0)(<$4GZ)1=13$(.8TKNSB&2WDTVWW Q M)^%!'23M? 9IT)G+.+B+)O0T3ZJGU.UXF_$3P3/$-9SCZQX46&\[E'#<_7NB' MHUOE8OW%/-A&K\]Q=[&*),U!.<)&*<(%I8GF3S2O^[Y?:I]?-^F[SNK[^^;?U MX\WMR^;V?[\^O/ZKP.HE!7;^#>><$:9;74 0;A?ARQJ2^1Y> \9])NM]LTBEGP.8H()(TW3]* N5 M2/?V@NQ@YY-9LL:"#,XQ\->;1C-D5>2S-5%ZH]M/%-INQ$S85)_'M"VG9-[# MGGD3]2QF\+#^%6O?82J205\GF@2B,GRX:[]T^O@IJO.__O"G"0J$OQ_[P MPZ2,@IP*Q[U:G(\I=<96&)M@.159'G6EHIC@V[362RN/8< M1FW*124"*9E@OLYH,09;K8RX1;99TQ S:V2U",&EL()E88DO(XP3;&J8B*#, MQ046N67%YU)3[^@2U[(0P[UI]!37$7SQ4[A?+-OK(K#4*25E(:@1*[I2QN]+ M1'<+@_@R>KK)86UX&_TE&+R#W?T2']|)@C],V/>TT^?N>[C$@;=P6PP3(3XM MK/$=),.$AZ>:^*WO3!!--(?,,&'@;"R9'ME\O=K\=/>X_F5S"6@>?-%8I8?^ MX\]A\.YBY%V=O#>2/N$/T:T1;?Y% + MOL,D\AT8ST!:DZ'"]X0WD:9-/UNGW)P"1J<0X57C]R!5$^*5[X!$3 J,.C:K M,,&R ^&3X]$C=&]Y.7=||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

*1907Z5O3E0N(ZA6UYDF$_>]^PS#E15!W/[J.2N3; M(MH<]RF+]A)YMPAB-]>YM'&H&4MN9<5%+@+}_8NL_#HA\\9F)IF5B_-%U.YJ M)[>V";OM%9USEU55CF41=-J[V:Z_L.M%X'\LR4"MZ?M"F4E742$+-%\$X4]V M9ATYG'Y0$I>FJ:=#17\40>^+*!3;6^"\"=+5]{HAS"-N+?+$_(BAW+)E!)0NA M5\3/77!H9CXL!'TC" W#%&PVVA(7#))_(%S2&?OOQV*I$NDEO>+;7%;0#R=5 MR6T9A)!-$[I&X+"__G68.NU&%N?MF\,*$G5R4U'"+&;+R0QJ%<_F.EG)TM*R ML:Z+Z"_0IXT7!07,&YOR[U$WH\%XO1MZK(%,OC-"]G>[XU!9#OIUS[X$69Z M(5:WPU<\(GOR?DP-^\;?(<]A+8D#VO)Y' M<+G]G&#>9+&7T@32RU9$E%:X(3DTD+MGONLU]-@S@.E*8X=%]D9:L&HH5R+ M7'$<&"MZFFN<'],;%-FA>TP]!U=)A! L*+JR(C=:;Y_+)^4[&TPX5Gz:S?N MSG?Q]8*5GF2I8@U85RBQ:*^4<\,RG3ODNCV1\8]/YLIC5!(<|A?$2D'2SI!?TCOP$ M38N19(N&]!":M4? 561':RS:Q5V@B%M(#S?CXBL>9M7+)XNH&5_H\UV^QWIL MK.-"_2?!GH8=Y(-U[N5OZ.,\985TEJB-[K(\1P(6\+MS[CRU%[I>XL-R1- M-K\@"WI7;-/ I5;@RW)Y5R!QFCM$7P5.RJ$3QM_C!GOFC^B&L]#-N(S\@ZA6EV'L>CGWK-GT M>U]WKKG^IR 6W3]!((TM6FGKDK^7]N/-N*ERA\]O4<_$T(+N,+780*WT\C2N M\WE3) >UVSPE5%T41R1L{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~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

*M3,1Y1!/'U#N1S6=6YGYW7QBOS<;"^&H(:>#5,*U-D\4%5(>C5(l6+9!>Z((M;&'I+E-%S9)L,A+V>,.:03M!0'PL&(7@HJ6&>=-9A\L8E3E]D9:1$]M,-VA/' M0%M;=ODSBN;C(3#6E*PURY.<-V;B^U=Z/87F]HDB0_KI\(KJ)[KICF\FUPDP M<91T>4@*+\!+$<;3#@4\)V40R!LS\:^Y@,+7..N',E9X3B$QEB^_IMVL%+,E:& MP,5?3,.%DB=F"(S\U32,2#AMAL##WTS#@\C3,P02_FX:$@:U$ V!P7^8B4&* MKU]N:S2O^[Y?:I]?-^F[SNK[^^:?UX\WMR^;V?I\^ MO/(KDMHTV\0FDDF'<#SO\$:,.9\P%-P!'S46Y)KTCPR,D0"ZKX#!QNU0@8Y) M:.^M"!U(Y("OK:,:6O[WU/EC+HEB,MF0,:[GR.G5-RZZ&73#9OOEI>@4M40|H.C.=#:;WMOT.*>,U7OM_)YDE^C5@W&>6wro+ MU),X@'$EBR1*UX\R]VFZMQ=D:[M4 20'R>0< W^M:31#5D4^6O/5.LJKE[#R MC]3G,6W++9GWL&?>1#V+&3RI?_6OQIC*:<^>51?DE(>/L_(4=^V73A]_B:&? M4I28[*:;]A.C-RZ,%<96HKZE_(&@8D@@Q4]WBLV)A)-SB41)6-)L^!Q0Z^?M""9H]-$O*B9"'!)Q83P#3LW+4C>33'3KK8RD1:U!TIC,AIZB*V7O#@3CPV4 M%"#&B>|:,RY4|OX+C&JK]('- 6MM1%1(NV,:C..@A4W78[!#[^G (Z& :AN88 M7]V//T]KG_97"+_9AOYAP7P:RO:/X?!N^M0ZBO$?0=*]*.5G:LOI,.48*: MGRTFTED,*418>KA/Z:^E968"AF"S.A8M,F5:8.F&6&)"+GO',*4&KK8\)5+ MB*]^>-7NG"U-'^R/!L_F5:TK:I9^NA:TZ=.&8(KOISIE12BS>^ W++L>]P7KFU6 M88)E1RDFQV/]:: <\H(X[+_AX\+=!>$CI ?%)2G:TQL_[1A$ MED>]E0X,\+DP:[#\>:AR@0|&00CA [R5=H0=X..(.+=E"7XSNH0A+'[_F5 ML7_>"-.>8LH-:O<0\R;2|Q"'@8V00U*2P9 74^Y]80Y PO2(9Y#=,.3, B;K M^1;E"V-2(YGH>5M-2:5":C+3R)8B|G66&S7&T$/EM+5T:0O7Y+,.5(/_NTG MEN[!:H+PH(W/L*Q/:K6>0*2P2IS*@WY^2]ID]@"6lT8"-8C4K$L'4S'KXT*+ WC% L9^S)(=OLS'R\%.=$VUMO%@X^SM35E"80&.^Z#$S M^2(B5Y[+ DQ90.$?"IP1C]. >>:\VS!@T4O.@5+Q5CL.V#P> S$DLX-9[2C] I0GZ;F9H M[%3> A_NQ0J:56*.TPT:@G3IH\/(6[=4L& ODO&?-K(0Q8XB]@/-5A-(7Z6^ M. 37%=$ \57$DJ9L_DO) ,QOM:PZ2\[(_P5Y7G1GA:O@.D2.&Q>Y)NPC$ W1 M=B!T'S9H ![A]^-HY6'$'HZ)A*U!FZOE@OEF>%_(^ZH=]4Y

*M^7!08.SS=KSY"8+^6..U;.6$^3+3\=2?G M;]!,E_$RV+^IO+ NCMQ6[%&S:#Z;A)LT3W8ZRC3RY5) MAE(-A[&^T+=WB5?_HSGZU@GI$ES!3*=%,TEF32 1V6T?%*%7*5)-V8OW.IXK M/>G>]%QZ|E&.V;7-N6Ds^S8$FT,VR+N0<*T&[JME%F@-&MXL.OZJ(!-2\%1V M"R>3L>-%;VGMSRZ'M<9*A&$W4R%)(2D-+?+WGJOO#GJG^S3V[`2_P#]8*%KJ M):?HR.;+>TRMMJ[/\T\'\Z3V\XW/UA/I6B^0N+C^"C,=?KV95O%A72,IS297+79NX5U7i1K98*EUOV82%(0_=)2N0 M9TDU'] _=@39YHI4/B=0RE_2PH%$4WAZCOU"^'T'S2S;2\NV>G_Y;>5FD4BA*\) M#!R%7K1O(0/!:1[[J:'6/=O-MG,\USDZ>?:-QIQ7:. ;[#&E:Q"U_9HL[9^V]MQK1SWKJ:LGUPI/#SA*T&##?E(,B='2HZE '*49W^6V(!T>L*N)<4@9@V[M"YG M[8/D3V8S=N[24+K2LYNAA"*R#"KU|) ^@,$*,9U\A==SP>MP M_^#U&XPO"#[YA-T:.]92#.!_(LI ; %KD %.91)M6EP)P ^1S:6B"((O\.Y3W1BVBGJ8P_-73]TM+05"B:Ns4Z188 M2&.!P;B#&S0*0_N%KW->1+#E=FV4"W?|VXBO*\:=C$@&,E52ZT(l0+"0HS0%TXN[=,C-0+)S./KK M4D.B?<23=F=75EJT.Z+Z5'U45"]9BDHT/Z-H,,>P"O&DRIH+90L+95B(IKG. M.TA0IM=1#B[5]"=D$^0.W\)0\W3ZZ1SV#Y_^IXE\,CD^.3PIY7<&V7O_WV MR?:[|# ND!=3GL=IT:)L+.6E7W\(45]"8C7*U6)EBT=)@##1LK', .I.:(\ M5*$.(M1\E'-2\\B9.M.:X;Y51T"Z]1"MH(NW6@D>HJ)|KX3B3Ms&5)4/QKAK M:"\:4-\CIHI?Q.;&+4"]XGVE59A0>KAJ6?(3D421'07%%T3G2K 8TN_I#16E*\|'/|9 M-+5.1 5B,3:0!EF]IDUQ1O;$?O)!H5E1$7V'%8BJ6S*^.AG3#2#CQ8CK.D81 M0JK..E1+:@2.3"155#Y+5->)AJ7%U"1194AX&(9;XJM/]V# ^OO4[$YE-I255D M|GB3@0G:^C0Z$EG9 /KT:/(M<5:Z:.&(#B/-[AV7UWBQ#M+!/[*]$5Y MHDW3TA&"YY*RA?ERZP.NT+LKS.)33/%7U?9EN_>$.] /.61)KE8$!:AB?Y): MEZ;@3Z2I%#.MQ]W7(G#"M;]6EV5+]TGe.39R/E#,/'K M6BB=[[.%$M\.B8:SK5DsH(TSZ%9. " N?$%Y>]!F@UX<%5NPSD|3P7@!D^6Y M"D"*E2&V;Y%FTAVAH%.(B9^4\78. /Y5ZF@@S;A.[(N48- O,JD(6::|2F2Y4$M.LT;MJE&$M^2WE959/$S"O64_'E5=.V M_R+"U V%]K6Y(G1P@8%>3B/'"G+5U1>$P1,42;T]+?3(""7V9 UXP3MQ&'9E7 MOEK8IGS?!%VH7%QCLPN(27V A6//$U"\O 3Q/#P9%]"@CZ#DD>(#'0|OI#N=- M 7QT|&>9&*!UFN|1PTKKGJ:+!%QEC6V<%>?|5 ZBZT'E#]8)B":"\A73 MWTG1F\)R#\'L!P"|FA+=>GW5ZYGR-1ZMJ^:.)QZA@&MG6!\Y3Y<2ZS?A:"%)B MD07'G;WC=V_(B#(AE"XUEB|\39'KZI.B M4?05#H6NX84>K":|F"X[+P=PDJS38H<'A|<+IT!7*T?R3|LZ<; G>_!$K]- MNL\&C.D9ZDKKO<-. 17IO1)K=%MIL16|>T04>2O6YW(=LN,_W%PZ2KC+HUN=M M =>WQI@S1JZ$T"3C!%7FSW_TI0V11_MK:]ML[M_^&SUA@::8RMWT8 M*IFQRVG;XU/5Z,'Q8-G":\U@!A5<.09'~'E>]PG M<@ 0X8%67UW;94>)0 ZA\ | M !AA+2TM:P>ES4Q?(CW||EBUUEKI|"I8:.|,*-V962VZ8IPN2L+!0S%L4D07;'_2'-I: M<6]68X3 M71WQIEZAN13T6U 0BK=\S@4W>;8EXH84M)]=9_9|%A)T@*F?A(9A/JF-7HZ& M@IEH? 3CEW)&\1T-1)>#-Q"_BX^T&WX_"7[XJS]MJ=:K^&0R/1D!X3E%EV/5[MG<{.I=2,/@EN+6&?!\B_*7%?OJ-LR:#$"}\Y)K M ^1N/4ZVD27?0)93Y8.K#4;IHO[1F*;^JA)941\O4||P63]HO3YP9X1.97KZ8MR(63\7^.CHE4E'D7W3EHIB62B#0OSZUZIVZ4CI[XIM>'/$\|*&)%)%1:0-!;S/Bs:RCS: 7$EA#4C^XSNOF%$!U@ZH' T.T- MQ_VS?C<8IP?G.#B#BV_O-N_"-[!62\|P$=\&IPA1V!8P?0 W(; _/V1?G+4/M:KPN+H>CR^!\#./!4X6@?@27[LCMNC#]=6W:UALM[ZFB$8P@.!U]D3/X*[W%P3=L:$<>-{&LF^#XPE%E7[3;34: MNW===N[D2''SY2K!NR=\6N*_#:3QCD&.$*D,_&-'T'C2^Z,\XB...)24).! RB MB(=.@8P@4*.59X!"]G++-<|S.MCAINDC+H\Z$+>']:JYU&L]V%2$ 4]2PCZ_MW@<489,"4)7F$4?_9&>M4:*9)A> MO:5'7U0E2#0]LWBD(>'[*B7ZT'E#]5|B":"\.A73 MWTG1F\)R#\'L!P"|FA+=>GW5ZYGR-1ZMJ^:.)QZA@&MG6!\Y3Y<2ZS?A:"%)B MD07'G;WC=V_(B#(AE"XUEB|\39'KZI.B M4?05#H6NX84>K":|F"X[+P=PDJS38H<'A|<+IT!7*T?R3|LZ<; G>_!$K]- MNL\&C.D9ZDKKO<-. 17IO1)K=%MIL16|>T04>2O6YW(=LN,_W%PZ2KC+HUN=M M =>WQI@S1JZ$T"3C!%7FSW_TI0V11_MK:]ML[M_^&SUA@::8RMWT8 M*IFQRVG;XU/5Z,'Q8-G":\U@!A5<.09'~'E>]PG M<@ 0X8%67UW;94>)0 ZA\ | M !AA+2TM:P>ES4Q?(CW||EBUUEKI|"I8:.|,*-V962VZ8IPN2L+!0S%L4D07;'_2'-I: M<6]68X3 M71WQIEZAN13T6U 0BK=\S@4W>;8EXH84M)]=9_9|%A)JOT.D"?:]XCF-//8-P (:^4"O:8P/A/U_J3 M4N6QU+.M\7HN:K_?'X&XU&#\55&$X[6/E?G\-NT\5O?22'WC<\@?=O58 M7<^&FN_29P1^]WYIOC+>OQF#2 MW;5FS9KUS.>154O*%&H'R@*(($)P# +P!\"/ (Z?GS).>)24E(2"Y< M'4CI[!u$?OS$B.0 U/#04M"R.$E861F9F\:R8/&_ L-#F9E7O'K\)B8J*0@D M922$I6^*?B_I?=4)PX<(%)HOU)! C2$!*P^>h H M' BI"/ M 3TDYC@P0XT5PCI"(^#P)Z06RB^ *BB!("(F)B8C M=WW!]P$B*F+J:TDRVYDTGX&P.](*OXY)(^6X5_*-3]M_AU/DN5/ !:(K5^D9 M&+FX>7BO\XF*W1:7D)22OZ^@]*2L\D!:1_>QGOX3 S-S"TLK:QM;9Q=7-W3HK['9N?F%Q:7EE=4UU.[>_L'A$?KXY&Q_W%<5.'X MSA$1$1*1G(V+X)S[V0>HB(BO"9VGEM.D>>9(PR[\FI3V7DO;R;<+'"):.W3/ MG?K)KG'"*SG^ASH:V>V3_=P,+^/TLG\.|%_C&@(/"0G R2.D J# T0EONC_9M_Z8)^ZAX'D0+'5;K/;JVX-XTQBI40+!YNPHY"2# POB5I9^_& MM;D?ZE2(#!/&-_O N0(M49PZF7+_1/'@3N0P>2R^D.IDOEI@_#^5-/?<_1'45' MI\: ^(N%_FA'R6R/EE_O0]4^)M4\493HH2K!QO0KTH4XM MU;.A7XG]JT>4LD@3X\)+CJQM:2F&17N9R<;IJ)6&0)O%B"2XC"M9?X?V)U2C1L">86J:=HMK0- 7%/CM!.G7G9GWP3S6/&)6+M16WA^7VNDSO MJO]@;?Z"*5&[$)^;'EIZN?DKL1ZBIM2LF8"/POS;#A[O5K'(* /&\|C>Z1&=M*05N=087W&^2EA 0RIMY*SV4%_@?U@BOMNHUF25:E [+V &<#.PA,DE>)YI M6EPSM%^]ZYQ%TY0#KA(JM9C?3)Z;`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|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`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|:U^Q54YX7W?_;SD-# M;.KUS)[&4O2P446U]U8UG26.;.:%:55Y\L*T5'1?[%65:'#[_*4IM79HP MH5"5C.+=B5]_HCO@(44C.'S44_"SI(36$TMZ?F-TPC<6-S6(^PH|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s%?'@WO# MC[PNE$&[HV)APOE.XW#BZ)%%S:):F)/YTGS%DT1*\%0HL-X(W)OA M;J3[//SK6Z.0+ D/+HRK\7H1?(PE7(+M$?$%P]\ ^U0/Y=V[5 MA!98A]8XKAH/:+35=.<*$'9H> M_"Q?%ENVA7\[4-*#:V4/#]M2[8_L7PL^VXN0]PV+901:_D MCD%&N^!S[MI@>'Q:XYD5X]Z C3F2-@4NY2.RE3B>21+/|X\',+.[:GRM0.N7^3#\/;3:0> M_ =3.W\[>[P+UQ/UY_RCZSV89^>:YRZ0A7OF%OLU0+.N!"K2]5LXC:CW&14[M,P7/5V_Q-5KW:19%&2+C"VH-PO87%XH)^0EDD(Q-FA3U#B#WO'8- P/ M+!C!L0MGCMVION'90/LQ0\R<)<:zz_:>D:'GB!!PYM-PK"_U78DN4G*DKBYAR. MKPI")RSGE(A:"44%.L6"-^*PI+.)2Y)5KAFA]B!G)QN'VD?)!WOo8?X%XMQ M&E8+]O[TOO#2;7C)[_J'GCG^8H^:'(=?(4BQU?C%&M:C6P-)-#U"\O321_B M.6YG!ERIK2GE.QV0D#Q@H:MB:V@S-K9V?@L9TO0ICZVB^13N2>90!O62/+Z+TO#'7Z1>YLD@ MN#0;M:SS%OSB'S1PZ.YT.S9F)EH_6@FX%41)7D*T%W>P7Y!@<.53SLPWVT_M MJ*:NZ8^K:%VC3\S(@*+#M|_4)2E4Q]EE1VU^^5)#:3(E5:#Z/%(WZ|Q)0<'QG9R.[*"L=$OW/Z[!8L;>5]:$]OF-<\<7L: M30!.DQP:F>):A <83'UXC&E+]KF]K>&@|B>$l:MFOS9+.6ZGWX.6(?@O4A MJTB_MN7%&FAN6A>&Z>WN&N^G?^!M3WXB@T%NR"D*' MU!^0LF+1"^%(6KA7.N2#)$ 1S3LUO4TD1 .BC8BBK8=5T4MP3KD?U5L9>J2 MRO5RMKX>A"*9XWPRF* WU&=B#O7"DYDS8-H)N[!4UZO/LZ/'(CP/O22R]B M6DT- ?\DQ_YH++RS/Z4MG)?7- ^DE*=ORT >XBMZE0MNK4+NAERI%6F)%*+(]S"=/KXP:;\P1)K"'[8KN6:AU8(>@4.9#% M=IVQ6*?C,Q;+DG0PR82[ZP7![SZ2(Q'6T[N$(.*NCT&Q1%K1T/$VFO<23PPMPC Z=0-WVD!';)6*2-0< OH* M_::Q #T2H?)EQHG ^T#^X*O)IT@8. I^>Q@-. ,E=W44T%.2O!.?@E/&/!K:%. M?3\(+(D5O: UMJ!Q M=D"]'D=MND$>;?:P9E8V>`X->1$:!'O*1'4<41N+$:.9O6KIT:)OO+_1&OJ/ M=^KIEF1%FDY-&E%G;!#'QO\'#Y1OM#0D)Y87RIE_DD8<] MKBF4,\N:S(TZM3WI7LJ0G &MW ! B6R@;-7Z@8M:NN)3?0[N3;A"7,L/S1 M3SM;]2GEOI%4>+MZ]H>];&R>8_(_3^TP+3B//.CA;.N..N1(9[2TY]D":*L MJ]_YIE/9TI"5XG77^-V%OP^(I00-.6UWG ^G.']$"[:/@*@+X^PHZ?)3<#YLHI[H^ MO[XFMV^;:*)|S]+-UE _HG4"7;.]*G10D5!$4D7V9+M%G]&OO.R!SF M86IO!O<=9$K/]_A>F Q33R4C7T#22##$\GC@XN5!G(\E7G,LEQOO%4QO/ QQ.#@! _G'A=9"0D4R]>0G#C=G]4|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|PIT]5G@K,%9%^VW)=N. M$0!3I7/G7%9B.T85H]4/1F34^J^KEP]W<$]YI*68I=M!TH$-8\S1+N' MPY@D*VA&BP0&74HK2:IJ#K,Y))]]:).64BD7[LRP+0:2L/S/3OKVRR,8QW-4JZ;:F9Y+Y+.V][5RWO;(MNX1:U;EL)P8^|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|II4[9)MR?\>8:+RH&#M= Y:;J8?I#AKK# MQ0[*,K3O#+O7YL'/>UCE;9(7ZXV*;V(9)PEH;.I)*M2<)2LE]"YW2'N) M[0>AQAEB7C$Z[$&;_N>!K,(N:><6'AR? %APFO8*NT="WD9A=+RBL#Y0T]. MMK$.P?&M0S8 >[4++6'B|(BP"T9W!SN]_/F@FL3K634--E$ ^7#153!0(@2?'FW:$I<#IM / MF6V1WTM\GC D?C_IO_/K\_U+KY"=[LH:#&HM615]"<3 M: +7OY&49/98RTU@I*$==]93HA@@MQ3.D#<1;#LC!37WJZ@Z_3V<2< MTS1S%QKD-21^Z$[Y+KTV:)IC3F'XCG!,O+SG?:.^KU6'%%6"AA4W?O0./=@N1 MOO-P2KE:45>)/L!T._UF],7Q-Z+CX:+8:5C?$U:I-&-7L M"W6@R\UJ'1-")YNMN$@UBP@5X,/8K3_D:&6FC1)4+B6S M+$<>>(>_]2D <_69$TPD:57Z4GY[NBDDNN=`FFGK8G-N\)(]9=M]-!TOD* M[!"IHLXYO(JMM0?2P*&>0128;1!P0.,2895:X.A;,/F4_8&J_Z&9(EODZ)O/IGTSWOIBA<[OSWLY<^)HD84+K* M$G5Y0+ ^2NK^ BU^C6X9?+KHX-65"M9OYG,WWQP^<:9$7B_S$&>>Z|K>#\;1# MVWJ/!F\Z0#*%$@B'#B')!L7|<[*9 OL?:M %GX9.-&//8')^-XU@F?KA0.>N M9%?-C?:AI .*D!/8KW+NNFMP|\7Y9C3W2#:R-UB^6]2|%(=M>8-*;YQ@#H5O-T'/L)8FW*AR%Z?Z>*|T&OL**K5W:?1!N>]_+OV<:U+:8%(F:T)<"(O^+(65Z|&9 MW.|P'XAFQ=HYLDQFB@LQM _1F*8QY-G%HKUSL67-2|\^"1O4J*.O+, TT7|& M_W%GGV 9#U |W'IQXQMNOQ]=Z,("6NKZ]V|#Q%T1KF2^G3/3;^,XS*1DK5%MU#_ <|;YXW9N-%XI(WJ6>5X;G0)|!?)9\.I(Y2P'&#-;M@:(*XH"YCTV#, MITBESV*/Z2IH*(4A]ZE*$.GZ[41|6)*2"LZ>Q*37)PO\B]H&>3R912.#R- M'&1 ^E!AL%B|JP,>:R/AB?|HLY=|

MZ]5:9H6NV9>4&O3]TM.0]W\].M6"T5;MA_HEL]7BQ_4MK=+:NE.U|%/:CCO M[:QSMON\N]U@(?/KPX&W==S;WC.#.H8G|:^(KG=99_YP2KNI//>/T^]_?96C MFXL^.4J_D_8(L/S#6Q8"3C3;S^)93_9WSLK:QOXK4^:?Z9>K-7\]Y;?LTVP_M.CV\2H6S.%?E64:LGIAYO[|"|)$B6U<#N\9%.\ZW2X5WFJR5>F4O?.??],YT MZ<5&=V:>|%V0:&GQW"8|W0.4-?FR'W$>;RA=#&WGO2,70]_F&5S6*YW\:]I M=$9P82&QSMM#$K68_L1'^(QWR8MGR%_ZKC3,=mM#2[*G1^C>'<,!?Q"H EYC M+OEE^[!9M$.997+41PC?DL8)EYW%C2X<9PP87PPG[54XM"TN+-P079]UF M]_NLS=Q_NO"/|I4ZA1^SZKD](K|R!XO?*

*FI72I:AQ:E*E34H9VY[S1^TYM|[5 MC\WUN/2_I_G.YZ1>5<'3>32/.:HPL><5W[IS_&Z%_/TG[5O'UVIY"A2PZFW MW6<B\Y6WEJO\9sYD_|^C%V: M_"/^\+5]XA_^:IN<<_2:@O<)-YX^/V_YXY\D1#>"0X??LOW1JL/)S]<:5*Q M_|=TK=V%Z[S%1YUS;]YG[OG^.BK.\(:XZ],[]?CD]JN?;*('|W16E9S(/T9 M]9K8;Z), ^#ZC>]4KY?:< ^_C5P M^*?SP__4^X*.|NU_U|WU]]I-#PW|O]- %!+ P04 " !#A@59N>PL2>$4 M 0#)7P$ $@ &EM9S(V-S$V,S@X-E\Q+FIP9^R[!5A<3|8ON@F?:X 2W8$&# MNT.(%H*|I2>IG$G6(#@%B#)*=]N[A8@N%OC3N,! !2_G#D$9^>,>W/N> _?(M]]VL_E<WM:5]N==NV]7TD_$#ZA?04\K&&=2[]!S % M7AY@! !4*

*$P2>/%H8CQ=O@T$ PJ.-IVAKI;3^\0F0 @#6CSU2 /D0#>WQ M6@3X(W'O3[_]+:_EM_R6W_):2LQ 12+G;F-&H6KB|& #,;$& ,1H^#_Q"=Q' MWI ;C? 7NS$VYD\V/ +R"/%|C 1X M6$.EL'1RLA-@9:5U9#$RA1B:L9A P*QN1G:L[^OLC("0]N=8DFUF1.%L9D% MR%:8|KBIC8X"9"T]LvDMSR9O\V*9+O<#!3]5!0, &P-N$W#L5D#3FI;2:0)PRMDV?*29+U[,507|FY"@ M!K8+RF5D#3Ei;6P=!=R$]*

*Y4NL"C_4UD3'$V4F8RMD99"I@;F3.;6QJRLU:,1IRLS.;FK$;&3*RLM9N'@YA%B ;M\0]Q_ M5[' AFB)"F:")C\42>(P[_JYK9__^[VS8@D;\AU?_BYF/]OQB/Y3\VO]=/ MGP]Q_EOH?Q\+UC^WO4?*

K+RWU\9<4_P7R&^0WR&^0WR"_07Z#_ :YGP7R5]9K M9OM(<5T?N>S# B !(",B(B$B(",A(]$@(Z\PT9]Y!C\#"QT+)\8B)"/$(M"4C(Z2A)R%Z2$!2L5"]I&=@>L5$3.'RC@IX@@T'CPWWT V\ X1+@_R;I,#>">P",@*

M(B&C/'V&^1BA!@MX @'OG^ 4 M?C&9^-2O$KP5,9.:#B-'R?/L,G("0B?DE+1\|_ R.7-P\O'+R#O1E)*6D:V MK:J-NH:FEK:.B:F9N84ER,K1R=G%UF9V:7X:N;VQN;>_L[L%. MS\XO+I^)*2 M7AY@! !4 $P2>/%H8CQ=O@T$ PJ.-IVAKI;3^\0F0 @#6CSU2 /D0#>WQ M6@3X(W'O3[_]+:_EM_R6W_):2LQ 12+G;F-&H6KB|& #,;$& ,1H^#_Q"=Q' MWI ;C? 7NS$VYD\V/ +R"/%|C 1X M6$.EL'1RLA-@9:5U9#$RA1B:L9A P*QN1G:L[^OLC("0]N=8DFUF1.%L9D% MR%:8|KBIC8X"9"T]LvDMSR9O\V*9+O<#!3]5!0, &P-N$W#L5D#3FI;2:0)PRMDV?*29+U[,507|FY"@ M!K8+RF5D#3Ei;6P=!=R$]*

*Y4NL"C_4UD3'$V4F8RMD99"I@;F3.;6QJRLU:,1IRLS.;FK$;&3*RLM9N'@YA%B ;M\0]Q_ M5[' AFB)"F:")C\42>(P[_JYK9__^[VS8@D;\AU?_BYF/]OQB/Y3\VO]=/ MGP]Q_EOH?Q\+UC^WO4?*

K+RWU\9<4_P7R&^0WR&^0WR"_07Z#_ :YGP7R5]9K M9OM(<5T?N>S# B !(",B(B$B(",A(]$@(Z\PT9]Y!C\#"QT+)\8B)"/$(M"4C(Z2A)R%Z2$!2L5"]I&=@>L5$3.'RC@IX@@T'CPWWT V\ X1+@_R;I,#>">P",@*

M(B&C/'V&^1BA!@MX @'OG^ 4 M?C&9^-2O$KP5,9.:#B-'R?/L,G("0B?DE+1\|_ R.7-P\O'+R#O1E)*6D:V MK:J-NH:FEK:.B:F9N84ER,K1R=G%UF9V:7X:N;VQN;>_L[L%. MS\XO+I^)*2 M7AY@! !4*

*$

*M1;-,8>GVR+MZ\;&GU?#FN5E$@26CH9OP5T-D|:\VE*?O3_9-N(H)G"(M=VP#: YQVCZ8CD.*,B=?G)-G)>RK?LXK\ZU]2=/<1.ELEWF]*TH!MLEH,PUO M12FK(GL/H1469SIR0!RXWX81C8Q[\K /GB:^1\ILUM7KD'4[^;RCS"NG-FL& MO\%ODS9]ZKV'YE4%59CH!U1C^ R+BZA75)S?I%L^ZˆZ:>GAM-B'Z[5T**]^E@ M+ˆRPU-<8MW9^I|((7) ^ T*HFC/:M="7>RLEZ2"VC;B[GDQ=>)-%CJB<-+DD MES2XS$&<7H1;3@\ESIZ-SI5SW> ^5&V4&H8K(1K,ZL]6Q]YDY9EQ\'59%N7 M,FLX4%FO7(MT.E^(ˆ3("BO@[8K++>5GI3ASVS@H]NXE%)GE*SBDK]*0T4M. MWNS ;'JZV)$ ^&OO.6IQ 9%BVP+JZ6>K>Q0CW\R*,1S5W ; UUQ:U.99*G.%.6 0*V15R9S_=K=_RS|M<%3FQF@1_X]7R?Z3I.VDJ':' #L]WLD$UH\?@COV(1=-_5G6VG;G@>KAU M>L-JFC&VNQ*)R=):$DVNIP5+XLPEYR(! ?SC&"& MV2 +J\!*O@PRD0W1YB,D13D+*RsLFBXQ7K+B;=9K;*&NTYIW/H#=N-C&CH/H M'Y^/]2IY4.\]J++18TAWM'D)O!FN&T3+J8YS+'G]572#*^Q=@IT7X"D'>U(BO(M*.I)*=H:X(S]O.#ELE0230AOM:K3#G2H%C!"(SNH:$]XD% MMW]"0:-2TR:[@=0^8D?JAC/I7/E1=YMN@%OC5C]4K MBL:?OLW2]\.(Y,"7'Z-4QB<4&R:L19]R2&*$WW=+M-DB:CH$D47PJYOV:KI: M6YDNOT\^P]SYSMHE$RP^ [[4)]"=A,RA%|+=EHXYV23H4*0(/=H]H?CS*.4U" M2"5_+ VEXB ZE9UO4N.9)\":KK[_Q<5A-&*]N/:MF9"EZUX#,7QRE4RH:S ,W ML4<0IZWQ_DKM"0 WO$5@G>](H/>++OE\.O-Q*$HETC3VM:KT'1-B.(W5NG?XOCB97I3/[IR<>3U%#F8>2=A MEZ,+<+=*P"2%I15>GO8[HV3I2<[>0KST7"INDSGO=$]?4B9XB ?(IL_=C M5.,Y.6N-K75L ,71FE9SO+2(]+IR|\"GGE-.0:8|\8@G:|#*$OSH)GBZV!?9NS M?]*_^V7)@W]/Y2ZL^8PUAS4?!+%.C*N^,U(D)'%FXQ#OZZ)+%B-B.L#L7Q"CYX3XTVA/RRB\9[_E/D M"UH.[?AM,O-G[^G,;L*Z? 'Y6FYG4F:TCQXMDUR%9NK3X ECH>Q6D[$#?)) MSM7,R3-\X_Z/4QJD7!EV$A2!#C&N0LN2I\3@Z8!+37S34#@(>E=LHAN1S]&* M!XF>8Z[6MD7Q[F+,KJY"6> ^!4&W7/TC|GK|U]#:UPXZ+|@>:.37O6#H>A>G MN18N_K&KU>.4\.S[MI;=C>:K;J9&9JA&&LQ0#O#*M\.D4Y? _ZFUMCI/0&_MV0KJH_-L$=GV84P:O)K+-,2[1OQ.R"[VO$X_:9IZ<'10!8|^=|)& K0>_ M@O*JU'!^-7X;IAGK8&2#N]2SH "R:AST.X%B,\G$G!MS=*UZ?X,K7,.DI 41 M'T%,K(OP3W9AQ[O/SU*+]QTLO$_WFG^-X[<;ZCGRJ/4GX44]2AO(§'-3]F^-? MJ528&(4C"@]06<1YBD[GCYF&'AU-Z[!9?|)86Y_*&IRLT]B=YQPH+N):&]!U MDC?0K&TXXPMX>]D8,SZ,X6OT!*N'UX@\\|5!DTQO^UH$O^QT=GFTA?/X$%]" M5'M%;W7T:B/6 O92F6NO:L?8B?2 &:UXC(GX|/2UU$BURW7HZ=_)0^28Z2 MR1.0QNJDB*D]-Z^:M:5E]0X-,4U)129$0+"/QE<']:#D?2,IF81YP5/*^V" MA)>-(IX+0PE-M*,K^PPY^2@H@N,U\0<)V_V\/_)Z\=>6. (F/IQ_2>I>&UD[MH>#^F>AFPYF6Z)!:WIN' +C3U1:#G8IT=T]D|=9^4J5:"2BL,W&/,I'BQ|$' M5['HIE5M;%DA>9Q.E# G$G0#N;V?W.E^^O)@(21LA=VGTD"+4';TW9I!R] M0\+)#@#X$Z7LDV*^9-XN:!5"OJ?O=$;7NYPZA4)<0?|<\,K:[D MZ]/K;(,-OMP$%9'2XX?D2F\.KO.*0#*%M\Z7A*;E36A6O>Z[M(75W*@4A:"3(9LOGB'/PUD),VV*!]D.YKFS*tT$U1;M\$Z30[E]>QGF#:[) MKR(T2'TCHEW<((/T25VD?&2M4]2TU85NLKW21$N^ R-OENL1FBYM+,T+7"V&Z)FG/BY@V6'8_NP%V*&T*#]/[6(@8+5K=Z[]=Z_N MP,W66/1^$P]UR@#P%;)[:+^SE]*@-H68)@N'Z{BV_1-9;2#5]ROS" +I*<40LOFGC>]E@3FZ;T]POG' M1Q@W/E-3K+N1XU#R8$*GSD0-.ZZFN;3 ,;^Z_#0\4CMVJ:I1- Y<)|M">-0: M>9 O[IU@V?+RWFUI7(FD!=3=YIN>-K[IR)=060I^JB_F1\(S2:N :V)IM*- M3F \2'UH7OL:MR !03]HOT"Y?7ZYC/("PH|NZG;@&.+X/(^N)I+?CC;2+6)P M4=:-2_9G6$(? >6L0,X76B5]A1P'XS:S&$;Y:7E3G>+#2NE'&E <+?.<I#_ M@X,XV8E@06EN HF<,?3+PKNOFE1HN/6]["%MX5%$L459, %3M0%+ $<#.QM)O%-@ Q?!"JO'2,E "=9.63E!;/Y1LOP84NFCF[^I!UL+/<!#US,ZC'V'@'L MMR=7+&EV%:.XT;>H[*+;"@3^^N1, PNLB/[5/'K)82]=/"|.WB]F7R[OQD&I[10EN:4>X1M)B4)]M):@4\@,V//HO4| M8)M(>)*<>I07(J[5HW%P8,-#(CN579YP^ /G/2:B.(W!0!V)>IZ/2 \QP^G MC(W3F17U_7T$M? (>IG*')NON' <#FC|PA[H(A'P0Y&G1'F#>;BR^94I,B%\ M35Z*35^>)=|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|KXC_R1N'<4(IT.S1OP%MB@YOPF3FUP_*=.G@7:-ST<'GKOVJPMPXXDJK]0FG1V4K"A ^]DFU':#"_KH^7 M9#:[KU)IF#HP'V"5*T,%-T@=,S%U.Z_9ZK** 63PHLSJT=M%Y M^:];F<|>D[7O%Z+LD1029NC++#)R|VF23B,=Z%[|#VFEB'Q[E ED 9X T/)#% M|MR,WD^<'")ER |$O&2#7**30*I2*UA5[3GK*):|RV6EMVBR.ZN8P$N]?SI PSP M6+6Z-:RPT,*9!]UC\2]W1+O9 M% 830U_R|M_6L*(6D1DG**-Q.P!EX&JC.P(' |:XNLD/LT H47 MD>,R'Y9YAY&'VQ%:L96HLCVSEQS.QM/67NJ/B&T!UELE^L&H*79SU3+%Q MIZ9B*61B@ONR><^7OXC2N.:I3C7Q#:UAX5!U"X\@/8E.N27XIQ+G%+&&V1X(M\,#+Y"-+8? FU0YEU@[$RPJ]DBS!Y@D97]L\LI86&,4DD%(RT+P/OS>"SZ4= M]#Z?ZG<33X<5@M0:A&!STS+B>*>5W?)FZ2:DB'T1)>SC6,I5M0[5G??/I*5 M2]>OS:&#RA!$ ^]&MA[, # `C('09X>>KPT',%UV_K3F7"FCY9-TF5PF1,"DP M@$W<#:7TZ4CR,.TMEH-+2GG$OEVTO*>=%-Z,59O4(O?H)-7VF3+'M/4 ^*T[\ MJ2[R6RX+"2_UG]?^?U",E#W_K:%%*U9N;5WC)(T?3]\F]KS>(,HQ5QW|B\Y4 M.'$R)P1GPZ"/Y%E54] @$?&(UO4S9N+/^%I/BUEQ1/P0N|/ M)-S((_J1STT#4 59U-&V<"?6;F32T?^:!9C9_P$C7"O^I=96ZO&(!%8YT_N M)1-;L!+[&Y#NIYOOF/I1Z^\Z^M?A_M:0W' M^:ZYO"2>&3@DS2'W;I:0CA*/(8 M_ J8+*"EQHR* "X\ZB)__ 8[8*NJ?8#?-)Z"]^O?[XK\QL9Z3, M8U\\CGB@]!..4:2.CR4RN%3P!?VE:<2^S6NPEBH8,\G1&N=]T3P<:1.4"8. MD:35UAR ^/JO ^^|O [^=" :;TOU^U/P% ^?UGJ[3(Q@'G7T(E>+!?FN9+(6&>,Y)>GO<[?T);D'Y? V%0L3|8]/ EZDK9+E&< M3#5?P-K])WF#|6'AT5* -;6V7\TS*OC@RU>U __NN_DR2:6=XIA*[3F')F4L4]' MP01&*F7])'MI]>GDYTGV8WJJC6;S2%6Z|.=?'R2%Z/U:,XQE+5Z-OQ'/, @L*'UFK-L>/# M*[>XG)'F3F,L#'?LOFXGK>"P$&:>F:$Q_"IN_!$Q&2#7***30*I2*UA5[3GK*):|OC\9R:?;]^[2%Z=

CN!M:4)DYAE@LCE]{PD28Z>HSEN;J)==!MV9$EG3/3C>O_EQK'A- M^\B/8A79_Q,'61;YVYS%>H5FVK.WO EPU-M@WH[+;@L\@$-Y_<*F<[B\@,'4"_GTM3UL]7|3L4V[U#)!<^60W17*

M9X^9UM+$O4?!C87XX(,G>*!_P,K^=:;;]15-7'UK5B%G"Y519;3,D*/?31[^ M&&=6*]*7Z# .@A^S,T^T#(0.KK15L/ V26]U+DLOM[X@XINP/0_P\W)N4UC%1]^\#DRN*^B? 3$&*

**/5 /\~WOKS\UGRN/7AW*%[X:CQ5GBVR{6>WX3M4D,OP'-A8X_IV-BWKT,/A/TRTG8E)#40L8UP(5RL-M/JM2@3B/1;/+..%-R>_IX%5E)V,UL(225,2D8&E_1@IF=]W&5$\C"S?7-M]%$XEXC]/ &\#G08.E#9!]_>T.$6>!"+/':9(:73O%%-4[OV"5&-U!X.S\I ME!DK.;C90.O/M@TC/M*6W4:7W#+8 <:,[Z^W:6K#W!9=OZ@E2DGI%-":<@(MHI!QOF%`]%;2%'G.AI^N1CN.?T56$_Q#5]OG[S1OM:R.F!$4ID>CLF M<:,)K^SGP^^"%!MNWE,S'-,2/S(IEF:.F)?H"G#W)GU6'-K0#5:M/IB)%f@~"%_ M56KB^FV6]BVPMP^L 1A.D:.!UKJ*7]*+1'HXQM84O%'GBK5NPEZ7.*RWM\:0 MWOWSOD4,9?J^-])*0HT3]E,C+;

.XI:P1$M)59_,O46)?Z.5R))FQ#FC8N MVOATJ,,"U)&F|!+49?X/;)@;8N#UP<1OYZM?.8F45A<-+0,AL]XZ'-P5>^-G ^A 94*60^G;2)+E(3'U#/0'AOC@%%% 6<.;>ULJ3D',$%);/*1]K;530(;;MIW4F7 MN^$(\OY9Z

*4C%YAIC.R/,1/'X)8N2^2^.+;E\KHYTS^^WNS/6U M(MD(K75.?N]^O+>>NF.X'M4P,$K^J4#R.L#YB@-B**Y?1.KF'+,.5^OX_U'"K\ M7]+/,^*#*>YPIN^YLO,AXTRX^_>?2N*Q3Q7_HD2OWC74S5W6;YOHSR B*WU*

MD)\O6[5-O=A/7EHHA78.U9:Y2&%&,O=MOL[%"-+'W;MR1 *<1-,^:#"M*1Q MWS!5K7>U\Y(MB[?+1)IQ_ID&BI.d(#E/=V<<<TXG- MT=ZEQUFT3|[[#&XI6W!E,.HFK9?G,75X@KG?PA1%,#JW)5S_\R+Y5]

MAPI3Y,"P]WK|P?M85H^:D/,B(-%9UY9)#[EUY=2M+|\N862)|@6LLP(U-M&@=P<= 2A>WM"XHOZA9R-N2~QCW(FUU&2!+>>#65(G&5<2 .]JG(;ZB9.3Y# MUY4)@>?;8J4H>PY)?*

*J2B=#_YOK.NXOP>.32+6U9EVA0JLC>MQB9"$4 MPEQ/1)9\# R&L4VIDS6P'SAE4?^U'*#A#D.8!29ZS<(/NF1T8EV3/58P#202. MHH%0[5MI9BJJ1U*C!0!A=KGUMI&S@'7=QLF$*11BUDWEH%)E2M-(B9M1<%ZB3?PR*

*MP67=+:?2K5YMOF(dBT*DEKO*L+0jG<&H10:(C7'DI'LiK)(=0-SL M82'\2&0#*H'[B(.%ZBHXJ_!DY M&R"T^7^0OH74I4XLZG(5+5B\@'ND847B54.'L14@V.5A_A->;6)1%BTY?CEJ MW\3-&M,YK^,AE&-*

#_[',W&8Q5N&O=)$M#|ID)@.LOG2\)\Y545Z)?F;R8<^'K% M6>.O,W:3Y/L5[$?>)|^Q]];B1R%T=CXQY3!9U8C+1#(3);EY>.YCTU[/=AGDW_ M(SRK&&#:02%) \ZE[98:^.)!^VQRWSA5B|HY&15%/,OR_??GN

M(,AKLT8)}BB\A8.BH57\H/`-31G- -U4Q59A-IO MD0P8X!"LF(W(MiMH"Y>YE-RDI/U?M9-CTG4+S7.M;&vIZ/ 4^M(BK;?MQ\5O+E<%@W3?;_9 4 -S4_A->;6)1%BTY?CEJ MW\3-&M,YK^,AE&-*

#_[',W&8Q5N&O=)$M#|ID)@.LOG2\)\Y545Z)?F;R8<^'K% M6>.O,W:3Y/L5[$?>)|^Q]];B1R%T=CXQY3!9U8C+1#(3);EY>.YCTU[/=AGDW_ M(SRK&&#:02%) \ZE[98:^.)!^VQRWSA5B|HY&15%/,OR_??GN

M(,AKLT8)}BB\A8.BH57\H/`-31G- -U4Q59A-IO MD0P8X!"LF(W(MiMH"Y>YE-RDI/U?M9-CTG4+S7.M;&vIZ/ 4^M*(BK;?MQ\5O+E<%@W3?;_9 +$/=;=#E>.`?9>Y"5LM+GYNTI(QTNPO^.&6<.>ULJ3D',$%);/*1]K;530(;;MIW4F7 MN^$(\OY9Z*VPEHO:/.P.AIU=$9$5:?*

I(13HP_=)e@%'I/_&2V M;>6BJB>1^'+=T9=)!"55S7WV_]U(A;7.VI8!SVI[F=[YU0N;G5[ZRQ;.EKYOM M858FC1$?\U:5.5W)X=*E'73&N.H3C.N'%=SB M5RFI;@Q?RIL H9Y.@E;5\:NYEU?U!.A_KBOJ$/+K3NPHN:TE)E'LEZ-^;$Z

M"T'Z51(&F@FEKV[18GBAF1-^Q75%XL?:$^UAY2,@:7"?YNM,9X7^5P.(fD^0PD.IGTUS&U5B|89>/HVT4?X)\)/R&1D&*CGQ!3B,_X0+=&S'/&Ej>;?3W<.%*<9I<&<K%>N^-7YQM:1_^WI*

MQ9&+_9H'3W)8#7LCP(@<_]:OE-U(f.DM^X>AG:Y-'%-$VGU>/E+O+O\O|5D!M-RDD1?WUV@/A_,P#IT.Y9"W>:,!4Q^7B^W6S5EQVEX\C9&Y>/UV. ^X]MA0%:,U|53S>>:CIDX|&`W(=H"X'4V/5OW!)9?O?*

*3C=PI8W:LC4\/7\'TT-) MQ3MYGNM.Y)"?TY"+-)'}RK+<%CXIC-W.05P(R!'83TV\>+(`M4*$AR9?@~ENIB?@DN"W5. MM$!N6A 8PH;5\->GNHN/5\PM MS_M/$4&_5)ZC<0S1;G<\G*NC<1#PE:|*

*j,6?V<6=7OI(VU(dBT*DEKO*L+0jG<&H10:(C7'DI'LiK)(=0-SL M82'\2&0#*H'[B(.%ZBHXJ_!DY M&R"T^7^0OH74I4XLZG(5+5B\@'ND847B54.'L14@V.5A

M;4$ZP\))N=TH<)-P"+9PKEO?R? M=;1Kf>\fC!FS!2=l/+7W"K8'N(/N2+V.*$;FCD$DEO*1&&#&DMX@:|U?KS:? MF9S$"MN0LH%-#E>-#5SH1=?0_HPQ<;JG-Z&DF-M$LH_;64&)?W5]+/;B)&JX-QNHWL@O?4)DV@H%S?C8_"H;_XF*\W!R=^__M;:1EDKXY7&U;\GNZF"0=Y1P>.'#...TI&@C\PY,_7_<<(/ZT5)?=8UP(5-X(MK.69^^M>X(1+I7%RV(U9FGYA0.E^-9T-RI2A/"B)4|C^F;R>+M-RAV;ZI"Y) M SAT??0B277<1E^"M7PEK]-G-1RL.7;FV)7C^\2?C CB2U8WP3TC\@<I=+E<M_7_NsIJ/IW1^);|<[<^:\3B;#9E4O)3OQS*':<9ZW57TR19B;6&=?9NZ-4sBO-MH;YV>1-+F G>V93(BKYB2NYFUI?>>W&JP.HA(-(FP|\79U\?3M@JBR&CMQ[373^LW#C\JB9/1<7J2KF 3!'0LZ+(=?RJP&3S\f\$B'$1TIGJ_U-MI==N\1>(C/W^2.PI;HK6W^?9\\f@@"\-Q!KOO6R.):fJ3Z MA%-`-+>2P26>>OI/PSAS*CZ5YJ;8ES.YCK-"6,K40&AE]_G30CE0,T5-21RX M;D'.2WA[HN#Y#0:&;?$@VMFS@^\Q:.,_=.(-63Q?,2L7(I$A5Q@<&"\Y.M?H MY@H$%N4*<[<\&8F>E:(+/Q_O=Y0TB:(XE_]-KH>4C:E)<#.Y3T6H*&?BH(&^M'SGC-"TD2NK7#[56/6<&\BZT010X[WN4I!-Y=*#0(EPH2&0/M.NRKS69:GI..M+W&6+8F+$;Z^WD2>Q]WK@=Y4)6L1+#J2$?M@(&Q2N$ I7I^^^?B^)8.V\ X.J!ND3)W\$56IU=-0LNN=C5R.1<4Z*=.+ MY&X05POM:$RL ;6AX#1J990U>D?ITSIHA5(Q#:X_Z(^TP M?'TOM5I((\QT&OIVT:N__BF&J.FP$^D @6.7GS8>JULTD-.+9.O IX\D7S)(.ME#|2886OTH0M?@>8'G:O.%\\6'_HT.">7^YBT(QZPV[K[OZ^.NX&<L_.D50 MI3Q7%/YQH..2HC_#. *U\DVW_^.[WUO?HY;MCYIT3OKM=A5MG6#QE%,8'F_@-MUUWI%.9&XOH_R6+#>.,.+1IBY05N7![)OI\/("0U54XZVI.#3V0%=*FDP"R.s0CY M#1IF/9UM2VU[_L.SV;?<4E.4NKX%@\(V/SWDGKB M$X4M#ROR#d:*@F>CI-[^& M.#$0; WJXY;6UV8MTZ/#R(:W-D]R\VXE5.5WG$\M#.7^15ZB1W4@I>N%*PL@-1<2DV $\GF(O:[*OXMZ.=G_'2P.$.X/S [4'[^C-M0.PS&LS(BY\04A";?K)YY(11X%7.4-9N>D5Y$Q.53X;/Q<\Y'23VZ.=]T M@QM34YFUR"Q8&+#KMGR5M+PD.,VXM;?EVHX O0P..>!#-F&&I(6QMNP\/5L0 M2>^E\O3>*6F6=(K0H=[SY$:W;/"IRH>$=#+++X3#U!fJW\U?A%P-L$/U!A7I3U@=*U'8,#X)P[L<7=-^@ M,>&UA4O&/,-*K5*PDTRSZ^>D:+0#5TV.'9[0(ZHF=?;)5|#:7[<9 /AU4O.LA-MHWPX]P^[,-Q;H(_!&\F!"D:+35<@,JU+D:/Z;Y=?R0>*CX\;1YA.7!>- M:EX^.,*#6^3T M&-M-3++%H|K$XK-RN8A7E2 G2E"!,Z8L[NDAW06Z0F.P)AM#W4SO3\AJO"O/%>]G M;9 Z;81?U %->CJ.^\&G_+UPIEVC>@F-R;?!9_?>\&HR24^"",]$SZ4,O>>Y M" ,5@PP9IH^,/F>)HI| "5G80'8>Y4_I M65;"%D3 C-IF9JQ(B2I#-T]"PF"'**RW#J.Y)7]\'<<+=$28U7AY/+YEYS75>;.MLDG2O*%$;W[LXTK<-<+T"ID3(79(X&I[3G3 N|{6;9?VCX[MNV^L 0(?\@Z5YEQTG>IIA-+K M&.:U:+#EEN&GY0%Z'ZY/RGW/KZ(:\(A=E$-$Y>;>/A_I&$&G]>Z)2\>%CUH/2 M4)7 F_$(5.4NZ\T-ZP^$$!!./U1|-DC.-],18/#^QB(_<.L%1 MXCO12GUSPK0@&'!IX(IH/6U9L.6_FKN^C^\2??+STE5&@EF+/*;/Q!N)9M&C M*KHE&-#.G29KN/CPIG>8L@:QK%!B.U\W'BE 7_TR ^O++JHU\Q_K^$G?C$#A M;:+,\Y-E>6IS_6GL=T4EY?=(7x N9'ZZ]|>6@86%@X@+&JA;.!!-$=)#;0 3TZ MN_KU:R[U%BQ(LMD\+CW9\5HCJ4'IXCL,G.:=]ET[_$"1OED4U2\6B@(;Y+!.= M\=SA/=4.R7I+U4L&RL>U^(S[7?3R$ '0@3XSZEWYUT#.IZJ*4\ YNK5WZ'OVJ<)#C.;8!|FV=JOU]_9'1!ISIC!.,E>)ES;9"/_3ZPB3>PX -!Z.5O!9AB M600\'C9 2@1& T;[&?P>Y?P5I3"C64L95RB=*P78Y%58V=C)^]F-N;>N(1Q MQL^U&>__<\09=IQ=!.:FF^.9U^G70TB8@C4UY%5Q640OC=7]_\VTM9C'5F =6 M.D:UQ+TI#$SS53;._'F7;)B-*EK9[_@67LY%HT32-?<2P?4=,V4D]7]+U]GL*RD[$?M-MKIFGR>J."_09 YV\V ;M)AU',.-W\Z.57IC-!3;W3K)'%@C JH0F|'-Vl,.MQ0C1KAQ>RlVDK+K5'j287LIKT55#^#\U9V6 P=WV9&'2I1NHBC%NZTC'@-E2M M-'.,'Z\/Q>VF&",RYMRO.<'|#DT:E&;=H6+EV8O5\X9^+ZHDAPEN 6 M'[VE MO6)&>Y_G(8,%Z,N^)[W);*=6^_&\/O0. DMLB0#YRHLDM; E(O]YUZ>M8VNO M+O4'X=ATWSD.7|8^D.;1 CECU;<&8 '@1+9T=NMLT?ICXW=CX"^&)E'O640J\&EVSSIK() 6H5>>0LT+Z5YIF>O^;,-*RD?0\WG*L$H7 =W)WOO*QK-,X+A.>#FKE1*MY.GAT1,/;0_1ME.$QE=M=[fW& WMOXN=G(W IA R MLZBR). &'+U[PL#IBU8C&MX<<5O?KNP4+O#$KBDJ24T 40.=2J8?U9.8(%54<5+O"\(V&:OH;//75OM1N.W1!XMI=M O MROFPKC$X5O44D'D=.;%/[VXY]^^(-)YNI9V@BE[[HK.YX&4i6 M^^.74\P6J29 U7^;-^LC7^G7EV.@[1@+_Y5_=_Z)83F'_U\+.P04 ^'# MA@59^E!%#GF(-#2NP $@.&EM9S(V-S$\5.9&X-E\R+FIP9^R![51<2Y<-M>@AN(;A+@@5MW#4$#Q (P258D.:UT280(+@%2(00(S"ZZ'X!;.<78-+XXU!'M_[G??;O-VO-O)DW\[\ZfQ9=BWW.J;[\V[^RO4]5(Z>1R\ #%05E!0 %:06(MN_I#D"OW3N4AMJ\!0$T-8 < M 0Q$'[MU\)]P$ 127,%D" jDU^N/GKIGW[[M#] P+WA'1H |\>WMVU%/#;S9U;*.5G @:$W_*.56 @:$W_*.56 @:$W_*.56

1JT^4!:T^\;@\1)Y35A<5-3^\+*))HPW8 'L'/^Z2]:F_-=@Q;Z/$1W)-M(F4,IQ%&#H5DCN/!=BTZIR.&X@&\W_;(9%Q;HKM4J0?R(G/W(M..NGW:,JFHT]'I1-)(O/AQ7-LD2IXF5@UQ.IP$Y&E4S@+tOVQ&8TEIO#(U&MT M;A3[4HMJ>=-!0EL$HTO Y%(<48WN&2G4]*LP-U64A YO-=\SHI5]VVHMYTMR MRX-J>X \V?!.,'/S[6MOA5TDU%<,/0RT:I(E8)<_SXV@.#:B&NW=[,3[_$\[/ MQ3VFWG"T2\-M*X5@^Hl+ G3I[\B?!SCUW@,AD/"-RJO+1+SI&N9)*H/'BU]D M5C0:\%Y1 BSZ?IO*:@sLXKM-S>7)=,+G GK+rZ(O)15Q_+&G2\AX[-)+H\P;n>&EW2MG M+4F19P14@=>(B65E+!OB[rLL:1Z-1RW1W+81/ M)%(U'K S']IZ$BI?:."18E87-KZ,.<:2 AA?["S9@YXWBVT=|>OD;I:0S_M7-MR7^,')[8NG:6O=HN341_D]Y_C+Y.W>E@N;+@ \BVI M.UMGWDH@0'JS A.JUG<)X0P+>=sQ)I8Z/-MHQ[%BZM'C1_K1TC;-'GKMR+?D +~|<C<.V1X&:B!I_J9=OY=@\K6O7V8BKEYZ-MI=I"N:(A42\UM/#B9AG"04$Y+Y(YSSST5M8/(3*M-2WY]-&; 23; FD=*[M2K$[S=$10(S1T7:AV)?^&?Q>>%^\P=1,D>+UPT1T..& +Z%0.)\;EJ:SPRI= M^X2$W*QLS9#*$Z(IL A32*.(<4 ?XXSA^KPH.%4H:YCU*8*7&&WN:Y; *O5OQ=<#!V%OB[?8RO6,E@,U:O MPM$R;X$ES|[FM3WOTI4(F1$=F3M:NK()6HIXVVF>UGDPV3?4S-3P4RR6.88J\<.@ I M:AN:O1C{'/<%31]#SZ%5.BU1 "D=KU:R!I%3OVFZ1Z2 MK+I.H:C/@\]_L 7]!W[>"H10<[%V3"HE($8ETYC%Q\<[E)SF7L+6-O$&)Z5?)W,- M!$20@;)T5\^H!,.^'|HN=P2)1+=^HEF4>]>F,N&+XRK+lP[")D;!BL!?AC/P MI_@%LNTHT?=%V47LY>\,$IA)ULE[0B6U>'H9K?I"Z'P'#@=>R]X!T-XEGDM, MH(O9\?&.>8*A+U2[HW\F$]35;(F$,HX.R-.78UWA^B/&KBAI68_N-V;B*6N&[\=]J1ADQX(:V$K < M%'[:.DG>+>]H#HCOID=L%4\'Q~,^(.V.=*)Q> 8-B^=-B^~=6Q_<+YE;C|0C:V=G-T-VJT:9 MG9*#"DJ]356R73X[-)E:Q!TW-82QOX0T5%*\;ZTO_UBOH)}5WEFW;,:7=F3#KU, GF<*5[;2-E*6_MCF-3TX&I1"[_O-IVG6L!G<.M%GAIGI+1#^0U0=5>H5&?,AZH52=4A<%).L-KV3Z8FOU*%+9ZZ)MF0<>DG7:.5 M^IP:NR$3V)?=_JOLUE#=)%(I8&TS\'@"09_6\A*IK9]U_3M0U6#G2NOD\'K M^33-IX5D7=KY)XUM9K%9-FD[2J\"*M3C9X>$.+ :Z X_|A;)X7DG-C/#;JZ%9N!9YIF\"Q'=,-9BBMY W_M^5P.D2QX5Q42 #FlZD\14U+A$@=SVY&A06E.=Y<7!\3&"Hl,_*SG(#+OM>249 M@.O^ZR"7C6.RI5Y+EH:);DL3_f//%"K3#\W##A1PY2,]-MZ5CB.)EQ$I,_^2 M!>* %5,M4VN\^BBP>1KH(\<:8*B*.P%W***^#VQKFM#]3CJ^S*6U0:=IP+-GI M21]XTI;PGO?R.G%ITX&E2^C*^K'K%80%)>\-C2MGB#^XX! SL"*

*@QJ K9K2%DPN M@E]&+XX.CH2FN@O4V*30I.LUQ_K@VO%2PUU15F???L-R[^C&((NDT|\W$_/# MW]U$.X0BXG>5M$MO>NG*HB9=0KO^,Z:A*:&U8%W7GJ$*]_]_V@_5QBDD:M! MGFK-BFF.[!FQ@%XY*=SOC~=I2MN UCOT@:W$3V]9/9PH1B7.F.,U7HBM*W6 MO%H(<C:B;ZX,._!Z%X#S;P9-6JDL5X%BZV<.G:@FC5#ZLH*

*K'][E9 M#QD:O6EAZY&\@F"B-VK3ZQ8=YNI7#Z2U.F.\[%ES>=F50G%9AA;8R<@=M=6K, M)H LW!$53'"4:HR8KO73+4<>,*2C[C;M)I9Z"\FD*(79C0&JW97]Y,5<;O<=-P-WQMP;>&^N3.T!:R[K;I1C; M+67&TCP% (OD/'QJO#N#@^:@XP^=2BXW^Y.^M_;AA+9R5ZDO):T:Q|C M)UU6,W MCSA-RG-MDTZ: E7F.;3C.J!"TI8^\?U3@-M"P^F"=]?$-[,25(,;"56SC$ M&&U3E4D[3QNQ2#<>#.;DI5N:1MI8^J8-S+V(,[5C\?9D2P2A5#ZCT?L0HEX-MX:T0GVD4-F-H_L=.=A-I2.=[7DAE$&JF"#'ISK8:-9K-JP35+[CA4H>)K1-M*YE.?>RZMT(IHM[WZA1/JI+7%@2>N46L=#=&MF^^.$.QG9&@(5*G8=S|<1Q2/-MDD7:*U:#?K$;_Y\2KE/5NP-D6B7_KA0+^&<+=E.2? &ZW7WVI7+S<.%AS-P2I M'8GL;-BJTQ=-.5%!92E&-/P6I8U'DL?XL8Q]K\EZO;EZ_D:6'@-G/=N'YOYZ M5#CHA\:MWL!3(\ IBB+2'G.VPD@%UD=Y+;++PT<9,@_Y'13V_.!-2AU:GCS M>B/111M9@ZZH"6"U!$:6'!=_XH*:6D^.[S*IL M=|C*VCAWZEE55<&M.G6"G2=,#"6Y-G%=(. @\7\'< B7,M/_1>[S'=.SR%07 MA[V?A!!Z3#WC7H9M+O7J^N5O?_-G\(-N_2O>:#1K]AU S@UK$/)VO^.!\EVU; M@6ZODNV?9KR^C?X2,IX7D@&P^ES^SQ-4_^4IG."XHG^>P?;?H\-^M^@_PWZ M/PDI4'H'>.-%MF@,:"\(J78T92:U-&9H7GIN!<.9'U3SN =5W]:^H_.[_M2#;&(>/5)^Q^R^%9O5G;_BW;^>$_T!]K|?)D5D4K1I$<_>-!+/)F_El0 MU%D^&@C'68&.+*DS<"8U%)*_K33MK+$M*X]^7.@2B+0%T?8<&C;4=TUY3(;D#,. M.:E.]++T6LLHDFC4,X=^5Z|M;4>@?]^HH9RS(9\K@G 59RC1A_]#PVYNM-Y* M%%AVHI'GF_#YR;W_KWSL/QQ%T60AY"GWY2@GEMF'0%W0F00FAMMGZJFW C8\-U6"$%@D=H"].C}{GO$U*>$;#;D9=)LRW@6K+ FTT"E:OE,4>]O4UJ8?Y7A/=%K/IS!TPD.%U5.! MQ8;*CQ,5V2\KE/5NP-D6B7_KA0+^&<+=E.2?&

2023-01-012023-06-30 0001768224 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-06-30 0001768224 arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMemberus-gaap:GrantMember 2023-01-012023-06-30 0001768224 arct:CslSegirusMemberarct:CollaborationRevenueMember 2023-04-012023-06-30 0001768224 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-012023-06-30 0001768224 srt:MaximumMemberarct:WellsFargoCreditAgreementMember 2022-12-232022-12-23 0001768224 arct:FebruaryTwoThousandAndTwentyLeaseAgreementMember 2024-01-012024-03-31 0001768224 arct:PhaseIClinicalStudyMemberarct:CslCollaborationAgreementMember 2023-01-012023-12-31 0001768224 arct:SeptemberTwoThousandAndTwentyOneLeaseAgreementMember 2021-09-30 0001768224 arct:SegirusIncMemberarct:ResearchCollaborationAndLicenseAgreementMember 2022-11-012022-11-01 0001768224 us-gaap:CommonStockMember 2023-03-31 0001768224 srt:MaximumMemberarct:TwentyTwentyOneInducementEquityIncentivePlanMember 2021-10-15 0001768224 arct:OtherMemberarct:CollaborationRevenueMember 2023-01-012023-06-30 0001768224 arct:CslCollaborationAgreementMember 2023-12-31 0001768224 us-gaap:RetainedEarningsMember 2024-03-31 0001768224 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0001768224 2024-08-02 0001768224 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0001768224 arct:CollaborationRevenueMember 2023-04-012023-06-30 0001768224 us-gaap:RetainedEarningsMember 2023-06-30 0001768224 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001768224 us-gaap:CommonStockMember 2023-12-31 0001768224 2023-04-012023-06-30 0001768224 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0001768224 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001768224 arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2024-01-012024-06-30 0001768224 arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember 2023-04-012023-06-30 0001768224 us-gaap:EmployeeStockOptionMemberarct:TwoThousandNineteenOmnibusIncentivePlanMember 2024-06-30 0001768224 us-gaap:CommonStockMember 2024-06-30 0001768224 2023-03-31 0001768224 us-gaap:CommonStockMember 2023-06-30 0001768224 2024-04-012024-06-30 0001768224 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001768224 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-06-30 0001768224 us-gaap:EquipmentMember 2023-12-31 0001768224 arct:IanceKuratoMember 2024-06-30 0001768224 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001768224 arct:SegirusIncMemberarct:Covid19VaccineMemberarct:ResearchCollaborationAndLicenseAgreementMember 2024-03-31 0001768224 us-gaap:ComputerEquipmentMember 2023-12-31 0001768224 us-gaap:ComputerEquipmentMember 2024-06-30 0001768224 us-gaap:RetainedEarningsMember 2023-12-31 0001768224 arct:WellsFargoCreditAgreementMember 2024-06-30 0001768224 arct:BiomedicalAdvancedResearchAndDevelopmentAuthorityMemberus-gaap:GrantMember 2024-04-012024-06-30 0001768224 arct:CysticFibrosisFoundationTherapeuticsIncMemberarct:UNARCFMemberarct:UnderlyingAgreementMember 2019-08-022023-09-25 0001768224 arct:CysticFibrosisFoundationTherapeuticsIncMemberarct:UnderlyingAgreementMember 2019-08-022023-09-25 0001768224 arct:WellsFargoCreditAgreementMember 2024-06-012024-06-30 pure shares arct:Segment iso4217:USD iso4217:USD shares0001768224falseQ2--12-31http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent10-Qtrue2024-06-302024false001-38942ARCTURUS THERAPEUTICS HOLDINGS INC.DE32-059534510620 Science Center DriveSuite 250San DiegoCA92121858900-2660Common Stock, par value $0.001 per shareARCTNASDAQYesYesAccelerated Filerfalsefalsefalse270422462603290002920050005500000055000000240850003206400075940007521000347000800386590000111820001242700028533000285000001885000188500038860800042940200013905000411899000-36786600025858300027851300038860800042940200045976000956500078574000892940003883000954000929700015100004985900010519000878710009080400058669000526680001122420001044360001231600021126000-55374000-51538000-40619000-388000149000-441000-17900033953000414800032520008164000572900017366000-51973000-43815000-1116000-15000057700021800068000017216000-52550000-44033000-1796000-0.64-0.64-1.98-1.98-1.64-1.64-0.07-0.0726967000269670000265630002656300026923000269230002655700026557000-17216000-52550000-44033000-1796000-17216000-52550000-44033000-17960000268280002700064632000-36786600027851300026817000-26817000100880001008800008900021880002188000269170002700065862800-39468300026397200017216000-17216000942400094240001250002403000240300027042000270006704550004118990002585830002655000270006084260003381410002703120005075400050754000818200081820008182000265550002700616608000-28730700032924800052550000525500008383000838300019000940009400026574000270006250850003399370002851750004403300017960001813000131500019512000165650004410001600003395300050200079790003500073000-4712000-2703000-199200008626000559300026310000-2983000-33619000249690001679000-2105000-3569900014936000568000104500056800010450004591000940002736400045910002727000031676000-13379000348890000393977000317214000380598000210200047300027360005770000 Note 1. Description of Business, Basis of Presentation and Summary of Significant Accounting Policies Description of Business Arcturus Therapeutics Holdings Inc. (the “Company” or “Arcturus”) is a global messenger RNA medicines company focused on the development of infectious disease vaccines and significant addressing unmet medical needs within liver and respiratory rare diseases. The Company became a clinical stage company during 2020 when it announced that its Investigational New Drug (“IND”) application for ornithine transcarbamylase (“OTC”) deficiency and its Clinical Trial Application (“CTA”) for candidate LUNAR-COV19 were approved by applicable health authorities. Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Arcturus and its subsidiaries and are unaudited. All intercompany accounts and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management’s opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. These condensed consolidated financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on management’s knowledge of current events and actions the Company may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Joint Ventures, Equity Method Investments and Variable Interest Entities Investments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company’s joint venture in ARCALIS, Inc. with Axcelead, Inc. (“Axcelead”). The Company’s share of the investee’s results is presented as either income or loss from equity-method investment in the accompanying condensed consolidated statements of operations and comprehensive loss. Liquidity The Company has incurred significant operating losses since its inception. As of June 30, 2024 and December 31, 2023, the Company had an accumulated deficit of $411.9 million and $367.9 million, respectively. The Company’s activities since inception have consisted principally of research and development activities, general and administrative activities, and raising capital. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company’s inception through June 30, 2024, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements, the sale of capital stock, expense reimbursements from government contracts and proceeds from long-term debt. At June 30, 2024, the Company’s balance of cash and cash equivalents, including restricted cash, was $317.2 million. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these condensed consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in securing additional funding, that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years. Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company’s operations and manage its business in one operating segment, which is the research and development of medical applications for the Company’s nucleic acid-focused technology. Revenue Recognition At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of Accounting Standards Codification (“ASC”) Topic 808, Collaborative Arrangements (“ASC 808”). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606. The Company determines revenue recognition for arrangements within the scope of ASC 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation. The terms of the Company’s revenue agreements include license fees, upfront payments, development or regulatory milestone payments, profit-sharing arrangements, reimbursement for research and development activities, option exercise fees, drug substance and drug product supply fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur. A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in ASC 606. A contract’s transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied. For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified. See “Note 2, Revenue” for specific details surrounding the Company’s arrangements. Leases The Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company’s operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company’s incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components. See “Note 9, Commitments and Contingencies” for specific details surrounding the Company’s leases. Research and Development Costs, Net All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), in-process research and development expenses, pre-launch inventory and license agreement expenses. Research and development expenses are presented net of any grants. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed. The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these

contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations ("CROs") and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. Pre-Launch Inventory Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its condensed consolidated statements of operations and comprehensive loss, in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory. Restricted Cash Restricted cash includes collateral pledged and held at the Company's securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association ("Wells Fargo") (Note 5). At June 30, 2024, such collateral amounted to $55.0 million. Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Company's offices. At June 30, 2024 and 2023, the Company had restricted cash of $1.9 million and $2.1 million, respectively, in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statement of cash flows as of June 30, 2024 and 2023:</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:61.6%;"></td><td style="width:1.38%;"></td><td style="width:1%;"></td><td style="width:15.82%;"></td><td style="width:1%;"></td><td style="width:1.38%;"></td><td style="width:1%;"></td><td style="width:15.82%;"></td><td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(in thousands)</p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2023</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 260,329 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">323,471</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">55,000</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Non-current restricted cash</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,885</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,127</p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total cash, cash equivalents and restricted</br> cash shown in the statement of cash flows</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 317,214 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 380,598 </td><td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td></tr></table> Net Loss per Share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock method. Dilutive shares of common stock for the three and six months ended June 30, 2024 were comprised of stock options and restricted stock units. Dilutive shares of common stock for the three and six months ended June 30, 2023 were comprised of stock options. No dividends were declared or paid during the reported periods. Recently Issued Accounting Standards Not Yet Adopted From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on the condensed consolidated financial statements and disclosures. Basis of Presentation The accompanying condensed consolidated financial statements include the accounts of Arcturus and its subsidiaries and are unaudited. All intercompany accounts and transactions have been eliminated in consolidation. These condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In management's opinion, the accompanying condensed consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation of the results for the interim periods presented. Interim financial results are not necessarily indicative of results anticipated for the full year. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023. These condensed consolidated financial statements are prepared in accordance with GAAP, which requires management to make estimates and assumptions regarding the valuation of certain debt and equity instruments, share-based compensation, accruals for liabilities, income taxes, revenue and deferred revenue, leases, and other matters that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on management's knowledge of current events and actions the Company may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Joint Ventures, Equity Method Investments and Variable Interest Entities Investments for which the Company exercises significant influence, but does not have control are accounted for under the equity method. Equity method investment activity is related to the Company's joint venture in ARCALIS, Inc. with Axcelead, Inc. ("Axcelead"). The Company's share of the investee's results is presented as either income or loss from equity-method investment in the accompanying condensed consolidated statements of operations and comprehensive loss. Liquidity The Company has incurred significant operating losses since its inception. As of June 30, 2024 and December 31, 2023, the Company had an accumulated deficit of $411.9 million and $367.9 million, respectively. The Company's activities since inception have consisted principally of research and development activities, general and administrative activities, and raising capital. The Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding before the Company achieves sustainable revenues and profit from operations. From the Company's inception through June 30, 2024, the Company has funded its operations principally with the proceeds from revenues earned through collaboration agreements, the sale of capital stock, expense

reimbursements from government contracts and proceeds from long-term debt. At June 30, 2024, the Company's balance of cash and cash equivalents, including restricted cash, was $317.2 million. Management believes that it has sufficient working capital on hand to fund operations through at least the next twelve months from the date these condensed consolidated financial statements were available to be issued. There can be no assurance that the Company will be successful in securing additional funding, that the Company's projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years. -411900000-367900000317200000 Segment Information Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company and its chief operating decision-maker view the Company's operations and manage its business in one operating segment, which is the research and development of medical applications for the Company's nucleic acid-focused technology. 1 Revenue Recognition At contract inception, the Company analyzes its collaboration arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities and therefore within the scope of Accounting Standards Codification ("ASC") Topic 808, Collaborative Arrangements ("ASC 808"). For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration reflect a vendor-customer relationship and are therefore within the scope of ASC 606. The Company determines revenue recognition for arrangements within the scope of ASC 606 by performing the following five steps: (i) identify the contract; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the company satisfies a performance obligation. The terms of the Company's revenue agreements include license fees, upfront payments, development or regulatory milestone payments, profit-sharing arrangements, reimbursement for research and development activities, option exercise fees, drug substance and drug product supply fees, consulting and related technology transfer fees and royalties on sales of commercialized products. The event-based milestone payments represent variable consideration, and the Company uses the most likely amount method to estimate this variable consideration because the Company will either receive the milestone payment or will not, which makes the potential milestone payment a binary event. The most likely amount method requires the Company to determine the likelihood of earning the milestone payment. Given the high degree of uncertainty around achievement of these milestones, the Company determines the milestone amounts to be fully constrained and does not recognize revenue until the uncertainty associated with these payments is resolved. The Company will recognize revenue from sales-based royalty payments when or as the sales occur. The Company will re-evaluate the transaction price in each reporting period as uncertain events are resolved and other changes in circumstances occur. A performance obligation is a promise in a contract to transfer a distinct good or service to the collaborative partner and is the unit of account in ASC 606. A contract's transaction price is allocated to each distinct performance obligation based on relative standalone selling price and recognized as revenue when, or as, the performance obligation is satisfied. For performance obligations that are recognized over time, the Company measures the progress using an input method. The input methods used are based on the effort expended or costs incurred toward the satisfaction of the performance obligation. The Company estimates the amount of effort expended, including the time estimated it will take to complete the activities, or costs incurred in a given period, relative to the estimated total effort or costs to satisfy the performance obligation. This approach requires the Company to make numerous estimates and use significant judgment. If estimates or judgments change over the course of the collaboration, a cumulative catch up of revenue is recognized in the period such changes are identified. See "Note 2, Revenue" for specific details surrounding the Company's arrangements. Leases The Company determines if an arrangement is a lease at inception. Lease right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease. For operating leases with an initial term greater than 12 months, the Company recognizes operating lease right-of-use assets and operating lease liabilities based on the present value of lease payments over the lease term at the commencement date. Operating lease right-of-use assets are comprised of the lease liability plus any lease payments made and excludes lease incentives. Lease terms include options to renew or terminate the lease when the Company is reasonably certain that the renewal option will be exercised or when it is reasonably certain that the termination option will not be exercised. For the Company's operating leases, if the interest rate used to determine the present value of future lease payments is not readily determinable, the Company estimates its incremental borrowing rate as the discount rate for the lease. The Company's incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The Company has elected the practical expedient to not separate lease and non-lease components. See "Note 9, Commitments and Contingencies" for specific details surrounding the Company's leases. Research and Development Costs, Net All research and development costs are expensed as incurred. Research and development costs consist primarily of salaries, employee benefits, costs associated with preclinical studies and clinical trials (including amounts paid to clinical research organizations and other professional services), in-process research and development expenses, pre-launch inventory and license agreement expenses. Research and development expenses are presented net of any grants. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods are received or the services are performed. The Company records accruals for estimated research and development costs, comprising payments for work performed by third party contractors, laboratories, participating clinical trial sites, and others. Some of these contractors bill monthly based on actual services performed, while others bill periodically based upon achieving certain contractual milestones. For the latter, the Company accrues the expenses as goods or services are used or rendered. Clinical trial activities performed by third parties are accrued and expensed based upon estimates of the proportion of work completed over the life of the individual clinical trial and patient enrollment rates in accordance with agreements established with Clinical Research Organizations ("CROs") and clinical trial sites. Estimates are determined by reviewing contracts, vendor agreements and purchase orders, and through discussions with internal clinical personnel and external service providers as to the progress or stage of completion of trials or services and the agreed-upon fee to be paid for such services. Pre-Launch Inventory Prior to obtaining initial regulatory approval for an investigational product candidate, the Company expenses costs relating to production of inventory as research and development expense in its condensed consolidated statements of operations and comprehensive loss, in the period incurred. When the Company believes regulatory approval and subsequent commercialization of an investigational product candidate is probable, and the Company also expects future economic benefit from the sales of the investigational product candidate to be realized, it will then capitalize the costs of production as inventory. Restricted Cash Restricted cash includes collateral pledged and held at the Company's securities accounts pursuant to a security agreement with Wells Fargo Bank, National Association ("Wells Fargo") (Note 5). At June 30, 2024, such collateral amounted to $55.0 million. Restricted cash also includes cash required to be set aside as security for lease payments and to maintain a letter of credit for the benefit of the landlord for the Company's offices. At June 30, 2024 and 2023, the Company had restricted cash of $1.9 million and $2.1 million, respectively, in conjunction with property leases in San Diego, California, and such restriction is expected to be removed at the end of the lease term.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets that sum to the total of the same such amounts shown in the unaudited condensed consolidated statement of cash flows as of June 30, 2024 and 2023:</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.6%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(in thousands)</p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2024</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">June 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Cash and cash equivalents</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 260,329 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 323,471 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 55,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 55,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-current restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,805 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,127 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalents and restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">317,214</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 380,598 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 550000001900000210000 <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.6%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cash and cash equivalents </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">260,329</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 323,471 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 55,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 55,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Non-current restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,885 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,127 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total cash, cash equivalents and restricted cash </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 317,214 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following table presents changes during the six months ended June 30, 2024 in the balances of contract assets and liabilities as compared to what was disclosed in the Company's Annual Report. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.272%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:13.337%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Additions </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Deductions </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Contract Assets </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-

content;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Accounts receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">32,064</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 55,132 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(63,111</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,085 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Contract Liabilities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Deferred revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">87,325</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,252 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">87,871</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,706 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> The following table summarizes the Company's revenues for the periods indicated. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.272%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:13.337%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months
Ended June 30, </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Six Months
Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> (in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Collaboration Revenue: </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> CSL Seqirus </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">45,911</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 7,607 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">78,292</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 85,824 </td> <td style="white-space:nowrap;vertical-align:middle;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Janssen </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 170 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 660 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Other collaboration revenue </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 65 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 1,788 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 282 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 2,810 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total collaboration revenue </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">45,976</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 9,565 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">78,574</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 89,294 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Grant revenue: </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> BARDA </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,883</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 954 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,297</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 1,510 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total grant revenue </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,883</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 9,297 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 1,510 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The following paragraphs provide information regarding the nature and purpose of the Company's most significant collaboration and grant arrangements. CSL Segirus On November 1, 2022, the Company entered into a Collaboration and License Agreement (as amended, the "CSL Collaboration Agreement") with Segirus, Inc., a part of CSL Limited ("CSL Segirus"), for the global exclusive rights to research, develop, manufacture, and commercialize vaccines. Under the terms of the CSL Collaboration Agreement, the Company provides CSL Segirus with an exclusive global license to its mRNA technology (including STARR<span style="color:#000000;white-

space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">®) and LUNAR® lipid-mediated delivery, along with mRNA drug substance and drug product manufacturing process. CSL Seqirus will lead development and commercialization of vaccines under the collaboration. The collaboration plans to advance vaccines against SARS-CoV-2 (COVID-19), influenza, pandemic preparedness as well as three other respiratory infectious diseases. The Company received a $200.0 million upfront payment and is eligible to receive over $1.3 billion in development milestones if all products are registered in the licensed fields and entitled to potentially receive up to $3.0 billion in commercial milestones based on "net sale" of vaccines in the various fields. In addition, the Company is eligible to receive a 40% net profit share for COVID-19 vaccine products and up to low double-digit royalties for vaccines against flu, pandemic preparedness and three other respiratory pathogens. During the second quarter of 2024, the Company achieved a $17.0 million development milestone related to the CSL Collaboration Agreement which was included in accounts receivable as of June 30, 2024. In evaluating the CSL Collaboration Agreement in accordance with ASC 606, the Company concluded that CSL Seqirus is a customer. The Company identified all promised goods/services within the CSL Collaboration Agreement, and when combining certain promised goods/services, the Company concluded that there are five distinct performance obligations. The nature of the performance obligations consists of delivery of the vaccine license, research and development services for COVID and non-COVID vaccines and regulatory activities for COVID vaccines. For each performance obligation, the Company estimated the standalone selling price based on 1) in the case of the license, the fair value using costs to recreate plus margin method and 2) in the case of research and development services and regulatory activities, cost plus margin for estimated full-time equivalent ("FTE") costs, direct costs including laboratory supplies, contractors, and other out-of-pocket expenses for research and development services and regulatory activities. As of June 30, 2024, the transaction price consisted of upfront consideration received and milestones achieved. Additional variable consideration was not included in the transaction price at June 30, 2024 because the Company could not conclude that it is probable that including the variable consideration will not result in a significant revenue reversal. The Company allocated the transaction price to the performance obligations in proportion to their standalone selling price. The vaccine license was recognized at the point in time it was transferred in 2022. The research and development and regulatory activities performance obligations are recognized over a period of time based on the percentage of services rendered using the input method, meaning actual costs incurred divided by total costs budgeted to satisfy the performance obligation. Any consideration related to sales-based royalties will be recognized when the amounts are probable of non-reversal, provided that the reported sales are reliably measurable and the Company has no remaining promised goods/services, as they are constrained and therefore have also been excluded from the transaction price. The revenue recognized in the second quarter of 2024 relates to the license delivered, milestones achieved and services performed through June 30, 2024. Total deferred revenue as of June 30, 2024 and December 31, 2023 for the CSL Collaboration Agreement was $53.7 million and $87.1 million, respectively. During 2023, the Company also received an advance payment of $23.6 million for the manufacturing and supply of ARCT-154 drug product. The advance payment was for specified manufacturing runs of ARCT-154 which include the drug substance utilized, as well as the reservation fees and related manufacturing requirements. The Company concluded that the promise to manufacture and supply ARCT-154 drug product is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The Company recognized $18.0 million in revenue related to this customer option during the second quarter of 2024. No amount related to this customer option remained in deferred revenue as of June 30, 2024. During 2023, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the Company agreed to sponsor and conduct a Phase 1 clinical study in the influenza field. As part of the amendment, the Company received $17.5 million from CSL Seqirus. The amendment also provides for up to $1.5 million in additional payments which are achievable upon meeting certain clinical milestones relating to the Phase 1 clinical study in the influenza field. The Company previously concluded that the expansion of research and development support services under the CSL Collaboration Agreement represented an option that was not a material right. Therefore the Company concluded the promise to sponsor and conduct the Phase 1 clinical study is a separate contract and the sole performance obligation under the new arrangement. During the quarter ended June 30, 2024, the Company recognized $3.0 million related to the performance obligation and the remaining amount of $9.8 million is included in deferred revenue. During the fourth quarter of 2023, the Company received an advance payment of $5.3 million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. During the first quarter of 2024, the Company received an additional advance payment of $5.1 million from CSL Seqirus for manufacturing activities related to COVID-19 vaccine product. The Company concluded that the promise to perform manufacturing activities is a customer option as part of the CSL Collaboration Agreement and is accounted for as a separate contract. The advance payments are included in deferred revenue as of June 30, 2024 and will be recognized as revenue when the vaccine product is transferred to CSL Seqirus. In March 2024, the Company entered into an amendment to the CSL Collaboration Agreement, pursuant to which the parties agreed to, among other things, adjust (i) the development plans for certain product candidates, (ii) various development milestones related to such product candidates, (iii) provisions of the CSL Collaboration Agreement related to specific royalty payments, (iii) provisions of the CSL Collaboration Agreement related to distributors, and (iv) proprietary payment calculations related to the foregoing. BARDA Grant In August 2022, the Company entered into a cost reimbursement contract (the "BARDA Contract") with the Biomedical Advanced Research and Development Authority ("BARDA"), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) for an award of up to $63.2 million for the development of a pandemic influenza vaccine using the Company's STARR® self-amplifying mRNA vaccine platform technology. The Company earns grant revenue for performing tasks under the agreement. The Company determined that the BARDA Contract is not in the scope of ASC 808 or ASC 606. Applying International Accounting Standards No. 20 ("IAS 20"), Accounting for Government Grants and Disclosure of Government Assistance, by analogy, the Company recognizes grant revenue from the reimbursement of direct out-of-pocket expenses, overhead allocations and fringe benefits for research costs associated with the grant. The costs associated with these reimbursements are reflected as a component of research and development expense in the Company's condensed consolidated statements of operations and comprehensive income (loss). The Company recognized $3.9 million and $1.0 million of revenue during the three months ended June 30, 2024 and 2023, respectively. As of June 30, 2024, the remaining available funding net of revenue earned was $44.5 million. The following table presents changes during the six months ended June 30, 2024 in the balances of contract assets and liabilities as compared to what was disclosed in the Company's Annual Report. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.272%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:13.337%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Additions </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Deductions </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Contract Assets: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td

style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Accounts receivable </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">32,064</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 55,132 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">63,111</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24,085 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Contract Liabilities: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> Deferred revenue </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">87,325</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 54,252 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">87,871</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 53,706 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>320640005513200-63111000240850008732500054252000-8787100053706000 The following table summarizes the Company's revenues for the periods indicated. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:42.272%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:10.798%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:1%;"></td> <td style="width:13.337%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months
Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Six Months
Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> (in thousands) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Collaboration Revenue: </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> CSL Segirus </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">45,911</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 7,607 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">78,292</p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 85,824 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Janssen </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td>

style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 170 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 660 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> Other collaboration revenue </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 65 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 1,788 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 282 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 2,810 </td> <td style="white-space:nowrap;vertical-align:middle;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total collaboration revenue </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">45,976</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 9,565 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">78,574</p></td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 89,294 </td> <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"> Grant revenue: </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;"> </td> <td colspan="2" style="vertical-align:middle;text-align:center;"> </td> <td style="vertical-align:middle;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"> BARDA </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,883</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"> 954 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,297</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;text-align:center;"> 1,510 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"> Total grant revenue </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,883</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 954 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:middle;"> </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,297</p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:middle;border-bottom:2.25pt double #000000;text-align:center;"> 1,510 </td> <td style="white-space:nowrap;vertical-align:middle;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table>4591100076070007829200085824000170000660000650001788000282000281000045976000956500078574000892940003883000954000929700015100003883000954000929700015100002000000001300006

style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Note 3. Fair Value Measurements The Company establishes the fair value of its assets and liabilities using the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company established a fair value hierarchy based on the inputs used to measure fair value. The three levels of the fair value hierarchy are as follows: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly. Level 3: Unobservable inputs in which little or no market data exists and are therefore determined using estimates and assumptions developed by the Company, which reflect those

that a market participant would use. The carrying value of cash, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their respective fair values due to their relative short maturities. As of June 30, 2024 and December 31, 2023, all assets measured at fair value on a recurring basis consisted of cash equivalents and money market funds, which were classified within Level 1 of the fair value hierarchy. The fair value of these financial instruments was measured based on quoted prices. Note 4. Balance Sheet Details Property and equipment, net balances consisted of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.6%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Research equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,784</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,046 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Computers and software </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,131 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Office equipment and furniture </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 703 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 958 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,644 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,655 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Construction in progress </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 233 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,262 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,167 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Less accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (10,080 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (8,740 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,182</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,427 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Depreciation and amortization expense was $0.9 million and $1.8 million for the three and six months ended June 30, 2024, respectively, and $0.7 million and $1.3 million for the three and six months ended June 30, 2023, respectively. Construction in progress is primarily comprised of research equipment not yet placed in service. Accrued liabilities consisted of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.6%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td style="vertical-align:bottom;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,206</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,918 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cystic Fibrosis Foundation liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,870 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,633 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Income tax payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 641 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Current portion of operating lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,917 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,309 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Clinical trial accruals </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 968 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,333 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vinbiocare contractual liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,514 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,514 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Other accrued research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,975 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,533 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,450</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 31,881 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> Property and equipment, net balances consisted of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.6%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Research equipment </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">16,704</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16,046 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Computers and software </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,131 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Office equipment and furniture </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 703 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 958 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Leasehold improvements </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,644 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,655 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Construction in progress </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 233 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,262 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 21,167 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Less accumulated depreciation and amortization </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (10,080 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,740 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Property and equipment, net </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11,182</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 12,427 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table><table style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> 167840001604600011310001275000703000958000264400026550002330002126200021167000100800000874000011182000124270009000001800000700001300000 Accrued liabilities consisted of the following: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:61.6%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td> <td style="width:1.38%;"></td> <td style="width:1%;"></td> <td style="width:15.82%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> June 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Accrued compensation </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,206</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,918 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Cystic Fibrosis Foundation liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,870 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,633 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Income tax payable </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> — </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 641 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Current portion of operating lease liability </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,917 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,309 </td> <td

style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Clinical trial accruals </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 968 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,333 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Vinbiocare contractual liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,514 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:middle;"> Other accrued research and development expenses </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11,975 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8,533 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35,450</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 31,881 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr></table>92060005918000687000076330066410003917000430900096800023330002514000251400011975000853300035450000311881000 Note 5. Debt Wells Fargo Credit Agreement The Company's wholly-owned subsidiary, Arcturus Therapeutics, Inc. ("Arcturus Therapeutics") entered into a credit agreement with Wells Fargo Bank on April 21, 2023, and amended on June 26, 2024, whereby Wells Fargo will make a $50.0 million revolving credit line available to the Company (the "Loan") and each draw on the Loan evidenced by a revolving line of credit note (the "Note"). Borrowings under the agreement will bear interest at a rate of 1.00% above either the Daily Simple SOFR or Term SOFR (as such terms are defined in the Note), with "SOFR" being the rate per annum equal to the secured overnight financing rate as administered by the Federal Reserve Bank of New York. If an Event of Default (as defined in the agreement) occurs, then all Loans shall bear interest at a rate equal to 2.00% above the interest rate applicable immediately prior to the occurrence of the Event of Default. The term of the agreement was originally two years, with an option for one-year renewals subject to Wells Fargo approval and Arcturus Therapeutics furnishing to Wells Fargo a non-refundable commitment fee equal to 0.25% of the Loan amount for each such renewal. There is no penalty for terminating the facility prior to the maturity date of the Note. As collateral, the Company has agreed to pledge $55.0 million in cash to be held at the Company's securities accounts with Wells Fargo Securities, LLC, an affiliate of Wells Fargo, pursuant to a security agreement. In June 2024, Arcturus Therapeutics and Wells Fargo entered into an amendment to the Note, whereby the term of the Note was extended by one year to April 2026. No borrowings were outstanding as of June 30, 2024. 500000000.010.02P2YP1Y0.002555000000P1Y0 Note 6. Stockholders' Equity Net Loss per Share Potentially dilutive securities that were not included in the calculation of diluted net loss per share for the three and six months ended June 30, 2024 as they were anti-dilutive totaled 1.1 million and 1.3 million, respectively, and 1.0 million and 0.8 million for the three and six months ended June 30, 2023, respectively. Sales Agreement On December 23, 2022, the Company entered into a Controlled Equity Offering℠ Sales Agreement, which was amended on August 7, 2023 (as amended, the "Sales Agreement") with Cantor Fitzgerald & Co. ("Cantor"),Wells Fargo Securities, LLC ("Wells Fargo Securities"), and William Blair & Company, L.L.C. ("William Blair") relating to shares of the Company's common stock. In accordance with the terms of the Sales Agreement, the Company may offer and sell shares of its common stock having an aggregate offering price of up to $200,000,000 from time to time through Cantor, Wells Fargo Securities, or William Blair, each acting as the Company's sales agent. During the period ended June 30, 2024 the Company did not offer or sell any shares of common stock pursuant to the Sales Agreement. 1100000130000010000000000002000000000 Note 7. Share-Based Compensation Expense In June 2024 at the Company's 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"), the stockholders of the Company approved an amendment to the Company's 2019 Omnibus Equity Incentive Plan (as amended, the "2019 Plan") which, among other things, increased the aggregate number of shares authorized for use in making awards to eligible persons under the 2019 Plan by 2,000,000 shares, for a total of up to 10,750,000 shares available for issuance. As of June 30, 2024, following the 2024 Annual Meeting, a total of 2,236,360 shares remain available for future issuance under the 2019 Plan, subject to the terms of the 2019 Plan. In October 2021, the Company adopted the 2021 Inducement Equity Incentive Plan which covers the award of up to 1,000,000 shares of common stock (the "2021 Plan") effective as of October 15, 2021. Approval of the Company's stockholders is not required as a condition to the effectiveness of the 2021 Plan for so long as the plan is in compliance with applicable Nasdaq inducement plan rules. In April 2022, the compensation committee of the Company's board of directors approved a proposal to reduce the total number of shares available for future issuance under the 2021 Plan to 130,000. As of June 30, 2024, a total of 124,697 shares remain available for future issuance under the 2021 Plan, subject to the terms of the 2021 Plan. Stock Options Share-based compensation expense included in the Company's condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023 was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.04%;"></td> <td style="width:1.1%;"></td> <td style="width:1%;"></td> <td style="width:8.816%;"></td> <td style="width:1%;"></td> <td style="width:1.1%;"></td> <td style="width:1.1%;"></td> <td style="width:1.1%;"></td> <td style="width:8.816%;"></td> <td style="width:1.1%;"></td> <td style="width:1.1%;"></td> <td style="width:1%;"></td> <td style="width:8.816%;"></td> <td style="width:1%;"></td> <td style="width:1.1%;"></td> <td style="width:1.1%;"></td> <td style="width:1%;"></td> <td style="width:8.816%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;">

 </td> <td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months
Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Six Months
Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,378</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,741 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,180</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,249 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,046 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,642</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,332</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,316</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> Total</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 9,424 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,383</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 19,512 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,565 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> 2000000107500002236360100000013000012469 7 Share-based compensation expense included in the Company's condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023 was as follows: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:49.04%;"></td> <td style="width:1.1%;"></td> <td style="width:1%;"></td> <td style="width:8.816%;"></td> <td style="width:1%;"></td> <td style="width:1.1%;"></td> <td style="width:1.1%;"></td> <td style="width:1%;"></td> <td style="width:8.816%;"></td> <td style="width:1%;"></td> <td style="width:1.1%;"></td> <td style="width:1.1%;"></td> <td style="width:8.816%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Three Months
Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="7" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the Six Months
Ended June 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> <span style="color:#000000;white-

space:pre-wrap;font-weight:bold;min-width:fit-content;">2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Research and development </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,378</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,741 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,180</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,249 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> General and administrative </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 5,046 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4,642 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> 10,332 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,316 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,424</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 8,383 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">19,512</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 16,565 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table>43780003741000918000072490005046000464200010332000931600094240008383000195120001656500 Note 8. Income Taxes The Company is subject to taxation in the United States and various states. The Company computes its quarterly income tax provision by using a forecasted annual effective tax rate and adjusts for any discrete items arising during the quarter. The primary difference between the effective tax rate and the federal statutory tax rate is due to federal and state income tax expense offset by valuation allowance on the Company's deferred tax assets. For the three and six months ended June 30, 2024, the Company recorded $(0.2) million and $0.2 million of income tax expense, respectively. For the three and six months ended June 30, 2023, the Company recorded $0.6 million and $0.7 million of income tax expense, respectively. No tax benefit was provided for losses incurred in United States because those losses are offset by a full valuation allowance. -2000002000006000007000000 Note 9. Commitments and Contingencies Cystic Fibrosis Foundation Agreement On September 25, 2023, the Company amended its Development Program Letter Agreement, dated May 16, 2017 and as amended July 13, 2018 and August 1, 2019, with the Cystic Fibrosis Foundation ("CFF"). Pursuant to the amendment, CFF increased the amount it will award to advance LUNAR-CF to $24.6 million from approximately $15.6 million and the Company agreed to incur at least $15.0 million toward activities under the research plan. Total contra expense of $0.8 million was recognized during the three and six months ended June 30, 2024. For the three and six months ended June 30, 2023, the Company recognized no contra expense related to the agreement. As of June 30, 2024 and December 31, 2023, $6.9 million and $7.6 million, respectively, remained in accrued liabilities. Leases In October 2017, the Company entered into a non-cancellable operating lease agreement for office space adjacent to its previously occupied headquarters. The commencement of the lease began in March 2018 and the lease extends for approximately 84 months from the commencement date with a remaining lease term through March 2025. Monthly rental payments are due under the lease and there are escalating rent payments during the term of the lease. The Company is also responsible for its proportional share of operating expenses of the building and common areas. In conjunction with the new lease, the Company received free rent for <span style="color:#000000;white-

space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four months and received a tenant improvement allowance of $0.1 million. In March 2024, the Company negotiated with the lessor to extend the lease through March 2027. The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $0.1 million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash. In February 2020, the Company entered into a second non-cancellable operating lease agreement for office space near its current headquarters. The lease extended for 13 months from the commencement date and included a right to extend the lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Company's headquarters. In January 2024, the Company vacated this office space with no intention of operating out of the location in the future. Because Arcturus was still engaged in the lease for the property and obligated to make the remaining lease payment through March 31, 2025, the Company recorded an impairment loss in the amount of $1.3 million during the three months ended March 31, 2024, as it would not receive any future economic benefit from the lease. In July 2024, the Company terminated the existing lease agreement, in accordance with its terms, thereby ending their contractual obligation to pay for premise. In September 2021, the Company entered into a third non-cancellable lease agreement for office, research and development, engineering and laboratory space near its current headquarters, and such lease term commenced during the second quarter of 2022. The initial term of this lease extends ten years and eight months from the date of possession, and the Company has the right to extend the term of the lease for an additional five-year period. When the lease term was determined for the operating lease right-of-use assets and lease liabilities, the extension option for the lease was not included. The lease has a monthly base rent ranging from $0.3 million to $0.4 million which escalates over the lease term. The Company received a free rent period of four months and also pays for various operating costs, including utilities and real property taxes. The Company entered into an irrevocable standby letter of credit with the landlord for a security deposit of $2.0 million upon executing the lease which is included (along with additional funds required to secure the letter of credit) in the balance of non-current restricted cash.</p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating lease right-of-use asset and liability on the condensed consolidated balance sheets represent the present value of remaining lease payments over the remaining lease terms. The Company does not allocate lease payments to non-lease components; therefore, payments for common-area-maintenance and administrative services are not included in the operating lease right-of-use asset and liability. The Company uses its incremental borrowing rate to calculate the present value of the lease payments, as the implicit rate in the lease is not readily determinable.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of June 30, 2024, the remaining payments of the operating lease liability were as follows:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:75.435%;"></td> <td style="width:1.68%;"></td> <td style="width:1%;"></td> <td style="width:20.884%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(in thousands)</p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Remaining Lease Payments</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,838 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,019 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,274 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 23,703 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total remaining lease payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 36,834 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Less: imputed interest </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (5,953 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total operating lease liabilities </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 30,881 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average remaining lease term </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> Operating lease costs consist of the fixed lease payments included in operating lease liability and are recorded on a straight-line basis over the lease terms. Operating lease costs were $1.5 million and $2.9 million for the three and six months ended June 30, 2024, respectively, and $1.4 million and $2.8 million for the three and six months ended June 30, 2023, respectively.</p>2460000015600000150000008000000800000006900000760000OP84MP4M100000100000P13Mthe lease for one twelve-month period. In February 2021, the Company opted to extend the lease through March 2025 to coincide with the lease term of the Company's headquarters.1300000P10Y8Mthe Company has the right to extend the term of the lease for an additional five-year period.3000004000002000000<p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of June 30, 2024, the remaining payments of the operating lease liability were as follows:</p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:75.435%;"></td> <td style="width:1.68%;"></td> <td style="width:1%;"></td> <td style="width:20.884%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">(in thousands)</p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Remaining Lease Payments</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-

align:bottom;text-align:center;"> 2,838 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2025 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;text-align:center;"> 5,019 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,274 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Thereafter </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 23,703 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"> Total remaining lease payments </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> $</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">36,834</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Less: imputed interest</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(5,953)</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total operating lease liabilities</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 30,881 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average remaining lease term </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7.5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"> Weighted-average discount rate </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4.8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table>2038000501900052740002370300036834000595300030881000P7Y6M0.048150000029000001400000280000 Note 10. Related Party Transactions See “Note 1, Joint Ventures, Equity Method Investments and Variable Interest Entities” for specific details surrounding the Company’s agreement with Axcelead to form the joint venture entity, ARCALIS, Inc. Rule 10b5-1 Trading Arrangements During the three months ended June 30, 2024, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” (as defined in Item 408 of Regulation S-K of the Exchange Act) intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, other than as follows: • Lance Kurata, our Chief Legal Officer, adopted a Rule 10b5-1 trading arrangement as of June 12, 2024. Mr. Kurata's trading arrangement provides for the exercise of up to an aggregate of 35,000 options to purchase shares of common stock and subsequent sale of such underlying shares of common stock, until June 12, 2025. falsefalseLance KurataChief Legal OfficertrueJune 12, 202435000June 12, 2025

"
–